role,name,affiliation,address,trial_id,processed_name,first_name,gender,gender_probability,gender_sample_count,Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
Principal Investigator,"Patrick Schrauwen, Prof. Dr.",Maastricht University,,NCT03992248,patrick schrauwen,patrick,male,0.99,153288,4,NCT03992248,Effect of Eating Within a Limited Time on Sugar Sensitivity and Liver Sugar Stores of People With Type 2 Diabetes.,TRF,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Behavioral: Time restricted feeding,Hepatic glycogen|Insulin sensitivity,Maastricht University|ZonMw: The Netherlands Organisation for Health Research and Development,All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,34,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NL67610068,"January 31, 2019",October 2019,December 2019,"June 20, 2019",,"June 20, 2019","Maastricht University, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT03992248
Study Director,Kun Lou,"Department of Medicine, CSPC Clinical Development Division",,NCT04161430,kun lou,kun,male,0.78,1297,8,NCT04161430,A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients,,Not yet recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: DBPR108; Placebo matching sitagliptin|Drug: Placebo matching DBPR108; Sitagliptin; DBPR108|Drug: Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108,"Change from baseline in HbA1c (%) compared to placebo comparator at week 24|Change from baseline in HbA1c (%) compared to active comparator at week 24|The percentage of subjects with HbA1c≤6.5% and HbA1c≤7% at week 24|Change from baseline in HbA1c (%) at week 12, week 40, week 52|The percentage of subjects with HbA1c≤6.5% and HbA1c≤7% at week 12, week 40, week 52|Change from baseline in fasting plasma glucose/2-hour postprandial plasma glucose/body weight at week 12,week 24","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,750,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CSPC/DBPR108201903/PRO-III-1,"January 20, 2020","April 27, 2024","June 28, 2024","November 13, 2019",,"November 13, 2019",,,https://ClinicalTrials.gov/show/NCT04161430
Principal Investigator,Lee Kheng Hock,Singapore General Hospital,,NCT03940482,lee kheng hock,lee,male,0.8,38767,10,NCT03940482,Time Restricted Eating As Treatment (TREAT) for Diabetes Mellitus: A Pre-Post 12 Week Study on the Effectiveness of Intermittent Fasting in Asians With Type 2 Diabetes Mellitus,TREAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Behavioral: Time Restricted Eating As Treatment (TREAT) for Diabetes.,"Change in glycaemic control of patients as measured by >= 5% reduction in glycosylated haemoglobin (HbA1C) over a 12 week period.|Change in glycaemic control of patients as measured by fasting glucose and 2 hour post prandial glucose over a 12 week period.|Change in Blood Pressure (BP) over a 12 week period.|Change in Weight over a 12 week period.|Change in Body Mass Index (BMI) over a 12 week period.|Change in Waist Circumference (WC) over a 12 week period.|Change in the lipid profiles of patients, namely Total Cholesterol (TC), High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Triglycerides (TG), over a 12 week period.|Change in a levels of ketonemia (Serum Beta-Hydroxybutyrate 0.5-3.0 mmol/L) over a 12 week period.",Singapore General Hospital|Duke-NUS Graduate Medical School,All,"21 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TREAT-DM-01,"January 14, 2019","June 30, 2020","June 30, 2020","May 7, 2019",,"March 19, 2020","Singapore General Hospital (Clinical Trials and Research Centre), Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT03940482
Principal Investigator,"Katherine Esposito, MD, PhD",Unit of Diabetology University of Campania Luigi Vanvitelli,,NCT04196231,katherine esposito,katherine,female,0.98,8451,12,NCT04196231,Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND),BEYOND,Recruiting,No Results Available,Type 2 Diabetes,Drug: IDegLira|Drug: IGlarLixi|Drug: Insulin/Canaglifozin|Drug: Insulin/Dapaglifozin|Drug: Insulin/Empaglifozin|Drug: Basal Bolus,Hba1c variability change|Proportions of patients with significant HbA1c change|Weight Change|BMI Change|Waist circumference change|Blood pressure change|Fasting glycemia change|Post-prandial glycemia change|C-peptide change|Change in total daily insulin dose|Change in lipide profile|Change in eGFR|Diabetes treatment satisfaction,"University of Campania ""Luigi Vanvitelli""",All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 4,105,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BEYOND Protocol,"January 1, 2020","December 31, 2021","January 31, 2023","December 12, 2019",,"March 18, 2020","Unit of Endocrinology and Metabolic Diseases, Naples, Italy",,https://ClinicalTrials.gov/show/NCT04196231
Principal Investigator,"Dario Giugliano, MD",Unit of Endocrinology and Metabolic Diseases University of Campania Luigi Vanvitelli,,NCT04196231,dario giugliano,dario,male,0.99,41022,12,NCT04196231,Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND),BEYOND,Recruiting,No Results Available,Type 2 Diabetes,Drug: IDegLira|Drug: IGlarLixi|Drug: Insulin/Canaglifozin|Drug: Insulin/Dapaglifozin|Drug: Insulin/Empaglifozin|Drug: Basal Bolus,Hba1c variability change|Proportions of patients with significant HbA1c change|Weight Change|BMI Change|Waist circumference change|Blood pressure change|Fasting glycemia change|Post-prandial glycemia change|C-peptide change|Change in total daily insulin dose|Change in lipide profile|Change in eGFR|Diabetes treatment satisfaction,"University of Campania ""Luigi Vanvitelli""",All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 4,105,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BEYOND Protocol,"January 1, 2020","December 31, 2021","January 31, 2023","December 12, 2019",,"March 18, 2020","Unit of Endocrinology and Metabolic Diseases, Naples, Italy",,https://ClinicalTrials.gov/show/NCT04196231
Study Chair,"Giuseppe Bellastella, MD, PhD",Unit of Endocrinology and Metabolic Diseases University of Campania Luigi Vanvitelli,,NCT04196231,giuseppe bellastella,giuseppe,male,0.99,163742,12,NCT04196231,Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND),BEYOND,Recruiting,No Results Available,Type 2 Diabetes,Drug: IDegLira|Drug: IGlarLixi|Drug: Insulin/Canaglifozin|Drug: Insulin/Dapaglifozin|Drug: Insulin/Empaglifozin|Drug: Basal Bolus,Hba1c variability change|Proportions of patients with significant HbA1c change|Weight Change|BMI Change|Waist circumference change|Blood pressure change|Fasting glycemia change|Post-prandial glycemia change|C-peptide change|Change in total daily insulin dose|Change in lipide profile|Change in eGFR|Diabetes treatment satisfaction,"University of Campania ""Luigi Vanvitelli""",All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 4,105,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BEYOND Protocol,"January 1, 2020","December 31, 2021","January 31, 2023","December 12, 2019",,"March 18, 2020","Unit of Endocrinology and Metabolic Diseases, Naples, Italy",,https://ClinicalTrials.gov/show/NCT04196231
Study Chair,"Maria Ida Maiorino, MD, PhD",Unit of Diabetology University of Campania Luigi Vanvitelli,,NCT04196231,maria ida maiorino,maria,female,0.98,334287,12,NCT04196231,Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND),BEYOND,Recruiting,No Results Available,Type 2 Diabetes,Drug: IDegLira|Drug: IGlarLixi|Drug: Insulin/Canaglifozin|Drug: Insulin/Dapaglifozin|Drug: Insulin/Empaglifozin|Drug: Basal Bolus,Hba1c variability change|Proportions of patients with significant HbA1c change|Weight Change|BMI Change|Waist circumference change|Blood pressure change|Fasting glycemia change|Post-prandial glycemia change|C-peptide change|Change in total daily insulin dose|Change in lipide profile|Change in eGFR|Diabetes treatment satisfaction,"University of Campania ""Luigi Vanvitelli""",All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 4,105,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BEYOND Protocol,"January 1, 2020","December 31, 2021","January 31, 2023","December 12, 2019",,"March 18, 2020","Unit of Endocrinology and Metabolic Diseases, Naples, Italy",,https://ClinicalTrials.gov/show/NCT04196231
Principal Investigator,Katherine Esposito,"University of Campania ""Luigi Vanvitelli""",,NCT03918148,katherine esposito,katherine,female,0.98,8451,52,NCT03918148,Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA),GIOIA,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: SGLT-2i|Drug: DPP-4i,Carotid intima-media thickness (CIMT)|Myocardial stiffness indexes|Urinary albumin to creatinine ratio excretion|Weight|Body mass index (BMI)|Waist circumference (WC)|Blood pressure|estimated Glomerular filtration rate (eGFR),"University of Campania ""Luigi Vanvitelli""",All,"35 Years to 75 Years   (Adult, Older Adult)",,555,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2193/2018,"January 15, 2018","December 31, 2023","December 31, 2025","April 17, 2019",,"April 17, 2019","Unit of Diabetes, Naples, Campania, Italy",,https://ClinicalTrials.gov/show/NCT03918148
Study Director,Dario Giugliano,"University of Campania ""Luigi Vanvitelli""",,NCT03918148,dario giugliano,dario,male,0.99,41022,52,NCT03918148,Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA),GIOIA,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: SGLT-2i|Drug: DPP-4i,Carotid intima-media thickness (CIMT)|Myocardial stiffness indexes|Urinary albumin to creatinine ratio excretion|Weight|Body mass index (BMI)|Waist circumference (WC)|Blood pressure|estimated Glomerular filtration rate (eGFR),"University of Campania ""Luigi Vanvitelli""",All,"35 Years to 75 Years   (Adult, Older Adult)",,555,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2193/2018,"January 15, 2018","December 31, 2023","December 31, 2025","April 17, 2019",,"April 17, 2019","Unit of Diabetes, Naples, Campania, Italy",,https://ClinicalTrials.gov/show/NCT03918148
Principal Investigator,"Maria Jocelyn Capuli-Isidro, MD",Makati Medical Center,,NCT04077216,maria jocelyn capuli-isidro,maria,female,0.98,334287,188,NCT04077216,Effect of Extra Virgin Olive Oil on Postprandial Blood Glucose in Type 2 Diabetes Mellitus Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Extra Virgin Olive Oil (EVOO),trans-meal blood glucose,Makati Medical Center,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,MakatiMedCtr,"September 1, 2018","November 30, 2018","November 30, 2018","September 4, 2019",,"September 4, 2019","Makati Medical Center, Makati City, NCR, Philippines","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT04077216/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04077216
Principal Investigator,"Ma. Cecilia Gonzales, MD",Makati Medical Center,,NCT04077216,ma. cecilia gonzales,ma,female,0.83,23029,188,NCT04077216,Effect of Extra Virgin Olive Oil on Postprandial Blood Glucose in Type 2 Diabetes Mellitus Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Extra Virgin Olive Oil (EVOO),trans-meal blood glucose,Makati Medical Center,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,MakatiMedCtr,"September 1, 2018","November 30, 2018","November 30, 2018","September 4, 2019",,"September 4, 2019","Makati Medical Center, Makati City, NCR, Philippines","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT04077216/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04077216
Principal Investigator,"Andrea Marie Macabuag-Oliva, MD",Makati Medical Center,,NCT04077216,andrea marie macabuag-oliva,andrea,male,0.62,302977,188,NCT04077216,Effect of Extra Virgin Olive Oil on Postprandial Blood Glucose in Type 2 Diabetes Mellitus Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Extra Virgin Olive Oil (EVOO),trans-meal blood glucose,Makati Medical Center,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,MakatiMedCtr,"September 1, 2018","November 30, 2018","November 30, 2018","September 4, 2019",,"September 4, 2019","Makati Medical Center, Makati City, NCR, Philippines","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT04077216/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04077216
Principal Investigator,"Maria Gorska, Prof.","Dept of Endocrinology, Diabetology and Internal Medicine",,NCT03792685,maria gorska,maria,female,0.98,334287,302,NCT03792685,Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention,,Recruiting,No Results Available,"Overweight and Obesity|Diabetes Mellitus, Type 2|Metabolic Syndrome|Genetic Predisposition|Diet Modification",Other: Normo-carbohydrate meal intake|Other: High-carbohydrate meal intake|Other: High-fat meal intake|Other: High-protein meal intake,"The postprandial change and differences in blood glucose levels associated with investigated single nucleotide polymorphisms.|The postprandial change and differences in serum insulin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial Triglycerides (TGs) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial Free Fatty Acids (FFAs) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial energy expenditure levels associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial substrates (carbohydrate, fat and protein) utilization levels associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial ghrelin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial leptin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial adiponectin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial peptide YY (PYY) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial plasma metabolites profiles associated with investigated single nucleotide polymorphisms.","Medical University of Bialystok|Ministry of Science and Higher Education, Poland",Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,N N402 477437,"September 24, 2009","October 1, 2021","January 1, 2022","January 3, 2019",,"January 18, 2020","Clinical Research Centre, Medical University of Bialystok, Bialystok, Polska, Poland",,https://ClinicalTrials.gov/show/NCT03792685
Study Director,"Edyta Adamska-Patruno, PhD","Clinical Research Centre, Medical University of Bialystok",,NCT03792685,edyta adamska-patruno,edyta,female,0.98,20720,302,NCT03792685,Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention,,Recruiting,No Results Available,"Overweight and Obesity|Diabetes Mellitus, Type 2|Metabolic Syndrome|Genetic Predisposition|Diet Modification",Other: Normo-carbohydrate meal intake|Other: High-carbohydrate meal intake|Other: High-fat meal intake|Other: High-protein meal intake,"The postprandial change and differences in blood glucose levels associated with investigated single nucleotide polymorphisms.|The postprandial change and differences in serum insulin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial Triglycerides (TGs) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial Free Fatty Acids (FFAs) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial energy expenditure levels associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial substrates (carbohydrate, fat and protein) utilization levels associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial ghrelin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial leptin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial adiponectin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial peptide YY (PYY) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial plasma metabolites profiles associated with investigated single nucleotide polymorphisms.","Medical University of Bialystok|Ministry of Science and Higher Education, Poland",Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,N N402 477437,"September 24, 2009","October 1, 2021","January 1, 2022","January 3, 2019",,"January 18, 2020","Clinical Research Centre, Medical University of Bialystok, Bialystok, Polska, Poland",,https://ClinicalTrials.gov/show/NCT03792685
Principal Investigator,"Adam Kretowski, Prof.","Dept of Endocrinology, Diabetology and Internal Medicine; Clinical Research Centre",,NCT03792685,adam kretowski,adam,male,0.98,116396,302,NCT03792685,Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention,,Recruiting,No Results Available,"Overweight and Obesity|Diabetes Mellitus, Type 2|Metabolic Syndrome|Genetic Predisposition|Diet Modification",Other: Normo-carbohydrate meal intake|Other: High-carbohydrate meal intake|Other: High-fat meal intake|Other: High-protein meal intake,"The postprandial change and differences in blood glucose levels associated with investigated single nucleotide polymorphisms.|The postprandial change and differences in serum insulin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial Triglycerides (TGs) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial Free Fatty Acids (FFAs) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial energy expenditure levels associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial substrates (carbohydrate, fat and protein) utilization levels associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial ghrelin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial leptin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial adiponectin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial peptide YY (PYY) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial plasma metabolites profiles associated with investigated single nucleotide polymorphisms.","Medical University of Bialystok|Ministry of Science and Higher Education, Poland",Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,N N402 477437,"September 24, 2009","October 1, 2021","January 1, 2022","January 3, 2019",,"January 18, 2020","Clinical Research Centre, Medical University of Bialystok, Bialystok, Polska, Poland",,https://ClinicalTrials.gov/show/NCT03792685
Principal Investigator,"Julio Alfredo García Puga, Ph.D.",Universidad de Sonora,,NCT04023539,julio alfredo garcía puga,julio,male,0.98,37832,13,NCT04023539,Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes,Dietary Supplement: Cinnamomum zeylanicum|Other: Placebo,Glycated hemoglobin|Fasting plasma glucose|Total cholesterol|HDL|LDL|Triglycerides|Weight|Waist circumference|Body Mass Index|Blood pressure,Universidad de Sonora,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Cinnamon-T2D-MEX-2019,"September 4, 2019","March 20, 2020","April 23, 2020","July 17, 2019",,"May 28, 2020","C.A.A.P.S., Hermosillo, Sonora, Mexico|ISSSTE Family Medicine Clinic, Hermosillo, Sonora, Mexico",,https://ClinicalTrials.gov/show/NCT04023539
Principal Investigator,Julio Nuñez Villota,Fundación para la Investigación del Hospital Clínico de Valencia,,NCT04197635,julio nuñez villota,julio,male,0.98,37832,135,NCT04197635,Short-term Effects of Dapagliflozin on Peak VO2 in HFrEF,DAPA-VO2,Recruiting,No Results Available,Heart Failure With Reduced Ejection Fraction|Type 2 Diabetes,Diagnostic Test: Maximal functional capacity by cardiopulmonary exercise testing|Diagnostic Test: Echocardiography|Behavioral: Evaluation of quality of life health related|Diagnostic Test: Submáximal functional capacity assesment by 6 minutes walk test|Other: Clinical evaluation,Functional capacity|Echocardiografy parameters|Evaluation of quality of life helath related: Minnesota Living with Heart Failure Questionnaire (MLHFQ)|Submáximal functional capacity assesment by 6 minutes walk test,Fundación para la Investigación del Hospital Clínico de Valencia,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,74,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ESR-17-13447(DAPA-HF)|2018-002614-12,"June 1, 2019","October 31, 2019","February 28, 2021","December 13, 2019",,"December 20, 2019","Hospital Clínico Universitario de Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT04197635
Principal Investigator,"Qingqing Lou, director",Nanjing University of Traditional Chinese Medicine,,NCT03932084,qingqing lou,qingqing,female,0.76,80,14,NCT03932084,Effects of Glucose Fluctuation Intervention on the Prognosis of Patients With Type 2 Diabetes and Cerebral Infarction,,Recruiting,No Results Available,Type 2 Diabetes and Cerebral Infarction,Behavioral: Control group|Behavioral: Glucose fluctuation targeted intervention,Stroke severity|Glycemic variability|Glucose fluctuation|Disability and health-related quality of life after stroke|Independent living skills|Glycemic control|Blood lipids,Nanjing University of Traditional Chinese Medicine,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,104,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N2017003,"February 1, 2017","May 25, 2019","June 18, 2019","April 30, 2019",,"April 30, 2019","Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT03932084
Study Director,"Talia A Hitt, MD/MPH",Children's Hospital of Philadelphia,,NCT04213547,talia a hitt,talia,female,0.97,1323,15,NCT04213547,Sleep and Glycemic Control in Type 2 Diabetes Adolescents,,Not yet recruiting,No Results Available,Type 2 Diabetes,Behavioral: Loss frame sleep extension intervention,Sleep duration|Glycemic control|BMI,Children's Hospital of Philadelphia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"12 Years to 20 Years   (Child, Adult)",Not Applicable,15,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,19-016599|2T32DK063688-16,June 2020,"January 1, 2021","January 1, 2021","December 30, 2019",,"March 16, 2020",,,https://ClinicalTrials.gov/show/NCT04213547
Principal Investigator,"Sujay Madduri, MD",MidMichigan Health,,NCT03997331,sujay madduri,sujay,male,0.98,154,16,NCT03997331,Chronicare for Type 2 Diabetes (Chronicare-T2D),CRX-T2D,Not yet recruiting,No Results Available,Type 2 Diabetes,Other: CRx Health|Other: Chronicare,Change in HbA1c|Fasting Blood Glucose|Mean Duration of Time to Reach Optimal Insulin Glargine Dose|Proportion of Patients Reaching Optimal Insulin Glargine Dose|Median Adherence to Insulin Glargine|Median Adherence to Metformin,QuiO|SHL Medical|MidMichigan Health,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,1433742-2,May 2020,December 2020,February 2021,"June 25, 2019",,"March 31, 2020","Clinical Research Department, Midland, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03997331
Study Chair,Alexander Dahmani,QuiO Technologies,,NCT03997331,alexander dahmani,alexander,male,0.99,66065,16,NCT03997331,Chronicare for Type 2 Diabetes (Chronicare-T2D),CRX-T2D,Not yet recruiting,No Results Available,Type 2 Diabetes,Other: CRx Health|Other: Chronicare,Change in HbA1c|Fasting Blood Glucose|Mean Duration of Time to Reach Optimal Insulin Glargine Dose|Proportion of Patients Reaching Optimal Insulin Glargine Dose|Median Adherence to Insulin Glargine|Median Adherence to Metformin,QuiO|SHL Medical|MidMichigan Health,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,1433742-2,May 2020,December 2020,February 2021,"June 25, 2019",,"March 31, 2020","Clinical Research Department, Midland, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03997331
Principal Investigator,"Alexander N Orekhov, DSc, Prof",Institute for Atherosclerosis Research,,NCT03877523,alexander n orekhov,alexander,male,0.99,66065,469,NCT03877523,Cocarnit Effects on Macrophages Polarization,COMP-DM,Completed,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Complications",Dietary Supplement: Cocarnit,Change in macrophages activation after single Cocarnit administration|Change in macrophages activation after 30-days Cocarnit administration,"Institute for Atherosclerosis Research, Russia",All,"Child, Adult, Older Adult",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IAR-CS1,"October 3, 2018","November 18, 2018","December 20, 2018","March 15, 2019",,"March 21, 2019","Institute for Atherosclerosis Research, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT03877523
Principal Investigator,"Alexander Mayorov, MD",National Medical Research Center of Endocrinology (ENC),,NCT04120974,alexander mayorov,alexander,male,0.99,66065,503,NCT04120974,The Role of Proper Insulin Injection Technique in the Treatment of Diabetes. Mellitus,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Lipohypertrophy",Behavioral: Optimal insulin injection,Change in Glycemic Control|Change in Insulin Total Daily Dose (TDD)|Incidence of Hypoglycemic Events|Change in Blood Glucose Levels,"Becton, Dickinson and Company",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DBC-19INJCTRU|BD-4MM,"October 1, 2019","June 1, 2020","June 30, 2020","October 9, 2019",,"October 9, 2019","State Healthcare Institution ""Sverdlovsk Regional Clinical Hospital No. 1"" (EKB), Ekaterinburg, Russian Federation|National Medical Research Center of Endocrinology (ENC), Moscow, Russian Federation|Russian Medical Academy of Continuing Professional Education (RMANPO), Moscow, Russian Federation|Moscow Regional Research Clinical Institute (MONIKI), Moscow, Russian Federation|Endocrinological Dispensary of the Moscow Department of Health (DZM), Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT04120974
Principal Investigator,"Aslaug Johanne Risøy, PhDCandidate",University of Bergen,,NCT03979768,aslaug johanne risøy,aslaug,female,0.96,25,17,NCT03979768,Risk Assessment of Type 2 Diabetes in Pharmacies,,Completed,No Results Available,Type2 Diabetes,Other: Diabetes risk assessment service in Norwegian community pharmacies,Number of Participants with undiagnosed type 2 diabetes|Explore if there was any difference in the number of participants with a high risk of developing type 2 diabetes in the risk test only (RTO)- group and the group that also offered a HbA1c-measurement (HbA1c-group),University of Bergen,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2016/808,"September 15, 2016","June 30, 2017","May 30, 2019","June 7, 2019",,"October 16, 2019",,,https://ClinicalTrials.gov/show/NCT03979768
Study Chair,"Tarek Mostafa, Ass Prof.",Tanta University,,NCT04107259,tarek mostafa,tarek,male,0.98,17364,18,NCT04107259,"IRAPe, Irisin and IL-34 in Patients With Type 2 Diabetes",,Completed,No Results Available,Type2 Diabetes Mellitus,Diagnostic Test: Blood sample,Fasting blood glucose (FBG) levels|Fasting plasma insulin (FPI)|HOMA-IR index|plasma IL-34|serum visfatin|IRAPe,Damanhour University|Tanta University,All,"35 Years to 65 Years   (Adult, Older Adult)",,120,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,"IRAPe, Irisin and IL-34","January 19, 2019","June 30, 2019","July 20, 2019","September 27, 2019",,"September 27, 2019","Tanta University, Tanta, El-Gharbia, Egypt",,https://ClinicalTrials.gov/show/NCT04107259
Study Director,"Tarek Mostafa, ass. Prof.",Tanta University - Faculty of Pharmacy,,NCT03925714,tarek mostafa,tarek,male,0.98,17364,357,NCT03925714,Impact of P53 and SIRT1 in Type 2 Diabetes,,Recruiting,No Results Available,DM,Other: life style|Drug: Metformin|Drug: Nigetella salivata,Number of patients with improved insulin resistance,Sherief Abd-Elsalam|Tanta University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,dm 2,"April 1, 2019",December 2028,December 2028,"April 24, 2019",,"April 24, 2019","Sherief Abd-Elsalam, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT03925714
Principal Investigator,"Eman SA Sawan, Msc",Tanta University - Faculty of Pharmacy,,NCT03925714,eman sa sawan,eman,female,0.78,2638,357,NCT03925714,Impact of P53 and SIRT1 in Type 2 Diabetes,,Recruiting,No Results Available,DM,Other: life style|Drug: Metformin|Drug: Nigetella salivata,Number of patients with improved insulin resistance,Sherief Abd-Elsalam|Tanta University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,dm 2,"April 1, 2019",December 2028,December 2028,"April 24, 2019",,"April 24, 2019","Sherief Abd-Elsalam, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT03925714
Principal Investigator,"Sahar Hegazy, Prof",Tanta University - Faculty of Pharmacy,,NCT03925714,sahar hegazy,sahar,female,0.95,5188,357,NCT03925714,Impact of P53 and SIRT1 in Type 2 Diabetes,,Recruiting,No Results Available,DM,Other: life style|Drug: Metformin|Drug: Nigetella salivata,Number of patients with improved insulin resistance,Sherief Abd-Elsalam|Tanta University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,dm 2,"April 1, 2019",December 2028,December 2028,"April 24, 2019",,"April 24, 2019","Sherief Abd-Elsalam, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT03925714
Study Chair,"Sherin El-Nidany, MD",Tanta University-Faculty of pharmacy,,NCT03925714,sherin el-nidany,sherin,female,0.82,460,357,NCT03925714,Impact of P53 and SIRT1 in Type 2 Diabetes,,Recruiting,No Results Available,DM,Other: life style|Drug: Metformin|Drug: Nigetella salivata,Number of patients with improved insulin resistance,Sherief Abd-Elsalam|Tanta University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,dm 2,"April 1, 2019",December 2028,December 2028,"April 24, 2019",,"April 24, 2019","Sherief Abd-Elsalam, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT03925714
Study Director,Luis M Ruilope Urioste,Hospital Universitario 12 de Octubre de Madrid,,NCT03887416,luis m ruilope urioste,luis,male,0.99,176693,21,NCT03887416,Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes,,Recruiting,No Results Available,Type2 Diabetes,Drug: Dapagliflozin 10 MG Oral Tablet [Farxiga]|Drug: Placebo Oral Tablet,Changes in nighttime blood pressure|Changes in office blood pressure. Both systolic and diastolic blood pressure will be assessed|Changes in albuminuria|Changes in HBA1C,LM Diagnósticos S.L.|AstraZeneca,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,225,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,DAPA-ESR-16-12460|2017-002125-38,"April 12, 2019",February 2020,February 2020,"March 25, 2019",,"September 3, 2019","Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03887416/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03887416
Principal Investigator,"Mary Sevick, MD",New York Langone Health,,NCT04108299,mary sevick,mary,female,0.99,142684,22,NCT04108299,Family Intervention for Chinese Americans With Type 2 Diabetes,,Not yet recruiting,No Results Available,Type 2 Diabetes,Behavioral: Wait-list control group|Behavioral: SMS intervention,Feasibility of study intervention|Acceptability|HbA1c|Self-efficacy measured using Diabetes Management Self-Efficacy Scale (DMSES)|Diabetes Self-Management Questionnaire (DSMQ)|23-item Michigan Diabetes Knowledge Test,NYU Langone Health,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care",19-01275,"October 19, 2019",November 2019,November 2020,"September 30, 2019",,"September 30, 2019","NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04108299
Principal Investigator,Anne Karen Jenum,University of Oslo,,NCT03870724,anne karen jenum,anne,female,0.97,78727,23,NCT03870724,Women and Risk of Type 2 Diabetes,,Enrolling by invitation,No Results Available,Type 2 Diabetes Mellitus,,Type 2 diabetes,University of Oslo|Norwegian Diabetes Association,Female,27 Years to 60 Years   (Adult),,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2018/2517,"August 27, 2019",December 2020,December 2021,"March 12, 2019",,"January 21, 2020","University of Oslo, Faculty of Medicine, Institute of Health and Society, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT03870724
Principal Investigator,"Anne Zanchi, PhD-PD",CHUV (Centre hospitalier Universitaire Vaudois),,NCT04190251,anne zanchi,anne,female,0.97,78727,494,NCT04190251,"PANDIA IRIS: Patients With Diabetes and Kidney Failure, an Interdisciplinary Medication Adherence Support Program",PANDIA_IRIS,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Renal Insufficiency, Chronic",Other: Inteprofessional medication adherence support program (IMAP),Medication adherence (longitudinal data)|Clinical outcomes|Medication adherence|Patients' satisfaction,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland|pharmaSuisse|santésuisse|Curafutura",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PB_2016-01674(454/15),"April 14, 2016","August 30, 2020","October 1, 2022","December 9, 2019",,"December 9, 2019","Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland|Unisante, Lausanne, Vaud, Switzerland",,https://ClinicalTrials.gov/show/NCT04190251
Principal Investigator,"Marie-Paule Schneider, Prof.","Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",,NCT04190251,marie-paule schneider,marie-paule,female,0.98,1153,494,NCT04190251,"PANDIA IRIS: Patients With Diabetes and Kidney Failure, an Interdisciplinary Medication Adherence Support Program",PANDIA_IRIS,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Renal Insufficiency, Chronic",Other: Inteprofessional medication adherence support program (IMAP),Medication adherence (longitudinal data)|Clinical outcomes|Medication adherence|Patients' satisfaction,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland|pharmaSuisse|santésuisse|Curafutura",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PB_2016-01674(454/15),"April 14, 2016","August 30, 2020","October 1, 2022","December 9, 2019",,"December 9, 2019","Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland|Unisante, Lausanne, Vaud, Switzerland",,https://ClinicalTrials.gov/show/NCT04190251
Principal Investigator,"Carole Bandiera, PhD student","Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",,NCT04190251,carole bandiera,carole,female,0.98,31642,494,NCT04190251,"PANDIA IRIS: Patients With Diabetes and Kidney Failure, an Interdisciplinary Medication Adherence Support Program",PANDIA_IRIS,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Renal Insufficiency, Chronic",Other: Inteprofessional medication adherence support program (IMAP),Medication adherence (longitudinal data)|Clinical outcomes|Medication adherence|Patients' satisfaction,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland|pharmaSuisse|santésuisse|Curafutura",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PB_2016-01674(454/15),"April 14, 2016","August 30, 2020","October 1, 2022","December 9, 2019",,"December 9, 2019","Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland|Unisante, Lausanne, Vaud, Switzerland",,https://ClinicalTrials.gov/show/NCT04190251
Study Director,"Mehmet Uzunlulu, Prof",IMU Goztepe Education and Research Hospital,,NCT04005261,mehmet uzunlulu,mehmet,male,0.97,228228,26,NCT04005261,C-peptide Concentrations in Type 2 Diabetes Treated With Insulin; is it Time to Revise the Treatment of Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes Treated With Insulin,Diagnostic Test: C-peptide concentrations,"The incidence of adequate, borderline and insufficient beta cell reserves assessed by the fasting C-peptide concentrations|Correlations of fasting C-peptide concentrations with patients characteristics and biochemical findings",Goztepe Training and Research Hospital,All,"18 Years and older   (Adult, Older Adult)",,249,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,C-peptide2019,"November 1, 2018","February 1, 2019","March 1, 2019","July 2, 2019",,"July 2, 2019","IMU Goztepe Education and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04005261
Principal Investigator,"Weiqing Wang, MD,PHD",Ruijin Hospital,,NCT04164784,weiqing wang,weiqing,male,0.73,15,28,NCT04164784,"Effect of ""Therapeutic Monitoring"" on Blood Glucose Control in Type 2 Diabetes",,Not yet recruiting,No Results Available,Type2 Diabetes,Behavioral: therapeutic monitoring,HbA1c|TIR|Fasting glucose levels|Fasting c-peptide levels|Serum Triglycerides|Serum total Cholesterol|Serum HDL-c|Serum LDL-c|Body weight|Height|Blood pressure|Creatinine|Uric acid|UCAR,Shanghai Jiao Tong University School of Medicine,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,480,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Ruijin-20191101,"December 10, 2019","August 15, 2020","November 15, 2020","November 15, 2019",,"December 13, 2019","Ruijin hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04164784
Principal Investigator,"Marine HALBRON, MD",APHP,,NCT04155996,marine halbron,marine,female,0.96,36464,29,NCT04155996,Data Acquisition Study in Inadequately Balanced Patients With Type 2 Diabetes Mellitus,,Recruiting,No Results Available,Type2 Diabetes,Device: data collection,Data collection - Blood glucose levels|Data collection - Number of steps|Data collection - Sleep hours|Data collection - Daily meals information|Data collection - Physical activity information|Data collection - Medical treatment information,ValoTec|APHP,All,"35 Years and older   (Adult, Older Adult)",,20,Industry|Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,VTC-MLS-EC01,"January 20, 2019","December 31, 2019","December 31, 2019","November 7, 2019",,"November 13, 2019","GH Pitié Salpêtrière Charles Foix, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT04155996
Principal Investigator,"Leonard E Egede, MD",Medical College of Wisconsin,,NCT04181424,leonard e egede,leonard,male,0.99,7781,30,NCT04181424,Lowering the Impact of Food Insecurity in African American Adults With Type 2 Diabetes Mellitus (LIFT-DM),LIFT-DM,"Active, not recruiting",No Results Available,Type 2 Diabetes,Behavioral: Diabetes Education Plus Monthly Food Vouchers|Behavioral: Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes|Behavioral: Diabetes Education Only|Behavioral: Diabetes Education Plus Monthly Stock Boxes,Glycemic control (HbA1c)|Quality of Life as measured by the SF-12|LDL-Cholesterol|Blood Pressure,Medical College of Wisconsin,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",5R01MD013826,"December 15, 2019","December 31, 2023","December 31, 2023","November 29, 2019",,"May 6, 2020","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04181424
Principal Investigator,"Rebekah J Walker, PhD",Medical College of Wisconsin,,NCT04181424,rebekah j walker,rebekah,female,0.99,604,30,NCT04181424,Lowering the Impact of Food Insecurity in African American Adults With Type 2 Diabetes Mellitus (LIFT-DM),LIFT-DM,"Active, not recruiting",No Results Available,Type 2 Diabetes,Behavioral: Diabetes Education Plus Monthly Food Vouchers|Behavioral: Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes|Behavioral: Diabetes Education Only|Behavioral: Diabetes Education Plus Monthly Stock Boxes,Glycemic control (HbA1c)|Quality of Life as measured by the SF-12|LDL-Cholesterol|Blood Pressure,Medical College of Wisconsin,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",5R01MD013826,"December 15, 2019","December 31, 2023","December 31, 2023","November 29, 2019",,"May 6, 2020","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04181424
Principal Investigator,"Leonard E Egede, MD, MS",Medical College of Wisconsin,,NCT04203173,leonard e egede,leonard,male,0.99,7781,156,NCT04203173,Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1,FINANCE-DM,"Active, not recruiting",No Results Available,Type 2 Diabetes,Behavioral: FINANCE-DM|Behavioral: Active Comparator,Glycemic control (HbA1c)|Resource Utilization and Cost|LDL-Cholesterol|Quality of Life as measured by SF-12|Systolic and Diastolic Blood Pressure|Self-Care Behavior|Self-Care Behavior Brooks Medication Adherence Scale (BMAS),Medical College of Wisconsin,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,450,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",1R01DK120861,"December 1, 2019","March 31, 2024","March 31, 2024","December 18, 2019",,"May 6, 2020","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04203173
Principal Investigator,"Leonard E Egede, MD, MS",Medical College of Wisconsin,,NCT04203147,leonard e egede,leonard,male,0.99,7781,157,NCT04203147,Home-based Diabetes-Modified Behavioral Activation Treatment for Low Income Seniors With T2DM,HOME DM-BAT,Suspended,No Results Available,Type 2 Diabetes,Behavioral: Supportive Therapy (Control)|Behavioral: Home DM-BAT,LDL-Cholesterol|Systolic and Diastolic Blood Pressure|Glycemic control (HbA1c)|Quality of Life as measured by SF-12|Self-Care Behaviors,Medical College of Wisconsin,All,65 Years and older   (Older Adult),Not Applicable,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",1R01DK118038-01A1,"January 3, 2020","January 31, 2024","January 31, 2024","December 18, 2019",,"May 6, 2020","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04203147
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT03861052,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,33,NCT03861052,A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes,SURPASS J-mono,"Active, not recruiting",No Results Available,Type 2 Diabetes,Drug: Tirzepatide|Drug: Dulaglutide,Change from Baseline in Hemoglobin A1c (HbA1c)|Percentage of Participants with HbA1c of <7.0%|Change from Baseline in Fasting Serum Glucose|Change from Baseline in Average 7-Point Self-Monitored Blood Glucose (SMBG) Values|Change from Baseline in Body Weight|Percentage of Participants who Achieve Weight Loss ≥5% from Baseline|Change from Baseline in Fasting Insulin|Change from Baseline in Fasting C-Peptide|Change from Baseline in Homeostasis Model Assessment B (HOMA-2B)|Change from Baseline in HOMA-2S|Rate of Total Hypoglycemia|Number of Participants with Anti-Tirzepatide Antibodies,Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 3,636,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",17077|I8F-JE-GPGO,"May 7, 2019","March 17, 2021","April 14, 2021","March 4, 2019",,"April 22, 2020","Medical corporation THY Tokuyama Clinic, Chiba Mihama-ku, Chiba, Japan|Akaicho Clinic, Chiba-shi, Chiba, Japan|National Hospital Organization Kure Medical Center, Kure, Hiroshima, Japan|Hasegawa Medicine Clinic, Chitose, Hokkaido, Japan|Yuri Ono Clinic, Sapporo, Hokkaido, Japan|Watanabe Naika Clinic, Nishinomiya, Hyogo, Japan|Hayashi Clinic, Nishinomiya, Hyogo, Japan|Naka Memorial Clinic, Naka, Ibaraki, Japan|Hayashi Diabetes Internal Medicine, Chigasaki-sh, Kanagawa, Japan|Matoba Diabetes Clinic, Ebina, Kanagawa, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Kanto Rosai Hospital, Kawasaki, Kanagawa, Japan|Yokohama Minoru Clinic, Yokohama, Kanagawa, Japan|H.E.C. Science Clinic, Yokohama, Kanagawa, Japan|OCROM Clinic, Suita, Osaka, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Senrichuo Ekimae Clinic, Toyonaka, Osaka, Japan|Asano Clinic, Kawagoe, Saitama, Japan|Kawaguchi General Hospital, Kawaguchi, Saitama, Japan|Wakakusa Clinic, Shimotsuke, Tochigi, Japan|Seiwa Clinic, Adachi-ku, Tokyo, Japan|Meiwa Hospital, Chiyodaku, Tokyo, Japan|HDC Atlas Clinic, Chiyoda, Tokyo, Japan|Asahi Life Foundation Adult Disease Research Center, Chuo-ku, Tokyo, Japan|Nihonbashi Sakura Clinic, Chuo-ku, Tokyo, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku, Tokyo, Japan|IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan|Sato Naika Clinic, Ota-ku, Tokyo, Japan|Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku, Tokyo, Japan|Tomonaga Clinic, Shinjuku-ku, Tokyo, Japan|Shinjuku Research Park Clinic, Shinjuku-Ku, Tokyo, Japan|Shinei Clinic, Suginami, Tokyo, Japan|Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan|Futata Tetsuhiro Clinic, Fukuoka, Japan|JR Hiroshima Hospital, Hiroshima, Japan|Yoshimura Clinic, Kumamoto, Japan|Keiseikai Kajiyama Clinic, Kyoto, Japan|Abe Diabetes Clinic, Oita, Japan|OKAYAMA Medical Center, Okayama, Japan|AMC nishi-umeda clinic, Osaka, Japan|Kitada Clinic, Osaka, Japan|Nanko Clinic, Osaka, Japan|Suruga Clinic, Shizuoka, Japan",,https://ClinicalTrials.gov/show/NCT03861052
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT03987919,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,42,NCT03987919,A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes,SURPASS-2,"Active, not recruiting",No Results Available,Type 2 Diabetes,Drug: Tirzepatide|Drug: Semaglutide,Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)|Change from Baseline in HbA1c (5 mg)|Change from Baseline in Body Weight|Percentage of Participants Achieving an HbA1c Target Value of <7%|Change from Baseline in Fasting Serum Glucose|Mean Change from Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values|Percentage of Participants who Achieved Weight Loss ≥5%|Change from Baseline in Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Rate of Documented Symptomatic Hypoglycemic Episodes,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1872,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17001|I8F-MC-GPGL|2018-004422-29,"July 30, 2019","January 26, 2021","February 23, 2021","June 17, 2019",,"June 4, 2020","Cahaba Research, Birmingham, Alabama, United States|Syed Research Consultants, LLC, Sheffield, Alabama, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|National Research Institute, Panorama City, California, United States|Artemis Institute for Clinical Research, Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Chase Medical Research, LLC, Hamden, Connecticut, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|East Coast Institute For Research, Lake City, Florida, United States|South Florida Wellness & Clinical Research Institute, Margate, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|South Broward Research LLC, Pembroke Pines, Florida, United States|United Osteoporosis Center, Gainesville, Georgia, United States|Sky Clinical Research Network, Union City, Georgia, United States|Elite Clinical Trials LLLP, Blackfoot, Idaho, United States|University of Iowa Hospital & Clinic, Iowa City, Iowa, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Cotton O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, United States|NECCR PrimaCare Research, LLC, Fall River, Massachusetts, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Clinvest Research LLC, Springfield, Missouri, United States|Premier Research, Trenton, New Jersey, United States|Endocrine Group, LLP, Albany, New York, United States|PharmQuest, Greensboro, North Carolina, United States|Diabetes & Endocrinology Consultants PC, Morehead City, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Aventiv Research, Columbus, Ohio, United States|Intend Research, Norman, Oklahoma, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Capital Area Research, Camp Hill, Pennsylvania, United States|Detweiler Family Medicine, Lansdale, Pennsylvania, United States|Green & Seidner Family Practice Associates PC, Lansdale, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Preferred Primary Care Physicians- Bower Hill, Pittsburgh, Pennsylvania, United States|Holston Medical Group, Bristol, Tennessee, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Biopharma Informatic, Inc., Houston, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Carl R. Meisner Medical Clinic, PLLC, Sugar Land, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Capital Clinical Research Center, Olympia, Washington, United States|Vancouver Clinic, Vancouver, Washington, United States|Centro de Investigaciones Metabólicas (CINME), Caba, Buenos Aires, Argentina|Investigaciones Medicas IMOBA S.R.L., Caba, Buenos Aires, Argentina|Centro Medico Dr Laura Maffei Investigacion Clinica Aplicada, Caba, Buenos Aires, Argentina|CEDIC-Centro de Investigaciones Clinicas, Caba, Buenos Aires, Argentina|Mautalen Salud e Investigacion-Centro de Osteopatías Médicas, Ciudad Autonoma De Buenos Air, Buenos Aires, Argentina|Centro de Investigacion y Prevencion Cardiovascular (CIPREC), Ciudad Autonoma de, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|CIPADI, Godoy Cruz, Mendoza, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Buenos Aire, Argentina|Instituto Centenario, Ciudad Autonoma de Buenos Aire, Argentina|Cemediab - Centro Médico Diabetológico Dr. Alejandro Chertkoff, Ciudad Autonoma de Buenos Aire, Argentina|Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina|Sanatorio Norte, Santiago del Estero, Argentina|Paratus Clinical Blacktown Clinic, Blacktown, New South Wales, Australia|Campbelltown Medical & Dental Centre, Campbelltown, New South Wales, Australia|Paratus Clinical Kanwal Clinic, Kanwal, New South Wales, Australia|Holdsworth House Medical Practice, Sydney, New South Wales, Australia|GenesisCare - Bundaberg, Bundaberg, Queensland, Australia|Royal Brisbane and Womens Hospital, Herston, Queensland, Australia|CORE Research Group Pty Ltd, Milton, Queensland, Australia|AusTrials Pty Ltd, Taringa, Queensland, Australia|Eastern Clinical Research Unit, Box Hill, Victoria, Australia|Barwon Health - The Geelong Hospital, Geelong, Victoria, Australia|GenesisCare Joondalup WA, Joondalup, Western Australia, Australia|GenesisCare - Wexford Medical Centre WA, Murdoch, Western Australia, Australia|Adelaide Medical Solutions, Woodville South, Australia|Cedoes Centro Diagnostico Pequisa Osteoporose E Santo Ltd, Vitoria, ES, Brazil|Centro de Pesquisas em Diabetes, Porto Alegre, Rio Grande Do Sul, Brazil|CPQuali Pesquisa Clínica Ltda., São Paulo, SP, Brazil|Cpclin Centro de Pesquisas Clinicas, São Paulo, SP, Brazil|CEPIC-Centro Paulista de Investigacao Clinica, São Paulo, SP, Brazil|ISPEM - Instituto São José dos Campos em Pesquisas Médicas, São José dos Campos, Brazil|Dr. Consulta Clínica Médica LTDA, São Paulo, Brazil|Manna Research, Inc., Burlington, Ontario, Canada|Milestone Research Inc., London, Ontario, Canada|Manna Research, Inc., Nepean, Ontario, Canada|Bluewater Clinical Research Group Inc, Sarnia, Ontario, Canada|Manna Research, Inc., Stoney Creek, Ontario, Canada|Dr. Anil K. Gupta Medicine Professional Corporation, Toronto, Ontario, Canada|Manna Research, Inc., Toronto, Ontario, Canada|Manna Research (Quebec), Levis, Quebec, Canada|Meir Medical Center, Kfar Saba, HaMerkaz, Israel|Clalit Health Services - Shuali Clinic, Raanana, HaMerkaz, Israel|Sheba Medical Center, Ramat Gan, HaMerkaz, Israel|Hadassah Medical Center, Jerusalem, Yerushalayim, Israel|Sakhnin Community Clinic, Clalit Health Services, Sakhnin, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv Jaffa, Israel|Diabetes Medical Center (DMC), Tel Aviv, Israel|Rambam Health Care Campus, Haifa, Ḥeifā, Israel|Linn Medical Center, Haifa, Ḥeifā, Israel|Centro Especializado en Diabetes Obesidad y Enfermedades, Mexico, D.f., Mexico|Diseno y Planeacion en Investigacion Medica S.C., Guadalajara, Jalisco, Mexico|Unidad de Investigacion Clinica, Guadalajara, Jalisco, Mexico|Instituto Jalisciense de Investigacion en Diabetes y Obesida, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, N.l., Mexico|Unidad Medica para la Salud Integral (UMSI), San Nicolás de los Garza, Nuevo León, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasc, Ciudad Madero, Tamaulipas, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|Paola Mansilla-Letelier, MD, Guaynabo, Puerto Rico|Ararat Research Center, Ponce, Puerto Rico|Research and Cardiovascular Corp., Ponce, Puerto Rico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|Martha Gomez Cuellar M.D., San Juan, Puerto Rico|Oldfield Surgery, Bath, Avon, United Kingdom|The Staploe Medical Centre, Ely, Cambridgeshire, United Kingdom|Fowey River Practice, Fowey, Cornwall, United Kingdom|Oak Tree Surgery, Liskeard, Cornwall, United Kingdom|Rame Medical Ltd, Torpoint, Cornwall, United Kingdom|Ashgate Medical Practice, Chesterfield, Derbyshire, United Kingdom|Knowle House Surgery, Plymouth, Devon, United Kingdom|Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom|Lister Hospital, Stevenage, Herts, United Kingdom|Oakenhurst Medical Practice, Blackburn, Lancashire, United Kingdom|Leicester General Hospital, Leicester, Leicestershire, United Kingdom|University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Warwickshire, United Kingdom|Rowden Surgery, Chippenham, United Kingdom|Wickersley Health Centre - Clifton Medical Centre, Rotherham, United Kingdom",,https://ClinicalTrials.gov/show/NCT03987919
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT04093752,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,43,NCT04093752,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo),,Recruiting,No Results Available,Type 2 Diabetes,Drug: Tirzepatide|Drug: Insulin Glargine,Mean Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)|Mean Change from Baseline in HbA1c (5 mg)|Mean Change from Baseline in Body Weight|Mean Change from Baseline in HbA1c|Percentage of Participants Achieving an HbA1c Target Value of <7.0%|Mean Change from Baseline in Fasting Serum Glucose|Mean Change from Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values|Percentage of Participants who Achieved Weight Loss ≥5%|Change from Baseline in Patient-Reported Outcomes as Measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Rate of Documented Symptomatic Hypoglycemic Episodes,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,956,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17210|I8F-MC-GPHO,"December 9, 2019","February 10, 2022","March 10, 2022","September 18, 2019",,"June 4, 2020","Paratus Clinical Blacktown Clinic, Blacktown, New South Wales, Australia|Campbelltown Medical & Dental Centre, Campbelltown, New South Wales, Australia|Paratus Clinical Kanwal Clinic, Kanwal, New South Wales, Australia|Holdsworth House Medical Practice, Sydney, New South Wales, Australia|Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia|Barwon Health - The Geelong Hospital, Geelong, Victoria, Australia|Adelaide Medical Solutions, Woodville South, Australia|The Second People's Hospital of Hefei, Hefei, Anhui, China|Peking University Peoples Hospital, Beijing, Beijing, China|Huizhou Municipal Central Hospital, Huizhou, Guangdong, China|CANGZHOU People's Hospital, Cangzhou, Hebei, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The 1st Affiliated Hospital of Henan Science and technology, Luoyang, Henan, China|Wuhan Union (Xiehe) Hospital, Wuhan, Hubei, China|The First People Hospital of Yueyang, Yueyang, Hunan, China|Baotou Central Hospital, Bao Tou, Inner Mongolia, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|The Affliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China|The First Hospital of Nanjing, Nanjing, Jiangsu, China|Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med, Nanjing, Jiangsu, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Nanjing Jiangning Hospital, Nanjing, Jiangsu, China|Suzhou Municipal Hospital, Suzhou, Jiangsu, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China|The First Hospital of Jilin University, Changchun, Jilin, China|Dalian University - The Affiliated Zhongshan Hospital, Dalian, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|1st affiliated Hospital of Shanxi Medical University, Tai Yuan, Shan XI, China|Jinan Central Hospital, Jinan, Shandong, China|Qingdao Central Hospital, Qingdao, Shandong, China|Shanghai 6th People's Hospital Affiliated to Jiao Tong, Shanghai, Shanghai, China|Shanghai Tongren Hospital, Shanghai, Shanghai, China|The First Affiliated Hospital of Xi'an Medical University, XI 'an, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Chengdu Fifth People's Hospital, Chengdu, Sichuan, China|Chongqing Three Gorges Central Hospital, Chongqing, Wanzhou, China|Chongqing General Hospital, Chongqing, Yuzhong District, China|Huzhou Central Hospital, Huzhou, Zhejiang, China|Shaoxing People's Hospital, Shaoxing, Zhejiang, China|Peking Union Medical College Hospital, Beijing, China|Beijing Pinggu Hospital, Beijing, China|Beijing Tsinghua Changgung Hospital, Beijing, China|The Third Hospital of Nanchang, Nanchang, China|Pingxiang People's Hospital, Pingxiang, China|Shanghai Putuo District Center Hospital, Shanghai, China|Shanghai Yangpu District Central Hospital, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China|Tianjin People's Hospital, Tianjin, China|The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China|The Fourth People's Hospital of Zigong City, Zigong, China|King Edward Memorial Hospital and Research Center, Mumbai, Maharashtra, India|BSES Municipal General Hsptl, Mumbai, Maharashtra, India|Apollo Gleneagles Hospitals, Kolkata, West Bengal, India|Fortis Hospital, New Delhi, India|Kyung Hee University Hospital, Seoul, Gangdong-gu, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Geonggi-do, Korea, Republic of|Bucheon St. Mary's Hospital, Bucheon,, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggido, Korea, Republic of|Yonse University Wonju Severance Christian Hospital, Gangwon-do, Kang Won-do, Korea, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Korea University Anam Hospital, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Taegu-Kwangyǒkshi, Korea, Republic of|Korea University Ansan Hospital, Kyunggi-Do, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04093752
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT04039503,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,45,NCT04039503,A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin,SURPASS-5,"Active, not recruiting",No Results Available,Type 2 Diabetes,Drug: Tirzepatide|Drug: Placebo,Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)|Change from Baseline in HbA1c|Change from Baseline in Body Weight|Percentage of Participants Achieving an HbA1c Target Value of <7%|Change from Baseline in Fasting Serum Glucose|Mean Change from Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values|Percentage of Participants who Achieved Weight Loss ≥5%|Change from Baseline in Daily Mean Insulin Glargine Dose|Rate of Documented Symptomatic Hypoglycemic Episodes|Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,472,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",16998|I8F-MC-GPGI|2019-000860-99,"August 30, 2019","January 25, 2021","January 25, 2021","July 31, 2019",,"June 4, 2020","Valley Endocrine, Fresno, Fresno, California, United States|Sun Coast Clinical Research, Inc, New Port Richey, Florida, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Manhattan Medical Research, New York, New York, United States|Intend Research, Norman, Oklahoma, United States|Milan Kvapil s.r.o., Pribram, Středočeský Kraj, Czechia|Diacentrum Brandys n.L. s.r.o., Brandys Nad Labem-Stara Bolesl, Czechia|Diabetologicka ordinace pro dospele, Krnov, Czechia|Diahelp s.r.o., Interni a diabetologicka ambulance, Pardubice, Czechia|Lekarna Dr. Max, Praha 1, Czechia|Milan Kvapil s.r.o., Praha 4, Czechia|RESTRIAL s.r.o., Praha 8, Czechia|Praxis Dr. Jörg Lüdemann, Falkensee, Brandenburg, Germany|Arztpraxis Dr. Cornelia Marck, Pohlheim, Hessen, Germany|InnoDiab Forschung GmbH, Essen, Nordrhein-Westfalen, Germany|Institut für Diabetesforschung Münster GmbH, Münster, Nordrhein-Westfalen, Germany|Praxis Dr. Kempe - Dr. Stemler, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany|Schwerpunktpraxis Diabetes, Saint Ingbert-Oberwürzbach, Saarland, Germany|SMO.MD GmbH, Magdeburg, Sachsen-Anhalt, Germany|RED-Institut GmbH, Oldenburg in Holstein, Schleswig Holstein, Germany|Diabetologische Schwerpunktpraxis B. Scholz/Dr. B. Paschen, Hamburg, Germany|Gemeinschaftspraxis für innere Medizin und Diabetologie, Hamburg, Germany|Kashiwa hospital, Kashiwa, Chiba, Japan|Manda Hospital, Sapporo, Hokkaido, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku, Tokyo, Japan|The Institute for Adult Diseases, Asahi Life Foundation, Chuou-ku, Tokyo, Japan|Sato Naika Clinic, Ota-ku, Tokyo, Japan|Jinnouchi Hospital, Kumamoto, Japan|Centrum Medyczne AMED, Warszawa, Mazowieckie, Poland|NZOZ ZDROWIE Osteo-Medic, Bialystok, Podlaskie, Poland|Centrum Badan Klinicznych, PI House, Gdansk, Pomorskie, Poland|NZOZ Przychodnia Specjalistyczna MEDICA, Lublin, Poland|Centro de Endocrinologia y Nutricion del Turabo, Caguas, Puerto Rico|Manati Center for Clinical Research Inc, Manati, Puerto Rico|Ambulancia vnútorného lekárstva Hnúša (Diabetes care), Hnusta, Slovakia|Sin Azucar, Malacky, Slovakia|Dia-Clarus.s.r.o., Prievidza, Slovakia|JAL, Trnava, Slovakia|Medivasa, s.r.o., Zilina, Slovakia|Hospital Clinico Universitario Virgen de la Victoria, Malaga, Andalucia, Spain|Hospital de la Ribera, Alcira, Valencia, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Infanta Luisa, Sevilla, Spain|Hospital Universitari i Politecnic La Fe-ENDO, València, Spain",,https://ClinicalTrials.gov/show/NCT04039503
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT04153981,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,55,NCT04153981,A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India,,Suspended,No Results Available,Type 2 Diabetes Mellitus,Drug: Insulin Glargine,Number or Participants with Hypoglycemic Events|Basal Insulin Dose|Change from Baseline in Body Weight|Change from Baseline in Hemoglobin A1c (HbA1c)|Change from Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values|Change from Week 4 in Insulin Treatment Satisfaction Questionnaire (ITSQ),Eli Lilly and Company,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,250,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17225|I4L-IN-ABEX,"December 16, 2019","December 30, 2020","December 30, 2020","November 6, 2019",,"May 19, 2020","Sir Ganga Ram Hospital, New Delhi, Delhi, India|DIACARE, Ahemdabad, Gujarat, India|Gujarat Endocrine Center, Ahmedabad, Gujarat, India|Nirmal Hospital Private Limited, Surat, Gujarat, India|Government Medical College & Sir Sayajirao General Hospital, Vadodara, Gujarat, India|Sumandeep Vidhyapeeth & Dhiraj General Hospital, Vadodara, Gujarat, India|Bangalore Diabetes Center, Bangalore, Karnataka, India|Supe Heart & Diabetes Hospital & Research Centre, Nasik, Maharashtra, India|GSVM Medical College, Kanpur, Uttar Pradesh, India|Popular Hospital, Varanasi, Uttar Pradesh, India|Maharaja Agrasen Hospital, New Delhi, India",,https://ClinicalTrials.gov/show/NCT04153981
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT03952143,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,61,NCT03952143,A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes,,Suspended,No Results Available,Type 2 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro|Drug: Insulin Glargine|Drug: Insulin Degludec,"Change from Baseline in Hemoglobin A1c (HbA1c)|1-hour Postprandial Glucose (PPG) Excursion during Mixed-Meal Tolerance Test (MMTT)|2-hour PPG Excursion during MMTT|Rate of Severe Hypoglycemia|Rate of Documented Symptomatic Postmeal Hypoglycemia|Change From Baseline in 1,5-Anhydroglucitol (1,5-AG)|Change from Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values|Change from Baseline in Insulin Dose|Proportion of Participants with HbA1c <7% and ≤6.5%",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,564,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",16830|I8B-FH-ITSE,"May 27, 2019","February 1, 2021","February 1, 2021","May 16, 2019",,"June 5, 2020","Centro de Investigaciones Metabólicas (CINME), Caba, Buenos Aires, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Buenos Aire, Argentina|Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|CANGZHOU People's Hospital, Cangzhou, Hebei, China|First hospital of Qinhuangdao, Qinhuangdao, Hebei, China|Xingtai People's Hospital, Xingtai, Hebei, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The First Hospital of Qiqihar, Qiqihar, Heilongjiang, China|The 1st Affiliated Hospital of Henan Science and technology, Luoyang, Henan, China|Wuhan Pu'ai Hospital, Wuhan, Hubei, China|Wuhan Central Hospital, Wuhan, Hubei, China|Yichang central people's hospital, Yichang, Hubei, China|Chenzhou NO.1 People's Hospital, Chenzhou, Hunan, China|The First People Hospital of Yueyang, Yueyang, Hunan, China|Inner Monglia People's Hospital, Hohhot, Inner Mongolia, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|The Affliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|The First Hospital of Nanjing, Nanjing, Jiangsu, China|Nanjing Jiangning Hospital, Nanjing, Jiangsu, China|Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China|China-Japan Union Hospital, CJUH., Changchun, Jilin, China|Siping central people's hospital, Siping, Jilin, China|Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|Qinghai University Affiliated Hospital, Xining, Qinghai, China|Jinan Central Hospital, Jinan, Shandong, China|Shanghai 6th People's Hospital Affiliated to Jiao Tong, Shanghai, Shanghai, China|The First Affiliated Hospital of Xi'an Medical University, XI 'an, Shanxi, China|Chongqing General Hospital, Chongqing, Yuzhong District, China|Peking Union Medical College Hospital, Beijing, China|Beijing Pinggu Hospital, Beijing, China|The Third Hospital of Nanchang, Nanchang, China|Pingxiang People's Hospital, Pingxiang, China|Shanghai Putuo District Center Hospital, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China|Unidad de patologia Clinica, Guadalajara, Jalisco, Mexico|Centro de Inv. Medica de Occidente, SC, Zapopan, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, N.l., Mexico|Unidad Medica para la Salud Integral (UMSI), Monterrey, Nuevo León, Mexico",,https://ClinicalTrials.gov/show/NCT03952143
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT03882970,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,63,NCT03882970,A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes,SURPASS-3,"Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus,Drug: Tirzepatide|Drug: Insulin Degludec,Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)|Change from Baseline in HbA1c|Change from Baseline in Body Weight|Change from Baseline in Fasting Serum Glucose|Percentage of Participants Achieving an HbA1c Target Value of <7%|Change from Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values|Percentage of Participants who Achieved Weight Loss ≥5%|Change from Baseline in Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Rate of Documented Symptomatic Hypoglycemic Episodes,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1420,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16997|I8F-MC-GPGH|2018-003422-84,"April 1, 2019","December 11, 2020","January 8, 2021","March 20, 2019",,"February 5, 2020","Arkansas Clinical Research, Little Rock, Arkansas, United States|Valley Research, Fresno, California, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|National Research Institute, Panorama City, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|East Coast Clinical Research, Jacksonville, Florida, United States|East Coast Institute For Research, Jacksonville, Florida, United States|Bayside Clinical Research, LLC, New Port Richey, Florida, United States|East Coast Institute For Research, Macon, Georgia, United States|Sky Clinical Research Network, Union City, Georgia, United States|Elite Clinical Trials LLLP, Blackfoot, Idaho, United States|Humphreys Diabetes Center, Boise, Idaho, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Springfield Diabetes & Endocrine Center, Springfield, Illinois, United States|Crescent City Clinical Research, Metairie, Louisiana, United States|Endocrine and Metabolic Consultants, Rockville, Maryland, United States|Troy Internal Medicine, PC, Troy, Michigan, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Palm Research Center, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Aventiv Research, Columbus, Ohio, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Detweiler Family Medicine, Lansdale, Pennsylvania, United States|Office of Dr. Osvaldo Brusco, Corpus Christi, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Mautalen Salud e Investigación - Servicio de Endocrinología, Caba, Buenos Aires, Argentina|Investigaciones Medicas IMOBA S.R.L., Caba, Buenos Aires, Argentina|CEDIC-Centro de Investigaciones Clinicas, Caba, Buenos Aires, Argentina|Centro de Investigacion y Prevencion Cardiovascular (CIPREC), Ciudad Autonoma de, Buenos Aires, Argentina|CIPADI, Godoy Cruz, Mendoza, Argentina|AXISMED SRL - Bioclinica Research Network, Buenos Aires, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Buenos Aire, Argentina|Instituto Centenario, Ciudad Autonoma de Buenos Aire, Argentina|CENUDIAB, Ciudad Autonoma de Buenos Aire, Argentina|Landesklinikum Korneuburg-Stockerau, Standort Stockerau, Stockerau, Niederösterreich, Austria|Universitätsklinikum Graz, Graz, Steiermark, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|KA Rudolfstiftung, Wien, Austria|Iatriko Palaiou Falirou, Medical Center, Palaio Faliro, Athens, Greece|Laiko General Hospital of Athens, Ampelokipoi, Attica, Greece|Gen Hospital of Athens G Gennimatas, Athens, Attiki, Greece|General Hospital of Thessaloniki Papageorgiou, N. Efkarpia, Thessaloniki, Greece|Thermi Clinic, Thermi, Thessaloniki, Greece|Athens Euroclinic, Athens, Greece|University General Hospital of Larissa, Larissa, Greece|AHEPA Hospital, Thessaloniki, Greece|Ippokrateio General Hospital of Thessaloniki, Thessaloniki, Greece|Euromedica - General Clinic of Thessaloniki, Thessaloniki, Greece|Kenezy Gyula Korhaz es Rendelointezet, Debrecen, Hajdu-Bihar, Hungary|Szent Margit Rendelointezet, Budapest, Hungary|ClinDiab Kft., Budapest, Hungary|XIII.ker Onkormanyzat Egeszsegugyi Szolgalat, Budapest, Hungary|Strazsahegy Medicina Bt., Budapest, Hungary|TRANTOR 99 Bt., Budapest, Hungary|Kanizsai Dorottya Korhaz, Nagykanizsa, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|Azienda ospedaliero-universitaria Mater Domini, Germaneto, Catanzaro, Italy|Policlinico Univ. Agostino Gemelli, Roma, Lazio, Italy|Centro Cardiologico Monzino, IRCCS, Milano, MI, Italy|Azienda Ospedaliera Policlinico Consorziale, Bari, Italy|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Ospedale Santa Maria Goretti, Latina, Italy|Bucheon St. Mary's Hospital, Bucheon,, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggido, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Korea, Republic of|Korea University Ansan Hospital, Ansan-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Kyunghee University Hospital at Gangdong, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Ambulatorium Barbara Bazela, Elblag, Warminsko-Mazurki, Poland|NZOZ ZDROWIE Osteo-Medic, Bialystok, Poland|Poradnia Diabetologiczna SN ZOZ Lege Artis, Bialystok, Poland|NZOZ Diab-Endo-Met, Krakow, Poland|Gabinet Lekarski Malgorzata Saryusz-Wolska, Lodz, Poland|Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A., Lodz, Poland|NZOZ Przychodnia Specjalistyczna MEDICA, Lublin, Poland|NZOZ Przychodnia Specjalistyczna Henryk RudzkiAndrzej Wittek, Ruda Slaska, Poland|Latin Clinical Trial Center, San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|San Miguel Medical, Trujillo Alto, Puerto Rico|S. C. Grandmed S.R.L., Str., Oradea, Bihor, Romania|Spitalul Judetean de Urgenta Satu Mare, Satu-Mare, Jud Satu-Mare, Romania|SC Diamed Obesity SRL, Galati, Judetul Galati, Romania|CMI DNBM Dr. Pop Lavinia, Baia Mare, Maramures, Romania|Cosamext SRL, Targu Mures, Mures, Romania|Societatea Civila Medicala ""Dr. Paveliu"", Bucuresti, Sect.5, Romania|Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL, Brasov, Romania|Cabinetul Medical Nicodiab SRL, Bucharest, Romania|SC Nutrilife SRL, Bucuresti, Romania|Consultmed SRL, Iasi, Romania|Hospital Infanta Luisa, Sevilla, Andalucía, Spain|Hospital Universitario Marques De Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Quiron Madrid, Pozuelo de Alarcon, Madrid, Spain|Instituto de Ciencias medicas, Alicante, Spain|Hospital Clinico Universitario San Cecilio, Granada, Spain|Clinica Juaneda, Palma de Mallorca, Spain|Clinica Nuevas Tecnologias en Diabetes y Endocrinologia, Seville, Spain|Policlinica Galileo, Teruel, Spain|Changhua Christian Hospital, Changhua, Taiwan|Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung City, Taiwan|Taipei Medical University- Shuang Ho Hospital, New Taipei, Taiwan|Chung Shan Medical University Hospital, Taichung City, Taiwan|Kuang Tien General Hospital, Taichung County, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi-Mei Medical Center, Tainan City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Dnipro City Clinical Hospital #9, Dnipro, Ukraine|V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine, Kyiv, Ukraine|Communal Institution ""Poltava Reg.Cl.H. n.a.M.V.Sklifosovskogo"", Poltava, Ukraine|Vinnytsia Regional Clinical Highly Specialized Endocrinology Center, Vinnytsia, Ukraine",,https://ClinicalTrials.gov/show/NCT03882970
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT03861039,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,64,NCT03861039,A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes,,"Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus,Drug: Tirzepatide,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Change from Baseline in Hemoglobin A1c (HbA1c)|Percentage of Participants who Achieve HbA1c <7%|Change from Baseline in Fasting Serum Glucose|Change from Baseline in Average 7-Point Self-Monitored Blood Glucose (SMBG) Values|Change from Baseline in Body Weight|Percentage of Participants who Achieve Weight Loss of ≥5% from Baseline|Change from Baseline in Fasting Insulin|Change from Baseline in Fasting C-Peptide|Change from Baseline in Homeostasis Model Assessment B (HOMA-2B)|Change from Baseline in HOMA-2S|Rate of Total Hypoglycemia|Number of Participants with Anti-Tirzepatide Antibodies,Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 3,441,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17078|I8F-JE-GPGP,"March 30, 2019","February 2, 2021","March 2, 2021","March 4, 2019",,"March 17, 2020","Akaicho Clinic, Chiba-shi, Chiba, Japan|Kashiwa hospital, Kashiwa, Chiba, Japan|Yuri Ono Clinic, Sapporo, Hokkaido, Japan|Manda Hospital, Sapporo, Hokkaido, Japan|Miyanomori Hospital, Sapporo, Hokkaido, Japan|Ikeda Hospital, Amagasaki, Hyogo, Japan|Nakamoto Naika Clinic, Mito, Ibaraki, Japan|Naka Memorial Clinic, Naka, Ibaraki, Japan|Ohishi Naika Clinic, Tsuchiura, Ibaraki, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Tsuruma Kaneshiro Diabetes Clinic, Yamato, Kanagawa, Japan|Yokohama Minoru Clinic, Yokohama, Kanagawa, Japan|H.E.C. Science Clinic, Yokohama, Kanagawa, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Otsu City Hospital, Otsu, Shiga, Japan|Wakakusa Clinic, Shimotsuke, Tochigi, Japan|Seiwa Clinic, Adachi-ku, Tokyo, Japan|HDC Atlas Clinic, Chiyoda, Tokyo, Japan|Asahi Life Foundation Adult Disease Research Center, Chuo-ku, Tokyo, Japan|Nihonbashi Sakura Clinic, Chuo-ku, Tokyo, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku, Tokyo, Japan|Kanno Naika, Mitaka, Tokyo, Japan|Shinjuku Research Park Clinic, Shinjuku-Ku, Tokyo, Japan|Futata Tetsuhiro Clinic, Fukuoka, Japan|Morinaga Ueno Clinic, Kumamoto, Japan|Jinnouchi Hospital, Kumamoto, Japan|Abe Diabetes Clinic, Oita, Japan|Saiseikai Noe Hospital, Osaka, Japan|Kitada Clinic, Osaka, Japan|Kansai Denryoku Hospital, Osaka, Japan|Shizuoka City Shizuoka Hospital, Shizuoka, Japan|Suruga Clinic, Shizuoka, Japan",,https://ClinicalTrials.gov/show/NCT03861039
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT03954834,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,67,NCT03954834,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone,SURPASS-1,"Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus,Drug: Tirzepatide|Drug: Placebo,Change from Baseline in Hemoglobin A1c (HbA1c)|Change from Baseline in Body Weight|Percentage of Participants with HbA1c Target Value of <7%|Change from Baseline in Fasting Serum Glucose|Percentage of Participants with HbA1c Target Value of <5.7%|Mean Change from Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values|Percentage of Participants who Achieved Weight Loss ≥5%|Rate of Documented Symptomatic Hypoglycemic Episodes|Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,472,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",17000|I8F-MC-GPGK,"June 3, 2019","October 5, 2020","November 2, 2020","May 17, 2019",,"March 17, 2020","National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|National Research Institute, Panorama City, California, United States|Southern California Dermatology, Santa Ana, California, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Encore Medical Research, LLC, Hollywood, Florida, United States|Axcess Medical Research, Loxahatchee Groves, Florida, United States|South Florida Wellness & Clinical Research Institute, Margate, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|Sky Clinical Research Network, Atlanta, Georgia, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|StudyMetrix Research, LLC, Saint Peters, Missouri, United States|Aventiv Research, Columbus, Ohio, United States|Intend Research, Norman, Oklahoma, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Capital Clinical Research Center, Olympia, Washington, United States|Rockwood Clinic Research Center, Spokane, Washington, United States|Dr. Jivraj Mehta Smarak Health Foundation, Ahmedabad, Gujarat, India|Bangalore Medical College and Research Institute, Bangalore, Karnataka, India|M S Ramaiah Medical College Hospital, Bangalore, Karnataka, India|BSES Municipal General Hsptl, Mumbai, Maharashtra, India|Ruby Hall Clinic and Grant Medical Foundation, Pune, Maharashtra, India|Vijay Vallabh Hospital, Virar, Maharashtra, India|Lifepoint Multispecialty Hsptl, Wakad, Pune, India|Ramdevrao Hospital, Hyderabad, Telangana, India|Gandhi Hospital, Telangana, India|Minamiakatsuka Clinic, Mito, Ibaraki, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Tsuruma Kaneshiro Diabetes Clinic, Yamato, Kanagawa, Japan|Yokohama Minoru Clinic, Yokohama, Kanagawa, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Meiwa Hospital, Chiyodaku, Tokyo, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan|Sato Naika Clinic, Ota-ku, Tokyo, Japan|Hospital Universitario UANL, Monterrey, Nuevo León, Mexico|Unidad Medica para la Salud Integral (UMSI), Monterrey, Nuevo León, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasc, Madero, Tamaulipas, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT03954834
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT03951753,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,220,NCT03951753,A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM),,Suspended,No Results Available,"Diabetes Mellitus, Type 2",Drug: Tirzepatide|Drug: Semaglutide|Drug: Placebo,Change from Baseline in Total Clamp Disposition Index (cDI)|Change from Baseline in Fasting Glucose|Change from Baseline in Postmeal Glucose|Change from Baseline in Hemoglobin A1c (HbA1c)|Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min)|Change from Baseline in Hyperinsulinemic Euglycemic Clamp M-value|Glucagon Concentration at Fasting|Glucagon Concentration at Postmeal|Change from Baseline in Food Intake During Ad Libitum Meal,Eli Lilly and Company,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 1,117,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",17091|I8F-MC-GPGT|2018-003343-37,"June 28, 2019","March 16, 2021","March 16, 2021","May 15, 2019",,"April 22, 2020","Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany|Profil Mainz GmbH & Co. KG, Mainz, Rheinland-Pfalz, Germany",,https://ClinicalTrials.gov/show/NCT03951753
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT03928379,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,222,NCT03928379,A Study of LY3305677 in Participants With Type 2 Diabetes,,Suspended,No Results Available,"Diabetes Mellitus, Type 2",Drug: LY3305677|Drug: Placebo,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug|Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3305677|PK: Area Under the Concentration-Time Curve (AUC) of LY3305677|Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose|PD: Change from Baseline in Fasting Plasma Insulin,Eli Lilly and Company,All,"20 Years to 69 Years   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",17011|I8P-MC-OXAD|2018-004779-11,"October 27, 2019","November 25, 2020","November 25, 2020","April 26, 2019",,"April 22, 2020","Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany",,https://ClinicalTrials.gov/show/NCT03928379
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT04143802,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,227,NCT04143802,A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM),,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: LY3437943|Drug: Dulaglutide|Drug: Placebo,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of LY3437943|PK: Maximum Concentration (Cmax) of LY3437943|Change from Baseline in Mean Daily Plasma Glucose (PG),Eli Lilly and Company,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 1,75,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",17137|J1I-MC-GZBB,"December 18, 2019","December 10, 2020","December 10, 2020","October 29, 2019",,"June 5, 2020","Anaheim Clinical Trials, LLC, Anaheim, California, United States|Miami Research Associates, Miami, Florida, United States|PRA Health Sciences, Lenexa, Kansas, United States",,https://ClinicalTrials.gov/show/NCT04143802
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT04050553,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,252,NCT04050553,A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Hypoglycemia",Drug: Tirzepatide|Drug: Placebo,Change in Mean Glucagon Concentration During Induced Hypoglycemia from Target Plasma Glucose (PG) Concentration of 100 Milligrams per Deciliter (mg/dL) to a Nadir Target of 45 mg/dL|Change in Mean Insulin Concentrations from Induced Hypoglycemia Target PG Nadir Concentration of 45 mg/dL to Recovery (PG Concentration 72 mg/dL)|Time from Termination of Insulin Infusion at PG Concentration of 45 mg/dL to Reach Recovery PG Concentration (72 mg/dL)|Change in Hypoglycemia Symptoms Score from Induced Hypoglycemia Target PG Nadir Concentration of 45 mg/dL to Recovery (PG Concentration 72 mg/dL)|Mean Change in Blood Pressure from Induced Hypoglycemia Target PG Nadir Concentration of 45 mg/dL to Recovery (PG Concentration 72 mg/dL)|Mean Change in Heart Rate from Induced Hypoglycemia Target PG Nadir Concentration of 45 mg/dL to Recovery (PG Concentration 72 mg/dL),Eli Lilly and Company,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",17222|I8F-MC-GPHG|2019-001360-29,"February 24, 2020","May 24, 2021","May 24, 2021","August 8, 2019",,"June 5, 2020","Universitätsklinikum Graz, Graz, Steiermark, Austria",,https://ClinicalTrials.gov/show/NCT04050553
Study Director,"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",Eli Lilly and Company,,NCT04184622,call 1-877-ctlilly (1-877-285-4559) or 1-317-615-4559 mon - fri 9 am - 5 pm eastern time (utc/gmt - 5 hours,call,male,0.75,449,394,NCT04184622,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight,SURMOUNT-1,Recruiting,No Results Available,Overweight|Obesity,Drug: Tirzepatide|Drug: Placebo,Percent Change from Baseline in Body Weight|Percentage of Participants who Achieve ≥5% Body Weight Reduction|Change from Baseline in Body Weight|Percentage of Participants who Achieve ≥10% Body Weight Reduction|Percentage of Participants who Achieve ≥15% Body Weight Reduction|Change from Baseline in Waist Circumference|Change from Baseline in Body Mass Index (BMI)|Change from Baseline in Fasting Glucose|Change from Baseline in Fasting Insulin|Time to Onset of Type 2 Diabetes|Change from Baseline in Hemoglobin A1c (HbA1c)|Change from Baseline in Triglycerides|Change from Baseline in Low-Density Lipoprotein (LDL) Cholesterol|Change from Baseline in Total Cholesterol|Change from Baseline in High-Density Lipoprotein (HDL) Cholesterol|Change from Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol|Change from Baseline in Free Fatty Acids|Change from Baseline in Systolic Blood Pressure|Change from Baseline in Diastolic Blood Pressure|Change from Baseline in Short Form Survey-36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score|Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score|Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2400,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",17244|I8F-MC-GPHK,"December 4, 2019","February 28, 2022","April 22, 2024","December 3, 2019",,"June 4, 2020","Cahaba Research, Pelham, Alabama, United States|Perseverance Research Center, Scottsdale, Arizona, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Valley Endocrine, Fresno, Fresno, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Chase Medical Research, LLC, Hamden, Connecticut, United States|Yale Center for Clinical Investigation, New Haven, Connecticut, United States|Suncoast Research Group, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|ForCare Clinical Research, Tampa, Florida, United States|United Osteoporosis Center, Gainesville, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|East West Medical Institute, Honolulu, Hawaii, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Iowa Diabetes Research, West Des Moines, Iowa, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|L-Marc Research Center, Louisville, Kentucky, United States|NECCR PrimaCare Research, LLC, Fall River, Massachusetts, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Troy Internal Medicine, PC, Troy, Michigan, United States|Sky Clinical Research - Quinn Healthcare, Ridgeland, Mississippi, United States|StudyMetrix Research, LLC, Saint Peters, Missouri, United States|Clinvest Research LLC, Springfield, Missouri, United States|Palm Research Center, Las Vegas, Nevada, United States|Premier Research, Trenton, New Jersey, United States|NYU Langone, New York, New York, United States|Weill Cornell Medicine, Comprehensive Weight Control Center, New York, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|University of North Carolina Diabetes Center, Chapel Hill, North Carolina, United States|PharmQuest, Greensboro, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Aventiv Research, Columbus, Ohio, United States|Intend Research, Norman, Oklahoma, United States|Summit Research Network Inc, Portland, Oregon, United States|Detweiler Family Medicine, Lansdale, Pennsylvania, United States|Preferred Primary Care Physicians - Jacob Murphy Lane, Uniontown, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States|ClinSearch, Chattanooga, Tennessee, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|North Texas Endocrine Center, Dallas, Texas, United States|Research Institute of Dallas, PA, Dallas, Texas, United States|Southern Endocrinology and Associates PA, Mesquite, Texas, United States|Texas Diabetes and Endocrinology, P.A., Round Rock, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Stat Research, Caba, Buenos Aires, Argentina|Centro de Investigaciones Metabólicas (CINME), Caba, Buenos Aires, Argentina|Mautalen Salud e Investigación - Servicio de Endocrinología, Caba, Buenos Aires, Argentina|Centro Medico CICEMO, Caba, Buenos Aires, Argentina|CEDIC-Centro de Investigaciones Clinicas, Caba, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|DIM Clinica Privada, Ramos Mejía, Buenos Aires, Argentina|GO Centro Médico San Nicolás, San Nicolás, Buenos Aires, Argentina|Sanatorio Norte, Santiago del Estero, Argentina|Centro Medico Privado de Reumatologia, Tucuman, Argentina|Cedoes Centro Diagnostico Pequisa Osteoporose E Santo Ltd, Vitoria, ES, Brazil|CCBR Brasil Centro de Analises e Pesquisas Clínicas LTDA, Rio de Janeiro, RJ, Brazil|Loema - Instituto de Pesquisa Clinica, Campinas, SP, Brazil|CPQuali Pesquisa Clínica Ltda., São Paulo, SP, Brazil|Cpclin Centro de Pesquisas Clinicas, São Paulo, SP, Brazil|CEPIC-Centro Paulista de Investigacao Clinica, São Paulo, SP, Brazil|Hospital da Clinicas da Faculdade de Medicina da USP, São Paulo, SP, Brazil|IPECC - Instituto de Pesquisa Clinica de Campinas, Campinas, São Paulo, Brazil|The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Nangang District, China|Jinan Central Hospital, Jinan, Shandong, China|The First Affiliated Hospital of Xi'an Medical University, XI 'an, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Ningbo First Hospital, Ningbo, Zhejiang, China|Beijing Tsinghua Changgung Hospital, Beijing, China|Care Hospital, Hyderabad, Andhra Pradesh, India|Gujarat Endocrine Center, Ahmedabad, Gujarat, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|CHL - Apollo Hospital, Indore, Madh Prad, India|Grant Medical College & Sir J.J. Group of Hospitals, Mumbai, Maharashtra, India|Topiwala National Medical College & BYL Nair Hospital, Mumbai, Maharashtra, India|Deenanth Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|ILS Hospital, Kolkata, West Bengal, India|All India Institue of Medical Sciences (AIIMS), New Delhi, India|Fortis Hospital, New Delhi, India|OCROM Clinic, Suita, Osaka, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku, Tokyo, Japan|AMC nishi-umeda clinic, Osaka, Japan|Ctro Inv en Artritis y Osteoporosis SC, Mexicali, Baja California, Mexico|Centro Especializado en Diabetes Obesidad y Enfermedades, Mexico, D.f., Mexico|Unidad de Investigacion Clinica y Atencion Medica HEPA S.C., Guadalajara, Jalisco, Mexico|Virgen Cardiovascular Research S.C, Guadalajara, Jalisco, Mexico|Inst. de Diabetes, Obesidad y Nutricion S.C, Cuernavaca, Morelos, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, N.l., Mexico|Centro Para el Desarrollo de la Medicina y de Asistencia Med, Culiacán, Sinaloa, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|RM Pharma Specialists S.A. de C.V., Distrito Federal, Mexico|Arke Estudios Clinicos S.A. de C.V., Veracruz, Mexico|Manati Center for Clinical Research Inc, Manati, Puerto Rico|Ponce School of Medicine CAIMED Center, Ponce, Puerto Rico|Latin Clinical Trial Center, San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|Consultorio Medico, San Juan, Puerto Rico|FSBI Scientific Research Institution of Therapy of Siberian Branch of RAMS, Novosibirsk, Novosibirsk Region, Russian Federation|City Hospital #38 n. a. N.A. Semashko, St. Petersburg, Pushkin, Russian Federation|Regional Public Health Institution ""Cardiology Dispensary"", Ivanovo, Russian Federation|BHI of Republic Udmurtiya ""City clinical hospital #9 of Ministry of healthcare of Republic Udmurtiya"", Izhevsk, Russian Federation|Clinical Trials Center of Medical Institute, Kaliningrad, Russian Federation|FSBI ""National Medical Research Center for Preventive Medicine"" of MOH of Russian Fed, Moscow, Russian Federation|Pirogov Russian National Research Medical University, Moscow, Russian Federation|FSBI Endocrinological Research Center of the MOH of the ROF, Moscow, Russian Federation|FSBI ""National Medical Research Center of Cardiology"" of MOH of Russian Federation, Moscow, Russian Federation|State Autonomous Healthcare Institution of the Tyumen Region ""Scientific - Pract Medical Center"", Tyumen, Russian Federation|Chung Shan Medical University Hospital, Taichung City, Taiwan|China Medical University Hospital, Taichung City, Taiwan|Chi-Mei Medical Center, Tainan City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan",,https://ClinicalTrials.gov/show/NCT04184622
Principal Investigator,"Siu Wai Maggie LAU, MPhil",Chinese Univeristy of Hong Kong,,NCT04092569,siu wai maggie lau,siu,male,0.59,479,35,NCT04092569,Effectiveness of Pre-medical Consultation Diabetes Self-care Education Programme on Glycemic Control in Type 2 Diabetes,PMC-SEP,Recruiting,No Results Available,Type 2 Diabetes,Behavioral: Pre-medical consultation structured diabetes self-care education programme,"Change from Baseline Blood Glycosylated haemoglobin, HbA1c at 6 months|Change from Baseline Blood Glycosylated haemoglobin, HbA1c at 9 months|The Chinese version of the Diabetes Management Self-Efficacy Scale Questionnaire|The Chinese version of the Diabetes Empowerment Scale Questionnaire - Short Form",Chinese University of Hong Kong,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2019.255,"September 10, 2019","December 31, 2020","December 31, 2020","September 17, 2019",,"September 25, 2019","Diabetes Centre, Alice Ho Miu Ling Nethersole Hospital, Tai Po, New Territories, Hong Kong",,https://ClinicalTrials.gov/show/NCT04092569
Principal Investigator,"Zhenqi Liu, MD","University of Virginia, Department of Endocrinoolgy",,NCT03883412,zhenqi liu,zhenqi,male,0.75,4,36,NCT03883412,Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007),ZQL007,Recruiting,No Results Available,Type2 Diabetes,Other: Exercise|Drug: Liraglutide,Microvascular Blood Volume - change from baseline|Augmentation Index - change from baseline|Flow Mediated Dilation - change from baseline|Pulse Wave Velocity - change from baseline|Post Ischemic Flow Velocity-Change from baseline|Insulin Sensitivity-Change from baseline,University of Virginia|American Diabetes Association|National Institutes of Health (NIH),All,21 Years to 60 Years   (Adult),Phase 4,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20320,"February 28, 2019",March 2022,March 2022,"March 20, 2019",,"March 20, 2019","University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03883412
Principal Investigator,"Paul Coen, PhD",Principal Investigator,,NCT04057677,paul coen,paul,male,0.99,148099,38,NCT04057677,Exercise Training as an Intervention to Improve Muscle Function and Recovery Following Bed Rest in Older Adults With Type 2 Diabetes,RECOVER,Recruiting,No Results Available,Type 2 Diabetes,Other: Bed Rest Intervention|Other: Resistance Exercise Program,"Change in leg lean mass measured at 5 time points|Change in protein synthesis rate assessed in muscle biopsy specimens using deuterium oxide, and also a mathematical model|Change in mitochondrial respiration measured in permeabilized muscle fibers using the Oxygraph 2K system","Translational Research Institute for Metabolism and Diabetes, Florida",All,"60 Years to 80 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1461891,"December 20, 2019",May 2023,May 2023,"August 15, 2019",,"March 10, 2020","AdventHealth Translational Research Institute, Orlando, Florida, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT04057677/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04057677
Study Director,"Paul F Crawford, MD",US Air Force,,NCT03938441,paul f crawford,paul,male,0.99,148099,118,NCT03938441,"Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study",,Recruiting,No Results Available,Diabetes Type 2|Pre-diabetes,Other: Intermittent Fasting,Number of hypoglycemic events,gino gaddini|Mike O'Callaghan Military Hospital,All,"18 Years to 69 Years   (Adult, Older Adult)",Not Applicable,40,U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FWH20190059H,"July 31, 2019",December 2020,December 2020,"May 6, 2019",,"May 21, 2020","Mike O'Callaghan Military Medical Center, Nellis Air Force Base, Nevada, United States",,https://ClinicalTrials.gov/show/NCT03938441
Principal Investigator,"Paul W Franks, PhD",Lund University,,NCT03814915,paul w franks,paul,male,0.99,148099,153,NCT03814915,Diabetes Research on Patient Stratification,DIRECT,Completed,No Results Available,Type2 Diabetes,,Glycemic deterioration,Lund University,All,"35 Years to 74 Years   (Adult, Older Adult)",,3049,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IMIDIRECT_2012,"October 15, 2012","July 31, 2019","July 31, 2019","January 24, 2019",,"January 18, 2020",,,https://ClinicalTrials.gov/show/NCT03814915
Principal Investigator,"Ewan Pearson, FRCP",University of Dundee,,NCT03814915,ewan pearson,ewan,male,0.97,862,153,NCT03814915,Diabetes Research on Patient Stratification,DIRECT,Completed,No Results Available,Type2 Diabetes,,Glycemic deterioration,Lund University,All,"35 Years to 74 Years   (Adult, Older Adult)",,3049,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IMIDIRECT_2012,"October 15, 2012","July 31, 2019","July 31, 2019","January 24, 2019",,"January 18, 2020",,,https://ClinicalTrials.gov/show/NCT03814915
Principal Investigator,"Jan Eriksson, MD",Uppsala University,,NCT03982381,jan eriksson,jan,male,0.95,142869,39,NCT03982381,SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes,SMARTEST,Recruiting,No Results Available,Type 2 Diabetes,Drug: Metformin|Drug: Dapagliflozin 10 MG,"Time to first occurence of a confirmed composite endpoint of death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer.|Ordinal analysis of components of primary endpoint (see above)|Time to first occurence of a confirmed composite endpoint of death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer (ICD10 diagnosis codes) or initiation of insulin treatment.|Time to first occurence of a confirmed composite endpoint of non-fatal myocardial infarction, stroke, heart failure, unstable angina or cardiovascular death.|Time to first occurence of a confirmed composite endpoint of heart failure or cardiovascular death.|Death|Microvascular events, first of; occurrence or progression of retinopathy, nephropathy, diabetic foot lesions|Need for insulin treatment|Treatment failure, defined as add-on or switch to another glucose-lowering drug|Change in glycemic control|Change in LDL-cholesterol|Change in HDL-cholesterol|Change in total cholesterol|Change in triglycerides|Change in albuminuria|Change in blood pressure|Change in body weight|Change in BMI|Health care costs|Health-related quality of life|Health-related quality of life with respect to diabetes treatment satisfaction.",Uppsala University|Uppsala University Hospital|Swedish Healthcare Regions|Swedish National Board of Health and Welfare|The Swedish National Diabetes Register,All,"18 Years and older   (Adult, Older Adult)",Phase 4,4300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,SMART-2019|2019-001046-17,"September 5, 2019","December 31, 2023","September 20, 2024","June 11, 2019",,"March 24, 2020","Uppsala University Hospital, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT03982381
Principal Investigator,Quanying Zhang,Second Affiliated Hospital of Suzhou University,,NCT04001231,quanying zhang,quanying,female,0.5,4,40,NCT04001231,Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus,,Withdrawn,No Results Available,Type 2 Diabetes,Drug: Exenatide Once-Weekly Suspension,"Plasma concentrations versus time profile of exenatide|Cmax|tmax|AUC(0-8h)|AUC(0-168h)|AUCτ,ss|Cav,ss|λ z|t½|CL/F|Vss/F|Rac|Ctrough|Electrocardiograms (ECGs)|Blood pressure (BP)|Pulse rate|Body temperature|Safety and tolerability as determined by abnormality in clinical chemistry compared to baseline.|Safety and tolerability as determined by abnormality in hematology compared to baseline.|Safety and tolerability as determined by abnormality in urinalysis compared to baseline.|Fasting blood glucose|Calcitonin|Number of subjects with adverse events|The presence and titer of anti-exenatide antibodies",AstraZeneca,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1,0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,D5553C00008,"June 30, 2020","July 2, 2021","July 2, 2021","June 28, 2019",,"June 4, 2020",,,https://ClinicalTrials.gov/show/NCT04001231
Principal Investigator,"Xiaoying Li, MD",Fudan University,,NCT04053959,xiaoying li,xiaoying,female,0.89,81,44,NCT04053959,Effect of Artificial Intelligence Assisted Insulin Titration System on Glucose Control in Type 2 Diabetes Mellitus Patients,,Not yet recruiting,No Results Available,Type 2 Diabetes,Drug: AI assisted insulin system|Drug: Physician based insulin regime,Proportion of time in which the blood glucose level is well controlled|Proportion of time in which the blood glucose level is over 10 mmol/L|Proportion of time in which the blood glucose level is below 3.9 mmol/L|Total insulin dose,Shanghai Zhongshan Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCDSS,"August 15, 2019","September 7, 2019","November 15, 2019","August 13, 2019",,"August 13, 2019",,,https://ClinicalTrials.gov/show/NCT04053959
Principal Investigator,"Miguel Angel Gomez Samano, MD",Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,NCT04090580,miguel angel gomez samano,miguel,male,0.99,158479,47,NCT04090580,Impact on Glycemic Variability After Treatment With Dapagliflozin on Type 2 Diabetes Patients,,Recruiting,No Results Available,Type 2 Diabetes,Diagnostic Test: Continuous glucose monitoring,Impact of dapagliflozin in glycemic variability|Impact of dapagliflozin in insulin level concentration|Impact of dapagliflozin in Hba1c|Impact of dapagliflozin on patients weight|Impact of dapagliflozin in blood pressure|Impact of dapagliflozin in waist circumference,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|AztraZeneca,All,"18 Years to 77 Years   (Adult, Older Adult)",Phase 4,36,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3089,"August 27, 2019","May 27, 2020","August 27, 2020","September 16, 2019",,"February 28, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán ''INCMNSZ'', Ciudad de mexico, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04090580/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04090580/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04090580
Principal Investigator,"Miguel Angel Gómez Sámano, MD",Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,NCT04127994,miguel angel gómez sámano,miguel,male,0.99,158479,141,NCT04127994,Glycemic Variability Comparing Two vs Six Meals in Type 2 Diabetes,,Recruiting,No Results Available,Diabetes Mellitus Type 2|Overweight and Obesity|Meal Time,Other: Comparing 3 versus 6 meals in type 2 diabetes patients,Impact of 3 stroke diet in glycemic variability compared to a 6 stroke diet|Impact of 3 stroke diet in Hba1c levels compared to a 6 stroke diet|Impact of 3 stroke diet in fasting glucose levels compared to a 6 stroke diet|Impact of 3 stroke diet in triglycerides levels compared to a 6 stroke diet|Impact of 3 stroke diet in cholesterol levels compared to a 6 stroke diet|Impact of 3 stroke diet in FGF-21 levels compared to a 6 stroke diet|Impact of 3 stroke diet in systolic and diastolic blood pressure compared to a 6 stroke diet|Impact of 3 stroke diet in satiety compared to a 6 stroke diet|Impact of 3 stroke diet in weight loss compared to a 6 stroke diet,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|L.N. Adrián Romero Villaseñor|L.N. Aurora Ramos Flores|L.N. Mariana Galindo Guzmán|Dr. Daniel Cuevas Ramos|Dr. Adrian Soto Mota|Dr. Francisco J. Gómez Pérez|Dr. Alfonso Gulias Herrero|Lucía Palacios Baez|Gerardo Saavedra Jiménez|Hector Donaldo Espinosa Salazar|Issa Lill Santiago Falfán|Cristina Aurora Tlapanco Beltrán|Horacio Correa Carranza|Alejandra Dominguez Sanchez,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2100,"August 17, 2018","December 12, 2019",February 2020,"October 16, 2019",,"October 16, 2019","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán ''INCMNSZ'', Ciudad de mexico, Mexico","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04127994/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04127994/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT04127994
Study Chair,Miguel Brito,Madrid Health Service,,NCT04092738,miguel brito,miguel,male,0.99,158479,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Principal Investigator,Anna Puig Ribera,Universitat de Vic,,NCT04092738,anna puig ribera,anna,female,0.98,383713,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,María Lorena López Catañon,Madrid Health Service,,NCT04092738,maría lorena lópez catañon,maría,female,0.99,232436,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,David Pérez Manchon,Madrid Health Service,,NCT04092738,david pérez manchon,david,male,0.99,501011,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Carlos Martin Cantera,Jordi Gol i Gurina Foundation - IDIAP Jordi Gol,,NCT04092738,carlos martin cantera,carlos,male,0.99,236888,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Francesc Alòs Colomer,Catalan Institute of Health,,NCT04092738,francesc alòs colomer,francesc,male,0.98,2929,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Francesc Garcia Cuyàs,Hospital Sant Joan de Déu (Barcelona),,NCT04092738,francesc garcia cuyàs,francesc,male,0.98,2929,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Ana Urpí Fernández,Catalan Institute of Health,,NCT04092738,ana urpí fernández,ana,female,0.98,273767,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Josep Maria Molina Aragonés,Catalan Institute of Health,,NCT04092738,josep maria molina aragonés,josep,male,0.99,10821,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Blanca Funollet Santos,Catalan Institute of Health,,NCT04092738,blanca funollet santos,blanca,female,0.98,9574,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Laura Illamola Martin,EAP Dreta de l'Eixample S.L.P,,NCT04092738,laura illamola martin,laura,female,0.98,288403,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Ignasi Saigí Ullastre,Consorci Hospitalari de Vic (CHV),,NCT04092738,ignasi saigí ullastre,ignasi,male,0.99,685,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Emi Chirveches-Pérez,Consorci Hospitalari de Vic (CHV),,NCT04092738,emi chirveches-pérez,emi,female,0.74,9928,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Montserrat Martín-Horcajo,Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC),,NCT04092738,montserrat martín-horcajo,montserrat,female,0.98,2756,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Montserrat Munuera Grau,Catalan Institute of Health,,NCT04092738,montserrat munuera grau,montserrat,female,0.98,2756,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Montserrat Solís Muñoz,Madrid Health Service,,NCT04092738,montserrat solís muñoz,montserrat,female,0.98,2756,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Judit Bort-Roig,University of Vic - Central University of Catalonia,,NCT04092738,judit bort-roig,judit,female,0.99,15922,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Study Chair,Mireia Félez-Nóbrega,Parc Sanitari Sant Joan de Déu (Sant Boi de Llobregat),,NCT04092738,mireia félez-nóbrega,mireia,female,0.99,6405,332,NCT04092738,"´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.",Walk@Work,Recruiting,No Results Available,"Diabetes Mellitus, Type II",Behavioral: Walk@WorkApp-Diab,Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity,Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,368,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PI17/01788,"March 4, 2019",January 2020,September 2021,"September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT04092738
Principal Investigator,Jonathan Chemouny,Rennes University Hospital,,NCT04006028,jonathan chemouny,jonathan,male,0.99,87986,49,NCT04006028,Kidney Biopsy Indications in Type 2 Diabetes Patients,RIB-R2D2,Recruiting,No Results Available,"Type 2 Diabetes, Chronic Kidney Disease",,Non-diabetic renal disease|Renal survival|Patient survival,Rennes University Hospital,All,"18 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,35RC19_30031_RIB-R2D2,"June 6, 2019","September 6, 2019","September 6, 2019","July 2, 2019",,"July 2, 2019","AP-HM, Hôpital de la Conception, Marseille, France|AP-HP, Hôpital Bichat-Claude Bernard, Paris, France|AP-HP, Hôpital Necker-Enfants Malades, Paris, France|Rennes University Hospital, Rennes, France|Hôpital Bretonneau, Tours, France",,https://ClinicalTrials.gov/show/NCT04006028
Study Director,"Fernando Grover Paez, PhD","Institute of Experimental and Clinical Therapeutics (INTEC), CUCS",,NCT04195243,fernando grover paez,fernando,male,0.99,88476,51,NCT04195243,Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus,,Not yet recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: Dapagliflozin Pill|Drug: Empagliflozin Pill|Drug: Placebo pill,Flow Mediated Dilation|Fasting plasma glucose|Total cholesterol|Triglycerides|High-density lipoprotein cholesterol|Low-density lipoprotein cholesterol|Creatinine|Blood pressure,"Centro Universitario de Ciencias de la Salud, Mexico",All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 3,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,CUCS-INTEC-MV-HADES-001,"December 2, 2019","June 29, 2020","December 30, 2020","December 11, 2019",,"December 11, 2019","Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara, Jalisco, Mexico",,https://ClinicalTrials.gov/show/NCT04195243
Study Chair,"Dr.Ramachandran Ambady, MD,PhD,DSc","President, India Diabetes Research Foundation",,NCT03901248,ramachandran ambady,ramachandran,male,0.94,164,53,NCT03901248,Study of Association of Salivary Adipokines With Prediabetes and Type 2 Diabetes Mellitus,,Completed,No Results Available,Type2 Diabetes Mellitus,Other: No Intervention,"Interrelationship of adipokines such as adiponectin, apelin, visfatin and vaspin in different glycaemic stages|Change in BMI|Change in Blood Pressure|Change in fasting blood glucose|Change in postprandial blood glucose|Comparative assessment of the sensitivity of the assays of the biomarkers in saliva and serum|Levels of these biomarkers in the presence of periodontitis|Change in HbA1c",India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals,All,"35 Years and older   (Adult, Older Adult)",,120,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,IDRFARH005,July 2015,September 2019,December 2019,"April 3, 2019",,"January 10, 2020",,,https://ClinicalTrials.gov/show/NCT03901248
Principal Investigator,Oliver Klein,Profil Institut fur Stoffwechselforschung GmbH,,NCT04100473,oliver klein,oliver,male,0.99,32776,56,NCT04100473,Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus,T2DM,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Inhaled Human Insulin|Drug: Insulin Lispro (Humalog U-100),Primary Pharmacokinetic Endpoint - PK 1|Primary Pharmacokinetic Endpoint - PK 2|Primary Pharmacodynamic Endpoint - PD 1|Primary Pharmacodynamic Endpoint - PD 2|Secondary Pharmacokinetic Endpoint - PK 1|Secondary Pharmacokinetic Endpoint - PK 2|Secondary Pharmacokinetic Endpoint - PK 3|Secondary Pharmacokinetic Endpoint - PK 4|Secondary Pharmacokinetic Endpoint - PK 5|Secondary Pharmacodynamic Endpoint - PD 1|Secondary Pharmacodynamic Endpoint - PD2|Secondary Pharmacodynamic Endpoint - PD3,Dance Biopharm Inc.|Profil Institut für Stoffwechselforschung GmbH,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Samba-04,"April 23, 2018","August 11, 2018","August 1, 2019","September 24, 2019",,"September 24, 2019","Profil Mainz, Mainz, Malakoff-Passage, Germany",,https://ClinicalTrials.gov/show/NCT04100473
Principal Investigator,"Zubin Punthakee, MD",McMaster University,,NCT03862716,zubin punthakee,zubin,male,0.97,77,57,NCT03862716,Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira,REMITiDegLira,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: IDegLira|Drug: insulin degludec|Drug: Metformin|Behavioral: Lifestyle Therapy,Proportion of participants achieving drug-free diabetes remission|Proportion of participants achieving drug-free normoglycemia|Proportion of participants achieving drug-free diabetes regression,Population Health Research Institute|Novo Nordisk A/S,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 3,160,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REMITiDegLira,"April 23, 2019","September 30, 2020","December 31, 2021","March 5, 2019",,"June 5, 2019","University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|McMaster University, Hamilton, Ontario, Canada|St. Joseph's Hospital, London, Ontario, Canada|Western University, London, Ontario, Canada|LMC Manna Research, Oakville, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03862716
Study Chair,"Hertzel Gerstein, MD",McMaster University,,NCT03862716,hertzel gerstein,hertzel,male,0.92,12,57,NCT03862716,Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira,REMITiDegLira,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: IDegLira|Drug: insulin degludec|Drug: Metformin|Behavioral: Lifestyle Therapy,Proportion of participants achieving drug-free diabetes remission|Proportion of participants achieving drug-free normoglycemia|Proportion of participants achieving drug-free diabetes regression,Population Health Research Institute|Novo Nordisk A/S,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 3,160,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REMITiDegLira,"April 23, 2019","September 30, 2020","December 31, 2021","March 5, 2019",,"June 5, 2019","University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|McMaster University, Hamilton, Ontario, Canada|St. Joseph's Hospital, London, Ontario, Canada|Western University, London, Ontario, Canada|LMC Manna Research, Oakville, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03862716
Study Director,Jianhua Ma,"Nanjing First Hospital, Affiliated to Nanjing Medical University",,NCT04120623,jianhua ma,jianhua,male,0.84,119,58,NCT04120623,Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus,,Not yet recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: Dapagliflozin 10 MG|Drug: Insulin Aspart,"the effect of dapagliflozin combined with CSII on glucose profile|the effects of dapagliflozin combined with CSII on weight|the effects of dapagliflozin combined with CSII on blood pressure|the effects of dapagliflozin combined with CSII on lipid metabolism(total cholesterol in mmol/l, total glyceride in mmol/l)","Nanjing First Hospital, Nanjing Medical University",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,KY20190926-03,"October 1, 2019","December 31, 2019","February 28, 2020","October 9, 2019",,"October 9, 2019",,,https://ClinicalTrials.gov/show/NCT04120623
Principal Investigator,"Phuong Thi-Bich Le, MSc-MD","Stem Cell Unit, Van Hanh General Hospital",,NCT03943940,phuong thi-bich le,phuong,female,0.66,1050,60,NCT03943940,BM-MNCs and UC-MSCs Infusion for Type 2 Diabetes Mellitus Patients,T2DM,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Biological: BM-MNC and UC-MSC|Other: Control,"The level of C-peptid and HOMA-β|The level of HOMA-IR and cytokines TNF-α, IL-1β|Blood glucose level|Hemoglobin A1c (HbA1c) level|Adverse events|Insulin dose and drug dosage",Van Hanh General Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TNLS012019-TBG,"April 24, 2019","December 30, 2019","August 30, 2020","May 9, 2019",,"May 10, 2019","Van Hanh General Hospital, Ho Chi Minh City, Ho Chi Minh, Vietnam",,https://ClinicalTrials.gov/show/NCT03943940
Principal Investigator,"Peter J Huckfeldt, PhD",University of Minnesota,,NCT03952728,peter j huckfeldt,peter,male,0.99,165452,62,NCT03952728,The Long-term Effects of an Intensive Lifestyle Intervention for Type 2 Diabetes on Medicare Outcomes,,"Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus,Behavioral: Intensive lifestyle intervention|Behavioral: Diabetes support and education,Total inpatient (general hospital/acute care) discharges|Total inpatient (general hospital/acute care) days|Total number of emergency department visits|Medicare Part D Prescription Drug Fill Count|Total Medicare spending|Medicare inpatient payments|Medicare Part D drug payments|Medicare Part D drug costs|Medicare outpatient visits|Medicare hospital outpatient payments|Medicare Part B physician payments|Medicare SNF payments,University of Minnesota|University of Southern California|Wake Forest University,All,"45 Years to 75 Years   (Adult, Older Adult)",,3574,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,UP-16-00706,"December 19, 2016",June 2021,June 2021,"May 16, 2019",,"November 1, 2019",,,https://ClinicalTrials.gov/show/NCT03952728
Principal Investigator,HaiYan Li,Peking University Third Hospital,,NCT03973515,haiyan li,haiyan,female,0.9,186,66,NCT03973515,Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus,,Completed,No Results Available,Type2 Diabetes Mellitus,Drug: glucokinase activator|Drug: Placebo,Time to peak(Tmax)|Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|The change for fasting plasma glucose (FPG)|The change for postprandial plasma glucose (PPG)|The change for plasma C-peptide|The change for plasma insulin,"PegBio Co., Ltd.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PB-201,"August 27, 2019","December 19, 2019","December 19, 2019","June 4, 2019",,"January 22, 2020","Peking University Third Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT03973515
Study Director,"Orville Kolterman, MD",Whole Biome,,NCT04047537,orville kolterman,orville,male,0.97,139,68,NCT04047537,Placebo-Controlled Clinical Nutrition Study of the Metabolic Effects of Food Product WBF-0011 in Type 2 Diabetes,,Enrolling by invitation,No Results Available,Type 2 Diabetes Mellitus,Other: Medical Food Formulation 1|Other: Medical Food Formulation 2|Other: Placebo,Hemoglobin A1c|3-hour blood glucose Area Under the Curve (AUC)|3-hour plasma glucose AUC|3-hour blood glucose AUC|24-hour CGM|Fasting Lipid Panel|Body weight|Adverse Events|Change from baseline in Laboratory Chemistry Values|Change from baseline in Laboratory Complete Blood count Values,Pendulum Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",AFCRO-104,"August 6, 2019","June 30, 2020","June 30, 2020","August 6, 2019",,"May 28, 2020","Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork, Ireland",,https://ClinicalTrials.gov/show/NCT04047537
Principal Investigator,"Orville G Kolterman, MD",Pendulum Therapeutics,,NCT03893422,orville g kolterman,orville,male,0.97,139,70,NCT03893422,Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes,,Completed,No Results Available,Type 2 Diabetes Mellitus,Other: WB-010|Other: WB-011|Other: Placebo,3-hour plasma glucose AUC|CRP|Incremental glucose AUC|Hemoglobin A1c|Fasting plasma glucose concentration|Fasting plasma insulin concentration|Plasma insulin AUC|Homeostatic Model Assessment (HOMA) of Insulin Resistance (IR)|Matsuda index|Fasting Lipid Panel|Inflammatory markers|Body weight in kilograms|Body Mass Index (BMI)|Waist Circumference|Fecal Microbiome Profile|Adverse Events|Laboratory (Chemistry panel + CBC) Values|Hospital Anxiety and Depression Scale,Pendulum Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,76,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WB201-202,"October 22, 2017","August 16, 2018","September 14, 2018","March 28, 2019",,"February 27, 2020","Science 37, Torrance, California, United States|Orange County Research Center, Tustin, California, United States|Northside Medical Center, Youngstown, Ohio, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Juno Research, LLC, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03893422
Principal Investigator,"Bimal Shah, MD, MBA",Livongo Health,,NCT03980236,bimal shah,bimal,male,0.97,178,75,NCT03980236,Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study],LISA Pilot,Recruiting,No Results Available,Type 2 Diabetes Treated With Insulin,Device: Livongo-Insulia Study App,Change in A1c,Livongo Health|Voluntis|Evidation Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,CP04573.A,"May 6, 2019",November 2019,November 2019,"June 10, 2019",,"June 10, 2019","Livongo, Mountain View, California, United States",,https://ClinicalTrials.gov/show/NCT03980236
Principal Investigator,"Ronald M. Goldenberg, MD",LMC Clinical Research Inc.,,NCT03813316,ronald m. goldenberg,ronald,male,0.99,23684,76,NCT03813316,Approaches To Therapy Escalation In T2D,ATTACC,Withdrawn,No Results Available,Type2 Diabetes,Drug: DPP-4 inhibitor|Drug: SGLT2 inhibitor|Drug: SGLT2 inhibitor and DPP-4 inhibitor,"The percentage of participants achieving an A1C value of ≤ 7% at 24 weeks|The percentage of participants achieving an A1C value ≤ 7% at 12 weeks|The absolute reduction in A1C from Baseline at 24 weeks|The percentage of participants requiring a change of therapy or rescue therapy at 12 weeks|Drug tolerability including percentage of participants with hypoglycemic events, and percentage with adverse events.events.|The absolute reduction in FPG from Baseline at 24 weeks|The absolute change in body weight from Baseline at 24 weeks|The absolute change in systolic blood pressure from Baseline at 24 weeks|The percentage of participants achieving the composite outcome of A1C ≤ 7.0%, no weight gain and no hypoglycemia at Week 24.|The percentage of participants on statin therapy at 24 weeks|The percentage of participants on antihypertensive therapy at Week 24.",LMC Diabetes & Endocrinology Ltd.|Merck Sharp & Dohme Corp.|Syreon Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,58214,"May 1, 2019","September 18, 2019","September 18, 2019","January 23, 2019",,"September 27, 2019",,,https://ClinicalTrials.gov/show/NCT03813316
Principal Investigator,"Frankie B Stentz, PhD",University of Tennessee Health Science Center,,NCT03832725,frankie b stentz,frankie,male,0.85,4199,77,NCT03832725,Pathobiology of Remission of Type 2 Diabetes,,Recruiting,No Results Available,Newly Diagnosed Type 2 Diabetes|Obese,Other: High Protein (HP) weight loss diet|Other: High carbohydrate (HC) weight loss diet,"Remission of Type 2 Diabetes|Weight loss|Cardiovascular Risk Factors (CVR)|Inflammation markers such as cytokines,|Metabolom Markers",University of Tennessee Health Science Center,All,20 Years to 50 Years   (Adult),Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",UTennHSCFS,"March 1, 2018","July 31, 2024","July 31, 2024","February 6, 2019",,"February 7, 2019","University of Tennessee Health Science Center, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03832725
Study Director,"Yi-lin Zhao, principal",Zhongshan Hospital Xiamen University,,NCT04127084,yi-lin zhao,yi-lin,female,0.5,6,79,NCT04127084,Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes,,Recruiting,No Results Available,Type 2 Diabetes|Diabetic Nephropathy,Drug: SGLT2 Inhibition,Change in urinary albuminuria|Change in eGFR|change in nephrin|change in TGF-β1|change in IL-6|change in TNFα|changes of AGEs|changes of 8-OH-dG|Change in uric acid|Change in aldosterone|Change in rennin|Change in angiotensin,Zhongshan Hospital Xiamen University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20191005,"October 15, 2019",October 2020,August 2021,"October 15, 2019",,"October 21, 2019","Zhongshan Hospital Xiamen University, Xiamen, Fujian, China",,https://ClinicalTrials.gov/show/NCT04127084
Principal Investigator,"Nazire Nur Yıldız, PT",AYBU Institute of Health Sciences Department of Physiotherapy and Rehabilitation Master Program/Master Degree Student,,NCT03885869,nazire nur yıldız,nazire,female,0.97,435,83,NCT03885869,"Relationships Between Joint Position Sense, Plantar Sensation, Balance and Dual Task Performance in Individuals With Type 2 Diabetes",,Not yet recruiting,No Results Available,Type 2 Diabetes Mellitus|Balance,Other: Ankle Joint Position Sensation Evaluation|Other: Knee Joint Position Sensation Evaluation|Other: The Evaluation of Plantar Sensation|Other: The Evaluation of Balance|Other: Evaluation of Dual Task Performance|Other: General Evaluation Form,The Evaluation of Ankle Joint Position Sensation|The Evaluation of Knee Joint Position Sensation|The Evaluation of Plantar Sensation|Evaluation of Balance Performance|The Evaluation of Dual Task Performance,Ankara Yildirim Beyazıt University,All,"30 Years to 65 Years   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,2019-83,"March 25, 2019","August 25, 2019","March 25, 2020","March 22, 2019",,"March 25, 2019","Ankara Yıldırım Beyazıt University, Institute of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT03885869
Study Director,Dan Lee,"Neuraly, Inc.",,NCT04159766,dan lee,dan,male,0.95,55986,85,NCT04159766,A Study With NLY01 in Subjects With Type 2 Diabetes,,"Active, not recruiting",No Results Available,"Type2 Diabetes|Diabetes Mellitus, Type 2",Drug: NLY01|Drug: Placebo,Number of participants with Treatment Emergent Adverse Events|Number of Incidences of Adverse Events|Plasma glucose|Change in serum insulin|Change in plasma glucagon,"Neuraly, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NLY01-D1,"October 16, 2019",September 2020,September 2020,"November 12, 2019",,"April 14, 2020","Profil Institute fur Stoffwechselforschung GmbH, Neuss, Germany|Profil Institute, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT04159766
Principal Investigator,"Farah Yasmin Hasbullah, MSc",Universiti Putra Malaysia,,NCT04190199,farah yasmin hasbullah,farah,female,0.92,9761,86,NCT04190199,Exploring Nutritype Signature of Type 2 Diabetes Risks in Women Post-Gestational Diabetes Mellitus,,Not yet recruiting,No Results Available,Type 2 Diabetes|Gestational Diabetes,Other: Observational,Nutritype signature of T2DM risks in women post-GDM|Prevalence of glucose intolerance|Socio-demographic background|Obstetric history|Nutritional status|Metabolite profile|Dietary pattern|Sleeping pattern|Perceived Stress Scale score|Physical activity level|Smoking habit and exposure,"Universiti Putra Malaysia|Ministry of Health, Malaysia|Universiti Teknologi Mara",Female,18 Years to 50 Years   (Adult),,270,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,5540099,May 2020,May 2021,May 2021,"December 9, 2019",,"December 9, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT04190199
Principal Investigator,"Geeta Appannah, PhD",Universiti Putra Malaysia,,NCT04190199,geeta appannah,geeta,female,0.95,354,86,NCT04190199,Exploring Nutritype Signature of Type 2 Diabetes Risks in Women Post-Gestational Diabetes Mellitus,,Not yet recruiting,No Results Available,Type 2 Diabetes|Gestational Diabetes,Other: Observational,Nutritype signature of T2DM risks in women post-GDM|Prevalence of glucose intolerance|Socio-demographic background|Obstetric history|Nutritional status|Metabolite profile|Dietary pattern|Sleeping pattern|Perceived Stress Scale score|Physical activity level|Smoking habit and exposure,"Universiti Putra Malaysia|Ministry of Health, Malaysia|Universiti Teknologi Mara",Female,18 Years to 50 Years   (Adult),,270,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,5540099,May 2020,May 2021,May 2021,"December 9, 2019",,"December 9, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT04190199
Principal Investigator,"Rohana Abdul Ghani, PhD",Universiti Teknologi Mara (UiTM),,NCT04190199,rohana abdul ghani,rohana,female,0.79,197,86,NCT04190199,Exploring Nutritype Signature of Type 2 Diabetes Risks in Women Post-Gestational Diabetes Mellitus,,Not yet recruiting,No Results Available,Type 2 Diabetes|Gestational Diabetes,Other: Observational,Nutritype signature of T2DM risks in women post-GDM|Prevalence of glucose intolerance|Socio-demographic background|Obstetric history|Nutritional status|Metabolite profile|Dietary pattern|Sleeping pattern|Perceived Stress Scale score|Physical activity level|Smoking habit and exposure,"Universiti Putra Malaysia|Ministry of Health, Malaysia|Universiti Teknologi Mara",Female,18 Years to 50 Years   (Adult),,270,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,5540099,May 2020,May 2021,May 2021,"December 9, 2019",,"December 9, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT04190199
Principal Investigator,"Zulfitri 'Azuan Mat Daud, PhD",Universiti Putra Malaysia,,NCT04190199,zulfitri 'azuan mat daud,zulfitri,male,0.67,6,86,NCT04190199,Exploring Nutritype Signature of Type 2 Diabetes Risks in Women Post-Gestational Diabetes Mellitus,,Not yet recruiting,No Results Available,Type 2 Diabetes|Gestational Diabetes,Other: Observational,Nutritype signature of T2DM risks in women post-GDM|Prevalence of glucose intolerance|Socio-demographic background|Obstetric history|Nutritional status|Metabolite profile|Dietary pattern|Sleeping pattern|Perceived Stress Scale score|Physical activity level|Smoking habit and exposure,"Universiti Putra Malaysia|Ministry of Health, Malaysia|Universiti Teknologi Mara",Female,18 Years to 50 Years   (Adult),,270,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,5540099,May 2020,May 2021,May 2021,"December 9, 2019",,"December 9, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT04190199
Principal Investigator,"Winnie Chee, PhD",International Medical University (IMU),,NCT04190199,winnie chee,winnie,female,0.88,4657,86,NCT04190199,Exploring Nutritype Signature of Type 2 Diabetes Risks in Women Post-Gestational Diabetes Mellitus,,Not yet recruiting,No Results Available,Type 2 Diabetes|Gestational Diabetes,Other: Observational,Nutritype signature of T2DM risks in women post-GDM|Prevalence of glucose intolerance|Socio-demographic background|Obstetric history|Nutritional status|Metabolite profile|Dietary pattern|Sleeping pattern|Perceived Stress Scale score|Physical activity level|Smoking habit and exposure,"Universiti Putra Malaysia|Ministry of Health, Malaysia|Universiti Teknologi Mara",Female,18 Years to 50 Years   (Adult),,270,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,5540099,May 2020,May 2021,May 2021,"December 9, 2019",,"December 9, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT04190199
Principal Investigator,"Winnie SS Chee, PhD",International Medical University,,NCT03881540,winnie ss chee,winnie,female,0.88,4657,293,NCT03881540,"Efficacy of tDNA Care on Weight Loss and Metabolic Outcomes in Patients With Overweight, Obesity and Type 2 Diabetes",,Completed,No Results Available,Diabetes|Obesity,Other: tDNA-MI group|Other: tDNA-CC group|Other: UC group,"Change in Weight|Change in Glycated haemoglobin (A1C)|Change in percentage body fat|Change in fasting blood glucose|Change in total cholesterol, LDL-C and HDL-C|Change in High sensitivity C-Reactive Protein (HsCRP)|Change in systolic and diastolic blood pressure|Change in energy intake and macronutrients|Change in Weight Efficacy Lifestyle (WEL) scores|Change in exercise minutes",International Medical University,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,230,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IMU R 134/2014,June 2014,December 2015,December 2015,"March 19, 2019",,"March 22, 2019","International Medical University, Kuala Lumpur, Malaysia",,https://ClinicalTrials.gov/show/NCT03881540
Principal Investigator,"Winnie C Chu, MD",Chinese University of Hong Kong,,NCT03875625,winnie c chu,winnie,female,0.88,4657,492,NCT03875625,Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention,,Recruiting,No Results Available,"Non-Alcoholic Fatty Liver Disease|Obesity, Morbid|Brown Fat|Metabolic Disease|Diabetes Mellitus|Insulin Resistance|Abdominal Subcutaneous Fat",Procedure: Bariatric surgery|Behavioral: Dietitian led life style modification intervention|Behavioral: Conventional care (control),Use of modified Dixon Magnetic Resonance Imaging method to measure the response of adipose tissue in different organs following life style modification program or Bariatric surgery|Use of modified Dixon Magnetic Resonance Imaging method to measure the response of adipose tissue in different organs following life style modification program or Bariatric surgery 2|Use of modified Dixon Magnetic Resonance Imaging method to measure the response of adipose tissue in different organs following life style modification program or Bariatric surgery- 3|Use of modified Dixon Magnetic Resonance Imaging method to measure the response of adipose tissue in different organs following life style modification program or Bariatric surgery- 4|Use of modified Dixon Magnetic Resonance Imaging method to assess the relationship between Brown Adipose Tissue and Non Alcoholic Fatty Liver Disease|Blood biochemistry for assessing β-cell function and insulin resistance (IR)|Blood biochemistry- 1|Blood biochemistry- 2|Blood biochemistry- 3|Blood biochemistry- 4|Blood biochemistry- 5|Blood biochemistry- 6|Anthropomorphic measurements using measuring tape and weight scale|Anthropomorphic measurements using BP machine,Chinese University of Hong Kong,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",No. 2018.612,"March 12, 2019","January 12, 2022","January 12, 2022","March 15, 2019",,"June 11, 2020","The Chinese University of Hong Kong, Prince of Wale Hospital, Hong Kong, Shatin, Hong Kong",,https://ClinicalTrials.gov/show/NCT03875625
Study Director,Nai-Jen Chang,Kaohsiung Medical University Department of Sports Medicine professor,,NCT04026139,nai-jen chang,nai-jen,male,1.0,1,87,NCT04026139,"Elastic Band Resistance Exercise on Glycated Haemoglobin and Muscle Strength, Balance, and Physical Function in Patients With Comorbid Type 2 Diabetes Mellitus and Knee Osteoarthritis",,Completed,No Results Available,Elastic Band Resistance Exercise With Comorbid Type 2 Diabetes Mellitus and Knee Osteoarthritis,Other: Elastic Band Resistance Exercise|Other: active joint range-of-motion exercises and isometric contraction exercises,HbA1c level|WOMAC physical function subscale scores|30-s chair stand test [CST]|3-m timed up and go test [TUG],Shu-Mei Chen|Chang Gung Memorial Hospital,All,"60 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,201700009B0D001,"August 1, 2017","January 31, 2018","January 31, 2018","July 19, 2019",,"July 19, 2019","Shu-Mei Chen, Kaohsiung, Taiwan",,https://ClinicalTrials.gov/show/NCT04026139
Principal Investigator,"Carel Le Roux, MD PhD",UCD,,NCT04149951,carel le roux,carel,male,0.83,563,88,NCT04149951,Effect of VeSTAL Device in Type 2 Diabetes Mellitus,,Enrolling by invitation,No Results Available,Type 2 Diabetes|Metabolic Syndrome,Device: Vestal Device|Device: Placebo device,Glycated Hemoglobin (HbA1c)|Difference in mean weight loss between the active-product and sham-treated groups.|Daily caloric intake|Blood pressure|Waist circumference|Hip circumference|Body mass index|Appetite|Cravings|Fullness,Neurovalens Ltd.|Compliance Solutions Ltd|University College Dublin|Exploristics Ltd,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UCD2,"June 3, 2020",December 2020,December 2020,"November 4, 2019",,"June 1, 2020","St Vincents Hospital, Dublin, Ireland",,https://ClinicalTrials.gov/show/NCT04149951
Principal Investigator,"Eugene J Barrett, MD PhD",University of Virginia,,NCT04203927,eugene j barrett,eugene,male,0.95,8915,90,NCT04203927,Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes,EJB051,Recruiting,No Results Available,Type2 Diabetes|Insulin Sensitivity,Drug: Empagliflozin 25 MG|Drug: Placebo oral tablet,Myocardial microvascular perfusion|Flow Mediated Dilation (FMD) Vascular measure of conduit artery stiffness Change in Flow Mediated Dilation (FMD) between baseline and after 2 hour insulin clamp Vascular measure of conduit artery stiffness Flow Mediated Dilation ( FMD)|Augmentation Index ( AI)|Pulse Wave Velocity ( PWV),"University of Virginia|National Heart, Lung, and Blood Institute (NHLBI)",All,18 Years to 60 Years   (Adult),Early Phase 1,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,21403|1R01HL142250-01A1,"February 1, 2020","October 22, 2022","November 30, 2022","December 18, 2019",,"February 24, 2020","University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04203927
Principal Investigator,"Stuart C Chipkin, MD","University of Massachusetts Amherst, Department of Kinesiology",,NCT03940937,stuart c chipkin,stuart,male,0.99,10695,91,NCT03940937,Cadence and Intensity in Adults With Type 2 Diabetes,CADENCE-T2DM,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Walking,,Cadence (steps/min)|Oxygen consumption (VO2; mL/kg/min),"University of Massachusetts, Amherst",All,"40 Years to 65 Years   (Adult, Older Adult)",,20,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,CADENCE-T2DM,May 2019,October 2019,October 2019,"May 7, 2019",,"May 7, 2019","Totman Building, Amherst, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03940937
Principal Investigator,"Chao Zheng, MD,PhD",the Second Affiliated Hospital Zhejiang University Schoolof Medicine,,NCT04146155,chao zheng,chao,male,0.85,1009,92,NCT04146155,Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease,,Recruiting,No Results Available,Type 2 Diabetes|Peripheral Vascular Disorder Due to Diabetes Mellitus,Drug: Liraglutide+standard-of-care treatment|Other: standard-of-care treatment,Initial and absolute claudication distance|Assess the effects on ABI of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Assess the effects on endothelial function of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Muscle microvascular perfusion by CEU|Assess the effects on the endothelial circulating progenitor cells concentration of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Changes from baseline in HbA1c,"Second Affiliated Hospital, School of Medicine, Zhejiang University",All,"40 Years and older   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,zhengchao,"May 1, 2020","December 31, 2021","December 31, 2021","October 31, 2019",,"May 12, 2020","The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT04146155
Principal Investigator,"Youjin Pan, MD.",Second Affiliated Hospital of Wenzhou Medical University,,NCT04146155,youjin pan,youjin,female,0.91,180,92,NCT04146155,Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease,,Recruiting,No Results Available,Type 2 Diabetes|Peripheral Vascular Disorder Due to Diabetes Mellitus,Drug: Liraglutide+standard-of-care treatment|Other: standard-of-care treatment,Initial and absolute claudication distance|Assess the effects on ABI of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Assess the effects on endothelial function of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Muscle microvascular perfusion by CEU|Assess the effects on the endothelial circulating progenitor cells concentration of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Changes from baseline in HbA1c,"Second Affiliated Hospital, School of Medicine, Zhejiang University",All,"40 Years and older   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,zhengchao,"May 1, 2020","December 31, 2021","December 31, 2021","October 31, 2019",,"May 12, 2020","The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT04146155
Principal Investigator,"Xia Li, MD,PhD",Central South University,,NCT04146155,xia li,xia,female,0.67,490,92,NCT04146155,Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease,,Recruiting,No Results Available,Type 2 Diabetes|Peripheral Vascular Disorder Due to Diabetes Mellitus,Drug: Liraglutide+standard-of-care treatment|Other: standard-of-care treatment,Initial and absolute claudication distance|Assess the effects on ABI of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Assess the effects on endothelial function of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Muscle microvascular perfusion by CEU|Assess the effects on the endothelial circulating progenitor cells concentration of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Changes from baseline in HbA1c,"Second Affiliated Hospital, School of Medicine, Zhejiang University",All,"40 Years and older   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,zhengchao,"May 1, 2020","December 31, 2021","December 31, 2021","October 31, 2019",,"May 12, 2020","The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT04146155
Principal Investigator,"Li Li, MD.",Ningbo Hospital of Zhejiang University,,NCT04146155,li li,li,female,0.63,5785,92,NCT04146155,Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease,,Recruiting,No Results Available,Type 2 Diabetes|Peripheral Vascular Disorder Due to Diabetes Mellitus,Drug: Liraglutide+standard-of-care treatment|Other: standard-of-care treatment,Initial and absolute claudication distance|Assess the effects on ABI of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Assess the effects on endothelial function of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Muscle microvascular perfusion by CEU|Assess the effects on the endothelial circulating progenitor cells concentration of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Changes from baseline in HbA1c,"Second Affiliated Hospital, School of Medicine, Zhejiang University",All,"40 Years and older   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,zhengchao,"May 1, 2020","December 31, 2021","December 31, 2021","October 31, 2019",,"May 12, 2020","The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT04146155
Principal Investigator,"Anna Solini, MD, PhD",University of Pisa,,NCT04176276,anna solini,anna,female,0.98,383713,93,NCT04176276,Determining Serum and Urinary Levels of miRNA 192 and miRNA 25 in Patients With and Without Type 2 Diabetes.,,Completed,No Results Available,Diabetic Kidney Disease|Type2 Diabetes,Other: no interventions required.,Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25,University of Pisa,All,"18 Years to 75 Years   (Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,AS0004,"March 1, 2018","December 31, 2019","March 1, 2020","November 25, 2019",,"June 5, 2020","University of Pisa, Pisa, Italy",,https://ClinicalTrials.gov/show/NCT04176276
Principal Investigator,Byung Wan Lee,Severance Hospital,,NCT03910361,byung wan lee,byung,male,0.99,849,94,NCT03910361,Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases,,Enrolling by invitation,No Results Available,Type2 Diabetes|Non-Alcoholic Fatty Liver Disease,Drug: Evogliptin|Drug: Pioglitazone,Changes from baseline intrahepatic fat (%),"Dong-A ST Co., Ltd.",All,"19 Years to 70 Years   (Adult, Older Adult)",Phase 4,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DA1229_NAFLD_IV,"May 7, 2019","September 30, 2020","September 30, 2020","April 10, 2019",,"July 9, 2019","Samsung Medical Center, Changwon, Korea, Republic of|Soonchunhyang University Hospital, Cheonan, Korea, Republic of|Keimyung Dongsan University Medical Center, Daegu, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Catholic University of Seoul ST.Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03910361
Principal Investigator,"Jiten Chhabra, MD, MS",Georgia Institute of Technology,,NCT03926598,jiten chhabra,jiten,male,0.99,172,95,NCT03926598,Guide To Goals: A Novel Care Coordination Tool for Children With Type Two Diabetes (T2D),GTG,Recruiting,No Results Available,Type2 Diabetes Mellitus,Behavioral: Patient and/or Family Member Intervention|Behavioral: Certified Diabetes Educator Intervention|Behavioral: Physician Intervention|Behavioral: Front Desk Staff Intervention|Behavioral: Nurse Intervention,Participant Task Completion Rate for Usability Testing Session,Georgia Institute of Technology|Emory University,All,"12 Years and older   (Child, Adult, Older Adult)",,10,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,H18426,"June 5, 2019","September 30, 2020","December 20, 2020","April 24, 2019",,"October 31, 2019","Children's Helathcare of Atlanta, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03926598
Principal Investigator,Michael D Jensen,Mayo Clinic,,NCT03867500,michael d jensen,michael,male,0.99,245870,97,NCT03867500,Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus,,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Obesity,Drug: Niacin|Other: Saline,Difference in insulin-stimulated glucose disposal between overnight saline control study and overnight/insulin clamp niacin infusion study.|Difference in insulin-stimulated phosphorylation of insulin-responsive signaling molecules between overnight saline control study and overnight/insulin clamp niacin infusion study.|Difference in incorporation of 13-palmitate and D9-palmitate into intramyocellular lipid intermediates between overnight saline control study and overnight/insulin clamp niacin infusion study.|Effects of niacin on adipocyte lipolysis proteins,Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 55 Years   (Adult),Early Phase 1,20,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,17-009977|5R01DK045343-27,"November 1, 2018","December 31, 2021","December 31, 2021","March 8, 2019",,"April 8, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03867500
Study Director,"Michael Horowitz, MD PhD",University of Adelaide,,NCT03864562,michael horowitz,michael,male,0.99,245870,221,NCT03864562,Gastric Emptying - Implications for the Pathogenesis of Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",,Gastric emptying rate|Serum Insulin concentration|Whole blood glucose concentration|Plasma glucagon concentration|Plasma GLP-1 concentration|Plasma GIP concentration|Serum C-peptide concentration|Attrition rate|Recruitment rate,University of Nottingham|University of Adelaide,All,18 Years to 60 Years   (Adult),,60,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,226-1901,"March 1, 2019","March 28, 2021","June 30, 2021","March 6, 2019",,"March 24, 2020","David Greenfield Human Physiology Unit, University of Nottingham, Nottingham, Notts, United Kingdom",,https://ClinicalTrials.gov/show/NCT03864562
Principal Investigator,"Michael J Paglia, MD, PhD",Geisinger Clinic,,NCT03912363,michael j paglia,michael,male,0.99,245870,350,NCT03912363,Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids,,Recruiting,No Results Available,Type II Diabetes Mellitus|Gestational Diabetes Mellitus,Other: Rotating fluids protocol|Other: Insulin infusion protocol,Neonatal blood glucose value|Mean neonatal blood glucose value|Incidence of maternal hypoglycemia|Mean intrapartum maternal blood glucose value|Maternal blood glucose value before delivery|Incidence of composite neonatal outcome,Geisinger Clinic,Female,"14 Years to 50 Years   (Child, Adult)",Not Applicable,74,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2018-0502,"November 1, 2019","December 31, 2020","June 30, 2021","April 11, 2019",,"November 4, 2019","Geisinger, Danville, Pennsylvania, United States|Geisinger Wyoming Valley, Wilkes-Barre, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03912363
Principal Investigator,"Michael A Helmrath, MD MS","Children's Hospital Medical Center, Cincinnati",,NCT04128995,michael a helmrath,michael,male,0.99,245870,366,NCT04128995,Surgical or Medical Treatment,ST2OMP,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Pediatric Obesity|Bariatric Surgery Candidate",Procedure: Bariatric Surgery|Drug: Advanced Medical Therapy,Glycemic Control|Glycemic Variability|Beta Cell Function|Alpha cell function|Incretin Response|Fatty Liver Disease|Dyslipidemia|Hypertension|Diabetic Kidney Disease,"Children's Hospital Medical Center, Cincinnati|Children's Hospital Colorado",All,"13 Years to 19 Years   (Child, Adult)",Phase 4,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DK119450,"December 15, 2019","January 5, 2022","August 30, 2024","October 16, 2019",,"January 2, 2020","Children's Hospital Colorado, Aurora, Colorado, United States|Cincinnati Childrens, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04128995
Principal Investigator,"Amy S Shah, MD MS",Cincinnati Childrens Hospital Medical Center,,NCT04128995,amy s shah,amy,female,0.97,31233,366,NCT04128995,Surgical or Medical Treatment,ST2OMP,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Pediatric Obesity|Bariatric Surgery Candidate",Procedure: Bariatric Surgery|Drug: Advanced Medical Therapy,Glycemic Control|Glycemic Variability|Beta Cell Function|Alpha cell function|Incretin Response|Fatty Liver Disease|Dyslipidemia|Hypertension|Diabetic Kidney Disease,"Children's Hospital Medical Center, Cincinnati|Children's Hospital Colorado",All,"13 Years to 19 Years   (Child, Adult)",Phase 4,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DK119450,"December 15, 2019","January 5, 2022","August 30, 2024","October 16, 2019",,"January 2, 2020","Children's Hospital Colorado, Aurora, Colorado, United States|Cincinnati Childrens, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04128995
Principal Investigator,"Kristen J Nadeau, MD MS",Children's Hospital Colorado,,NCT04128995,kristen j nadeau,kristen,female,0.85,1525,366,NCT04128995,Surgical or Medical Treatment,ST2OMP,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Pediatric Obesity|Bariatric Surgery Candidate",Procedure: Bariatric Surgery|Drug: Advanced Medical Therapy,Glycemic Control|Glycemic Variability|Beta Cell Function|Alpha cell function|Incretin Response|Fatty Liver Disease|Dyslipidemia|Hypertension|Diabetic Kidney Disease,"Children's Hospital Medical Center, Cincinnati|Children's Hospital Colorado",All,"13 Years to 19 Years   (Child, Adult)",Phase 4,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DK119450,"December 15, 2019","January 5, 2022","August 30, 2024","October 16, 2019",,"January 2, 2020","Children's Hospital Colorado, Aurora, Colorado, United States|Cincinnati Childrens, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04128995
Principal Investigator,"Thomas H Inge, MD PhD",Children's Hospital Colorado,,NCT04128995,thomas h inge,thomas,male,0.99,176440,366,NCT04128995,Surgical or Medical Treatment,ST2OMP,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Pediatric Obesity|Bariatric Surgery Candidate",Procedure: Bariatric Surgery|Drug: Advanced Medical Therapy,Glycemic Control|Glycemic Variability|Beta Cell Function|Alpha cell function|Incretin Response|Fatty Liver Disease|Dyslipidemia|Hypertension|Diabetic Kidney Disease,"Children's Hospital Medical Center, Cincinnati|Children's Hospital Colorado",All,"13 Years to 19 Years   (Child, Adult)",Phase 4,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DK119450,"December 15, 2019","January 5, 2022","August 30, 2024","October 16, 2019",,"January 2, 2020","Children's Hospital Colorado, Aurora, Colorado, United States|Cincinnati Childrens, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04128995
Principal Investigator,"Michael H Brent, MD, FRCSC","University Health Network, Toronto Western Hospital",,NCT03927859,michael h brent,michael,male,0.99,245870,507,NCT03927859,Increasing DR Screening Through TOP: Supporting Implementation and Identifying Opportunities for Scale up in Ontario,TOP,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","Other: a mail letter, a phone call and a phone call plus mailed letter",Number of bookings made through the TOP program|Number of self-reported booking made outside of TOP,Women's College Hospital|Canadian Institutes of Health Research (CIHR)|Diabetes Action Canada,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,420,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2018-0068-E,"July 5, 2018","June 30, 2019","August 30, 2019","April 25, 2019",,"April 25, 2019","Black Creek Community Health Centre, Toronto, Ontario, Canada|Women's College Hospital Family Health Team, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03927859
Principal Investigator,"Laura Desveaux, PhD",Women's College Hospital,,NCT03927859,laura desveaux,laura,female,0.98,288403,507,NCT03927859,Increasing DR Screening Through TOP: Supporting Implementation and Identifying Opportunities for Scale up in Ontario,TOP,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","Other: a mail letter, a phone call and a phone call plus mailed letter",Number of bookings made through the TOP program|Number of self-reported booking made outside of TOP,Women's College Hospital|Canadian Institutes of Health Research (CIHR)|Diabetes Action Canada,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,420,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2018-0068-E,"July 5, 2018","June 30, 2019","August 30, 2019","April 25, 2019",,"April 25, 2019","Black Creek Community Health Centre, Toronto, Ontario, Canada|Women's College Hospital Family Health Team, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03927859
Principal Investigator,"Onil Bhattacharyya, MD, PhD",Women's College Hospital,,NCT03927859,onil bhattacharyya,onil,male,0.91,142,507,NCT03927859,Increasing DR Screening Through TOP: Supporting Implementation and Identifying Opportunities for Scale up in Ontario,TOP,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","Other: a mail letter, a phone call and a phone call plus mailed letter",Number of bookings made through the TOP program|Number of self-reported booking made outside of TOP,Women's College Hospital|Canadian Institutes of Health Research (CIHR)|Diabetes Action Canada,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,420,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2018-0068-E,"July 5, 2018","June 30, 2019","August 30, 2019","April 25, 2019",,"April 25, 2019","Black Creek Community Health Centre, Toronto, Ontario, Canada|Women's College Hospital Family Health Team, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03927859
Principal Investigator,"Vess Stamenova, PhD",Women's College Hospital,,NCT03927859,vess stamenova,vess,male,0.61,38,507,NCT03927859,Increasing DR Screening Through TOP: Supporting Implementation and Identifying Opportunities for Scale up in Ontario,TOP,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","Other: a mail letter, a phone call and a phone call plus mailed letter",Number of bookings made through the TOP program|Number of self-reported booking made outside of TOP,Women's College Hospital|Canadian Institutes of Health Research (CIHR)|Diabetes Action Canada,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,420,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2018-0068-E,"July 5, 2018","June 30, 2019","August 30, 2019","April 25, 2019",,"April 25, 2019","Black Creek Community Health Centre, Toronto, Ontario, Canada|Women's College Hospital Family Health Team, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03927859
Principal Investigator,"Olov Rolandsson, Professor",Umeå University,,NCT03877783,olov rolandsson,olov,male,0.97,90,98,NCT03877783,DEMAND - Multifactorial Study to Reduce Dementia in People With Type 2 Diabetes,DEMAND,Not yet recruiting,No Results Available,Type 2 Diabetes Mellitus|Mild Cognitive Impairment,Dietary Supplement: mediterranean diet|Behavioral: individualized fitness program|Other: recommended modified pharmacological treatment,inclusion rate|adherence rate|retention rate|Metabolic change|Memory function,Umeå University|Uppsala University,All,65 Years and older   (Older Adult),Not Applicable,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other",DEMAND pilot,"February 1, 2020","December 31, 2021","June 30, 2022","March 18, 2019",,"February 7, 2020","Uppsala University, Uppsala, Uppsala Län, Sweden|Umeå University, Umeå, Västerbotten, Sweden",,https://ClinicalTrials.gov/show/NCT03877783
Principal Investigator,"Jamie Creason, RD",Sansum Diabetes Research Institute,,NCT04016584,jamie creason,jamie,male,0.81,19333,99,NCT04016584,Diabetes Pueblo Program - Application and Acceptability of Culturally Appropriate Latino Education for Insulin Therapy,DiabPueblo,Recruiting,No Results Available,Type2 Diabetes,Behavioral: Diabetes Pueblo,"Success (evaluated by a Yes/No format) recruiting and completing a new targeted diabetes and insulin education program, Diabetes Pueblo, for Latino adults with type 2 diabetes.|Diabetes self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes Pueblo evaluated by questionnaire",Sansum Diabetes Research Institute|Eli Lilly and Company,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,30,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LY2017-6000,"May 10, 2019","March 30, 2020","March 30, 2020","July 11, 2019",,"March 20, 2020","Sansum Diabetes Research Institute, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT04016584
Principal Investigator,Jingya Yan,The University of Hong Kong-Shenzhen Hospital,,NCT04120844,jingya yan,jingya,female,1.0,11,100,NCT04120844,Effectiveness of Motivational Interviewing on Improving Care for Type 2 Diabetes Mellitus Patients in China,,Completed,No Results Available,Diabete Type 2,Behavioral: Motivational interviewing (MI)-based patient empowerment program (PEP)|Behavioral: Traditional lecture style health education,"Problem Areas in Diabetic (PAID) Questionnaire|""Patient Enablement Index"" (PEI) score|Stages of Change score",The University of Hong Kong-Shenzhen Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,225,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,JCYJ20150331142757385,"May 1, 2016","April 1, 2017","September 26, 2019","October 9, 2019",,"October 9, 2019",,,https://ClinicalTrials.gov/show/NCT04120844
Principal Investigator,Wei Liang,"The University of Hong Kong - Shenzhen Hospital, Shenzhen, China.",,NCT04120844,wei liang,wei,male,0.72,5779,100,NCT04120844,Effectiveness of Motivational Interviewing on Improving Care for Type 2 Diabetes Mellitus Patients in China,,Completed,No Results Available,Diabete Type 2,Behavioral: Motivational interviewing (MI)-based patient empowerment program (PEP)|Behavioral: Traditional lecture style health education,"Problem Areas in Diabetic (PAID) Questionnaire|""Patient Enablement Index"" (PEI) score|Stages of Change score",The University of Hong Kong-Shenzhen Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,225,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,JCYJ20150331142757385,"May 1, 2016","April 1, 2017","September 26, 2019","October 9, 2019",,"October 9, 2019",,,https://ClinicalTrials.gov/show/NCT04120844
Principal Investigator,Chen Qingqi,The University of Hong Kong-Shenzhen Hospital,,NCT04120844,chen qingqi,chen,male,0.62,5003,100,NCT04120844,Effectiveness of Motivational Interviewing on Improving Care for Type 2 Diabetes Mellitus Patients in China,,Completed,No Results Available,Diabete Type 2,Behavioral: Motivational interviewing (MI)-based patient empowerment program (PEP)|Behavioral: Traditional lecture style health education,"Problem Areas in Diabetic (PAID) Questionnaire|""Patient Enablement Index"" (PEI) score|Stages of Change score",The University of Hong Kong-Shenzhen Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,225,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,JCYJ20150331142757385,"May 1, 2016","April 1, 2017","September 26, 2019","October 9, 2019",,"October 9, 2019",,,https://ClinicalTrials.gov/show/NCT04120844
Principal Investigator,Wong Chi Wai William,The University of Hong Kong-Shenzhen Hospital,,NCT04120844,wong chi wai william,wong,male,0.62,3159,100,NCT04120844,Effectiveness of Motivational Interviewing on Improving Care for Type 2 Diabetes Mellitus Patients in China,,Completed,No Results Available,Diabete Type 2,Behavioral: Motivational interviewing (MI)-based patient empowerment program (PEP)|Behavioral: Traditional lecture style health education,"Problem Areas in Diabetic (PAID) Questionnaire|""Patient Enablement Index"" (PEI) score|Stages of Change score",The University of Hong Kong-Shenzhen Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,225,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,JCYJ20150331142757385,"May 1, 2016","April 1, 2017","September 26, 2019","October 9, 2019",,"October 9, 2019",,,https://ClinicalTrials.gov/show/NCT04120844
Principal Investigator,Jennifer Li,The University of Hong Kong-Shenzhen Hospital,,NCT04120844,jennifer li,jennifer,female,0.98,90255,100,NCT04120844,Effectiveness of Motivational Interviewing on Improving Care for Type 2 Diabetes Mellitus Patients in China,,Completed,No Results Available,Diabete Type 2,Behavioral: Motivational interviewing (MI)-based patient empowerment program (PEP)|Behavioral: Traditional lecture style health education,"Problem Areas in Diabetic (PAID) Questionnaire|""Patient Enablement Index"" (PEI) score|Stages of Change score",The University of Hong Kong-Shenzhen Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,225,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,JCYJ20150331142757385,"May 1, 2016","April 1, 2017","September 26, 2019","October 9, 2019",,"October 9, 2019",,,https://ClinicalTrials.gov/show/NCT04120844
Principal Investigator,"Wei Chen, M.D.",Peking Union Medical College Hospital,,NCT03972904,wei chen,wei,male,0.72,5779,228,NCT03972904,A Clinical Trial of Overweight/Obesity With Type 2 Diabetes,ELFOOD,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Overweight and Obesity",Dietary Supplement: Light-Fat Rice® combined with Active Peptide®+ lifestyle guidance|Dietary Supplement: A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin + lifestyle guidance,Dynamic blood glucose changes (average blood glucose)|Insulin resistance index changes|Blood glucose control compliance rate|Glycated albumin changes,"Peking Union Medical College Hospital|Hebei Dongfangyun Health Management Co.,Ltd",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",HS-1910,"June 20, 2019","September 20, 2020","July 20, 2021","June 4, 2019",,"May 20, 2020","Dongcheng district，Peking union medical college hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03972904
Principal Investigator,"Jennifer L Reed, PhD",Ottawa Heart Institute Research Corporation,,NCT04190212,jennifer l reed,jennifer,female,0.98,90255,313,NCT04190212,The Effect of High-Intensity Interval Training on Glucose Variability and Atrial Fibrillation Symptoms,Glucose-AF,"Active, not recruiting",No Results Available,Atrial Fibrillation|Type 2 Diabetes,Behavioral: High-intensity interval training + standard care,Glucose variability|Atrial fibrillation symptom severity|Atrial fibrillation-related quality of life|General quality of life|Sleep quality|Changes in blood biomarker concentrations,Ottawa Heart Institute Research Corporation,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other",20190687,"January 20, 2020","August 1, 2021","December 31, 2021","December 9, 2019",,"April 3, 2020","University of Ottawa Heart Institute, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04190212
Principal Investigator,"Qiuhe Ph.D Ji, M.D.","Department of Endocrinology,Xi jing Hospital,Fourth Military Medical University",,NCT03796975,qiuhe ph.d ji,qiuhe,male,1.0,1,101,NCT03796975,Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease,,"Active, not recruiting",No Results Available,Type2 Diabetes Mellitus|Non-alcoholic Fatty Liver Disease,Drug: Combination of Pioglitazone and Metformin Tablets|Drug: Metformin Hydrochloride Tablets,Decreased of liver fat content of fatty liver after 24 weeks treatment as assessed by B-ultrasound|Change of B-cell function after 24 weeks treatment as assessed by homeostasis model assessment of insulin resistance index|Change of liver enzyme after 24 weeks treatment as assessed by blood test|Decreased of HbA1c after 24 weeks treatment as assessed by blood test|Decreased of fasting blood glucose after 24 weeks treatment as assessed by blood test|Change of weight and waistline after 24 weeks treatment as assessed by standard measurement,Xijing Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KY20172053-1,"April 20, 2018",February 2019,February 2019,"January 8, 2019",,"January 8, 2019","Xijing Hospital, Fourth Military Medical university, Xi'an, Shaanxi, China",,https://ClinicalTrials.gov/show/NCT03796975
Principal Investigator,"Grégory BAUD, MD","University Hospital, Lille",,NCT03821636,grégory baud,grégory,male,1.0,29,102,NCT03821636,Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients.,PRECI-Surg,Not yet recruiting,No Results Available,Diabetes Mellitus Type 2 in Obese,Procedure: Standard Roux-en-Y gastric bypass|Procedure: Long alimentary limb Roux-en-Y gastric bypass,Rate of type 2 diabetes remission|Absolute weight loss (aWL in kg)|Excess Weight Loss percentage (EWL%)|Excess BMI Loss percentage (EBL%)|Medical and surgical complication rates|Type and severity of early and late complications for each procedure|Patient's quality of life score according to the Impact of Weight on Quality of Life (IWQOL) questionnaire|Patient's quality of life score according to the Gastrointestinal Quality of Life Index (GIQLI) questionnaire adapted to bariatric surgery.|Change in glucose homeostasis|Change in HbA1c|Change in fasting glycemia|changes in fasting insulinemia|change in fasting c-peptide|Number of antidiabetic treatments|Changes in blood lipids profile|change in vitamins status assessment|change in prealbumin levels,"University Hospital, Lille|Ministry of Health, France",All,18 Years to 60 Years   (Adult),Not Applicable,396,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2017_02|2017-A01761-52|PHRCI-16-090,December 2019,January 2022,January 2022,"January 30, 2019",,"July 11, 2019",,,https://ClinicalTrials.gov/show/NCT03821636
Principal Investigator,"Karen E Atler, PhD",Colorado State University,,NCT04164030,karen e atler,karen,female,0.95,48557,104,NCT04164030,Education and Exercise Program for Adults With Type 2 Diabetes,,Recruiting,No Results Available,Type 2 Diabetes,Behavioral: Education and Exercise Program for Adults with Type 2 Diabetes|Behavioral: Nutrition Education plus Occupational Therapy plus Yoga,Change in habits measured using the Self-Report Habit Index|Change in diabetes distress measured using the Diabetes Distress Scale,Colorado State University|American Occupational Therapy Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,140898,"August 26, 2019","June 15, 2020","September 30, 2020","November 15, 2019",,"November 15, 2019","Colorado State University, Fort Collins, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04164030
Principal Investigator,"Jae Hyeon Kim, MD PhD",Samsung Medical Center,,NCT04161170,jae hyeon kim,jae,male,0.87,3923,105,NCT04161170,Digital Integrated Healthcare Platform in Patients With Type 2 Diabetes,,Recruiting,No Results Available,Type 2 Diabetes,Device: Digital integrated healthcare platform,Change of HbA1c (glycated hemoglobin) at 6months from baseline|HbA1c|number of intervention for education in interventinal group C|hypoglycemic events|adverse events|patient satisfaction questionnaire score|body weight|BMI (body mass index)|body fat (%)|step count|burned calories|walking distances|intake calories|fasting glucose level|total cholesterol level|HDL cholesterol level|Triglycerides level|LDL cholesterol level|mean glucose level by CGMS (continuous glucose monitoring system) in interventional group C|glycemic variability by CGMS in interventional group C|standard deviation by CGMS in interventional group C|average applying time of CGMS in interventional group C|time in range of <54mg/dL by CGMS in interventional group C|time in range of <70mg/dL by CGMS in interventional group C|time in range of 70-180 mg/dL by CGMS in interventional group C|time in range of >180 mg/dL by CGMS in interventional group C|time in range of >250 mg/dL by CGMS in interventional group C,Samsung Medical Center,All,"19 Years to 70 Years   (Adult, Older Adult)",Not Applicable,294,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019-05-028-007,"November 20, 2019","August 31, 2021","December 31, 2021","November 13, 2019",,"January 18, 2020","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04161170
Study Director,"Keivan Ahmadi, PhD","Associate Professor in Pharmacology & Therapeutics, Lincoln Medical School",,NCT04081766,keivan ahmadi,keivan,male,0.98,245,106,NCT04081766,Pharmacist-Led Study in Controlling Hypoglycemia in Older Adults With Type 2 Diabetes Mellitus,ROSE-ADAM,Recruiting,No Results Available,Diabetes Mellitus Type 2 With Hypoglycemia,Behavioral: SUGAR Handshake,Frequency of total episodes of hypoglycaemia|Frequency of severe hypoglycaemia|Frequency of asymptomatic hypoglycemia|Frequency of symptomatic hypoglycemia|Change in HbA1c level.,University of Lincoln,All,65 Years and older   (Older Adult),Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,2019-May-0170,"February 9, 2020",September 2020,October 2020,"September 9, 2019",,"March 2, 2020","King Abdullah University Hospital, Irbid, Jordan",,https://ClinicalTrials.gov/show/NCT04081766
Study Director,"Roman Hovorka, PhD",University of Cambridge,,NCT04025775,roman hovorka,roman,male,0.98,54731,107,NCT04025775,Closed-loop in Adults With T2D Requiring Dialysis,AP-Renal,Recruiting,No Results Available,Type 2 Diabetes|End Stage Renal Disease,Device: CamAPS HX Closed-loop|Other: Multiple Daily Insulin Injections (Control),"Time in the target glucose range (5.6 to 10.0 mmol/l)|Time spent above target glucose (10.0 mmol/l)|Mean glucose|Time spent in hypoglycaemia (<3.9 mmol/l)|Time spent below target glucose (5.6 mmol/l)|Standard deviation of glucose levels|Coefficient of variation of glucose levels|Time spent below <3.0 mmol/l|Time in significant hyperglycaemia (> 20 mmol/l)|Total, basal and bolus insulin dose|AUC of glucose below 3.5 mmol/l","University of Cambridge|University Hospital Inselspital, Berne",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AP-Renal,"August 1, 2019",December 2020,December 2020,"July 19, 2019",,"February 18, 2020","Inselspital, Bern University Hospital, Bern, Switzerland|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT04025775
Principal Investigator,"Penny M Kris-Etherton, PhD, RDN",Penn State,,NCT03826472,penny m kris-etherton,penny,female,0.9,3861,108,NCT03826472,Almond Butter and Fasting Glucose,,Completed,No Results Available,Type2 Diabetes,Other: Almond Butter,Fasting glucose|Glucose trends|Inhibitory control,Penn State University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PKE AlmondButter,"March 8, 2019","March 1, 2020","March 1, 2020","February 1, 2019",,"March 27, 2020","Penn State, University Park, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03826472
Principal Investigator,"Penny Gowland, PhD",Sir Peter Mansfield Imaging Centre,,NCT04004273,penny gowland,penny,female,0.9,3861,333,NCT04004273,"Diabetes, Exercise and Liver Fat (DELIVER)",(DELIVER),Recruiting,No Results Available,Type 2 Diabetes Mellitus|Non-Alcoholic Fatty Liver Disease|Obesity|Insulin Resistance|Liver Diseases|Fatty Liver|Diabetes Mellitus|Glucose Metabolism Disorders|Glucose Intolerance|Metabolic Disease,Behavioral: Exercise,Change in liver saturated lipid index (%) determined by proton magnetic resonance spectroscopy (1H-MRS) using a 3T MRI scanner|Change in Liver unsaturated lipid index (%) - measured using 1H-MRS|Change in Liver polyunsaturated lipid index (%) - measured using 1H-MRS|Change in total hepatic lipid composition (%) - measured using 1H-MRS|Change in liver inflammation - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in visceral adipose tissue - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in subcutaneous abdominal adipose tissue - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in body mass|Change in body fat percentage|Change in aerobic fitness (peak oxygen uptake)|Change in liver enzymes|Change in glucose|Change in insulin|Change in lipids|Change in HbA1c|Change in homeostasis model assessment of insulin resistance (HOMA-IR; surrogate marker of hepatic insulin resistance)|Change in adipose tissue insulin resistance (ADIPO-IR; surrogate marker of adipose tissue insulin resistance)|Change in circulating Inflammatory proteins|Change in Hepatokines|Change in objectively measured sedentary time - GENEactiv physical activity monitor|Change in objectively measured physical activity - GENEactiv physical activity monitor|Change in energy intake|Change in macronutrient intake,"James King|University Hospitals, Leicester|Nottingham University Hospitals NHS Trust|University of Nottingham|Loughborough University",Male,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,241046,"October 30, 2018","April 1, 2020","April 1, 2020","July 2, 2019",,"July 2, 2019","University Hospitals of Leicester Nhs Trust, Leicester, East Midlands, United Kingdom|NIHR Clinical Research Network, Leicester, East Midlands, United Kingdom|Sir Peter Mansfield Imaging Centre, Nottingham, East Midlands, United Kingdom|Nottingham University Hospitals Nhs Trust, Nottingham, East Midlands, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04004273/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04004273/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04004273
Principal Investigator,"James A King, PhD",Loughborough University,,NCT04004273,james a king,james,male,0.99,117309,333,NCT04004273,"Diabetes, Exercise and Liver Fat (DELIVER)",(DELIVER),Recruiting,No Results Available,Type 2 Diabetes Mellitus|Non-Alcoholic Fatty Liver Disease|Obesity|Insulin Resistance|Liver Diseases|Fatty Liver|Diabetes Mellitus|Glucose Metabolism Disorders|Glucose Intolerance|Metabolic Disease,Behavioral: Exercise,Change in liver saturated lipid index (%) determined by proton magnetic resonance spectroscopy (1H-MRS) using a 3T MRI scanner|Change in Liver unsaturated lipid index (%) - measured using 1H-MRS|Change in Liver polyunsaturated lipid index (%) - measured using 1H-MRS|Change in total hepatic lipid composition (%) - measured using 1H-MRS|Change in liver inflammation - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in visceral adipose tissue - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in subcutaneous abdominal adipose tissue - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in body mass|Change in body fat percentage|Change in aerobic fitness (peak oxygen uptake)|Change in liver enzymes|Change in glucose|Change in insulin|Change in lipids|Change in HbA1c|Change in homeostasis model assessment of insulin resistance (HOMA-IR; surrogate marker of hepatic insulin resistance)|Change in adipose tissue insulin resistance (ADIPO-IR; surrogate marker of adipose tissue insulin resistance)|Change in circulating Inflammatory proteins|Change in Hepatokines|Change in objectively measured sedentary time - GENEactiv physical activity monitor|Change in objectively measured physical activity - GENEactiv physical activity monitor|Change in energy intake|Change in macronutrient intake,"James King|University Hospitals, Leicester|Nottingham University Hospitals NHS Trust|University of Nottingham|Loughborough University",Male,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,241046,"October 30, 2018","April 1, 2020","April 1, 2020","July 2, 2019",,"July 2, 2019","University Hospitals of Leicester Nhs Trust, Leicester, East Midlands, United Kingdom|NIHR Clinical Research Network, Leicester, East Midlands, United Kingdom|Sir Peter Mansfield Imaging Centre, Nottingham, East Midlands, United Kingdom|Nottingham University Hospitals Nhs Trust, Nottingham, East Midlands, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04004273/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04004273/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04004273
Principal Investigator,"David Webb, PhD",Leicester Diabetes Research Centre,,NCT04004273,david webb,david,male,0.99,501011,333,NCT04004273,"Diabetes, Exercise and Liver Fat (DELIVER)",(DELIVER),Recruiting,No Results Available,Type 2 Diabetes Mellitus|Non-Alcoholic Fatty Liver Disease|Obesity|Insulin Resistance|Liver Diseases|Fatty Liver|Diabetes Mellitus|Glucose Metabolism Disorders|Glucose Intolerance|Metabolic Disease,Behavioral: Exercise,Change in liver saturated lipid index (%) determined by proton magnetic resonance spectroscopy (1H-MRS) using a 3T MRI scanner|Change in Liver unsaturated lipid index (%) - measured using 1H-MRS|Change in Liver polyunsaturated lipid index (%) - measured using 1H-MRS|Change in total hepatic lipid composition (%) - measured using 1H-MRS|Change in liver inflammation - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in visceral adipose tissue - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in subcutaneous abdominal adipose tissue - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in body mass|Change in body fat percentage|Change in aerobic fitness (peak oxygen uptake)|Change in liver enzymes|Change in glucose|Change in insulin|Change in lipids|Change in HbA1c|Change in homeostasis model assessment of insulin resistance (HOMA-IR; surrogate marker of hepatic insulin resistance)|Change in adipose tissue insulin resistance (ADIPO-IR; surrogate marker of adipose tissue insulin resistance)|Change in circulating Inflammatory proteins|Change in Hepatokines|Change in objectively measured sedentary time - GENEactiv physical activity monitor|Change in objectively measured physical activity - GENEactiv physical activity monitor|Change in energy intake|Change in macronutrient intake,"James King|University Hospitals, Leicester|Nottingham University Hospitals NHS Trust|University of Nottingham|Loughborough University",Male,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,241046,"October 30, 2018","April 1, 2020","April 1, 2020","July 2, 2019",,"July 2, 2019","University Hospitals of Leicester Nhs Trust, Leicester, East Midlands, United Kingdom|NIHR Clinical Research Network, Leicester, East Midlands, United Kingdom|Sir Peter Mansfield Imaging Centre, Nottingham, East Midlands, United Kingdom|Nottingham University Hospitals Nhs Trust, Nottingham, East Midlands, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04004273/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04004273/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04004273
Principal Investigator,"Ronnie Aronson, MD",LMC Diabetes & Endocrinology,,NCT04175665,ronnie aronson,ronnie,male,0.94,6898,109,NCT04175665,Real-world Health Outcomes in Canadian Patients Using Semaglutide,,Completed,No Results Available,Type 2 Diabetes,Drug: Semaglutide,Change in HbA1c|Change in body weight|Change in body mass index (BMI)|Change in systolic blood pressure (SBP)|Change in diastolic blood pressure (DBP)|Change in triglycerides|Change in LDL cholesterol|Change in non-HDL cholesterol|Change in estimated glomerular filtration rate (eGFR)|Change in alanine amino transaminase (ALT)|Proportion of patients who report ≥ 1 weekly incidence of any hypoglycemia|Proportion of patients who report ≥ 1 yearly incidence of severe hypoglycemia|Proportion of patients who achieve HbA1c ≤7.0%|Proportion of patients who achieve HbA1c ≤8.0%|Proportion of patients who achieve HbA1c reduction ≥0.5%|Proportion of patients who achieve HbA1c reduction ≥1.0%|Proportion of patients who achieve weight loss ≥5%|Proportion of patients who achieve weight loss ≥10%,LMC Diabetes & Endocrinology Ltd.,All,"18 Years and older   (Adult, Older Adult)",,1133,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,SPARE,"January 6, 2020","February 9, 2020","February 9, 2020","November 25, 2019",,"February 21, 2020","LMC Diabetes & Endocrinology, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04175665
Principal Investigator,"Monica C Skarulis, MD",Hamad Medical Corporation,,NCT04081064,monica c skarulis,monica,female,0.99,81357,110,NCT04081064,"Impact of Body Composition and Exercise on Clinical, Metabolic and Molecular Parameters in Type 2 Diabetics in Qatar",,Recruiting,No Results Available,Type 2 Diabetes,Behavioral: 10-week exercise programme based on aerobic interval and resistance training,Insulin sensitivity|Glucose regulation/ insulin sensitivity|Pancreatic beta-cell function|Hepatic insulin resistance index|Vascular reactivity|Body Mass Index (BMI)|Body fat profiling|Total body fat|Non-fat mass|Visceral adipose volume|Cardiorespiratory fitness (estimated maximal oxygen uptake)|Upper body strength|Physical function|Lower body strength|Fasting Plasma glucose,Hamad Medical Corporation|Hamad Bin Khalifa University,All,18 Years to 60 Years   (Adult),Not Applicable,60,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MRC-03-17-0025,"January 15, 2019","December 31, 2020","July 31, 2022","September 6, 2019",,"October 7, 2019","Hamad Medical Corporation, Doha, Qatar",,https://ClinicalTrials.gov/show/NCT04081064
Study Chair,"Massimo Federici, Professor",Department of Systems Medicine,,NCT04190160,massimo federici,massimo,male,0.99,69361,111,NCT04190160,Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira),XETD2,"Active, not recruiting",No Results Available,Type2 Diabetes,Drug: IDegLira,Self reported quality of Life (CASP-19)|The Diabetes Treatment Satisfaction (DTSQ)|Glycemic control|Hypoglycaemia|Self reported depression (GDS)|Hypoglycaemic related hospitalizations|Cognitive function (MMSE),Stefano Rizza|University of Rome Tor Vergata,All,75 Years to 99 Years   (Older Adult),Not Applicable,35,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,141/18 XETD2,"November 19, 2018","November 22, 2019","March 16, 2020","December 9, 2019",,"December 9, 2019","Stefano Rizza, Roma, Italy",,https://ClinicalTrials.gov/show/NCT04190160
Principal Investigator,Gary Frost,Imperial College London,,NCT03949582,gary frost,gary,male,0.99,29381,116,NCT03949582,Acute Mycoprotein Effect on Glycaemic Control in South Asians,ACMYCO,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: Test food containing different types of dietary protein,Blood glucose|Blood insulin|Subjective appetite feelings|Ad libitum energy intake|Energy intake 72 hours post study visit,Imperial College London,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",18HH4870,"May 1, 2019","June 30, 2021","June 30, 2021","May 14, 2019",,"September 17, 2019","NIHR Imperial Clinical Research Facility, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03949582
Principal Investigator,"Saleem A. Banihani, PHD",Jordan University of Science and Technology,,NCT03902288,saleem a. banihani,saleem,male,0.99,1873,120,NCT03902288,Short-term Effect of Pomegranate Juice on Blood Sugar and Its Controlling Hormones in Pre-diabetic and Type II Diabetic Patients.,,Completed,No Results Available,Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L),Other: Fresh pomegranate juice,Fasting serum glucose measurement|Insulin hormone measurement|Erythropoietin hormone measurement|Thyroxine hormone measurement|Cortisol hormone measurement|Melatonin hormone measurement|Testosterone hormone measurement|Aldosterone hormone measurement|Serum total antioxidant activity measurement,Jordan University of Science and Technology,All,35 Years to 60 Years   (Adult),Not Applicable,85,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-20120189,October 2012,April 2013,April 2013,"April 4, 2019",,"April 4, 2019","Jordan University of Science and Technology, Irbid, Jordan",,https://ClinicalTrials.gov/show/NCT03902288
Principal Investigator,"John H Kelly, M.D.",Loma Linda University; Black Hills Lifestyle Medicine Center,,NCT03862963,john h kelly,john,male,0.99,218952,121,NCT03862963,Lifestyle Intervention to Treat Diabetes in the Marshall Islands,,Completed,No Results Available,Type 2 Diabetes Mellitus,Behavioral: Standard of diabetes care|Behavioral: Lifestyle Intervention,"Fasting glucose|HbA1c|Fasting insulin|HOMA-IR|Usage of diabetes medications|Cholesterol (total, HDL, LDL) and triglycerides|Blood pressure|Heart rate|High-sensitivity C-reactive protein|Body weight|Body mass index (BMI)|Waist circumference","University of Alabama at Birmingham|United States Department of Defense|Loma Linda University|Brenda Davis Nutrition Consultation Services|Canvasback Missions, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,138,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-170414009,"June 1, 2006","July 31, 2008",,"March 5, 2019",,"March 5, 2019",,,https://ClinicalTrials.gov/show/NCT03862963
Principal Investigator,"John W Winkelman, MD/PhD",Massachusetts General Hospital,,NCT03818581,john w winkelman,john,male,0.99,218952,145,NCT03818581,Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes,,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Insomnia|Sleep Disorder|Inflammation,Drug: Suvorexant|Other: Placebo,Subjective Total Sleep Time|Subjective Wake After Sleep Onset|Insomnia Severity Index,Massachusetts General Hospital,All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 4,86,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2019P000076,"March 15, 2019","March 15, 2021","September 15, 2021","January 28, 2019",,"August 14, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03818581
Principal Investigator,"John A. Thymis, MD","2nd Department of Cardiology,University of Athens",,NCT03878706,john a. thymis,john,male,0.99,218952,369,NCT03878706,"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination",,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",,Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.|Comparison of arterial stiffness markers difference among treatment groups.|Comparison of wave reflection markers difference among treatment groups|Comparison of central aortic blood pressure differences among treatment groups|Comparison of endothelial glycocalyx thickness difference among treatment groups|Comparison of oxidative stress biomarkers differences among treatment groups,University of Athens,All,"45 Years to 80 Years   (Adult, Older Adult)",,160,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2790/03-11-2017,"November 3, 2017","December 31, 2020","December 31, 2020","March 18, 2019",,"March 18, 2019","""Attikon"" University General Hospital, Athens, Attiki, Greece",,https://ClinicalTrials.gov/show/NCT03878706
Principal Investigator,"Ignatios Ikonomidis, Prof","2nd Department of Cardiology, National and Kapodistrian University of Athens",,NCT03878706,ignatios ikonomidis,ignatios,male,0.98,62,369,NCT03878706,"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination",,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",,Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.|Comparison of arterial stiffness markers difference among treatment groups.|Comparison of wave reflection markers difference among treatment groups|Comparison of central aortic blood pressure differences among treatment groups|Comparison of endothelial glycocalyx thickness difference among treatment groups|Comparison of oxidative stress biomarkers differences among treatment groups,University of Athens,All,"45 Years to 80 Years   (Adult, Older Adult)",,160,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2790/03-11-2017,"November 3, 2017","December 31, 2020","December 31, 2020","March 18, 2019",,"March 18, 2019","""Attikon"" University General Hospital, Athens, Attiki, Greece",,https://ClinicalTrials.gov/show/NCT03878706
Principal Investigator,"Aimilianos N. Kalogeris, MD","2nd Department of Cardiology, University of Athens",,NCT03878706,aimilianos n. kalogeris,aimilianos,male,1.0,5,369,NCT03878706,"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination",,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",,Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.|Comparison of arterial stiffness markers difference among treatment groups.|Comparison of wave reflection markers difference among treatment groups|Comparison of central aortic blood pressure differences among treatment groups|Comparison of endothelial glycocalyx thickness difference among treatment groups|Comparison of oxidative stress biomarkers differences among treatment groups,University of Athens,All,"45 Years to 80 Years   (Adult, Older Adult)",,160,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2790/03-11-2017,"November 3, 2017","December 31, 2020","December 31, 2020","March 18, 2019",,"March 18, 2019","""Attikon"" University General Hospital, Athens, Attiki, Greece",,https://ClinicalTrials.gov/show/NCT03878706
Principal Investigator,"Vaia Lambadiari, Prof.",National and Kapodistrian University of Athens,,NCT03878706,vaia lambadiari,vaia,female,0.93,73,369,NCT03878706,"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination",,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",,Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.|Comparison of arterial stiffness markers difference among treatment groups.|Comparison of wave reflection markers difference among treatment groups|Comparison of central aortic blood pressure differences among treatment groups|Comparison of endothelial glycocalyx thickness difference among treatment groups|Comparison of oxidative stress biomarkers differences among treatment groups,University of Athens,All,"45 Years to 80 Years   (Adult, Older Adult)",,160,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2790/03-11-2017,"November 3, 2017","December 31, 2020","December 31, 2020","March 18, 2019",,"March 18, 2019","""Attikon"" University General Hospital, Athens, Attiki, Greece",,https://ClinicalTrials.gov/show/NCT03878706
Study Chair,"Georgios Dimitriadis, Prof.",National and Kapodistrian University of Athens,,NCT03878706,georgios dimitriadis,georgios,male,0.99,2379,369,NCT03878706,"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination",,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",,Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.|Comparison of arterial stiffness markers difference among treatment groups.|Comparison of wave reflection markers difference among treatment groups|Comparison of central aortic blood pressure differences among treatment groups|Comparison of endothelial glycocalyx thickness difference among treatment groups|Comparison of oxidative stress biomarkers differences among treatment groups,University of Athens,All,"45 Years to 80 Years   (Adult, Older Adult)",,160,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2790/03-11-2017,"November 3, 2017","December 31, 2020","December 31, 2020","March 18, 2019",,"March 18, 2019","""Attikon"" University General Hospital, Athens, Attiki, Greece",,https://ClinicalTrials.gov/show/NCT03878706
Study Chair,"Efstathios Iliodromitis, Prof.",National and Kapodistrian University of Athens,,NCT03878706,efstathios iliodromitis,efstathios,male,1.0,62,369,NCT03878706,"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination",,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",,Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.|Comparison of arterial stiffness markers difference among treatment groups.|Comparison of wave reflection markers difference among treatment groups|Comparison of central aortic blood pressure differences among treatment groups|Comparison of endothelial glycocalyx thickness difference among treatment groups|Comparison of oxidative stress biomarkers differences among treatment groups,University of Athens,All,"45 Years to 80 Years   (Adult, Older Adult)",,160,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2790/03-11-2017,"November 3, 2017","December 31, 2020","December 31, 2020","March 18, 2019",,"March 18, 2019","""Attikon"" University General Hospital, Athens, Attiki, Greece",,https://ClinicalTrials.gov/show/NCT03878706
Principal Investigator,"John Sievenpiper, MD,PhD,FRCPC",University of Toronto,,NCT04094194,john sievenpiper,john,male,0.99,218952,444,NCT04094194,Meta-analysis of the Nordic Dietary Pattern on Cardiometabolic Risk and Cardiovascular Outcomes,,"Active, not recruiting",No Results Available,"Body Weight|Obesity|Overweight and Obesity|Obesity, Abdominal|Hypertension|Hyperlipidemias|Cardiovascular Diseases|Coronary Heart Disease|Stroke|Mortality|Dyslipidemias|Diabetes|PreDiabetes|Insulin Tolerance|Dysglycemia|Metabolic Syndrome",Other: Nordic diet,Incident Cardiovascular Disease (Prospective Cohort Studies)|LDL-cholesterol (randomized and non-randomized controlled trials)|Glycemic control - Fasting blood glucose (randomized and non-randomized controlled trials)|Glycemic control - HbA1c (randomized and non-randomized controlled trials)|Glycemic control - Fasting insulin (randomized and non-randomized controlled trials)|Blood lipids - non-HDL-cholesterol (randomized and non-randomized controlled trials)|Blood lipids - HDL-cholesterol (randomized and non-randomized controlled trials)|Blood lipids - Triglycerides (randomized and non-randomized controlled trials)|Blood lipids - apo B (randomized and non-randomized controlled trials)|Adiposity - Body mass index (BMI) (randomized and non-randomized controlled trials)|Adiposity - Body weight (randomized and non-randomized controlled trials)|Adiposity - Waist circumference (randomized and non-randomized controlled trials)|Blood pressure - systolic blood pressure (randomized and non-randomized controlled trials)|Blood pressure - diastolic blood pressure (randomized and non-randomized controlled trials)|Inflammation - C-reactive protein (CRP) (randomized and non-randomized controlled trials)|Incident Coronary Heart Disease (Prospective Cohort Studies)|Incident Stroke (Prospective Cohort Studies),University of Toronto|Canadian Institutes of Health Research (CIHR)|Canada Research Chairs Endowment of the Federal Government of Canada|The Physicians' Services Incorporated Foundation|Canadian Diabetes Association,All,"Child, Adult, Older Adult",,1,Other,Observational,Observational Model: Other|Time Perspective: Prospective,DNSG-Nordic diet,"December 1, 2017","December 1, 2019","December 1, 2019","September 18, 2019",,"September 18, 2019","The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04094194
Principal Investigator,"Rick Hecht, MD","University of California, San Francisco",,NCT03837405,rick hecht,rick,male,0.99,16772,122,NCT03837405,"(R33 Phase) Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger",Delish R33,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Behavioral: Carbohydrate-restricted diet|Behavioral: Mindfuless,"diet adherence between intervention arms as measured by ketones|diet adherence between intervention arms as measured by 24- hour diet recall--dichotomous|executive functioning /decreased impulsivity-Delayed Discounting|emotion-related eating|Glycemic control--a1c|frequency of eating in response to cravings|diet adherence between intervention arms as measured by 24- hour diet recall--total carbs, continuous|executive functioning /decreased impulsivity--Relative Reinforcing Value of Food (RRVF)|Salzburg Stress Eating Scale|dietary resilience (resumption of dietary adherence) after dietary non-adherence occurs|Weight change","University of California, San Francisco|National Center for Complementary and Integrative Health (NCCIH)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,4R33AT009333|AT009333,"December 12, 2018","September 30, 2021","September 30, 2021","February 12, 2019",,"February 12, 2019","Osher Center for Integrative Medicine, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03837405
Principal Investigator,"Elissa Epel, PhD","University of California, San Francisco",,NCT03837405,elissa epel,elissa,female,0.97,1258,122,NCT03837405,"(R33 Phase) Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger",Delish R33,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Behavioral: Carbohydrate-restricted diet|Behavioral: Mindfuless,"diet adherence between intervention arms as measured by ketones|diet adherence between intervention arms as measured by 24- hour diet recall--dichotomous|executive functioning /decreased impulsivity-Delayed Discounting|emotion-related eating|Glycemic control--a1c|frequency of eating in response to cravings|diet adherence between intervention arms as measured by 24- hour diet recall--total carbs, continuous|executive functioning /decreased impulsivity--Relative Reinforcing Value of Food (RRVF)|Salzburg Stress Eating Scale|dietary resilience (resumption of dietary adherence) after dietary non-adherence occurs|Weight change","University of California, San Francisco|National Center for Complementary and Integrative Health (NCCIH)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,4R33AT009333|AT009333,"December 12, 2018","September 30, 2021","September 30, 2021","February 12, 2019",,"February 12, 2019","Osher Center for Integrative Medicine, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03837405
Principal Investigator,"Wan Zul Haikal Hafiz Wan Zukiman, Mmed",Universiti Putra Malaysia,,NCT03817099,wan zul haikal hafiz wan zukiman,wan,male,0.51,5604,124,NCT03817099,Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study,MyDia-RNP,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: Nutrition Intervention based on My Dia-RNP|Other: Usual Care,Rate of participants completed the study|Rate of participants adhered to the intervention|Efficacy potential on the rate of hypoglycemia|Efficacy potential on the fructosamine level|Efficacy potential on fasting glucose|Efficacy potential on glycemic control|Efficacy potential on functional status|Efficacy potential on body mass index,Universiti Putra Malaysia|Nestle Health Science|Joslin Diabetes Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MyDia-RNP study,"April 1, 2019","December 1, 2019","December 30, 2019","January 25, 2019",,"August 12, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT03817099
Principal Investigator,"Noraida Omar, PhD",Universiti Putra Malaysia,,NCT03817099,noraida omar,noraida,female,1.0,91,124,NCT03817099,Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study,MyDia-RNP,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: Nutrition Intervention based on My Dia-RNP|Other: Usual Care,Rate of participants completed the study|Rate of participants adhered to the intervention|Efficacy potential on the rate of hypoglycemia|Efficacy potential on the fructosamine level|Efficacy potential on fasting glucose|Efficacy potential on glycemic control|Efficacy potential on functional status|Efficacy potential on body mass index,Universiti Putra Malaysia|Nestle Health Science|Joslin Diabetes Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MyDia-RNP study,"April 1, 2019","December 1, 2019","December 30, 2019","January 25, 2019",,"August 12, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT03817099
Principal Investigator,"Zalina Abu Zaid, PhD",Universiti Putra Malaysia,,NCT03817099,zalina abu zaid,zalina,female,0.97,306,124,NCT03817099,Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study,MyDia-RNP,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: Nutrition Intervention based on My Dia-RNP|Other: Usual Care,Rate of participants completed the study|Rate of participants adhered to the intervention|Efficacy potential on the rate of hypoglycemia|Efficacy potential on the fructosamine level|Efficacy potential on fasting glucose|Efficacy potential on glycemic control|Efficacy potential on functional status|Efficacy potential on body mass index,Universiti Putra Malaysia|Nestle Health Science|Joslin Diabetes Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MyDia-RNP study,"April 1, 2019","December 1, 2019","December 30, 2019","January 25, 2019",,"August 12, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT03817099
Principal Investigator,"Azrina Azlan, PhD",Universiti Putra Malaysia,,NCT03817099,azrina azlan,azrina,female,0.98,46,124,NCT03817099,Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study,MyDia-RNP,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: Nutrition Intervention based on My Dia-RNP|Other: Usual Care,Rate of participants completed the study|Rate of participants adhered to the intervention|Efficacy potential on the rate of hypoglycemia|Efficacy potential on the fructosamine level|Efficacy potential on fasting glucose|Efficacy potential on glycemic control|Efficacy potential on functional status|Efficacy potential on body mass index,Universiti Putra Malaysia|Nestle Health Science|Joslin Diabetes Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MyDia-RNP study,"April 1, 2019","December 1, 2019","December 30, 2019","January 25, 2019",,"August 12, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT03817099
Principal Investigator,"Firdaus Mamat @ Mukhtar, PhD",Universiti Putra Malaysia,,NCT03817099,firdaus mamat @ mukhtar,firdaus,male,0.92,805,124,NCT03817099,Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study,MyDia-RNP,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: Nutrition Intervention based on My Dia-RNP|Other: Usual Care,Rate of participants completed the study|Rate of participants adhered to the intervention|Efficacy potential on the rate of hypoglycemia|Efficacy potential on the fructosamine level|Efficacy potential on fasting glucose|Efficacy potential on glycemic control|Efficacy potential on functional status|Efficacy potential on body mass index,Universiti Putra Malaysia|Nestle Health Science|Joslin Diabetes Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MyDia-RNP study,"April 1, 2019","December 1, 2019","December 30, 2019","January 25, 2019",,"August 12, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT03817099
Principal Investigator,"Norhasmah Sulaiman, PhD",Universiti Putra Malaysia,,NCT03817099,norhasmah sulaiman,norhasmah,female,1.0,3,124,NCT03817099,Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study,MyDia-RNP,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: Nutrition Intervention based on My Dia-RNP|Other: Usual Care,Rate of participants completed the study|Rate of participants adhered to the intervention|Efficacy potential on the rate of hypoglycemia|Efficacy potential on the fructosamine level|Efficacy potential on fasting glucose|Efficacy potential on glycemic control|Efficacy potential on functional status|Efficacy potential on body mass index,Universiti Putra Malaysia|Nestle Health Science|Joslin Diabetes Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MyDia-RNP study,"April 1, 2019","December 1, 2019","December 30, 2019","January 25, 2019",,"August 12, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT03817099
Principal Investigator,"Siti NurA'syura Adznam, PhD",Universiti Putra Malaysia,,NCT03817099,siti nura'syura adznam,siti,female,0.99,12114,124,NCT03817099,Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study,MyDia-RNP,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: Nutrition Intervention based on My Dia-RNP|Other: Usual Care,Rate of participants completed the study|Rate of participants adhered to the intervention|Efficacy potential on the rate of hypoglycemia|Efficacy potential on the fructosamine level|Efficacy potential on fasting glucose|Efficacy potential on glycemic control|Efficacy potential on functional status|Efficacy potential on body mass index,Universiti Putra Malaysia|Nestle Health Science|Joslin Diabetes Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MyDia-RNP study,"April 1, 2019","December 1, 2019","December 30, 2019","January 25, 2019",,"August 12, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT03817099
Principal Investigator,"Nur Maziah Hanum Osman, Master",Universiti Putra Malaysia,,NCT03817099,nur maziah hanum osman,nur,female,0.9,24229,124,NCT03817099,Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study,MyDia-RNP,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: Nutrition Intervention based on My Dia-RNP|Other: Usual Care,Rate of participants completed the study|Rate of participants adhered to the intervention|Efficacy potential on the rate of hypoglycemia|Efficacy potential on the fructosamine level|Efficacy potential on fasting glucose|Efficacy potential on glycemic control|Efficacy potential on functional status|Efficacy potential on body mass index,Universiti Putra Malaysia|Nestle Health Science|Joslin Diabetes Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MyDia-RNP study,"April 1, 2019","December 1, 2019","December 30, 2019","January 25, 2019",,"August 12, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT03817099
Principal Investigator,"Nor Farahain Yahya, Degree",Universiti Putra Malaysia,,NCT03817099,nor farahain yahya,nor,female,0.78,7905,124,NCT03817099,Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study,MyDia-RNP,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: Nutrition Intervention based on My Dia-RNP|Other: Usual Care,Rate of participants completed the study|Rate of participants adhered to the intervention|Efficacy potential on the rate of hypoglycemia|Efficacy potential on the fructosamine level|Efficacy potential on fasting glucose|Efficacy potential on glycemic control|Efficacy potential on functional status|Efficacy potential on body mass index,Universiti Putra Malaysia|Nestle Health Science|Joslin Diabetes Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MyDia-RNP study,"April 1, 2019","December 1, 2019","December 30, 2019","January 25, 2019",,"August 12, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT03817099
Principal Investigator,"Osama Hamdy, MD, PhD",Joslin Diabetes Centre,,NCT03817099,osama hamdy,osama,male,0.98,8125,124,NCT03817099,Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study,MyDia-RNP,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: Nutrition Intervention based on My Dia-RNP|Other: Usual Care,Rate of participants completed the study|Rate of participants adhered to the intervention|Efficacy potential on the rate of hypoglycemia|Efficacy potential on the fructosamine level|Efficacy potential on fasting glucose|Efficacy potential on glycemic control|Efficacy potential on functional status|Efficacy potential on body mass index,Universiti Putra Malaysia|Nestle Health Science|Joslin Diabetes Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MyDia-RNP study,"April 1, 2019","December 1, 2019","December 30, 2019","January 25, 2019",,"August 12, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT03817099
Principal Investigator,"Phil Schauer, MD",The Cleveland Clinic,,NCT03955952,phil schauer,phil,male,0.98,28225,125,NCT03955952,Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes,,Completed,No Results Available,Obesity|Type2 Diabetes|Bariatric Surgery Candidate,Procedure: Bariatric Surgery,Composite of All-Cause Mortality and Cardiovascular Outcomes|Incidence of Major Adverse Cardiovascular Event (MACE-3)|All-Cause Mortality|Incidence of Coronary Disease Events|Incidence of Cerebrovascular Events|Incidence of Heart Failure|Development of Nephropathy|Incidence of Atrial Fibrillation,The Cleveland Clinic,All,"18 Years to 80 Years   (Adult, Older Adult)",,13722,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,19-066,"June 5, 2019","July 12, 2019","August 26, 2019","May 20, 2019",,"January 2, 2020","Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03955952
Principal Investigator,"Olivier MD, PHD Bourron",Hopital Universitaire La Pitié-Salpêtrière,,NCT03968354,olivier md,olivier,male,0.99,76702,126,NCT03968354,NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL),NADRANK-1,Not yet recruiting,No Results Available,Diabetes type2|NASH - Nonalcoholic Steatohepatitis|NAFLD,"Biological: ""Collection of additional blood tubes; Biobanking (plasma, liver tissue).",Measure of RANKL mRNA expression in the liver|Serum concentrations of RANKL|Serum osteoprotegerin concentrations|HOMA-IR|Measure of RANKL mRNA|Measure of RANKL protein levels|Measure of RANK mRNA|Measure of RANK protein levels|RANK/RANKL genes polymorphisms|NF-kB pathway in hepatocytes and Kupffer cells,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,K171105J|2018-A02468-47,February 2020,June 2021,October 2021,"May 30, 2019",,"January 28, 2020",,,https://ClinicalTrials.gov/show/NCT03968354
Principal Investigator,"Olivier BOURRON, MD, PhD",Assistance Publique Hoptiaux de Paris,,NCT03920683,olivier bourron,olivier,male,0.99,76702,380,NCT03920683,Toe-brachial Index and Coronary Calcification in Type 1 and 2 Diabetes,ACCoDiab,Recruiting,No Results Available,Coronary Artery Calcification,Other: Data collection,Toe-brachial index|Vital statuts|Coronary artery calcification|Stress myocardial perfusion tomography|Coronary angiography,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",,650,Other,Observational,Observational Model: Cohort|Time Perspective: Other,APHP180409|2018-A02748-47,"July 8, 2019",April 2020,April 2020,"April 19, 2019",,"September 10, 2019","Diabetology department, Pitié-Salpêtrière hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03920683
Principal Investigator,"Bo Feldt-Rasmussen, Professor","Department of Nephrology, Rishospitalet, University of Copenhagen",,NCT03826381,bo feldt-rasmussen,bo,male,0.79,6996,127,NCT03826381,NAFLD Among Patients With Type 2 Diabetes and CKD,,Recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease|Chronic Kidney Diseases|Type2 Diabetes,Diagnostic Test: Magnetic resonance (MR) spectroscopy of the liver|Diagnostic Test: Fibroscan|Device: Continuous glucose monitoring (CGM) for four days.|Radiation: Dual Energy X-ray Absorptiometry (DEXA) scan|Biological: Blood samples|Other: Clinical and demographic data,"Prevalence of NAFLD and actual estimate of liver signal measured by MR spectroscopy|Prevalence and actual estimate of liver lipid signal measured by MR spectroscopy in relation to bile acids measured in the blood|NAFLD, as measured by MR spectroscopy, and its association with metabolomics and lipidomic profiles measured in the blood in relation to impaired renal function|The prevalence of fibrosis|NAFLD, as measured by MR spectroscopy, and its association with glucose profiles in relation to impaired renal function","Rigshospitalet, Denmark",All,"18 Years to 90 Years   (Adult, Older Adult)",,108,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,NAFLD and CKD - Study 1,"May 6, 2019",August 2021,December 2021,"February 1, 2019",,"May 30, 2019","Department of Nephrology, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT03826381
Principal Investigator,"Juliana Chan, MD",Chinese University of Hong Kong,,NCT04049149,juliana chan,juliana,female,0.98,14372,129,NCT04049149,Precision Medicine in Chinese Patients With Young Onset Diabetes,,Recruiting,No Results Available,Type 2 Diabetes,Other: Biogenetic explanation and endocrinologist intensive managment|Other: Usual care management,Prevalence of C-Peptide (CP) and Glutamic Acid Decarboxylase Antibody (GADA) in Chinese adult patients with T2D (Part 1 of study)|The correlation of C-Peptide (CP) and Glutamic Acid Decarboxylase Antibody (GADA) on clinical outcomes (Part 1 of study)|Incidence of young-onset type 2 diabetes and its genetic susceptibility (Part 2 of study)|Incidence of any diabetes-related micro/macrovascular endpoints (Part 3 of study)|The levels of CP and GADA and the number of genetic variants for disease prognositication and classification to guide precision medicine in YOD (Part 1 and 2 of study)|The number of genetic variants for disease prognositication and classification to guide precision medicine in YOD (Part 1 and 2 of study)|The number of novel targets and pathways for discovery of drug targets with companian diagnostics (Part 1 and 2 of study)|The number of patients attaining ≥3 cardiometabolic risk factors (Part 3 of study)|Incidence of severe hypoglycaemia (Part 3 of study)|Rate of changes in glycaemic control (Part 3 of study)|On-treatment changes in blood pressure (Part 3 of study)|On-treatment changes in lipid profiles (Part 3 of study)|On-treatment changes in Body Mass Index (Part 3 of study)|On-treatment changes in CP (Part 3 of study)|Rate of changes in use of medications (Part 3 of study)|Changes in patient's Quality of life (Part 3 of study)|Changes in patient's reported outcomes : Depression (Part 3 of study)|Changes in patient's compliance (Part 3 of study)|Changes in patient's diabetes empowerment (Part 3 of study)|Changes in patient's diabetes self care activities (Part 3 of study)|Changes in patient's perceived personal control (Part 3 of study)|Changes in patient's genetic counseling satisfaction (Part 3 of study)|Changes in patient's diabetes related distress (Part 3 of study)|Changes in patient's Depression Anxiety Stress (Part 3 of study),Chinese University of Hong Kong,All,18 Years to 50 Years   (Adult),Not Applicable,860,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,CRE-2019.080,"January 14, 2020","September 1, 2023","September 1, 2023","August 7, 2019",,"January 21, 2020","The Chinese University of Hong Kong, Sha Tin, Hong Kong",,https://ClinicalTrials.gov/show/NCT04049149
Principal Investigator,"Kathryn Tan, MD",The University of Hong Kong,,NCT03959501,kathryn tan,kathryn,female,0.98,2307,131,NCT03959501,Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy,,Recruiting,No Results Available,Type 2 Diabetes|Ketonemia,Drug: Dapagliflozin 10 mg|Drug: Sitagliptin 100mg,Change in serum ketone levels after treatment|Change in fasting glucose|Change in glycated haemoglobin|Change in body weight|Change in blood pressure|Change in fasting lipid|Change in free fatty acid levels|Change in fasting glucagon levels|Change in homeostasis model assessment 2 steady-state beta-cell function,The University of Hong Kong,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UW-17-166,"August 16, 2017","June 30, 2020","June 30, 2020","May 22, 2019",,"May 24, 2019","L2 Diabetes Centre, Queen Mary Hospital, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT03959501
Principal Investigator,"Mark Kipnes, M.D.","Diabetes and Glandular Disease Clinic, P.A.",,NCT04125082,mark kipnes,mark,male,0.99,119313,132,NCT04125082,A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections,,"Active, not recruiting",No Results Available,Type 2 Diabetes Treated With Insulin,Drug: Afrezza Inhalant Product,Time In Range|Hypoglycemia|Hemoglobin A1c|Quality of Life Questionnaires,"Diabetes and Glandular Disease Clinic|Mannkind Corporation|DexCom, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,29,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MK-001,"February 27, 2019","March 15, 2020","March 15, 2020","October 14, 2019",,"January 30, 2020","Diabetes and Glandular Disease Clinic, P.A., San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT04125082
Study Director,"Mark Andrew, MD",Medality Medical,,NCT03953963,mark andrew,mark,male,0.99,119313,205,NCT03953963,Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Insulin Resistance",Device: HydraSolve T2D™,Change in blood glucose control|Lack of serious adverse events (SAEs)|Change in Insulin Sensitivity|Change in fasting plasma glucose (FPG)|Reduction in body weight,Medality Medical,All,"22 Years to 75 Years   (Adult, Older Adult)",Not Applicable,12,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CIP-00001,"October 18, 2019","July 30, 2021","March 15, 2022","May 17, 2019",,"March 5, 2020","University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03953963
Principal Investigator,"Ralph DeFronzo, MD",University of Texas,,NCT03953963,ralph defronzo,ralph,male,0.99,10130,205,NCT03953963,Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Insulin Resistance",Device: HydraSolve T2D™,Change in blood glucose control|Lack of serious adverse events (SAEs)|Change in Insulin Sensitivity|Change in fasting plasma glucose (FPG)|Reduction in body weight,Medality Medical,All,"22 Years to 75 Years   (Adult, Older Adult)",Not Applicable,12,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CIP-00001,"October 18, 2019","July 30, 2021","March 15, 2022","May 17, 2019",,"March 5, 2020","University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03953963
Principal Investigator,"Mark Gilchrist, MB ChB, PhD",University of Exeter,,NCT04076007,mark gilchrist,mark,male,0.99,119313,283,NCT04076007,"The Effect of Dietary Nitrate on Blood Pressure, Insulin Sensitivity, and Vascular Function in Type 2 Diabetes",,Completed,No Results Available,Diabetes|Hypertension,Dietary Supplement: Beetroot juice|Dietary Supplement: Nitrate depleted beetroot juice,24 hour Ambulatory Blood Pressure monitoring after 2 weeks active juice|24 hour Ambulatory Blood Pressure monitoring after 2 weeks placebo juice|Brachial artery Flow mediated vasodilation|Microvascular response to Iontophoresis of Acetylcholine and Sodium Nitroprusside|Peak reactive hyperemia|Maximum hyperemia in response to heating|Cognitive function|Insulin sensitivity,University of Exeter,All,"35 Years to 75 Years   (Adult, Older Adult)",Not Applicable,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CRF035,December 2009,August 2012,February 2015,"September 3, 2019",,"September 3, 2019","NIHR Exeter Clinical Research Facility, Exeter, Devon, United Kingdom",,https://ClinicalTrials.gov/show/NCT04076007
Study Director,"Giorgio Sesti, MD",University Sapienza of Rome,,NCT04183868,giorgio sesti,giorgio,male,0.99,41494,134,NCT04183868,Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study),FIORE,Recruiting,No Results Available,Type 2 Diabetes|Cardiovascular Risk Factor,Drug: Empagliflozin 10 MG|Drug: Glimepiride 2 mg,Change of myocardial metabolic rate of glucose|Change of glycemic parameters|Change of insulin sensitivity|Change of blood pressure|Change of left ventricular systolic and diastolic function|Change of pro-BNP|Change of inflammatory state|Change of cardiovascular biomarkers|Change of heart rate variability|Change of lipid profile,University of Catanzaro,All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 4,26,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2016.43,April 2016,December 2020,April 2021,"December 3, 2019",,"December 3, 2019","Universital Hospital Mater Domini, Catanzaro, Italy",,https://ClinicalTrials.gov/show/NCT04183868
Study Director,"Shih Te Tu, MD",Changhua Christian Hospital,,NCT03983551,shih te tu,shih,male,0.62,267,136,NCT03983551,Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas,,Completed,No Results Available,Type 2 Diabetes Mellitus|Proteinuria,Drug: Dipeptidyl Peptidase 4 Inhibitor|Drug: Sulfonylurea,Change in urinary albumin-to-creatinine ratio|Change in serum glycated hemoglobin A1c|Change in body weight|Change in serum creatinine|Change in systolic blood pressure,Changhua Christian Hospital,All,"20 Years to 95 Years   (Adult, Older Adult)",Phase 4,101,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,190512,"March 1, 2016","February 10, 2018","February 28, 2018","June 12, 2019",,"June 14, 2019",,,https://ClinicalTrials.gov/show/NCT03983551
Principal Investigator,"James Hill, PhD",University of Alabama at Birmingham,,NCT03832933,james hill,james,male,0.99,117309,137,NCT03832933,Comparing High and Normal Protein Diets for the Dietary Remission of Type 2 Diabetes,,Recruiting,No Results Available,Diabetes Type 2|Obesity|Diet Modification,Behavioral: High Protein Diet|Behavioral: Standard Protein Diet,Change in body weight by weight scale|Change in T2D diagnosis criteria|Change in % body fat|Change in % fat free mass (FFM)|Change in % FFM,University of Alabama at Birmingham,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-300002928,"July 1, 2019","September 30, 2020","September 30, 2021","February 6, 2019",,"April 17, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03832933
Study Chair,"James L Januzzi, MD",Harvard Medical School,,NCT04083339,james l januzzi,james,male,0.99,117309,431,NCT04083339,Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy,,Recruiting,No Results Available,Diabetic Cardiomyopathies,Drug: AT-001|Drug: Placebo,Peak VO2 during cardio-pulmonary exercise test (CPET)|Changes in NT-proBNP|Changes in the modified Kansas City Cardiomyopathy Questionnaire (KCCQ) score|Percentages of patients with clinically significant changes in Peak VO2,"Applied Therapeutics, Inc.",All,"40 Years and older   (Adult, Older Adult)",Phase 3,675,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AT-001-2001,"September 20, 2019",September 2021,September 2023,"September 10, 2019",,"October 16, 2019","Mountain View Clinical Research, Greer, South Carolina, United States|Juno Research, LLC - Northwest Site, Houston, Texas, United States|Juno Research, LLC - Southwest Houston Site, Houston, Texas, United States|Juno Research, LLC - Katy, Katy, Texas, United States",,https://ClinicalTrials.gov/show/NCT04083339
Principal Investigator,"Isela Juarez Rojop, Ph.D",Universidad Juárez Autonoma de Tabasco,,NCT03978286,isela juarez rojop,isela,female,1.0,184,138,NCT03978286,Vortioxetine vs Sertraline in Mexicans,,Completed,No Results Available,Depression|Type 2 Diabetes Mellitus,Drug: Vortioxetine|Drug: Sertraline,Effect of antidepressant treatment (sertraline versus vortioxetine) in remission of depression in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in severity of depression in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in treatment of diabetes related stress in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in fasting plasma glucose level in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in glycemic control in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in cholesterol control in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in triglycerides control in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in weigh in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in waist circumference in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in anthropometric variables in depressed type 2 diabetic patients.,Universidad Juárez Autónoma de Tabasco,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 4,21,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",00228/16.,"June 30, 2016","June 30, 2017","June 30, 2018","June 7, 2019",,"June 13, 2019",,,https://ClinicalTrials.gov/show/NCT03978286
Principal Investigator,"Ali K M.Sami, Ph.D.","College of Medicine, University of Sulaimani",,NCT04082351,ali k m.sami,ali,male,0.95,319583,139,NCT04082351,Using Nanotechnology Structured Water to Control Blood Glucose in Type 2 Diabetic Patients.,,Completed,No Results Available,Type2 Diabetes,Dietary Supplement: Nanotechnology structured water ( Magnalife)|Dietary Supplement: ordinary water,HbA1c,ALI KAMAL M. SAMI|University of Sulaimani,All,"Child, Adult, Older Adult",Not Applicable,387,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",USulaimani,"July 3, 2016","February 16, 2018","February 16, 2018","September 9, 2019",,"September 10, 2019",,,https://ClinicalTrials.gov/show/NCT04082351
Principal Investigator,"Ji-Young Park, M.D, Ph.D","Korea University Anam Hospital / Seoul, Seongbuk-Gu, South Korea",,NCT04156685,ji-young park,ji-young,female,0.87,123,140,NCT04156685,"Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1",,Completed,No Results Available,Type2 Diabetes Mellitus,"Drug: Part A, Reference (D635 10/500mg, Astrazeneca)|Drug: Part B, Reference (D635 10/500mg, Astrazeneca)",Part A : Cmax under fasting condition|Part A : AUClast under fasting condition|Part B : Cmax under fed condition|Part B : AUClast under fed condition|Part A : AUCinf under fasting condition|Part A : Tmax under fasting condition|Part A : t1/2 under fasting condition|Part B : AUCinf under fed condition|Part B : Tmax under fed condition|Part B : t1/2 under fed condition,Chong Kun Dang Pharmaceutical,All,19 Years to 45 Years   (Adult),Phase 1,58,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,A84_07BE1908,"August 6, 2019","August 30, 2019","October 2, 2019","November 7, 2019",,"November 7, 2019","Korea University Anam Hospital, Seoul, Seongbuk-Gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04156685
Principal Investigator,"Giuditta Benincasa, MSc",Clinical Department of Internal Medicine and Specialistics,,NCT03792607,giuditta benincasa,giuditta,female,0.98,915,143,NCT03792607,Network-based Approach in Type 2 Diabetes and Its Cardiovascular Risk,PIRAMIDE,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Cardiovascular Diseases,,DNA methylation status both of CD4+ and CD8+ cells|Bioinformatics analysis to predict putative novel T2D candidate genes|RNA sequencing analysis both in CD4+ and CD8+ cells|ROC curves to evaluate putative DNA methylation/microRNA interactions as prognostic biomarkers of cardiovascular dysfunction in T2D patients,"Giuditta Benincasa|University of Campania ""Luigi Vanvitelli""",All,"50 Years and older   (Adult, Older Adult)",,35,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RRC-2015-2360454,"February 14, 2019","January 14, 2020","June 14, 2020","January 3, 2019",,"September 18, 2019","Università della Campania Luigi Vanvitelli, Naples, Italy",,https://ClinicalTrials.gov/show/NCT03792607
Principal Investigator,"Echo Ting Ting Go, Nursing",The University of Hong Kong,,NCT04207541,echo ting ting go,echo,female,0.58,940,144,NCT04207541,Promoting Insulin Initiation Among Suboptimal Diabetic Control Patients,,Recruiting,No Results Available,Type 2 Diabetes,Behavioral: Brief motivational interview,Proportion of insulin acceptance|Proportion of insulin initiation,The University of Hong Kong,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130,Other,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UW 19-614,"October 1, 2019","September 30, 2020","June 30, 2021","December 23, 2019",,"December 23, 2019","Hospital Authority, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT04207541
Principal Investigator,"Guang Ning, MD, PhD",Shanghai Jiao Tong University School of Medicine,,NCT03839667,guang ning,guang,male,0.92,294,146,NCT03839667,Intensive Diet and Physical Activity on Diabetes,IDEATE,Recruiting,No Results Available,Type2 Diabetes|Life Style,Behavioral: intensive diet intervention|Behavioral: Enhanced physical activity intervention|Behavioral: Standard education,change in HbA1C level (%)|proportion of reversal of diabetes|reduction in the dosage of hypoglycemic drugs|change in insulin sensitivity|change in islet β-cell function|change in liver steatosis quantified by MRI-PDFF (percentage)|change in pancreatic adipose content quantified by MRI-PDFF (percentage)|change in body mass index (BMI)|change in visceral fat (cm^2)|change in serum fetuin-A concentration (μg/mL)|change in serum GREM2 concentration (pg/ml)|change in serum Caspase-cleaved Keratin 1 concentration (U/L)|changes in serum FGF21 concentration (pg/ml)|changes in overall gut microbiota profile|depression|health related quality of life|cardiovascular risk,Shanghai Jiao Tong University School of Medicine,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,324,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Ruijin-2018-174-2,"February 28, 2019","July 15, 2020","July 15, 2020","February 15, 2019",,"February 15, 2019","Ruijin hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03839667
Principal Investigator,"Christopher C Thompson, MD",Brigham and Women's Hospital,,NCT04101669,christopher c thompson,christopher,male,0.99,53539,147,NCT04101669,EndoBarrier System Pivotal Trial(Rev B),STEP-1,Recruiting,No Results Available,Diabetes type2|Obesity,Device: EndoBarrier Liner|Other: Sham,Change in HbA1c|HbA1c value|Weight Loss|Insulin use|LDL cholesterol|Triglycerides|Blood pressure|Change in daily fasting glucose level|Change in Nonalcoholic Fatty Liver Disease (NAFLD)|Change in Nonalcoholic Steatohepatitis (NASH)|HOMA-IR|Questionnaire|Change in Risk Level of CKD eGFR|Change in Risk Level of CKD albumin,"GI Dynamics|Biostatistical Consulting, Inc.",All,30 Years to 55 Years   (Adult),Not Applicable,240,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",18-1,"September 9, 2019","April 1, 2023","April 1, 2024","September 24, 2019",,"September 24, 2019","Surgical Specialists of Louisianna, Metairie, Louisiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Michigan Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, Michigan, United States|Jefferson University Hospital/Diabetes Research Center, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04101669
Principal Investigator,"Christopher Gardner, PhD",Stanford University,,NCT03810378,christopher gardner,christopher,male,0.99,53539,265,NCT03810378,Contrasting Ketogenic and Mediterranean Diets in Individuals With Type 2 Diabetes and Prediabetes: The Keto-Med Trial,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2|PreDiabetes",Behavioral: Mediterranean Diet (Med-Plus)|Behavioral: Well-Formulated Ketogenic Diet (WFKD),Hemoglobin A1c (HbA1c)|Microbiota composition|Microbiota function|LDL Cholesterol|HDL Cholesterol|Triglycerides|Fasting insulin|Blood pressure,Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,61,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",49218,"June 5, 2019",December 2020,December 2020,"January 18, 2019",,"March 27, 2020","Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT03810378
Principal Investigator,"Christopher Granger, MD",Duke Clinical Research Institute,,NCT03936660,christopher granger,christopher,male,0.99,53539,356,NCT03936660,A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease,COORDINATE,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Cardiovascular Diseases",Other: Intense Education Intervention,Implementing a clinic-level multifaceted intervention|Proportion of patients on guideline recommended therapies at 12 months.|Changes in cholesterol levels over 12 months.|Changes in blood pressure control over 12 months.|Changes in glycemic control over 12 months|Measurement of average time from baseline to patient event.,Duke University|Boehringer Ingelheim|Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1380,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Pro00101556,"July 18, 2019","August 1, 2021","August 1, 2026","May 3, 2019",,"March 24, 2020","Grandview Health/Alabama Cardiovascular Group, Birmingham, Alabama, United States|Alaska Heart and Vascular Institute, Anchorage, Alaska, United States|Dignity Health/DHMG Specialty Medicine, Phoenix, Arizona, United States|Stanford University, Stanford, California, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Orlando Heart and Vascular Institute, Altamonte Springs, Florida, United States|Riverside Medical Center, Bradenton, Florida, United States|Baptist Health Research Institute, Jacksonville, Florida, United States|Advanced Research for Health Improvement, LLC, Naples, Florida, United States|Bayfront Cardiovascular Associates, Saint Petersburg, Florida, United States|Interventional Cardiac Consultants, Trinity, Florida, United States|Emory/Grady Memorial Hospital, Atlanta, Georgia, United States|SouthCoast Health Cardiology, Savannah, Georgia, United States|Advocate Heart Institute, Chicago, Illinois, United States|Advanced Heart Care Group/Medicoricium LLC, Fairview Heights, Illinois, United States|Specialty Physicians of Illinois, Olympia Fields, Illinois, United States|UnityPoint Health Cardiovascular Services, Peoria, Illinois, United States|Prairie Cardiovascular Consultants, Springfield, Illinois, United States|Iowa Heart Center, Des Moines, Iowa, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Endeavor Medical Research, Alpena, Michigan, United States|Cardiology Institute of Michigan, Flint, Michigan, United States|Rajendra H Mehta, MD, PC, Jackson, Michigan, United States|Hannibal Regional Medical Group, Hannibal, Missouri, United States|Advanced Heartcare LLC, Bridgewater, New Jersey, United States|New Jersey Heart, Linden, New Jersey, United States|Garden State Heart Care, Manalapan, New Jersey, United States|Cardiovasculare Associates of the Delaware Valley, Sewell, New Jersey, United States|Long Island Cardiovascular Consultants, Lake Success, New York, United States|Northwell Health/Lenox Hill Hospital, Manhasset, New York, United States|Kernodle Clinic, Burlington, North Carolina, United States|Cone Health/LeBauer Brodie Ctr for Cardiovascular Rsch, Greensboro, North Carolina, United States|Cardiovascular Health Clinic, Oklahoma City, Oklahoma, United States|Guthrie Medical Group, Sayre, Pennsylvania, United States|Advanced Cardiology Associates, Greenwood, South Carolina, United States|Black Hills Cardiovascular Research, Rapid City, South Dakota, United States|ProHealth Care Heart and Vascular, Waukesha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03936660
Principal Investigator,"Irum Yaqoob, MSNMPT",Riphah International University,,NCT04127448,irum yaqoob,irum,female,0.93,97,148,NCT04127448,Exergaming Versus Aerobic Exercises on Mild Cognitive Impairment,,Completed,No Results Available,Type 2 Diabetes|Cognitive Impairment,Other: Exergaming Training Group|Other: Aerobic Exercise Group,"Change in Standardized Mini-mental State Examination (SMMSE) from baseline to 6th week.|Change in Montreal cognitive assessment scale (MOCA, Urdu version) from baseline to 6th week.|Change in Trail Making Test-A (TMT-A) from baseline to 6th week|Change in Trail Making Test-B (TMT-B) from baseline to 6th week|Change in Verbal fluency test (VFT) from baseline to 6th week|Change in Random Blood sugar (RBS) from baseline to 6th week",Riphah International University,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Riphah IU Raana Ali,"March 1, 2017","August 1, 2017","August 1, 2017","October 15, 2019",,"October 15, 2019","Riphah International University, Islamabad, Federal, Pakistan",,https://ClinicalTrials.gov/show/NCT04127448
Principal Investigator,"Jessica R Wilson, MD, MS",University of Pennsylvania,,NCT04024631,jessica r wilson,jessica,female,0.98,144795,149,NCT04024631,Phenotyping Genetic Risk for Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Genetics","Other: 75g glucose beverage (Glucola, Trutol, or similar brand)|Other: DXA, whole body",Glucose response to an oral glucose load|Visceral adiposity index|HOMA-IR|Disposition index,University of Pennsylvania,All,"10 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,831865,"June 17, 2019","June 30, 2023","June 30, 2023","July 18, 2019",,"July 19, 2019","Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04024631
Principal Investigator,"Lorraine Levitt Katz, MD",Childrens Hospital of Philadelphia,,NCT04024631,lorraine levitt katz,lorraine,female,0.98,6673,149,NCT04024631,Phenotyping Genetic Risk for Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Genetics","Other: 75g glucose beverage (Glucola, Trutol, or similar brand)|Other: DXA, whole body",Glucose response to an oral glucose load|Visceral adiposity index|HOMA-IR|Disposition index,University of Pennsylvania,All,"10 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,831865,"June 17, 2019","June 30, 2023","June 30, 2023","July 18, 2019",,"July 19, 2019","Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04024631
Study Chair,"Jessica M Franklin, PHD",Brigham and Women's Hospital,,NCT04034524,jessica m franklin,jessica,female,0.98,144795,255,NCT04034524,Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Drug: GLP-1 receptor agonist|Drug: Insulin,"Time until first composite CV event (myocardial infarction, stroke)|Time until first myocardial infarction|Time until first stroke|Time until first serious hypoglycemic event|Time until first episode of acute pancreatitis|Time until first episode of acute cholecystitis",Brigham and Women's Hospital,All,"18 Years and older   (Adult, Older Adult)",,20000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2011P002580-118,"May 1, 2019","October 31, 2019","October 31, 2019","July 26, 2019",,"July 31, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04034524
Principal Investigator,"Jessica Franklin, PhD",Brigham and Womens,,NCT03936010,jessica franklin,jessica,female,0.98,144795,374,NCT03936010,Replication of the CANVAS Diabetes Trial in Healthcare Claims,,"Active, not recruiting",No Results Available,Diabetes,Drug: Canagliflozin|Drug: DPP-4 inhibitor,"Relative hazard of composite outcome of Stroke, MI, and Mortality",Brigham and Women's Hospital,All,"18 Years and older   (Adult, Older Adult)",,152202,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,DUPLICATE-CANVAS,"September 22, 2017","September 22, 2020","September 22, 2020","May 3, 2019",,"January 2, 2020","Brigham & Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03936010/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03936010
Principal Investigator,"Lin Liao, MD",Shandong Provincial Qianfoshan Hospital,,NCT03805191,lin liao,lin,female,0.63,6642,150,NCT03805191,A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients,FLAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Poor Glycemic Control,,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c",Qilu Hospital of Shandong University|Bayer,All,"18 Years and older   (Adult, Older Adult)",,900,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,RD-OI-1257,"January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,https://ClinicalTrials.gov/show/NCT03805191
Principal Investigator,"Lin Sun, MD",Affiliated hospital of jining medical college,,NCT03805191,lin sun,lin,female,0.63,6642,150,NCT03805191,A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients,FLAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Poor Glycemic Control,,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c",Qilu Hospital of Shandong University|Bayer,All,"18 Years and older   (Adult, Older Adult)",,900,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,RD-OI-1257,"January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,https://ClinicalTrials.gov/show/NCT03805191
Principal Investigator,"Yuping Zhou, MD",Weihai Municipal Hospital,,NCT03805191,yuping zhou,yuping,female,0.58,38,150,NCT03805191,A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients,FLAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Poor Glycemic Control,,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c",Qilu Hospital of Shandong University|Bayer,All,"18 Years and older   (Adult, Older Adult)",,900,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,RD-OI-1257,"January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,https://ClinicalTrials.gov/show/NCT03805191
Principal Investigator,"Shuguang Pang, MD",Jinan Central Hospital,,NCT03805191,shuguang pang,shuguang,male,0.87,15,150,NCT03805191,A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients,FLAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Poor Glycemic Control,,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c",Qilu Hospital of Shandong University|Bayer,All,"18 Years and older   (Adult, Older Adult)",,900,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,RD-OI-1257,"January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,https://ClinicalTrials.gov/show/NCT03805191
Principal Investigator,"Fei Wang, MD","Huangdao Branch of Affiliated Hospital of Medical College,Qingdao University",,NCT03805191,fei wang,fei,male,0.54,1207,150,NCT03805191,A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients,FLAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Poor Glycemic Control,,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c",Qilu Hospital of Shandong University|Bayer,All,"18 Years and older   (Adult, Older Adult)",,900,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,RD-OI-1257,"January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,https://ClinicalTrials.gov/show/NCT03805191
Principal Investigator,"Yongjun Jin, MD",Yantai Branch of Affiliated Binzhou Medical College,,NCT03805191,yongjun jin,yongjun,male,0.99,120,150,NCT03805191,A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients,FLAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Poor Glycemic Control,,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c",Qilu Hospital of Shandong University|Bayer,All,"18 Years and older   (Adult, Older Adult)",,900,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,RD-OI-1257,"January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,https://ClinicalTrials.gov/show/NCT03805191
Principal Investigator,"Tianying Xu, MD",People's hospital of Qihe county,,NCT03805191,tianying xu,tianying,female,0.73,11,150,NCT03805191,A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients,FLAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Poor Glycemic Control,,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c",Qilu Hospital of Shandong University|Bayer,All,"18 Years and older   (Adult, Older Adult)",,900,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,RD-OI-1257,"January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,https://ClinicalTrials.gov/show/NCT03805191
Principal Investigator,"Guangzhen Zhang, MD",Liaocheng People's Hospital,,NCT03805191,guangzhen zhang,guangzhen,male,0.83,6,150,NCT03805191,A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients,FLAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Poor Glycemic Control,,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c",Qilu Hospital of Shandong University|Bayer,All,"18 Years and older   (Adult, Older Adult)",,900,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,RD-OI-1257,"January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,https://ClinicalTrials.gov/show/NCT03805191
Principal Investigator,"Yunfeng Zhang, MD",Linyi lanshan district diabetes hospital,,NCT03805191,yunfeng zhang,yunfeng,male,0.93,57,150,NCT03805191,A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients,FLAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Poor Glycemic Control,,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c",Qilu Hospital of Shandong University|Bayer,All,"18 Years and older   (Adult, Older Adult)",,900,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,RD-OI-1257,"January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,https://ClinicalTrials.gov/show/NCT03805191
Principal Investigator,"Dadong Fei, MD",Zaozhuang municipal hospital,,NCT03805191,dadong fei,dadong,male,1.0,3,150,NCT03805191,A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients,FLAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Poor Glycemic Control,,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c",Qilu Hospital of Shandong University|Bayer,All,"18 Years and older   (Adult, Older Adult)",,900,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,RD-OI-1257,"January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,https://ClinicalTrials.gov/show/NCT03805191
Principal Investigator,"Guangling Xu, MD",Guanxian people's hospital of liaocheng city,,NCT03805191,guangling xu,guangling,male,1.0,1,150,NCT03805191,A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients,FLAT,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Poor Glycemic Control,,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c",Qilu Hospital of Shandong University|Bayer,All,"18 Years and older   (Adult, Older Adult)",,900,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,RD-OI-1257,"January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,https://ClinicalTrials.gov/show/NCT03805191
Principal Investigator,"Emmanuel DISSE, MD, PhD",Centre de Recherche en Nutrition Humaine Rhône-Alpes,,NCT03847701,emmanuel disse,emmanuel,male,0.99,45589,151,NCT03847701,Cardio-metabolic and Inflammatory Impact of Starch Digestibility in Type 2 Diabetic Patients,,Recruiting,No Results Available,Type2 Diabetes,Other: Balanced diet high in Slowly Digestible Starch|Other: Balanced diet low in Slowly Digestible Starch,"MAGE comparison following 3 months of intake of a diet either high or low in SDS|Glycemia iAUC characterisation of a standard challenge test (FlexMeal) during the first metabolic day|Insulin iAUC characterisation of a standard challenge test (FlexMeal) during the first metabolic day|GLP1 iAUC characterisation of a standard challenge test (FlexMeal) during the first metabolic day|Inflammatory status comparison during the first metabolic day : CRPus concentration|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : TNFa iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : IL6 iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : IL1Ra iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : IL18 iAUC|Glycemic impacts comparison following the intake of a diet either high or low in SDS during the time course of the study|Insulinemic impacts comparison following the intake of a diet either high or low in SDS during the time course of the study|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : CRPus concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : TNFa concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : IL6 concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : IL1Ra concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : IL18 concentration|Oxidative Stress comparison following the intake of a diet either high or low in SDS during the time course of the study : MDA concentration|Oxidative Stress comparison following the intake of a diet either high or low in SDS during the time course of the study : Urinary isoprostanes concentration|Cardiovascular risk markers comparison following the intake of a diet either high or low in SDS during the time course of the study : MCP1 concentration|Cardiovascular risk markers comparison following the intake of a diet either high or low in SDS during the time course of the study : sICAM concentration|Cardiovascular risk markers comparison following the intake of a diet either high or low in SDS during the time course of the study : sVCAM concentration|Glycemic impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day|Insulinemic impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day|GLP1 iAUC characterisation of a standard challenge test (FlexMeal) during the second metabolic day|Inflammatory impacts comparison following 3 months of intake of a diet either high or low in SDS : CRPus concentration|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : TNFa iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : IL6 iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : IL1Ra iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : IL18 iAUC|Cardiovascular risk markers characterisation following the intake of a diet either high or low in SDS : MCP1 concentration|Cardiovascular risk markers characterisation following the intake of a diet either high or low in SDS : sICAM concentration|Cardiovascular risk markers characterisation following the intake of a diet either high or low in SDS : sVCAM concentration|Oxydative stress characterisation following the intake of a diet either high or low in SDS : MDA concentration|Oxydative stress characterisation following the intake of a diet either high or low in SDS : Urinary isoprostanes concentration|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : MAGE|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : MAGE|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : TIR|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : TIR|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : CV|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : CV|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : SD|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : SD|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : MIME|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : MIME|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : MODD|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : MODD|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : CONGA|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : CONGA|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : ADRR|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : ADRR|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : LGBI|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : LGBI|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : HGBI|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : HGBI|Mean daylong incremental Area Under the Curve (iAUC), measured by CGMS, following the intake of a diet either high or low in SDS during the time course of the study|Mean daylong total Area Under the Curve (tAUC), measured by CGMS, following the intake of a diet either high or low in SDS during the time course of the study|Compare diabetes follow-up markers during the first metabolic day : HbA1c|Compare diabetes follow-up markers following the intake of a diet either high or low in SDS during the time course of the study : HbA1c concentration|Compare diabetes follow-up markers following the 3 months consumption of a diet either high or low in SDS : HbA1c concentration|Compare Diabetes follow-up markers during the first metabolic day : Fructosamine concentration|Compare Diabetes follow-up markers following the intake of a diet either high or low in SDS during the time course of the study : fructosamine concentration|Compare Diabetes follow-up markers following the 3 months consumption of a diet either high or low in SDS : Fructosamine concentration|Compare Diabetes follow-up markers during the first metabolic day : Glycated Albumin concentration|Compare Diabetes follow-up markers following the intake of a diet either high or low in SDS during the time course of the study : glycated albumin concentration|Compare Diabetes follow-up markers following the 3 months consumption of a diet either high or low in SDS : Glycated Albumin concentration|Arterial Endothelial Function characterisation following the intake of a diet either high or low in SDS during the time course of the study : RHI|Arterial Endothelial Function characterisation following the intake of a diet either high or low in SDS during the time course of the study : AI|Arterial Endothelial Function characterisation following the intake of a diet either high or low in SDS during the time course of the study : HRV|Anthropometry parameters characterisation during the first metabolic day : height|Anthropometry parameters characterisation during the first metabolic day : body weight|Anthropometry parameters characterisation during the first metabolic day : waist circumference|Anthropometry parameters characterisation during the first metabolic day : hip circumference|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : height|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : body weight|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : waist circumference|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : hip circumference|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : height|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : body weight|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : waist circumference|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : hip circumference|Body composition parameters characterisation during the first metabolic day: total body water|Body composition parameters characterisation during the first metabolic day: body fat|Body composition parameters characterisation during the first metabolic day: lean mass.|Body composition parameters characterisation following the 3 months consumption of a diet either high or low in SDS : total body water|Body composition parameters characterisation following the 3 months consumption of a diet either high or low in SDS : body fat|Body composition parameters characterisation following the 3 months consumption of a diet either high or low in SDS : lean mass|Resting energy metabolism profile during the first metabolic day: Resting Metabolism Rate|Resting energy metabolism profile following the 3 months consumption of a diet either high or low in SDS : Resting Metabolism Rate|Diabetic glycemic variability characterisation following the 3 months consumption of a diet either high or low in SDS|Level of physical activity characterisation following the intake of a diet either high or low in SDS during the time course of the study : IPAQ|Characterisation of acceptability to H-SDS diet in free living conditions|Characterisation of the percent of compliance to H-SDS diet in free living conditions","Mondelēz International, Inc.|Centre de Recherche en Nutrition Humaine Rhone-Alpe|Biofortis Mérieux NutriSciences",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,80,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",KBE045,"June 25, 2019",July 2020,December 2020,"February 20, 2019",,"May 27, 2020","Centre de Recherche en Nutrition Humaine Rhone-Alpes, Pierre-Bénite, France",,https://ClinicalTrials.gov/show/NCT03847701
Study Chair,"Martine LAVILLE, MD, PhD",Centre de Recherche en Nutrition Humaine Rhône-Alpes,,NCT03847701,martine laville,martine,female,0.98,39487,151,NCT03847701,Cardio-metabolic and Inflammatory Impact of Starch Digestibility in Type 2 Diabetic Patients,,Recruiting,No Results Available,Type2 Diabetes,Other: Balanced diet high in Slowly Digestible Starch|Other: Balanced diet low in Slowly Digestible Starch,"MAGE comparison following 3 months of intake of a diet either high or low in SDS|Glycemia iAUC characterisation of a standard challenge test (FlexMeal) during the first metabolic day|Insulin iAUC characterisation of a standard challenge test (FlexMeal) during the first metabolic day|GLP1 iAUC characterisation of a standard challenge test (FlexMeal) during the first metabolic day|Inflammatory status comparison during the first metabolic day : CRPus concentration|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : TNFa iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : IL6 iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : IL1Ra iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : IL18 iAUC|Glycemic impacts comparison following the intake of a diet either high or low in SDS during the time course of the study|Insulinemic impacts comparison following the intake of a diet either high or low in SDS during the time course of the study|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : CRPus concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : TNFa concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : IL6 concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : IL1Ra concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : IL18 concentration|Oxidative Stress comparison following the intake of a diet either high or low in SDS during the time course of the study : MDA concentration|Oxidative Stress comparison following the intake of a diet either high or low in SDS during the time course of the study : Urinary isoprostanes concentration|Cardiovascular risk markers comparison following the intake of a diet either high or low in SDS during the time course of the study : MCP1 concentration|Cardiovascular risk markers comparison following the intake of a diet either high or low in SDS during the time course of the study : sICAM concentration|Cardiovascular risk markers comparison following the intake of a diet either high or low in SDS during the time course of the study : sVCAM concentration|Glycemic impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day|Insulinemic impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day|GLP1 iAUC characterisation of a standard challenge test (FlexMeal) during the second metabolic day|Inflammatory impacts comparison following 3 months of intake of a diet either high or low in SDS : CRPus concentration|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : TNFa iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : IL6 iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : IL1Ra iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : IL18 iAUC|Cardiovascular risk markers characterisation following the intake of a diet either high or low in SDS : MCP1 concentration|Cardiovascular risk markers characterisation following the intake of a diet either high or low in SDS : sICAM concentration|Cardiovascular risk markers characterisation following the intake of a diet either high or low in SDS : sVCAM concentration|Oxydative stress characterisation following the intake of a diet either high or low in SDS : MDA concentration|Oxydative stress characterisation following the intake of a diet either high or low in SDS : Urinary isoprostanes concentration|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : MAGE|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : MAGE|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : TIR|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : TIR|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : CV|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : CV|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : SD|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : SD|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : MIME|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : MIME|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : MODD|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : MODD|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : CONGA|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : CONGA|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : ADRR|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : ADRR|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : LGBI|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : LGBI|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : HGBI|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : HGBI|Mean daylong incremental Area Under the Curve (iAUC), measured by CGMS, following the intake of a diet either high or low in SDS during the time course of the study|Mean daylong total Area Under the Curve (tAUC), measured by CGMS, following the intake of a diet either high or low in SDS during the time course of the study|Compare diabetes follow-up markers during the first metabolic day : HbA1c|Compare diabetes follow-up markers following the intake of a diet either high or low in SDS during the time course of the study : HbA1c concentration|Compare diabetes follow-up markers following the 3 months consumption of a diet either high or low in SDS : HbA1c concentration|Compare Diabetes follow-up markers during the first metabolic day : Fructosamine concentration|Compare Diabetes follow-up markers following the intake of a diet either high or low in SDS during the time course of the study : fructosamine concentration|Compare Diabetes follow-up markers following the 3 months consumption of a diet either high or low in SDS : Fructosamine concentration|Compare Diabetes follow-up markers during the first metabolic day : Glycated Albumin concentration|Compare Diabetes follow-up markers following the intake of a diet either high or low in SDS during the time course of the study : glycated albumin concentration|Compare Diabetes follow-up markers following the 3 months consumption of a diet either high or low in SDS : Glycated Albumin concentration|Arterial Endothelial Function characterisation following the intake of a diet either high or low in SDS during the time course of the study : RHI|Arterial Endothelial Function characterisation following the intake of a diet either high or low in SDS during the time course of the study : AI|Arterial Endothelial Function characterisation following the intake of a diet either high or low in SDS during the time course of the study : HRV|Anthropometry parameters characterisation during the first metabolic day : height|Anthropometry parameters characterisation during the first metabolic day : body weight|Anthropometry parameters characterisation during the first metabolic day : waist circumference|Anthropometry parameters characterisation during the first metabolic day : hip circumference|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : height|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : body weight|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : waist circumference|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : hip circumference|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : height|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : body weight|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : waist circumference|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : hip circumference|Body composition parameters characterisation during the first metabolic day: total body water|Body composition parameters characterisation during the first metabolic day: body fat|Body composition parameters characterisation during the first metabolic day: lean mass.|Body composition parameters characterisation following the 3 months consumption of a diet either high or low in SDS : total body water|Body composition parameters characterisation following the 3 months consumption of a diet either high or low in SDS : body fat|Body composition parameters characterisation following the 3 months consumption of a diet either high or low in SDS : lean mass|Resting energy metabolism profile during the first metabolic day: Resting Metabolism Rate|Resting energy metabolism profile following the 3 months consumption of a diet either high or low in SDS : Resting Metabolism Rate|Diabetic glycemic variability characterisation following the 3 months consumption of a diet either high or low in SDS|Level of physical activity characterisation following the intake of a diet either high or low in SDS during the time course of the study : IPAQ|Characterisation of acceptability to H-SDS diet in free living conditions|Characterisation of the percent of compliance to H-SDS diet in free living conditions","Mondelēz International, Inc.|Centre de Recherche en Nutrition Humaine Rhone-Alpe|Biofortis Mérieux NutriSciences",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,80,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",KBE045,"June 25, 2019",July 2020,December 2020,"February 20, 2019",,"May 27, 2020","Centre de Recherche en Nutrition Humaine Rhone-Alpes, Pierre-Bénite, France",,https://ClinicalTrials.gov/show/NCT03847701
Study Director,"Mette Rosenkilde, MD",University of Copenhagen,,NCT03867656,mette rosenkilde,mette,female,0.97,3117,154,NCT03867656,Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19,,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Other: GLP-2|Other: GIP|Other: Placebo,CTX|P1NP|PTH|Sclerostin|Glucose|Insulin|C-peptide|GIP|GLP-2|Glucagon|Blood pressure|Heart rate,University of Copenhagen|Hvidovre University Hospital,Male,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,KS-4-Diabetes-19,"February 26, 2019","June 26, 2020","June 26, 2020","March 8, 2019",,"January 18, 2020","Hvidovre University Hospital, Hvidovre, Denmark",,https://ClinicalTrials.gov/show/NCT03867656
Principal Investigator,"Vallo Volke, MD, PhD","University of Tartu, Institute of Biomedicine and Translational Medicine",,NCT04151849,vallo volke,vallo,male,0.92,62,158,NCT04151849,Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota,,Recruiting,No Results Available,Type 2 Diabetes,Drug: GLP-1 receptor agonist|Drug: SGLT2 inhibitor,Urinary aldosterone at 3 months|Change in gastrointestinal microbiota.|Urinary aldosterone at 12 months,University of Tartu,All,"18 Years and older   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,290/T-20,"January 10, 2020","December 31, 2023","December 31, 2023","November 5, 2019",,"January 13, 2020","Tartu University Hospital, Tartu, Estonia",,https://ClinicalTrials.gov/show/NCT04151849
Study Chair,yueying peng,Clinical Medicine Department CSPC R&D Business Division,,NCT03940183,yueying peng,yueying,female,0.78,9,161,NCT03940183,Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Trelagliptin Succinate|Drug: Placebo Oral Tablet,HbA1c|Fasting blood glucose|2-hour postprandial blood glucose|fasting insulin|fasting glucagon|active Glucagon-like peptide-1（GLP-1） level|The percentage of HbA1c＜6.5% and HbA1c＜7%|body weight|Body Mass Index,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,240,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CSPC/HC1425/201801,"July 8, 2019","June 30, 2021","July 31, 2021","May 7, 2019",,"April 28, 2020","Beijing Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03940183
Principal Investigator,Ching Y Chan,Chinese University of Hong Kong,,NCT04092023,ching y chan,ching,female,0.55,1238,162,NCT04092023,Self-care Management Programme for Type 2 Adult DM Patients With Poor Glycemic Control,T2DM,Completed,No Results Available,Type 2 Diabetes,Other: nursing education,Glycemic control|Diabetes Knowledge|Self-Efficacy: Diabetes Empowerment Scale - Short Form (C-DES-SF)|QOL: Audit of Diabetes Dependent Quality of Life (ADDQoL-19),Chinese University of Hong Kong,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,ChanCY_RP1,"October 2, 2018","September 1, 2019","September 1, 2019","September 17, 2019",,"September 18, 2019","KWC FM & PHC, Hospital Authority, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT04092023
Principal Investigator,"Ching Yong Chin, Master",Nanhua University,,NCT04177420,ching yong chin,ching,female,0.55,1238,428,NCT04177420,Investigation for Health Efficacy of Infrared-C Radiation on Diabetes Patients in Senior's Activity Center,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Device: FIR-C mattress|Device: FIR-C abdominal pad|Device: fake FIR-C mattress|Device: fake FIR-C abdominal pad,"Hemoglobin A1c, HbA1c|Fasting Blood Sugar, GLU-AC|Insulin|Superoxide, O2−|Osteocalcin|Procollagen-I N-telopeptide, PINP|C-telopeptide of type I collagen，CTx|Total Antioxidant Capacity, TAC|Advanced glycation end-product，AGEs|Insulin resistance assessment|Beta-cell function assessment|Autonomic nervous system assessment - Heart Rate|Autonomic nervous system assessment - blood pressure|Autonomic nervous system assessment - Heart Rate Variability|Autonomic nervous system assessment - Low Frequency|Autonomic nervous system assessment - High Frequency|Autonomic nervous system assessment - Low/High Frequency standard|Autonomic nervous system assessment - Irregular Heartbeat standard|Pittsburgh sleep quality index (PSQI)|Knee Pain - Numeric Rating Scale, Knee Pain - NRS|Geriatric Depression Scale-15, GDS-15","Nanhua University|Buddhist Dalin Tzu Chi General Hospital|Solano Semiconductor Technology., LTD.",All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,B10701016,"March 23, 2018","December 31, 2019","February 15, 2020","November 26, 2019",,"November 26, 2019","Department of Natural Biotechnology, Master's program in Natural Healing Sciences Nanhua University, Dalin, Chiayi, Taiwan",,https://ClinicalTrials.gov/show/NCT04177420
Principal Investigator,"Yi-Wen Huang, Master",Nanhua University,,NCT04177420,yi-wen huang,yi-wen,female,0.67,6,428,NCT04177420,Investigation for Health Efficacy of Infrared-C Radiation on Diabetes Patients in Senior's Activity Center,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Device: FIR-C mattress|Device: FIR-C abdominal pad|Device: fake FIR-C mattress|Device: fake FIR-C abdominal pad,"Hemoglobin A1c, HbA1c|Fasting Blood Sugar, GLU-AC|Insulin|Superoxide, O2−|Osteocalcin|Procollagen-I N-telopeptide, PINP|C-telopeptide of type I collagen，CTx|Total Antioxidant Capacity, TAC|Advanced glycation end-product，AGEs|Insulin resistance assessment|Beta-cell function assessment|Autonomic nervous system assessment - Heart Rate|Autonomic nervous system assessment - blood pressure|Autonomic nervous system assessment - Heart Rate Variability|Autonomic nervous system assessment - Low Frequency|Autonomic nervous system assessment - High Frequency|Autonomic nervous system assessment - Low/High Frequency standard|Autonomic nervous system assessment - Irregular Heartbeat standard|Pittsburgh sleep quality index (PSQI)|Knee Pain - Numeric Rating Scale, Knee Pain - NRS|Geriatric Depression Scale-15, GDS-15","Nanhua University|Buddhist Dalin Tzu Chi General Hospital|Solano Semiconductor Technology., LTD.",All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,B10701016,"March 23, 2018","December 31, 2019","February 15, 2020","November 26, 2019",,"November 26, 2019","Department of Natural Biotechnology, Master's program in Natural Healing Sciences Nanhua University, Dalin, Chiayi, Taiwan",,https://ClinicalTrials.gov/show/NCT04177420
Principal Investigator,"Brittany Smalls, PhD",University of Kentucky,,NCT04210024,brittany smalls,brittany,female,0.98,903,165,NCT04210024,Rural Dwelling Older Adults With T2DM,,Enrolling by invitation,No Results Available,Type2 Diabetes,Other: Diabetes Empowerment Education Program,Change in Diabetes Knowledge|Change in Health Literacy,Brittany L Smalls|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Kentucky,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,200,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,45657|1K01DK116923,"May 30, 2019","December 31, 2024","December 31, 2024","December 24, 2019",,"December 24, 2019","UK Center for Excellence in Rural Health, Kentucky Homeplace, Hyden, Kentucky, United States|Stinnett Area Community Center, Stinnett, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT04210024
Principal Investigator,Uthai Suvanakoot,"International Bio Service Co., Ltd.",,NCT04070794,uthai suvanakoot,uthai,male,0.9,104,166,NCT04070794,Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting Conditions,,Not yet recruiting,No Results Available,Type2 Diabetes,Drug: Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)|Drug: Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed),"Peak Plasma Concentration (Cmax) of gemigliptin, LC 15-0636 and metformin|AUC0-tlast of gemigliptin, LC 15-0636 and metformin|AUC0-∞ of gemigliptin, LC 15-0636 and metformin",LG Chem,All,18 Years to 55 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LG-DMCL008,"November 1, 2019","November 30, 2019","December 30, 2019","August 28, 2019",,"August 28, 2019",,,https://ClinicalTrials.gov/show/NCT04070794
Principal Investigator,Uthai Suvanakoot,"International Bio Service Co., Ltd.",,NCT04050098,uthai suvanakoot,uthai,male,0.9,104,167,NCT04050098,Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.,,Not yet recruiting,No Results Available,Type2 Diabetes,Drug: gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|Drug: Gemigliptin tartrate sesquihydrate and metformin,bioequivalence study,LG Chem,All,18 Years to 55 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LG-DMCL007,"November 1, 2019","November 30, 2019","November 30, 2019","August 8, 2019",,"August 8, 2019",,,https://ClinicalTrials.gov/show/NCT04050098
Principal Investigator,"Sung Dae Kwon, M.D., Ph.D.",Metro Hospital,,NCT03944200,sung dae kwon,sung,male,0.86,3580,168,NCT03944200,A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fed State,,Completed,No Results Available,Type2 Diabetes,"Drug: DA-1229_01(A), Sugamet SR Tab 5/1000mg®|Drug: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)",Area under the concentration-time curve(AUCt)|Maximum plasmaconcentration of drug in plasma(Cmax)|Area under the plasma drug concentration-time curve from time 0 to infinity(AUCinf)|AUCt/AUCinf|Time to reach the maximum plasma concentration(Tmax)|Terminal elimination rate constant(ramda z)|Terminal elimination half-life(t1/2),"Dong-A ST Co., Ltd.",All,"19 Years and older   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,DDS18-034BE,"February 7, 2019","March 25, 2019","March 25, 2019","May 9, 2019",,"May 20, 2020","Metro Hospital, Anyang si, Gyeonggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03944200
Principal Investigator,"Sung Dae Kwon, M.D., Ph.D.",Metro Hospital,,NCT03939143,sung dae kwon,sung,male,0.86,3580,169,NCT03939143,A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fasting State,,Completed,No Results Available,Type2 Diabetes,"Drug: DA-1229_01(A), Sugamet SR Tab 5/1000mg®|Drug: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)",Area under the concentration-time curve(AUCt)|Maximum plasmaconcentration of drug in plasma(Cmax)|Area under the plasma drug concentration-time curve from time 0 to infinity(AUCinf)|AUCt/AUCinf|Time to reach the maximum plasma concentration(Tmax)|Terminal elimination rate constant(ramda z)|Terminal elimination half-life(t1/2),"Dong-A ST Co., Ltd.",All,"19 Years and older   (Adult, Older Adult)",Phase 1,34,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,DDS18-033BE,"February 7, 2019","April 4, 2019","April 4, 2019","May 6, 2019",,"May 20, 2020","Metro Hospital, Anyang-si, Gyeonggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03939143
Principal Investigator,"Galateia Kazakia, PhD","University of California, San Francisco",,NCT04208230,galateia kazakia,galateia,female,1.0,22,170,NCT04208230,Progression and Etiology of Cortical Porosity in Diabetic Bone Disease,PREPT2D,Recruiting,No Results Available,Type 2 Diabetes,Device: XtremeCT,"Amount of fat within cortical pores at the distal tibia at baseline|Amount of vessels within cortical pores at the distal tibia at baseline.|Association between Type 2 diabetes status, marrow, and longitudinal changes in cortical porosity at the distal tibia","University of California, San Francisco",All,"50 Years to 70 Years   (Adult, Older Adult)",,96,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,iRIS 16-20196,"January 3, 2017","December 31, 2021","December 31, 2021","December 23, 2019",,"December 24, 2019","University of California San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT04208230
Study Director,"Ching-Ju Chiu, Ph.D.","Institute of Gerontology, NCKU",,NCT03792399,ching-ju chiu,ching-ju,male,1.0,1,174,NCT03792399,Continuous Glucose Monitoring With Immediate or Delayed Counseling Feedback,,Completed,No Results Available,Type2 Diabetes,Behavioral: feedback counseling,"Change of HbA1c|Change of score for self efficacy|Change of score for diabetes associated stress|Change of score for depression|Change in diet composition|Change in exercise amount, time spent in light activity|Change in exercise amount, time spent in moderate activity|Change in exercise amount, time spent in intense activity|Change in exercise amount (time spent in sedentary behavior)",National Cheng-Kung University Hospital,All,"45 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,NCKUH-10508011,"March 7, 2016","October 12, 2017","October 12, 2017","January 3, 2019",,"January 3, 2019",,,https://ClinicalTrials.gov/show/NCT03792399
Study Director,"Filip K Knop, MD, PhD","University Hospital, Gentofte, Copenhagen",,NCT04043065,filip k knop,filip,male,0.98,23771,177,NCT04043065,Liver-enriched Antimicrobial Peptide 2,,Completed,No Results Available,Type 2 Diabetes,Biological: Liver-enriched antimicrobial peptide 2|Other: Placebo,"Plasma insulin|Beta-cell secretion|LEAP-2|Resting energy expenditure|Appetite, satiety, and general well-being","University Hospital, Gentofte, Copenhagen|Gubra ApS",Male,18 Years to 25 Years   (Adult),Early Phase 1,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LEAP-2,"January 28, 2019","May 20, 2019","May 20, 2019","August 2, 2019",,"August 5, 2019","Center for Clinical Metabolic Research, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT04043065
Study Chair,"Gian Paolo Fadini, MD PhD",University of Padova,,NCT03959865,gian paolo fadini,gian,male,0.98,10303,178,NCT03959865,GLP-1 REceptor Agonists and Real World EvIdeNce,GLP-1REWIN,"Active, not recruiting",No Results Available,Type 2 Diabetes,Drug: Long-acting GLP-1RA|Drug: Short-acting GLP-1RA|Drug: Human-based GLP-1RA|Drug: Exendin-based GLP-1RA|Drug: Fixed ratio BI/GLP-1RA combination|Drug: Flexible BI/GLP-1RA combination,HbA1c|Weight|Blood pressure|Persistence,University of Padova|Azienda Ospedaliera di Padova,All,"18 Years to 80 Years   (Adult, Older Adult)",,6000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,4462/AO/18,"December 19, 2018","February 11, 2019","May 31, 2019","May 22, 2019",,"May 22, 2019","Servizio di Diabetologia UOC Medicina Generale, Cittadella, Padova, Italy|U.O.S Diabetologia, Ospedale di Schiavonia, Monselice, Padova, Italy|U.O. Diabetologia ULSS2, Pieve di Soligo, Treviso, Italy|U.O. Diabetologia e Dietetica ULSS6, Padova, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Diabetologia ULSS2, Treviso, Italy",,https://ClinicalTrials.gov/show/NCT03959865
Principal Investigator,"Renee Pekmezaris, PhD",Feinstein Institute for Medical Research,,NCT03960424,renee pekmezaris,renee,female,0.89,3998,179,NCT03960424,Patient and Caregiver-Centered Diabetes Telemanagement Program for Hispanic/Latino Patients,,Not yet recruiting,No Results Available,Type 2 Diabetes Mellitus|Type2 Diabetes,Other: Comprehensive Outpatient Management|Behavioral: Diabetes Telemonitoring,HbA1c|Hypoglycemia episodes|Adherence|Diabetes self-efficacy|PAID|Weight|Cholesterol|Blood Pressure|Diabetes Quality of life,Northwell Health|Patient-Centered Outcomes Research Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AD-2017C3-9185,"September 1, 2019","May 1, 2022","June 30, 2022","May 23, 2019",,"July 22, 2019","Feinstein Institute of Medical Research, Manhasset, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03960424/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03960424/ICF_003.pdf",https://ClinicalTrials.gov/show/NCT03960424
Principal Investigator,"Jill K Hamilton, MD",The Hospital for Sick Children,,NCT04126291,jill k hamilton,jill,female,0.93,5787,180,NCT04126291,Type 2 Diabetes Prevention Toolkit for Health-Care Professionals,,Recruiting,No Results Available,Childhood Obesity,Behavioral: Evaluation of whiteboard videos,Change in self-efficacy/confidence related to pediatric obesity management|Change in knowledge|Change in self-efficacy/confidence related to pediatric weight management|Change in practice related to pediatric weight management,The Hospital for Sick Children|University of Ottawa,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,65,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,1000060439,"October 1, 2019",October 2020,December 2020,"October 15, 2019",,"March 24, 2020","The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04126291
Principal Investigator,"Noor N Suleiman, MD",Hamad Medical Corporation,,NCT03998267,noor n suleiman,noor,female,0.73,11213,181,NCT03998267,Qatar Diabetes Mobile Application Trial,QDMAT,Recruiting,No Results Available,Type2 Diabetes Mellitus,Device: Droobi|Other: Standard of care,Difference in mean HbA1c|Subject perceptions of diabetes self management|Change in subjects attitudes towards disease|Changes in insulin doses|Changes in reported hypoglycemia|Time to achieve normoglycemia|Number of clinical interactions|Missed clinical appointments|Weight|Blood Pressure|Lipids,Hamad Medical Corporation|Qatar Computing Research Institute (QCRI)|Droobi Health,All,18 Years to 60 Years   (Adult),Not Applicable,180,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17292,"August 22, 2019","August 17, 2020","December 31, 2020","June 26, 2019",,"February 17, 2020","Hamad General Hospital, Doha, Qatar",,https://ClinicalTrials.gov/show/NCT03998267
Principal Investigator,"Kwan Woo Lee, MD, Ph.D",Ajou University School of Medicine,,NCT03793023,kwan woo lee,kwan,male,0.5,1111,184,NCT03793023,Observational Study to Evaluate the Efficacy and Safety of Teneligliptin,,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: Teneligliptin 20mg,"Change in HbA1c|Change in FBG|Change in body weight, BMI|Change in lipid profile(Total cholesterol, LDL cholesterol, HDL cholesterol)|The percentage of patients with HbA1c <7.0% and <6.5%|The percentage of patients with a decrease from baseline in HbA1c|Safety Outcome",Handok Inc.,All,"19 Years and older   (Adult, Older Adult)",,4875,Industry,Observational,Observational Model: Case-Crossover|Time Perspective: Prospective,HD_TEN_OS2015,January 2016,December 2020,December 2020,"January 4, 2019",,"January 7, 2019","Ajou University Hospital, Suwon, Gyeonggi, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03793023
Principal Investigator,"Meizi He, PhD",The University of Texas at San Antonio,,NCT03934593,meizi he,meizi,female,0.89,56,185,NCT03934593,Building a Healthy Temple: a Diabetes Self-management Support Program in Hispanic Faith Community Settings,,Recruiting,No Results Available,Type2 Diabetes Mellitus,"Behavioral: Faith-Based (FB, BHT DSMS)|Other: Faith-Placed (FP, Stanford DSMP)",The change in HbA1c|Waist circumference|Body Mass Index|Quality of Life (QoL)|Diabetes Self-care practices|The barriers to diabetes care.|Physical Activity (PA) level assessment|Occupational physical activity,The University of Texas at San Antonio|American Diabetes Association,All,"21 Years to 85 Years   (Adult, Older Adult)",Not Applicable,360,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,ADA#1-17-ICTS-029,"January 1, 2017","June 30, 2020","June 30, 2020","May 2, 2019",,"May 2, 2019","Human Nutrition Lab, UTSA, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03934593
Principal Investigator,"Min Soo Park, Ph.D. M.D.",Severance Hospital,,NCT03849261,min soo park,min,male,0.57,7493,187,NCT03849261,Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy Adults,,"Active, not recruiting",No Results Available,Type2 Diabetes Mellitus,Drug: CKD-387|Drug: D635,Cmax of Dapagliflozin|Cmax of Metformin|AUClast of Dapagliflozin|AUClast of Metformin|AUCinf of Dapagliflozin|AUCinf of Metformin|Tmax of Dapagliflozin|Tmax of Metformin|T1/2 of Dapagliflozin|T1/2 of Metformin|Vd/F of Dapagliflozin|Vd/F of Metformin|CL/F of Dapagliflozin|CL/F of Metformin,Chong Kun Dang Pharmaceutical,All,19 Years to 55 Years   (Adult),Phase 1,36,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,184BE18026,"January 14, 2019","February 1, 2019","February 22, 2019","February 21, 2019",,"February 21, 2019","Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03849261
Principal Investigator,"Min Soo Park, Ph.D. M.D.",Severance Hospital,,NCT03849339,min soo park,min,male,0.57,7493,193,NCT03849339,Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition,,"Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus,Drug: CKD-387|Drug: D635,Cmax of Metformin|AUClast of Metformin|AUCinf of Metformin|Tmax of Metformin|t1/2 of Metformin|CL/F of Metformin|Vd/F of Metformin,Chong Kun Dang Pharmaceutical,All,19 Years to 55 Years   (Adult),Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,184BE18028,"January 28, 2019","February 21, 2019","February 28, 2019","February 21, 2019",,"February 21, 2019","Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03849339
Principal Investigator,"Jose Carlos Fernandez-Garcia, MD, PhD",Virgen de la Victoria Hospital,,NCT03919656,jose carlos fernandez-garcia,jose,male,0.98,451671,189,NCT03919656,"SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease",,Not yet recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: Dapagliflozin 10 mg|Drug: Placebo Oral Tablet,Metabolomics changes in blood|Metabolomics changes in urine|BMI (body mass index) changes|Changes in insulin resistance|Changes in metabolic control|Changes in Quality of Life: 36-Item Short Form Health Survey (SF-36) questionnaire|Changes in albuminuria,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",FIM-DAPA-2018-01,May 2019,December 2019,April 2020,"April 18, 2019",,"April 23, 2019","Virgen de la Victoria University Hospital. Endocrinology Department, Malaga, Spain",,https://ClinicalTrials.gov/show/NCT03919656
Principal Investigator,"Martin Haluzik, Prof. DSc.",Institute for Clinical and Experimental Medicine,,NCT03864705,martin haluzik,martin,male,0.98,180687,190,NCT03864705,Compliance of Diabetic Patients Treated With Metformin,CODAMET,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Diagnostic Test: Measurement of plasma metformin levels,Plasma metformin levels,Institute for Clinical and Experimental Medicine,All,"18 Years and older   (Adult, Older Adult)",,400,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,001,"March 1, 2019","December 31, 2020","December 31, 2020","March 6, 2019",,"March 6, 2019","Institute for Clinical and Experimental Medicine, Prague, Czechia",,https://ClinicalTrials.gov/show/NCT03864705
Principal Investigator,"Martin Halle, Prof. Dr. med.",Klinikum rechts der Isar Technische Universität München,,NCT03835923,martin halle,martin,male,0.98,180687,435,NCT03835923,Lifestyle Intervention in Chronic Ischemic Heart Disease and Diabetes,LeIKD,"Active, not recruiting",No Results Available,"Ischemic Heart Disease Chronic|Diabetes Mellitus, Type 2",Behavioral: lifestyle intervention|Behavioral: usual care,"Change in HbA1c|Change in health literacy|Change in daily physical activity|Change in average steps per day|Change in eating behavior|Change in quality of life|Change of medical care expenses|Change in weight|Change in waist circumference|Change in LDL-cholesterol concentrations|Change in HDL-cholesterol concentrations|Change in triglyceride concentrations|Change in systolic blood pressure|Change in diastolic blood pressure|Number of the combined endpoint ""4P-MACE""","Techniker Krankenkasse|Technische Universität München|privates Institut für angewandte Versorgungsforschung GmbH|IDS Diagnostic Systems AG|Federal Joint Committee, Germany",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,01NVF17015|DRKS00015140,"February 12, 2019",October 2020,April 2021,"February 11, 2019",,"June 11, 2020","University Hospital: Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany|University Hospital: Charité - Universitätsmedizin Berlin, Berlin, Germany|University Hospital: Herzzentrum Dresden, Dresden, Germany|University Hospital: Universitäts-Herzzentrum Freiburg - Bad Krozingen, Freiburg, Germany|University Hospital: Universitätsmedizin Greifswald, Greifswald, Germany|Doctor's Practice: Dr. Rüdell, Kassel, Germany|University Hospital: Klinik und Poliklinik für Kardiologie - Universitätsklinikum Leipzig, Leipzig, Germany|University Hospital: Magdeburg, Magdeburg, Germany|University Hospital: Klinikum rechts der Isar, Technische Universität München, Munich, Germany|Doctor's Practice: Prof. Dr. Jacob und Dr. Jacob, Villingen-Schwenningen, Germany",,https://ClinicalTrials.gov/show/NCT03835923
Principal Investigator,"Kyung Sang Yu, Ph.D. M.D.",Seoul National University Hospital,,NCT03849495,kyung sang yu,kyung,male,0.62,1633,192,NCT03849495,Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-370 and D745 in Healthy Adults,,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: CKD-370|Drug: D745,AUClast of Empagliflozin|Cmax of Empagliflozin|AUCinf of Empagliflozin|Tmax of Empagliflozin|T1/2 of Empagliflozin|CL/F of Empagliflozin|Vd/F of Empagliflozin,Chong Kun Dang Pharmaceutical,All,19 Years to 50 Years   (Adult),Phase 1,28,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,191BE18033,"February 19, 2019","March 17, 2019","March 21, 2019","February 21, 2019",,"March 12, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03849495
Principal Investigator,"Kyung-Sang Yu, M.D., Ph.D",Seoul National University Hospital,,NCT03848637,kyung-sang yu,kyung-sang,male,1.0,3,194,NCT03848637,The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375,,Not yet recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: CKD-375|Drug: D387,Maximum plasma concentration of Empagliflozin|Maximum plasma concentration of Metformin|Area under the plasma concentration of Empagliflozin-time curve from time zero to time of last measurable concentration|Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration|Area under the plasma concentration of Empagliflozin-time curve from time zero to infinity|Area under the plasma concentration of Metformin-time curve from time zero to infinity|Time to reach maximum (peak) plasma concentration of Empagliflozin following drug administration|Time to reach maximum (peak) plasma concentration of Metformin following drug administration|Half-life of Empagliflozin|Half-life of Metformin|Apparent clearance of Empagliflozin|Apparent clearance of Metformin|Apparent volume of distribution of Empagliflozin|Apparent volume of distribution of Metformin,Chong Kun Dang Pharmaceutical,All,19 Years to 50 Years   (Adult),Phase 1,28,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,192BE18036,"April 14, 2019","April 24, 2019","May 1, 2019","February 21, 2019",,"March 6, 2019",,,https://ClinicalTrials.gov/show/NCT03848637
Principal Investigator,Amalia Yanni,Harokopio University,,NCT03926806,amalia yanni,amalia,female,0.98,7700,195,NCT03926806,"Yoghurt Consumption, Body Weight Management and Glycemic Control of T2DM Patients",,Completed,No Results Available,Type 2 Diabetes Mellitus,Other: Plain yoghurt|Other: Vitamin B yoghurt,Body weight management|Glycemic control|Change of ghrelin response|Change of GLP-1 response,Harokopio University|National and Kapodistrian University of Athens,All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",1354.18-11-16,"November 25, 2016","August 8, 2018","December 29, 2018","April 25, 2019",,"April 26, 2019",,,https://ClinicalTrials.gov/show/NCT03926806
Study Chair,Nikolaos Tentolouris,National and Kapodistrian University of Athens,,NCT03926806,nikolaos tentolouris,nikolaos,male,0.99,1396,195,NCT03926806,"Yoghurt Consumption, Body Weight Management and Glycemic Control of T2DM Patients",,Completed,No Results Available,Type 2 Diabetes Mellitus,Other: Plain yoghurt|Other: Vitamin B yoghurt,Body weight management|Glycemic control|Change of ghrelin response|Change of GLP-1 response,Harokopio University|National and Kapodistrian University of Athens,All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",1354.18-11-16,"November 25, 2016","August 8, 2018","December 29, 2018","April 25, 2019",,"April 26, 2019",,,https://ClinicalTrials.gov/show/NCT03926806
Study Director,Vaios Karathanos,Harokopio University,,NCT03926806,vaios karathanos,vaios,male,0.99,236,195,NCT03926806,"Yoghurt Consumption, Body Weight Management and Glycemic Control of T2DM Patients",,Completed,No Results Available,Type 2 Diabetes Mellitus,Other: Plain yoghurt|Other: Vitamin B yoghurt,Body weight management|Glycemic control|Change of ghrelin response|Change of GLP-1 response,Harokopio University|National and Kapodistrian University of Athens,All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",1354.18-11-16,"November 25, 2016","August 8, 2018","December 29, 2018","April 25, 2019",,"April 26, 2019",,,https://ClinicalTrials.gov/show/NCT03926806
Principal Investigator,Katarzyna Nabrdalik,Medical University of Silesia,,NCT04089280,katarzyna nabrdalik,katarzyna,female,0.98,72905,196,NCT04089280,Probiotics in Metformin Intolerant Patients With Type 2 Diabetes,ProGasMet,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Metformin Adverse Reaction",Dietary Supplement: Sanprobi Barrier-multispecies probiotic|Other: Placebo Comparator,Adverse gastrointestinal symptoms related to metformin treatment|Intestinal barrier permeability and inflammation - zonulin blood concentration|Intestinal barrier permeability and inflammation - immunoglobulins (IG) against zonulin|Intestinal barrier permeability and inflammation - CRP|Intestinal barrier permeability and inflammation - stool concentration of zonulin|Intestinal barrier permeability and inflammation - blood concentration of calprotectin|Intestinal barrier permeability and inflammation - stool concentration of calprotectin|Faecal microbiota composition|Short chain fatty acids (SCFAs)|Cardiometabolic state - lipid parameters|Cardiometabolic state - Body Mass Index|Cardiometabolic state - blood pressure|Cardiometabolic state - heart rate|Cardiometabolic state - HbA1c|Oxidative stress markers - SOD|Oxidative stress markers - GPx|Oxidative stress markers - CAT|Oxidative stress markers - GR|Oxidative stress markers - TOC|Oxidative stress markers - LHP|Oxidative stress markers - LPS|Oxidative stress markers - PSH|Oxidative stress markers - MDA|Oxidative stress markers - GSH|Oxidative stress markers - TAS,"Medical University of Silesia|Sanprobi Sp. z o.o., Sp. k., Szczecin, Poland",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SilesianMU2,"October 16, 2018","October 16, 2020","May 16, 2021","September 13, 2019",,"September 26, 2019","Department of Internal Diseases, Diabetology and Nephrology, Zabrze, Poland",,https://ClinicalTrials.gov/show/NCT04089280
Principal Investigator,"Tim Heise, MD",Profil Institut für Stoffwechselforschung GmbH,,NCT03907202,tim heise,tim,male,0.99,47038,197,NCT03907202,"A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM",,Recruiting,No Results Available,Type II Diabetes Mellitus,Drug: Daily injection of KBP/placebo for up to 28 days,Treatment Emergent Adverse Events (TEAEs).|Vital sign - Blood Pressure.|Vital sign - Pulse (beats per min).|Vital sign - Body Temperature.|Vital sign - Respiratory frequency.|Electrocardiogram (ECG) - PQ interval.|Electrocardiogram (ECG) - QRS complex.|Electrocardiogram (ECG) - QT interval.|Safety laboratory parameter - lipids.|Safety laboratory parameter - haematology.|Safety laboratory parameter - coagulation.|Safety laboratory parameter - urinalysis.|Pharmacokinetic Evaluation - KBP-089 Area Under Curve.|Pharmacokinetic Evaluation - KBP-089 Cmax.|Gastric emptying - Paracetamol Cmax.|Gastric emptying - Paracetamol Tmax.|Gastric emptying - Paracetamol Area Under Curve (AUC).|Fasting and postprandial glucose concentration.|Fasting and postprandial insulin concentration.|Fasting and postprandial C-peptide concentration.|Fasting and postprandial glucagon concentration.|Body weight.|N-(1-deoxy)-fructosyl-haemoglobin (HbA1c).|Fridericia's corrected QT interval (QTcF).,KeyBioscience AG|Eli Lilly and Company|Nordic Bioscience A/S|Profil Institut für Stoffwechselforschung GmbH,All,18 Years to 64 Years   (Adult),Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",KBP089/CD/002,"April 17, 2018",December 2019,December 2019,"April 8, 2019",,"April 8, 2019","Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03907202
Principal Investigator,"Luiz FM Kruel, phd",Federal University of Rio Grande do Sul,,NCT03967561,luiz fm kruel,luiz,male,0.98,3656,198,NCT03967561,Progressive vs. Non-progressive Water-based Aerobic Training on Type 2 Diabetes Control: a Randomized Clinical Trial,PAT-DM2,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Progressive water-based aerobic training|Other: Non-progressive aerobic training,"Glycated Hemoglobin levels (HbA1c)|Fasting plasma glucose|Fasting insulin|Insulin-resistance index (HOMA-IR)|Total cholesterol|High density lipoprotein|Low density lipoprotein|Triglycerides|Plasma renin|C-reactive protein|Peak oxygen uptake|Oxygen uptake at the second ventilatory threshold.|Percentage of oxygen consumption in the second ventilatory threshold from the peak oxygen uptake|Systolic blood pressure.|Diastolic blood pressure.|Resting heart rate|Maximum dynamic muscle strength (1RM) in the knees extension exercise|Muscular resistance (maximal repetitions) in the knees extension exercise.|Timed up-and-go test performed at the usual speed.|Timed up-and-go test performed at the maximal speed.|Overall quality of life and in physical, psychological, social relationships and environment domains, evaluated by instrument of World Health Organization (WHOQOL).|Depressive symptoms, evaluated by Depression Inventory Patient Health Questionnaire (PHQ-9)|Sleep quality, evaluated by Pittsburgh Sleep Scale|Physical activity levels, evaluated by International Physical Activity Questionnaire (IPAQ) - Long Form.",Federal University of Rio Grande do Sul|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2.855.513,"June 10, 2019","October 30, 2019","November 15, 2019","May 30, 2019",,"June 4, 2019",,,https://ClinicalTrials.gov/show/NCT03967561
Principal Investigator,"Stephanie T Chung, M.D.",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,NCT04209075,stephanie t chung,stephanie,female,0.98,68107,199,NCT04209075,Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber),,Recruiting,No Results Available,Diabetes,Dietary Supplement: Biomebliss|Drug: Metformin|Dietary Supplement: Placebo,GI Tolerability score|Stool Short Chain Fatty Acids (SCFA),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"10 Years to 25 Years   (Child, Adult)",Phase 2,50,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",200018|20-DK-0018,"March 10, 2020","December 14, 2023","December 14, 2023","December 23, 2019",,"March 27, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04209075
Principal Investigator,"Stephanie Anzman Frasca, PhD",Assistant Professor,,NCT04051008,stephanie anzman frasca,stephanie,female,0.98,68107,520,NCT04051008,CTSI Pilot: Improving Adherence to Diabetic Diet,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diet, Healthy|Pre-diabetes",Behavioral: Online - use of online grocery shopping platform|Behavioral: Default - use of online grocery shopping platform with default shopping carts,Calories purchased|Change in calories purchased|Carbohydrates purchased|Change in carbohydrates purchased|Sugars purchased|Change in sugars purchased|Nutritional quality of purchases|Change in nutritional quality of purchases|Dollars spent|Change in dollars spent|Nutritional quality of foods consumed,State University of New York at Buffalo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,STUDY00003054|1154678,"October 14, 2019","December 31, 2020","December 31, 2020","August 9, 2019",,"May 1, 2020","State University of New York at Buffalo, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT04051008
Principal Investigator,"Romeu Mendes, MD, PhD","EPIUnit - Instituto de Saúde Pública, Universidade do Porto",,NCT03810846,romeu mendes,romeu,male,0.99,759,201,NCT03810846,Feasibility and Safety of Walking Football in Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Walking football exercise program,Exercise intensity - subjective internal load|Exercise intensity - objective internal load|Exercise intensity - external load|Acute glycemic effect|Acute systolic blood pressure effect|Acute diastolic blood pressure effect|Incidence of falls|Incidence of foot injuries|Incidence of musculoskeletal injuries|Rate of Enjoyment|Glycemic control|Blood lipid profile|Clinical systolic blood pressure|Clinical diastolic blood pressure|Body mass index|Waist circumference|Body fat|Body lean mass|Agility/balance|Habitual physical activity|Food pattern|Cognitive state|Health-related quality of life|Medication,"Universidade do Porto|Federação Portuguesa de Futebol, Portugal|Administração Regional de Saúde do Norte, Portugal|Fédération Internationale de Football Association",Male,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISPUP-RMFIFA2018,"September 17, 2018","January 31, 2019","June 30, 2019","January 22, 2019",,"August 22, 2019","Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal",,https://ClinicalTrials.gov/show/NCT03810846
Principal Investigator,"Nazia Raja-Khan, MD",Milton S. Hershey Medical Center,,NCT04016415,nazia raja-khan,nazia,female,0.97,525,202,NCT04016415,Decreasing Stress in Type 2 Diabetes,DESTRESS-T2D,Recruiting,No Results Available,"Stress|Diabetes Mellitus, Type 2",Behavioral: Mindfulness Based Stress Reduction|Behavioral: Stress Management Education,Change in Hemoglobin A1c from Baseline to 6 months|Change in Hemoglobin A1c from Baseline to 1 year|Change in Hemoglobin A1c from Baseline to 2 months|Change in Diabetes Distress Scale from Baseline to 2 months|Change in Diabetes Distress Scale from Baseline to 6 months|Change in Diabetes Distress Scale from Baseline to 1 year|Change in Perceived Stress Scale-10 from Baseline to 2 months|Change in Perceived Stress Scale-10 from Baseline to 6 months|Change in Perceived Stress Scale-10 from Baseline to 1 year,Milton S. Hershey Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health (NIH)|Penn State University|Rowan University|West Chester University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,290,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10532|1R01DK119379-01,"July 1, 2020","March 31, 2025","March 31, 2025","July 11, 2019",,"March 30, 2020","Penn State College of Medicine, Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04016415
Principal Investigator,"Zoltán J Taybani, MD",Bekes County Central Hospital,,NCT04020445,zoltán j taybani,zoltán,male,0.99,2117,204,NCT04020445,Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes,,Recruiting,No Results Available,HBA1c|Body Weight|Hypoglycemia,Other: de-escalation of complex insulin regimens,change in HbA1c|change in body weight|change in risk of hypoglycemia,Bekes County Central Hospital|University of Debrecen|Szeged University,All,"18 Years and older   (Adult, Older Adult)",,150,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,BekesCCH,"January 1, 2016","January 1, 2021","January 1, 2021","July 16, 2019",,"July 16, 2019","Zoltán Taybani, Békéscsaba, Békés, Hungary",,https://ClinicalTrials.gov/show/NCT04020445
Principal Investigator,"Timothy Frayling, PhD",University of Exeter,,NCT04040595,timothy frayling,timothy,male,0.99,13105,206,NCT04040595,The Genetics of Adipose Tissue Function and Its Link to Type 2 Diabetes and Heart Disease,FATFUNgenes,Recruiting,No Results Available,Diabetes Mellitus,Procedure: Abdominal fat biopsy,"Mean adipocyte size (µm2) assessed using Image J software.|Adipose tissue expression of genes that are markers of adipogenesis (PPARy, CREBP).|Adipose tissue expression of genes that are markers of fibrosis (SPARC, collagens, TGFbeta, LOX).|Adipose tissue expression of genes that are determinants of adipose inflammation (IL-1beta, IL-6, and 8, TNFalpha, MCP-1/CCL2).",Royal Devon and Exeter NHS Foundation Trust|University of Exeter|NIHR Exeter Clinical Research Facility,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,IRAS: 257693|105009|19/SW/0012|1909872,"March 7, 2019","February 28, 2021","August 31, 2021","July 31, 2019",,"July 31, 2019","Royal Devon and Exeter NHS Foundation Trust / University of Exeter, Exeter, Devon, United Kingdom",,https://ClinicalTrials.gov/show/NCT04040595
Principal Investigator,"Juan F Roy, PhD",Camilo Jose Cela University,,NCT04097483,juan f roy,juan,male,0.98,274814,207,NCT04097483,Treatment Adherence Intervention in Patients With Type 2 Diabetes and Comorbid Depression,TELE-DD,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2|Depression",Behavioral: Telephone Intervention Group,"Diabetes control measured by Glycosylated Haemoglobin|Patient Health Questionnaire (PHQ-9)|Medication possession ratio (MPR)|MBG questionnaire|LDL-Cholesterol|Diabetes Distress Scale (DDS)|Sociodemographic data Gender, age, marital status, education, occupation, economical level|Blood pressure|Body mass index (BMI)|Research nurse qualitative and quantitative evaluation about Treatment Adherence and diseases management.",Instituto de Investigación Sanitaria Aragón|Universidad de Zaragoza,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,428,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",TELE-DD,January 2017,December 2018,March 2020,"September 20, 2019",,"February 25, 2020",,,https://ClinicalTrials.gov/show/NCT04097483
Principal Investigator,"Gulin Findikoglu, Assoc Prof","Pamukkale University,Medical Faculty, PMR Department",,NCT04068285,gulin findikoglu,gulin,female,0.89,97,208,NCT04068285,Neuromuscular Adaptations to Exercise In Patients With Type 2 Diabetes Mellitus,,Completed,No Results Available,"Gait, Unsteady|Aerobic Exercise",Other: Aerobic Exercise,walking speed,Pamukkale University,All,30 Years to 60 Years   (Adult),Not Applicable,72,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",60116787-0,"November 4, 2019","June 1, 2020","June 1, 2020","August 28, 2019",,"June 4, 2020","Pamukkale University, Denizli, Turkey",,https://ClinicalTrials.gov/show/NCT04068285
Principal Investigator,"Gulin Findikoglu, Assoc Prof","Pamukkale University,Medical Faculty, PMR Department",,NCT04181853,gulin findikoglu,gulin,female,0.89,97,417,NCT04181853,The Effect of Aerobic Exercise on Genetic Molecules,xnx,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Aerobic Exercise|Genetic Response",Other: exercise,genetic molecules,Pamukkale University,All,"30 Years to 74 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",60116787-020/83243,"February 5, 2020","June 30, 2020","December 31, 2021","December 2, 2019",,"February 6, 2020","Pamukkale University, Denizli, Turkey|Pamukkale University, Denizli, Turkey",,https://ClinicalTrials.gov/show/NCT04181853
Principal Investigator,"Normand Boulé, PhD",University of Alberta,,NCT03908281,normand boulé,normand,male,0.82,267,209,NCT03908281,Fasted Exercise Training in Type 2 Diabetes,FED,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Fasted Exercise|Behavioral: Postprandial Exercise,Concentration of HbA1c (mmol/mol)|Liver fat (%)|Pancreatic fat (%)|Muscle fat (%)|Concentrations of Fasting glucose|Concentrations of Fasting insulin|Concentrations of Fasting lipids|Concentrations of Liver enzymes|Aerobic fitness|Height (centimeters)|Waist circumference (centimeters)|Hip circumference (centimeters)|Body weight (kilograms)|Continuous glucose monitoring,University of Alberta,All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Pro00088195,"September 1, 2019",December 2020,January 2021,"April 9, 2019",,"September 26, 2019","University of Alberta, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT03908281
Principal Investigator,"Earle Chambers, PhD",Albert Einstein College of Medicine,,NCT04104243,earle chambers,earle,male,0.97,58,210,NCT04104243,Power-Up: An Effectiveness Trial of the Diabetes Prevention Program,Power-Up,Not yet recruiting,No Results Available,Type 2 Diabetes|Pre-Diabetes,Other: Men-Tailored DPP (Power-Up),Percent of Patients with Weight Loss|Comparison of Engagement and Retention of Men vs Standard Diabetes Prevention Program,Albert Einstein College of Medicine|New York City Department Of Health and Mental Hygiene (NYCDOHMH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Male,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,300,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2019-10343|R01DK121896,March 2021,January 2024,June 2024,"September 26, 2019",,"May 5, 2020",,,https://ClinicalTrials.gov/show/NCT04104243
Principal Investigator,"Lisse Angarita, PhD","Universidad Andrés Bello, Facultad de Medicina - Sede Concepción",,NCT03829800,lisse angarita,lisse,female,0.86,98,211,NCT03829800,"Formulas for Diabetes With Sucromalt & Isomaltulose on Glycemic Index, Hormones & Subjective Appetite in Type 2 Diabetes",,Completed,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Ensure® Abbott Nutrition|Dietary Supplement: Glucerna® Abbott Nutrition|Dietary Supplement: Diasip® Nutricia Advanced|Dietary Supplement: Glicolab®,Change from baseline Glycemia at 180 minutes|Change from baseline Insulin at 180 minutes|Glycemic Index (GI)|Glycemic Load (GL)|Change from baseline GLP-1 at 180 minutes|Change from baseline GIP at 180 minutes|Change from baseline Hunger at 180 minutes|Change from baseline Fullness at 180 minutes|Change from baseline Desire to eat at 180 minutes|Change from baseline Prospective food consumption at 180 minutes|Change from baseline Subjective appetite at 180 minutes|Age|Weight|Height|Body Mass Index|Hip Circumference|Total Cholesterol|HDL-C|LDL-C|Triacylglycerides|HbA1c,Universidad del Zulia,All,51 Years to 63 Years   (Adult),Not Applicable,23,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science",1001092016,"September 1, 2016","September 1, 2017","November 15, 2018","February 4, 2019",,"February 4, 2019",,,https://ClinicalTrials.gov/show/NCT03829800
Principal Investigator,"Dawn K Coletta, PhD",University of Arizona,,NCT04126551,dawn k coletta,dawn,female,0.95,6743,212,NCT04126551,Mitochondrial Methylation in Type 2 Diabetes,,Recruiting,No Results Available,"Obesity|Diabetes Mellitus, Type 2|Insulin Resistance",Other: Methylation status,Mitochondrial DNA methylation|Mitochondrial Function,University of Arizona,All,35 Years to 55 Years   (Adult),,36,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1901254125,"July 23, 2019","December 31, 2021","December 31, 2022","October 15, 2019",,"October 15, 2019","Clinical and Translational Research Center (CaTS), Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04126551
Principal Investigator,"Per M Humpert, M. D.",Director of Stoffwechselzentrum Rhein-Pfalz,,NCT03805802,per m humpert,per,male,0.97,8746,214,NCT03805802,Influence of a Liquid Oat Bran Product on Blood Glucose in Patients With Poorly Controlled Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Obesity|Overweight|Metabolic Syndrome",Other: active product|Other: reference product,Fasting glucose|HBA1c|Self-documented glucose|Weight|BMI|Lipid metabolism: Serum triglycerides|Lipid metabolism: apolipoprotein A (mg/dl)|Lipid metabolism: Apolipoprotein B mg/dl|Lipid metabolism: Apolipoprotein B / Apolipoprotein A ratio|Lipid metabolism: HDL-cholesterol|Lipid metabolism: LDL- cholesterol mg/dl|Microbiome|Inflammation: Il-6|Inflammation: hsCRP,Stoffwechselzentrum Rhein - Pfalz|Glucanova AB,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",012019,"February 4, 2019",December 2019,March 2020,"January 16, 2019",,"April 4, 2019","Stoffwechselzentrum Rhein-Pfalz, Mannheim, Baden-Württemberg, Germany",,https://ClinicalTrials.gov/show/NCT03805802
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03914326,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,215,NCT03914326,A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes,SOUL,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Placebo (semaglutide),"Time to first occurrence of a major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death/non-fatal myocardial infarction/non-fatal stroke|Time to first occurrence of a composite endpoint|Time to occurrence of CV death|Time to first occurrence of major adverse limb events (MALE), a composite endpoint consisting of: acute limb ischemia hospitalisation/chronic limb ischemia hospitalisation|Time to first occurrence of an expanded MACE composite endpoint consisting of: CV death/non-fatal myocardial infarction/ non-fatal stroke/coronary revascularisation/unstable angina requiring hospitalisation|Time to first occurrence of a composite heart failure endpoint consisting of: CV death/heart failure requiring hospitalisation/urgent heart failure visit|Time to first occurrence of a composite CKD endpoint|Time to occurrence of all-cause death|Time to first occurrence of non-fatal myocardial infarction (MI)|Time to first occurrence of non-fatal stroke|Time to first occurrence of heart failure requiring hospitalisation|Time to first occurrence of urgent heart failure visit|Time to first occurrence of coronary revascularisation|Time to first occurrence of unstable angina requiring hospitalisation|Time to occurrence of renal death|Time to first occurrence of onset of persistent 50% or more reduction in eGFR|Time to first occurrence of onset of persistent eGFR (CKD-EPI) below 15 mL/min/1.73 m^2|Time to first occurrence of initiation of chronic renal replacement therapy (dialysis or kidney transplantation)|Time to first occurrence of a composite endpoint consisting of: all-cause death/non-fatal myocardial infarction/non-fatal stroke|Time to first occurrence of acute limb ischemia|Time to first occurrence of chronic limb ischemia|Annual rate of change in eGFR (CKD-EPI) (total eGFR slope)|Change in glycosylated haemoglobin (HbA1c)|Change in body weight|Number of severe hypoglycaemic episodes|Time to first occurrence of a severe hypoglycaemic episode",Novo Nordisk A/S,All,"50 Years and older   (Adult, Older Adult)",Phase 3,9642,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EX9924-4473|2018-003141-42|U1111-1218-5368,"June 17, 2019","July 29, 2024","July 29, 2024","April 16, 2019",,"June 11, 2020","Novo Nordisk Investigational Site, Montgomery, Alabama, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Los Alamitos, California, United States|Novo Nordisk Investigational Site, Mission Hills, California, United States|Novo Nordisk Investigational Site, Monterey, California, United States|Novo Nordisk Investigational Site, Palm Springs, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Torrance, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Gurnee, Illinois, United States|Novo Nordisk Investigational Site, Franklin, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Michigan City, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, West Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Slidell, Louisiana, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Lebanon, New Hampshire, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Westfield, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Burlington, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, New Bern, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Marion, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Twinsburg, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Murrells Inlet, South Carolina, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Tullahoma, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, Midland, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Kenosha, Wisconsin, United States|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Constantine, Algeria|Novo Nordisk Investigational Site, Oran, Algeria|Novo Nordisk Investigational Site, Setif, Algeria|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Capital Federal, Argentina|Novo Nordisk Investigational Site, Cordoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Lanus Este, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, Rosario, Santa Fe, Argentina|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Saint Stefan, Austria|Novo Nordisk Investigational Site, Vienna, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Gent, Belgium|Novo Nordisk Investigational Site, Kortrijk, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Roeselare, Belgium|Novo Nordisk Investigational Site, Brasilia, Distrito Federal, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Passo Fundo, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Barrie, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Mirabel, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Cangzhou, Hebei, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Barranquilla, Colombia|Novo Nordisk Investigational Site, Bucaramanga, Colombia|Novo Nordisk Investigational Site, Cali, Colombia|Novo Nordisk Investigational Site, San Juan De Pasto, Colombia|Novo Nordisk Investigational Site, Soledad, Colombia|Novo Nordisk Investigational Site, Krapinske Toplice, Croatia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Pula, Croatia|Novo Nordisk Investigational Site, Rijeka, Croatia|Novo Nordisk Investigational Site, Split, Croatia|Novo Nordisk Investigational Site, Varazdin, Croatia|Novo Nordisk Investigational Site, Zadar, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Chrudim, Czechia|Novo Nordisk Investigational Site, Hradec Kralove, Czechia|Novo Nordisk Investigational Site, Moravska Ostrava, Czechia|Novo Nordisk Investigational Site, Ostrava, Czechia|Novo Nordisk Investigational Site, Plzen, Czechia|Novo Nordisk Investigational Site, Plzen, Czechia|Novo Nordisk Investigational Site, Plzeň, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, Hillerød, Denmark|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Slagelse, Denmark|Novo Nordisk Investigational Site, Svendborg, Denmark|Novo Nordisk Investigational Site, Besançon cedex, France|Novo Nordisk Investigational Site, DIJON cedex, France|Novo Nordisk Investigational Site, Le Coudray, France|Novo Nordisk Investigational Site, Marseille, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Pessac, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Jerichow, Germany|Novo Nordisk Investigational Site, Lingen, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Witten, Germany|Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Guwahati, Assam, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Rohtak, Haryana, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Coimbatore, Tamil Nadu, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, Ludhiana, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Thriruvananthapuram, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Nahariya, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Bari, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Chieti, Italy|Novo Nordisk Investigational Site, Lucca, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Padova, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Perugia, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Bunkyo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Chiba, Japan|Novo Nordisk Investigational Site, Ehime, Japan|Novo Nordisk Investigational Site, Fukui, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Kyoto-shi, Kyoto, Japan|Novo Nordisk Investigational Site, Kyoto, Japan|Novo Nordisk Investigational Site, Miyagi, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Nagano, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Saga-shi, Saga, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Takamatsu-shi, Kagawa, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, Tokorozawa-shi, Saitama, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Gyeonggi-do, Korea, Republic of|Novo Nordisk Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Alor Setar, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Malaysia|Novo Nordisk Investigational Site, Kota Samarahan, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuching, Malaysia|Novo Nordisk Investigational Site, Putrajaya, Malaysia|Novo Nordisk Investigational Site, Sarawak, Malaysia|Novo Nordisk Investigational Site, Seremban, Malaysia|Novo Nordisk Investigational Site, Sungai Buloh, Malaysia|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Tlalpan, México, D.F., Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, San Nicolas de los Garza, Nuevo León, Mexico|Novo Nordisk Investigational Site, Hermosillo, Sonora, Mexico|Novo Nordisk Investigational Site, Merida, Yucatan, Mexico|Novo Nordisk Investigational Site, Mérida, Yucatan, Mexico|Novo Nordisk Investigational Site, Aguascalientes, Mexico|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Delft, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Groningen, Netherlands|Novo Nordisk Investigational Site, Hoogeveen, Netherlands|Novo Nordisk Investigational Site, Maastricht, Netherlands|Novo Nordisk Investigational Site, Nijmegen, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Targoviste, Dambovita, Romania|Novo Nordisk Investigational Site, Targu Mures, Mures, Romania|Novo Nordisk Investigational Site, Tirgu Mures, Mures, Romania|Novo Nordisk Investigational Site, Ploiesti, Prahova, Romania|Novo Nordisk Investigational Site, Ploiesti, Prahova, Romania|Novo Nordisk Investigational Site, Bacau, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Galati, Romania|Novo Nordisk Investigational Site, Sibiu, Romania|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kemerovo, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Krompachy, Slovakia|Novo Nordisk Investigational Site, Nitra, Slovakia|Novo Nordisk Investigational Site, Poprad, Slovakia|Novo Nordisk Investigational Site, Prievidza, Slovakia|Novo Nordisk Investigational Site, Rimavska Sobota, Slovakia|Novo Nordisk Investigational Site, Roznava, Slovakia|Novo Nordisk Investigational Site, Vrutky, Slovakia|Novo Nordisk Investigational Site, Benoni, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Berea, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Alcorcón, Spain|Novo Nordisk Investigational Site, Antequera, Spain|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Burela, Spain|Novo Nordisk Investigational Site, Córdoba, Spain|Novo Nordisk Investigational Site, La Coruña, Spain|Novo Nordisk Investigational Site, Las Palmas de Gran Canaria, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Pozuelo de Alarcon, Spain|Novo Nordisk Investigational Site, Sanlúcar De Barrameda - Cádiz-, Spain|Novo Nordisk Investigational Site, Santander, Spain|Novo Nordisk Investigational Site, Santiago de Compostela, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Changhua City, Taiwan|Novo Nordisk Investigational Site, Taichung City, Taiwan|Novo Nordisk Investigational Site, Taoyuan, Taiwan|Novo Nordisk Investigational Site, Bangkoknoi, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Nakhon Ratchasima, Thailand|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Bursa, Turkey|Novo Nordisk Investigational Site, Erzurum, Turkey|Novo Nordisk Investigational Site, Eskisehir, Turkey|Novo Nordisk Investigational Site, Hatay, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Kayseri, Turkey|Novo Nordisk Investigational Site, Sivas, Turkey|Novo Nordisk Investigational Site, Trabzon, Turkey|Novo Nordisk Investigational Site, Cherkasy, Ukraine|Novo Nordisk Investigational Site, Chernivtsi, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, Odesa, Ukraine|Novo Nordisk Investigational Site, Poltava, Ukraine|Novo Nordisk Investigational Site, Uzhhorod, Ukraine|Novo Nordisk Investigational Site, Zhytomyr, Ukraine|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Addlestone, United Kingdom|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Bradford-on-Avon, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Chippenham, United Kingdom|Novo Nordisk Investigational Site, Coventry, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Harrogate, United Kingdom|Novo Nordisk Investigational Site, Hinckley, United Kingdom|Novo Nordisk Investigational Site, Hull, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Norfolk, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Redhill, United Kingdom|Novo Nordisk Investigational Site, Soham, United Kingdom|Novo Nordisk Investigational Site, Swansea, United Kingdom",,https://ClinicalTrials.gov/show/NCT03914326
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04136067,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,226,NCT04136067,A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: NNC0268-0965|Drug: insulin glargine,Number of treatment-emergent adverse events (AEs)|Number of treatment-emergent hypoglycaemic episodes|Area under the serum NNC0268-0965 concentration-time curve during one dosing interval at steady state|Maximum observed serum NNC0268-0965 concentration after the last dose,Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NN1965-4457|U1111-1227-8683|2019-000754-58,"October 29, 2019","July 28, 2020","July 28, 2020","October 23, 2019",,"April 27, 2020","Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT04136067
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03811561,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,229,NCT03811561,A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes,FOCUS,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Placebo (semaglutide),"Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression.|Time from randomisation to first at least 3 steps ETDRS subject level progression or central involved diabetic macular oedema (ciDME) in either eye.|Change in visual acuity in the worse seeing eye.|Change in visual acuity in the better seeing eye.|Occurrence of treatment for diabetic retinopathy or diabetic macular oedema in either eye with focal/grid laser photocoagulation.|Occurrence of treatment for diabetic retinopathy or diabetic macular oedema in either eye with pan-retinal laser photocoagulation.|Occurrence of treatment for diabetic retinopathy or diabetic macular oedema in either eye with intravitreal injection with anti-vascular endothelial growth factor (VEGF).|Occurrence of treatment for diabetic retinopathy or diabetic macular oedema in either eye with intravitreal injection with steroid.|Occurrence of treatment for diabetic retinopathy or diabetic macular oedema in either eye with vitrectomy.|Presence of at least 3 steps ETDRS subject level improvement.|Presence of at least 2 steps ETDRS subject level progression.|Presence of at least 2 steps ETDRS subject level improvement.|Presence of persistent visual acuity up to 38 ETDRS letters in either eye.|Presence of persistent at least 2 lines (10 letters) ETDRS worsening in visual acuity in either eye from baseline.|Presence of persistent at least 3 lines (15 letters) ETDRS worsening in visual acuity in either eye from baseline.|Presence of persistent at least 2 lines (10 letters) ETDRS improvement in visual acuity in either eye from baseline.|Persistent at least 3 lines (15 letters) ETDRS improvement in visual acuity in either eye from baseline.|Presence of ciDME in either eye.|Change in glycosylated haemoglobin (HbA1c).|Change in body weight.|Change in systolic and diastolic blood pressure.|Change in Lipids: Total-cholesterol, High density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol and triglycerides.",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1500,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NN9535-4352|U1111-1201-6256|2017-003619-20,"May 8, 2019","January 13, 2026","February 18, 2026","January 22, 2019",,"June 4, 2020","Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Costa Mesa, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Moreno Valley, California, United States|Novo Nordisk Investigational Site, Rancho Cucamonga, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, Santa Monica, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Ocala, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, West Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Paducah, Kentucky, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Ann Arbor, Michigan, United States|Novo Nordisk Investigational Site, Richfield, Minnesota, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Bristol, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Shavano Park, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Murray, Utah, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, Oakville, Ontario, Canada|Novo Nordisk Investigational Site, Ottawa, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Hradec Kralove, Czechia|Novo Nordisk Investigational Site, Praha 10, Czechia|Novo Nordisk Investigational Site, Praha 4, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Kochi, Kerala, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Delhi, New Delhi, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Madurai, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Bangalore, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Jelgava, Latvia|Novo Nordisk Investigational Site, Ogre, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Distrito Federal, México, D.F., Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Chorzow, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Plonsk, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Almada, Portugal|Novo Nordisk Investigational Site, Aveiro, Portugal|Novo Nordisk Investigational Site, Coimbra, Portugal|Novo Nordisk Investigational Site, Guimarães, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Matosinhos, Portugal|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Setubal, Portugal|Novo Nordisk Investigational Site, Cluj Napoca, Cluj, Romania|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Hospitalet de Llobregat, Spain|Novo Nordisk Investigational Site, La Coruña, Spain|Novo Nordisk Investigational Site, Pamplona, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Norfolk, United Kingdom|Novo Nordisk Investigational Site, North Yorkshire, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Nuneaton, United Kingdom|Novo Nordisk Investigational Site, Somerset, United Kingdom|Novo Nordisk Investigational Site, Truro, United Kingdom",,https://ClinicalTrials.gov/show/NCT03811561
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04032197,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,234,NCT04032197,A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Placebo (semaglutide),Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries|Change in maximum target-to-background ratio (TBR) for 68Ga-DOTATATE in the carotid arteries|Change in myocardial perfusion reserve (MPR)|Change in total wall volume of the most diseased carotid artery,Novo Nordisk A/S,All,"50 Years and older   (Adult, Older Adult)",Phase 1,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NN9535-4430|U1111-1215-4058|2018-002289-38,"August 12, 2019","May 6, 2020","September 30, 2021","July 25, 2019",,"February 19, 2020","Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Gentofte, Denmark|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT04032197
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04109547,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,235,NCT04109547,A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes,PIONEER 11,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Oral semaglutide|Drug: Placebo,Change in (glycosylated haemoglobin) HbA1c|Change in body weight|Change in fasting plasma glucose (FPG)|Change in fasting 7 point self-measured plasma glucose (SMPG) profile: Mean 7-point profile|Change in fasting 7 point self-measured plasma glucose (SMPG) profile: Mean postprandial increment (over all meals)|Change in body mass index (BMI)|Change in waist circumference|Change in fasting lipid profile: total cholesterol|Change in fasting lipid profile: low-density lipoprotein (LDL) cholesterol|Change in fasting lipid profile: high-density lipoprotein (HDL) cholesterol|Change in fasting lipid profile: triglycerides|Change in Short Form-36 version 2 (SF-36v2™) (acute version) health survey|If a subject achieves HbA1c below 7.0 percent (53 mmol/mol) (American Diabetes Association (ADA) target) (yes/no)|If a subject achieves HbA1c equal to or below 6.5 percent (48 mmol/mol) (American Association of Clinical Endocrinologists (AACE) target) (yes/no)|If a subject achieves HbA1c reduction equal to or above 1 percent-point (10.9 mmol/mol) (yes/no)|If a subject achieves body weight loss equal to or above 3 percent (yes/no)|If a subject achieves body weight loss equal to or above 5 percent (yes/no)|If a subject achieves body weight loss equal to or above 10 percent (yes/no)|If a subject achieves HbA1c below 7.0 percent (53 mmol/mol) without hypoglycaemia (treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes) and no body weight gain (yes/no)|If a subject achieves HbA1c reduction equal to or above 1 percent-point (10.9 mmol/mol) and body weight loss equal to or above 3 percent (yes/no)|Time to rescue medication|Number of treatment-emergent adverse events (TEAEs) during exposure to trial product|Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during exposure to trial product|Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during exposure to trial product (yes/no),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,664,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NN9924-4338|U1111-1188-1173|2018-002590-22,"October 1, 2019","September 1, 2021","October 7, 2021","September 30, 2019",,"June 11, 2020","Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Chongqing, Chongqing, China|Novo Nordisk Investigational Site, ChongQing, Chongqing, China|Novo Nordisk Investigational Site, Fuzhou, Fujian, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Huizhou, Guangdong, China|Novo Nordisk Investigational Site, Shantou, Guangdong, China|Novo Nordisk Investigational Site, Cangzhou, Hebei, China|Novo Nordisk Investigational Site, Handan, Hebei, China|Novo Nordisk Investigational Site, Hengshui, Hebei, China|Novo Nordisk Investigational Site, Shijiazhuang, Hebei, China|Novo Nordisk Investigational Site, Zhengzhou, Henan, China|Novo Nordisk Investigational Site, Shiyan, Hubei, China|Novo Nordisk Investigational Site, Changde, Hunan, China|Novo Nordisk Investigational Site, Chenzhou, Hunan, China|Novo Nordisk Investigational Site, Yueyang, Hunan, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Huai'an, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Wuxi, Jiangsu, China|Novo Nordisk Investigational Site, Xuzhou, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Jiaxing, Jiangxi, China|Novo Nordisk Investigational Site, Nanchang, Jiangxi, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Yinchuan, Ningxia, China|Novo Nordisk Investigational Site, Xining, Qinghai, China|Novo Nordisk Investigational Site, Xi'an, Shaanxi, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Jining, Shandong, China|Novo Nordisk Investigational Site, Qingdao, Shandong, China|Novo Nordisk Investigational Site, Pudong New District, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Chengdu, Sichuan, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Kunming, Yunnan, China|Novo Nordisk Investigational Site, Changsha, China|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Nagykanizsa, Hungary|Novo Nordisk Investigational Site, Tatabánya, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, Hungary|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taoyuan, Taiwan|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Khmelnytskyi, Ukraine|Novo Nordisk Investigational Site, Mykolaiv, Ukraine|Novo Nordisk Investigational Site, Poltava, Ukraine|Novo Nordisk Investigational Site, Ternopil, Ukraine|Novo Nordisk Investigational Site, Zaporizhia, Ukraine",,https://ClinicalTrials.gov/show/NCT04109547
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04017832,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,237,NCT04017832,A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes,PIONEER 12,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Oral semaglutide|Drug: Sitagliptin|Drug: Placebo (oral semaglutide)|Drug: Placebo (sitagliptin),Change in (glycosylated haemoglobin) HbA1c|Change in body weight|Change in fasting plasma glucose (FPG)|Change in fasting 7 point self-measured plasma glucose (SMPG) profile: Mean 7-point profile|Change in fasting 7 point self-measured plasma glucose (SMPG) profile: Mean postprandial increment (over all meals)|Change in body mass index (BMI)|Change in waist circumference|Change in fasting lipid profile: total cholesterol|Change in fasting lipid profile: low-density lipoprotein (LDL) cholesterol|Change in fasting lipid profile: very-low-density lipoprotein (VLDL) cholesterol|Change in fasting lipid profile: high-density lipoprotein (HDL) cholesterol|Change in fasting lipid profile: triglycerides|Change in fasting lipid profile: free fatty acids|Change in Short Form-36 version 2 (SF-36v2™) (acute version) health survey|If a subject achieves HbA1c below 7.0 percent (53 mmol/mol) (American Diabetes Association (ADA) target) (yes/no)|If a subject achieves HbA1c equal to or below 6.5 percent (48 mmol/mol) (American Association of Clinical Endocrinologists (AACE) target) (yes/no)|If a subject achieves HbA1c reduction equal to or above 1 percent-point (10.9 mmol/mol) (yes/no)|If a subject achieves body weight loss equal to or above 3 percent (yes/no)|If a subject achieves body weight loss equal to or above 5 percent (yes/no)|If a subject achieves body weight loss equal to or above 10 percent (yes/no)|If a subject achieves HbA1c below 7.0 percent (53 mmol/mol) without hypoglycaemia (treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes) and no body weight gain (yes/no)|If a subject achieves HbA1c reduction equal to or above 1 percent-point (10.9 mmol/mol) and body weight loss equal to or above 3 percent (yes/no)|Time to rescue medication|Number of treatment-emergent adverse events (TEAEs) during exposure to trial product|Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during exposure to trial product|Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during exposure to trial product (yes/no),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1444,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NN9924-4309|U1111-1188-1256|2018-002589-38,"July 29, 2019","August 11, 2021","September 13, 2021","July 12, 2019",,"June 2, 2020","Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Chongqing, Chongqing, China|Novo Nordisk Investigational Site, Quanzhou, Fujian, China|Novo Nordisk Investigational Site, Foshan, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Huizhou, Guangdong, China|Novo Nordisk Investigational Site, Shantou, Guangdong, China|Novo Nordisk Investigational Site, Cangzhou, Hebei, China|Novo Nordisk Investigational Site, Hengshui, Hebei, China|Novo Nordisk Investigational Site, Shijiazhuang, Hebei, China|Novo Nordisk Investigational Site, Kaifeng, Henan, China|Novo Nordisk Investigational Site, Luoyang, Henan, China|Novo Nordisk Investigational Site, Zhengzhou, Henan, China|Novo Nordisk Investigational Site, Shiyan, Hubei, China|Novo Nordisk Investigational Site, Wuhan, Hubei, China|Novo Nordisk Investigational Site, Changsha, Hunan, China|Novo Nordisk Investigational Site, Chenzhou, Hunan, China|Novo Nordisk Investigational Site, Hengyang, Hunan, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Suzhou, Jiangsu, China|Novo Nordisk Investigational Site, Suzhou, Jiangsu, China|Novo Nordisk Investigational Site, Wuxi, Jiangsu, China|Novo Nordisk Investigational Site, Xuzhou, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Yinchuan, Ningxia, China|Novo Nordisk Investigational Site, Xining, Qinghai, China|Novo Nordisk Investigational Site, Xi'an, Shaanxi, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Qingdao, Shandong, China|Novo Nordisk Investigational Site, Weifang, Shandong, China|Novo Nordisk Investigational Site, Pudong New District, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Kunming, Yunnan, China|Novo Nordisk Investigational Site, Kunming, Yunnan, China|Novo Nordisk Investigational Site, Hangzhou, Zhejiang, China|Novo Nordisk Investigational Site, Beijing, China|Novo Nordisk Investigational Site, Changsha, China|Novo Nordisk Investigational Site, Pingxiang, China|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Chrudim, Czechia|Novo Nordisk Investigational Site, Liberec, Czechia|Novo Nordisk Investigational Site, Praha 4, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong|Novo Nordisk Investigational Site, Oradea, Bihor, Romania|Novo Nordisk Investigational Site, Oradea, Bihor, Romania|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Constanta, Romania|Novo Nordisk Investigational Site, Oradea, Romania|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Arcadia, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Kempton Park, Gauteng, South Africa|Novo Nordisk Investigational Site, Soshanguve, Gauteng, South Africa|Novo Nordisk Investigational Site, Brits, North West, South Africa|Novo Nordisk Investigational Site, Kuilsriver, Western Cape, South Africa|Novo Nordisk Investigational Site, Paarl, Western Cape, South Africa|Novo Nordisk Investigational Site, Alberton, South Africa|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taoyuan, Taiwan",,https://ClinicalTrials.gov/show/NCT04017832
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03960814,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,241,NCT03960814,A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Insulin detemir,Age at all cause death or censoring|Age at death of cardiovascular disease,Novo Nordisk A/S,All,"40 Years and older   (Adult, Older Adult)",,12847,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,NN304-4528|U1111-1233-0930|EUPAS29708,"May 21, 2019","June 7, 2019","June 7, 2019","May 23, 2019",,"July 18, 2019","Novo Nordisk Investigational Site, Bagsværd, Denmark",,https://ClinicalTrials.gov/show/NCT03960814
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03811288,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,249,NCT03811288,An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes,CAPTURE-IO,Completed,No Results Available,"Diabetes Mellitus, Type 2",Other: No treatment given,Participants with a history of established cardiovascular disease (CVD)|Participants with high risk of CVD according to the risk engine from the United Kingdom Prospective Diabetes Study (UKPDS),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",,7548,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,NN2211-4446|U1111-1215-4005,"December 10, 2018","September 30, 2019","September 30, 2019","January 22, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Batna, Algeria|Novo Nordisk Investigational Site, Constantine, Algeria|Novo Nordisk Investigational Site, Tiaret, Algeria|Novo Nordisk Investigational Site, Tizi Ouzou, Algeria|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Chacabuco, Argentina|Novo Nordisk Investigational Site, Cordoba, Argentina|Novo Nordisk Investigational Site, Coronel Suarez, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Godoy Cruz, Argentina|Novo Nordisk Investigational Site, Lanus Este, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, Morón, Argentina|Novo Nordisk Investigational Site, Blacktown, New South Wales, Australia|Novo Nordisk Investigational Site, Brookvale, New South Wales, Australia|Novo Nordisk Investigational Site, Campbelltown, New South Wales, Australia|Novo Nordisk Investigational Site, Coffs Harbour, New South Wales, Australia|Novo Nordisk Investigational Site, Maroubra, New South Wales, Australia|Novo Nordisk Investigational Site, Wollongong, New South Wales, Australia|Novo Nordisk Investigational Site, Herston, Queensland, Australia|Novo Nordisk Investigational Site, Morayfield, Queensland, Australia|Novo Nordisk Investigational Site, North Ipswich, Queensland, Australia|Novo Nordisk Investigational Site, Sherwood, Queensland, Australia|Novo Nordisk Investigational Site, Victoria Point, Queensland, Australia|Novo Nordisk Investigational Site, Forest Hill, Victoria, Australia|Novo Nordisk Investigational Site, Moonee Ponds, Victoria, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Preston, Victoria, Australia|Novo Nordisk Investigational Site, Ringwood, Victoria, Australia|Novo Nordisk Investigational Site, Fremantle, Western Australia, Australia|Novo Nordisk Investigational Site, Geelong, Australia|Novo Nordisk Investigational Site, Fortaleza, Ceara, Brazil|Novo Nordisk Investigational Site, Aparecida de Goiania, Goias, Brazil|Novo Nordisk Investigational Site, Goiânia, Goias, Brazil|Novo Nordisk Investigational Site, Belo Horizonte, Minas Gerais, Brazil|Novo Nordisk Investigational Site, Belo Horizonte, Minas Gerais, Brazil|Novo Nordisk Investigational Site, Uberaba, Minas Gerais, Brazil|Novo Nordisk Investigational Site, Campina Grande do Sul, Parana, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Maringa, Parana, Brazil|Novo Nordisk Investigational Site, Maringa, Parana, Brazil|Novo Nordisk Investigational Site, Passo Fundo, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Santo André, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Tatui, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Votuporanga, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Fortaleza, Brazil|Novo Nordisk Investigational Site, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Lanzhou, Gansu, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guiyang, Guizhou, China|Novo Nordisk Investigational Site, Wuxi, Jiangsu, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Luzhou, Sichuan, China|Novo Nordisk Investigational Site, Nanchong, Sichuan, China|Novo Nordisk Investigational Site, Ningbo, Zhejiang, China|Novo Nordisk Investigational Site, Nanjing, China|Novo Nordisk Investigational Site, Bat Yam, Israel|Novo Nordisk Investigational Site, Beer sheva, Israel|Novo Nordisk Investigational Site, Beer-Sheva HaDarom, Israel|Novo Nordisk Investigational Site, Bnei Brak, Israel|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kiryat Bialik, Israel|Novo Nordisk Investigational Site, Nahariya, Israel|Novo Nordisk Investigational Site, Nazareth, Israel|Novo Nordisk Investigational Site, Petach Tikva, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Ra'anana, Israel|Novo Nordisk Investigational Site, Tel Aviv, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Zefat, Israel|Novo Nordisk Investigational Site, Chiba-shi, Chiba, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Ebina-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Fukushima, Japan|Novo Nordisk Investigational Site, Hamamatsu-Shi Shizuoka, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kawagoe-shi, Saitama, Japan|Novo Nordisk Investigational Site, Koshigaya-shi,Saitama, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Mito-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Nishi-ku Sapporo, Japan|Novo Nordisk Investigational Site, Oita-shi, Japan|Novo Nordisk Investigational Site, Okawa-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Ota-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Oyama-shi, Japan|Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi, Japan|Novo Nordisk Investigational Site, Shinjyuku-ku Tokyo, Japan|Novo Nordisk Investigational Site, Tijuana, Baja California Norte, Mexico|Novo Nordisk Investigational Site, Monclova, Coahuila, Mexico|Novo Nordisk Investigational Site, Mexico, Estado De México, Mexico|Novo Nordisk Investigational Site, Celaya, Guanajuato, Mexico|Novo Nordisk Investigational Site, León, Guanajuato, Mexico|Novo Nordisk Investigational Site, Acapulco de Juarez, Guerrero, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Puerto Vallarta, Jalisco, Mexico|Novo Nordisk Investigational Site, Zapopan, Jalisco, Mexico|Novo Nordisk Investigational Site, Zapopan, Jalisco, Mexico|Novo Nordisk Investigational Site, Cuernavaca, Morelos, Mexico|Novo Nordisk Investigational Site, Benito Juárez, México, D.F., Mexico|Novo Nordisk Investigational Site, Cuauhtemoc, México, D.F., Mexico|Novo Nordisk Investigational Site, Gustavo A Madero, México, D.F., Mexico|Novo Nordisk Investigational Site, Mexico City, México, D.F., Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, San Luis Potosí, San Luis Potosi, Mexico|Novo Nordisk Investigational Site, Culiacán, Sinaloa, Mexico|Novo Nordisk Investigational Site, Hermosillo, Sonora, Mexico|Novo Nordisk Investigational Site, Ciudad Madero, Tamaulipas, Mexico|Novo Nordisk Investigational Site, Aguascalientes, Mexico|Novo Nordisk Investigational Site, Guadalajara, Mexico|Novo Nordisk Investigational Site, Mexico City, Mexico|Novo Nordisk Investigational Site, Monterrey, Mexico|Novo Nordisk Investigational Site, Queretaro, Mexico|Novo Nordisk Investigational Site, San Luis Potosi, Mexico|Novo Nordisk Investigational Site, Veracruz, Mexico|Novo Nordisk Investigational Site, Al Ihsa, Saudi Arabia|Novo Nordisk Investigational Site, Buraydah, Saudi Arabia|Novo Nordisk Investigational Site, Jeddah, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Taif, Saudi Arabia|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Edirne, Turkey|Novo Nordisk Investigational Site, Elazig, Turkey|Novo Nordisk Investigational Site, Eskisehir, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Kayseri, Turkey|Novo Nordisk Investigational Site, Malatya, Turkey|Novo Nordisk Investigational Site, Tekirdag, Turkey|Novo Nordisk Investigational Site, Zonguldak, Turkey",,https://ClinicalTrials.gov/show/NCT03811288
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03888157,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,250,NCT03888157,"A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine",VIEW-Iran,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Drug: Liraglutide,Change in glycated haemoglobin A1c (HbA1c) (percentage)|Change in HbA1c (mmol/mol)|Change in body weight (kilogram)|Change in body weight (percentage)|Change in waist circumference|Change in fasting blood glucose (FBG) (self-measured)|Change in total cholesterol (TC)|Change in low density lipoprotein cholesterol (LDL-C)|Change in high density lipoprotein cholesterol (HDL-C)|Change in triglyceride (TG)|Change in free fatty acid (FFA)|Number of patients permanently discontinuing treatment with Victoza®|Reasons for permanent treatment discontinuations|Changes in quality of life (EQ-5D index score)|Changes in quality of life (EQ VAS),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",,830,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN2211-4438|U1111-1213-4238,"March 10, 2019","August 14, 2020","August 14, 2020","March 25, 2019",,"April 6, 2020","Novo Nordisk Investigational Site, Ahvaz, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Ardabil, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Babol, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Gorgan, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Hamedan, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Hormozgan, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Isfahan, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Islamshahr, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Karaj, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Kerman, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Mashad, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Mashahd, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Mashhad, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Sari, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Shiraz, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Tehran, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Yazd, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT03888157
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03945656,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,251,NCT03945656,A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Insulin 287|Drug: Insulin glargine,"Clinically significant hypoglycaemia (Double dose): Clinically significant hypoglycaemia (Plasma glucose [PG] less than 3.0 mmol/L [54 mg/dL]) after 2 times the individualised optimal basal dose of insulin|PG (nadir) - PG concentration at nadir after 2 and 3 times the individualised optimal basal dose of insulin|t (decline, PG 5.5 mmol/L - PG 3.0 mmol/L) - Time from start of hypoglycaemia induction until a PG concentration of 3.0 mmol/L (54 mg/dL) is reached after 2 and 3 times the individualised optimal basal dose of insulin|t (decline, PG 5.5 mmol/L - PG nadir) - Time from start of hypoglycaemia induction until PGnadir is reached after 2 and 3 times the individualised optimal basal dose of insulin|t (recovery, PG nadir - PG 5.5 mmol/L) - Time to increase from PGnadir to a PG concentration of 5.5 mmol/L (100 mg/dL) after 2 and 3 times the individualised optimal basal dose of insulin|C (glucagon, PG nadir) - Plasma glucagon concentration at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|C (adrenaline, PG nadir) - Plasma adrenaline concentration at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|C (noradrenaline, PG nadir) - Plasma noradrenaline concentration at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|C (growth hormone [GH], PG nadir) - Serum growth hormone concentration at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|C (cortisol, PG nadir) - Serum cortisol concentration at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Pulse (PG 5.5 mmol/L - PG nadir) - Change in pulse rate from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Diastolic blood pressure (DBP) (PG 5.5 mmol/L - PG nadir) - Change in diastolic blood pressure from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Systolic blood pressure (SBP) (PG 5.5 mmol/L - PG nadir) - Change in systolic blood pressure from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Digit Symbol Substitution Test (DSST) (PG 5.5 mmol/L - PG nadir) - Change in DSST score from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Four-Choice Reaction Time (4CRT) (reaction 4CRT) (PG 5.5 mmol/L - PG nadir) - Change in 4CRT performance from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|4CRT (% correct answers) (PG 5.5 mmol/L - PG nadir) - Change in 4CRT performance (% correct answers) from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Trail Making B test (TMB) (PG 5.5 mmol/L - PG nadir) - Change in TMB from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Hypoglycaemic symptoms score (HSS) (PG 5.5 mmol/L - PG nadir) - Change in HSS from a PG concentration of 5.5 mmol/L (100 mg/dL) to PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Hypoglycaemia awareness (HA) (PG nadir) - HA at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|AUC (GIR, recovery, PG nadir -PG 5.5 mmol/L) - Area under the glucose infusion rate-time profile during recovery from PGnadir to a PG concentration of 5.5 mmol/L (100 mg/dL) after 2 and 3 times the individualised optimal basal dose of insulin|AUC (GIR, recovery, PG 5.5 mmol/L, 0-6h)-Area under the glucose infusion rate-time profile during 6 hours at a PG concentration of 5.5 mmol/L (100 mg/dL) after recovery from hypoglycaemia after 2 & 3 times the individualised optimal basal dose of insulin|Clinically significant hypoglycaemia (Triple dose) - Clinically significant hypoglycaemia [PG less than 3.0 mmol/L (54 mg/dL)], after 3 times the individualised optimal basal dose of insulin",Novo Nordisk A/S,All,"18 Years to 72 Years   (Adult, Older Adult)",Phase 1,43,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1436-4462|U1111-1214-2688|2018-001993-74,"May 7, 2019","November 20, 2020","November 20, 2020","May 10, 2019",,"April 6, 2020","Novo Nordisk Investigational Site, Graz, Austria",,https://ClinicalTrials.gov/show/NCT03945656
Study Director,Clinical Reporting Anchor and Disclosure 1452,Novo Nordisk A/S,,NCT03862690,clinical reporting anchor and disclosure 1452,clinical,female,0.5,4,253,NCT03862690,"A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria",B Simple,Withdrawn,No Results Available,"Diabetes Mellitus, Type 2",Drug: BIAsp 30,Change in glycosylated haemoglobin A1c (HbA1c)|Participants achieving HbA1c below 7.0%|Particpants achieving HbA1c below 7.5%|Partcipants achieving HbA1c below 8.0%|Change in rate of severe hypoglycaemia|Change in total insulin dose|Change in Diabetes Treatment Satisfaction (DTSQ) score|Change in health-related quality of life (EQ-5D),Novo Nordisk A/S,All,"19 Years and older   (Adult, Older Adult)",,0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,BIASP-4439|U1111-1208-5168,"May 28, 2020","June 28, 2021","June 28, 2021","March 5, 2019",,"June 4, 2020","Novo Nordisk Investigational Site, Algiers, Algeria",,https://ClinicalTrials.gov/show/NCT03862690
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04083820,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,257,NCT04083820,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)",SURE FRANCE,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 2",Drug: semaglutide,Change in Glycated Haemoglobin A1c (HbA1c)|Change in body weight|Change in waist circumference|HbA1c level below 8.0% (64 mmol/mol) (yes/no)|HbA1c level below 7.5% (59 mmol/mol) (yes/no)|HbA1c level below 7.0% (53 mmol/mol) (yes/no)|Reduction in HbA1c of 1.0% point or more (yes/no)|Weight reduction of 3.0% or more (yes/no)|Weight reduction of 5.0% or more (yes/no)|HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)|Patient reported severe or documented hypoglycaemia (yes/no)|Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction|Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction|Change in score for Short Form (SF)-36 v2: Physical summary component|Change in score for SF-36 v2: Mental summary component|Patient completed the study under treatment with semaglutide (yes/no),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",,217,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN9535-4495|U1111-1222-5620,"September 16, 2019","September 15, 2021","September 15, 2021","September 10, 2019",,"June 4, 2020","Novo Nordisk Investigational Site, Angers, France|Novo Nordisk Investigational Site, Annecy, France|Novo Nordisk Investigational Site, Auffay, France|Novo Nordisk Investigational Site, Avignon, France|Novo Nordisk Investigational Site, Besançon, France|Novo Nordisk Investigational Site, Bethoncourt, France|Novo Nordisk Investigational Site, Beze, France|Novo Nordisk Investigational Site, Bourgoin-jallieu, France|Novo Nordisk Investigational Site, Bry sur Marne, France|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, Challes les Eaux, France|Novo Nordisk Investigational Site, Chalon sur Saone, France|Novo Nordisk Investigational Site, Chalons Sur Saone, France|Novo Nordisk Investigational Site, Charleville-Mézières, France|Novo Nordisk Investigational Site, Chelles, France|Novo Nordisk Investigational Site, Clichy, France|Novo Nordisk Investigational Site, Colmar, France|Novo Nordisk Investigational Site, Colmar, France|Novo Nordisk Investigational Site, DIJON cedex, France|Novo Nordisk Investigational Site, Dijon, France|Novo Nordisk Investigational Site, Dole, France|Novo Nordisk Investigational Site, Doudeville, France|Novo Nordisk Investigational Site, Elancourt, France|Novo Nordisk Investigational Site, Guiscard, France|Novo Nordisk Investigational Site, La Bouëxière, France|Novo Nordisk Investigational Site, La Madeleine, France|Novo Nordisk Investigational Site, Lambersart, France|Novo Nordisk Investigational Site, Le Puy en Velay, France|Novo Nordisk Investigational Site, Lomme, France|Novo Nordisk Investigational Site, Lyon, France|Novo Nordisk Investigational Site, Maison-Alfort, France|Novo Nordisk Investigational Site, Marseille, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France|Novo Nordisk Investigational Site, Montélimar, France|Novo Nordisk Investigational Site, Nevers, France|Novo Nordisk Investigational Site, NICE cedex 3, France|Novo Nordisk Investigational Site, Noisy le Grand, France|Novo Nordisk Investigational Site, Orry-la-ville, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Pessac, France|Novo Nordisk Investigational Site, Pierre-Bénite, France|Novo Nordisk Investigational Site, Six Fours les plages, France|Novo Nordisk Investigational Site, Ste Foy Lès Lyon, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Toulouse, France|Novo Nordisk Investigational Site, Tours, France|Novo Nordisk Investigational Site, Valence, France|Novo Nordisk Investigational Site, Vichy, France|Novo Nordisk Investigational Site, Vienne, France|Novo Nordisk Investigational Site, Vitré, France|Novo Nordisk Investigational Site, Yerres, France",,https://ClinicalTrials.gov/show/NCT04083820
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03819153,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,259,NCT03819153,A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease,FLOW,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Placebo (semaglutide),"Time to first occurrence of a composite primary outcome event defined as persistent eGFR decline of greater than or equal to 50 percentage from trial start, reaching ESRD, death from kidney disease or death from cardiovascular disease|Annual rate of change in eGFR (chronic kidney disease - epidemiology collaboration (CKD-EPI)) (total eGFR slope)|Time to first occurrence of a composite cardiovascular major adverse cardiovascular event (MACE) endpoint consisting of: Non-fatal myocardial infarction, non-fatal stroke, and cardiovascular (CV) death|Time to occurrence of all-cause death|Time to occurrence of each of the individual components of the primary composite endpoint and of the confirmatory secondary MACE endpoint|Time to first occurrence of major adverse limb events (MALE), a composite endpoint consisting of: Acute limb ischemia hospitalisation and chronic limb ischemia hospitalisation|Annual rate of change in eGFR (CKD-EPI) (chronic eGFR slope)|Change in eGFR (CKD-EPI)|Change in eGFR (cystatin C CKD-EPI)|Relative change in urinary albumin-to-creatinine ratio (UACR)|Change in body weight|Change in glycosylated haemoglobin (HbA1c)|Change in systolic blood pressure|Change in diastolic blood pressure|Number of severe hypoglycaemic episodes",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3160,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NN9535-4321|U1111-1217-6259|2018-002878-50|JapicCTI-194843,"June 17, 2019","August 19, 2024","August 19, 2024","January 28, 2019",,"June 11, 2020","Novo Nordisk Investigational Site, Anniston, Alabama, United States|Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Chula Vista, California, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Lakewood, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Lincoln, California, United States|Novo Nordisk Investigational Site, Loma Linda, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Palm Springs, California, United States|Novo Nordisk Investigational Site, Port Hueneme, California, United States|Novo Nordisk Investigational Site, Rancho Cucamonga, California, United States|Novo Nordisk Investigational Site, Rialto, California, United States|Novo Nordisk Investigational Site, Roseville, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Dimas, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Torrance, California, United States|Novo Nordisk Investigational Site, Van Nuys, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Coral Gables, Florida, United States|Novo Nordisk Investigational Site, Fleming Island, Florida, United States|Novo Nordisk Investigational Site, Gainesville, Florida, United States|Novo Nordisk Investigational Site, Hialeah, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Homestead, Florida, United States|Novo Nordisk Investigational Site, Miami Lakes, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Port Charlotte, Florida, United States|Novo Nordisk Investigational Site, Saint Augustine, Florida, United States|Novo Nordisk Investigational Site, Sarasota, Florida, United States|Novo Nordisk Investigational Site, Winter Haven, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Nampa, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gurnee, Illinois, United States|Novo Nordisk Investigational Site, Skokie, Illinois, United States|Novo Nordisk Investigational Site, Valparaiso, Indiana, United States|Novo Nordisk Investigational Site, Council Bluffs, Iowa, United States|Novo Nordisk Investigational Site, Manhattan, Kansas, United States|Novo Nordisk Investigational Site, Paducah, Kentucky, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, Annapolis, Maryland, United States|Novo Nordisk Investigational Site, Beltsville, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Rochester, Minnesota, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Mineola, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Morganton, North Carolina, United States|Novo Nordisk Investigational Site, New Bern, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Winston-Salem, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Bethlehem, Pennsylvania, United States|Novo Nordisk Investigational Site, Jersey Shore, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Little River, South Carolina, United States|Novo Nordisk Investigational Site, Murrells Inlet, South Carolina, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, United States|Novo Nordisk Investigational Site, Orangeburg, South Carolina, United States|Novo Nordisk Investigational Site, Bartlett, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, El Paso, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Rockwall, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Schertz, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Salem, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Tacoma, Washington, United States|Novo Nordisk Investigational Site, Wauwatosa, Wisconsin, United States|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Villa Dominico, Argentina|Novo Nordisk Investigational Site, Gosford, New South Wales, Australia|Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Westmead, New South Wales, Australia|Novo Nordisk Investigational Site, Milton, Queensland, Australia|Novo Nordisk Investigational Site, Caulfield, Victoria, Australia|Novo Nordisk Investigational Site, Clayton, Victoria, Australia|Novo Nordisk Investigational Site, Fitzroy, Victoria, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Bruxelles, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Gent, Belgium|Novo Nordisk Investigational Site, Jette, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Liège, Belgium|Novo Nordisk Investigational Site, Roeselare, Belgium|Novo Nordisk Investigational Site, Fortaleza, Ceara, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Santo André, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Kozloduy, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Sliven, Bulgaria|Novo Nordisk Investigational Site, Smolyan, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, Bulgaria|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Red Deer, Alberta, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, St. Johns, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Burlington, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Nepean, Ontario, Canada|Novo Nordisk Investigational Site, Oshawa, Ontario, Canada|Novo Nordisk Investigational Site, Oshawa, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Scarborough, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Laval, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Beijing, China|Novo Nordisk Investigational Site, Annonay, France|Novo Nordisk Investigational Site, BRON cedex, France|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, Grenoble - Cédex 09, France|Novo Nordisk Investigational Site, La Roche-sur-yon, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Saint Herblain, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Bad Oeynhausen, Germany|Novo Nordisk Investigational Site, Düsseldorf, Germany|Novo Nordisk Investigational Site, Erlangen, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Haidari-Athens, Greece|Novo Nordisk Investigational Site, Lamia, Greece|Novo Nordisk Investigational Site, Patra, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Baja, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Gyula, Hungary|Novo Nordisk Investigational Site, Nagykanizsa, Hungary|Novo Nordisk Investigational Site, Pécs, Hungary|Novo Nordisk Investigational Site, Siófok, Hungary|Novo Nordisk Investigational Site, Szombathely, Hungary|Novo Nordisk Investigational Site, Guntur, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderbad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Kochi, Kerala, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Rehovot, Israel|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Pisa, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Chiba, Japan|Novo Nordisk Investigational Site, Fukui, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Fukushima, Japan|Novo Nordisk Investigational Site, Gunma, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Ishikawa, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Kyoto, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Okayama, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Saitama, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Alor Setar, Malaysia|Novo Nordisk Investigational Site, Ipoh, Perak, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuching, Malaysia|Novo Nordisk Investigational Site, Pulau Pinang, Malaysia|Novo Nordisk Investigational Site, Serdang, Malaysia|Novo Nordisk Investigational Site, Actopan, Hidalgo, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Distrito Federal, México, D.F., Mexico|Novo Nordisk Investigational Site, Mexico City, México, D.F., Mexico|Novo Nordisk Investigational Site, Culiacán, Sinaloa, Mexico|Novo Nordisk Investigational Site, Ciudad Madero, Tamaulipas, Mexico|Novo Nordisk Investigational Site, Alkmaar, Netherlands|Novo Nordisk Investigational Site, Almelo, Netherlands|Novo Nordisk Investigational Site, Almere, Netherlands|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Arnhem, Netherlands|Novo Nordisk Investigational Site, Hilversum, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Kielce, Poland|Novo Nordisk Investigational Site, Olsztyn, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Radom, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kemerovo, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Voronezh, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Lubochna, Slovakia|Novo Nordisk Investigational Site, Lucenec, Slovakia|Novo Nordisk Investigational Site, Nitra, Slovakia|Novo Nordisk Investigational Site, Trebisov, Slovakia|Novo Nordisk Investigational Site, Trstena, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Bloemfontein, Free State, South Africa|Novo Nordisk Investigational Site, Benoni, Gauteng, South Africa|Novo Nordisk Investigational Site, Cosmo City, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, South Africa|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Burela, Spain|Novo Nordisk Investigational Site, Getafe, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Bangkoknoi, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Kahramanmaras, Turkey|Novo Nordisk Investigational Site, Kocaeli, Turkey|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Ivano-Frankivsk, Ukraine|Novo Nordisk Investigational Site, Kharkiv, Ukraine|Novo Nordisk Investigational Site, Kharkiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Zaporizhia, Ukraine|Novo Nordisk Investigational Site, Zaporizhia, Ukraine|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Cardiff, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Ipswich, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Tooting, United Kingdom",,https://ClinicalTrials.gov/show/NCT03819153
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03823339,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,262,NCT03823339,"A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates",INTENSIFY,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 2",Drug: Insulin degludec/liraglutide,"Change in laboratory measured glycosylated haemoglobin A1c (HbA1c)|Patients reached HbA1c less than 7% at end of study (Yes/No )|Change in laboratory measured fasting plasma glucose (FPG)|Average dose step of Xultophy® at end of the study|Change of body weight|Change in number of patient self-reported overall non-severe hypoglycaemic episodes based on recollection|Change in number of patient self-reported nocturnal non-severe hypoglycaemic episodes based on recollection|Change in number of patient self-reported severe hypoglycaemic episodes based on recollection (overall)|Reason(s) for discontinuing treatment with Xultophy® during the treatment period, if applicable",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",,343,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN9068-4458|U1111-1213-4338,"January 15, 2019","September 25, 2020","September 25, 2020","January 30, 2019",,"March 6, 2020","Novo Nordisk Investigational Site, AbuDhabi, United Arab Emirates|Novo Nordisk Investigational Site, Ajman, United Arab Emirates|Novo Nordisk Investigational Site, Dubai, United Arab Emirates",,https://ClinicalTrials.gov/show/NCT03823339
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03876015,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,264,NCT03876015,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)",SURE UK,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Drug: Semaglutide,Change in Glycated Haemoglobin A1c (HbA1c)|Change in HbA1c|Change in body weight|Change in waist circumference|HbA1c level at end of study: <8.0% (64 mmol/mol) (yes/no)|HbA1c level at end of study: <7.5% (59 mmol/mol) (yes/no)|HbA1c level at end of study: <7.0% (53 mmol/mol) (yes/no)|Reduction in HbA1c of 1.0% point or more (yes/no)|Weight reduction of 3.0% or more (yes/no)|Weight reduction of 5.0% or more (yes/no)|HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)|Patient reported severe or documented hypoglycaemia (yes/no)|Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction|Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction|Change in score for Short Form (SF)-36 v2: Physical summary component|Change in score for SF-36 v2: Mental summary component|Patient completed the study under treatment with semaglutide (yes/no),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",,217,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN9535-4366|U1111-1199-9050,"May 1, 2019","August 28, 2020","August 28, 2020","March 15, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Atherstone, United Kingdom|Novo Nordisk Investigational Site, Berkshire, United Kingdom|Novo Nordisk Investigational Site, Bradford, United Kingdom|Novo Nordisk Investigational Site, Brighton, United Kingdom|Novo Nordisk Investigational Site, Camberley, United Kingdom|Novo Nordisk Investigational Site, Cambridgeshire, United Kingdom|Novo Nordisk Investigational Site, Chiswick, United Kingdom|Novo Nordisk Investigational Site, Co Durham, United Kingdom|Novo Nordisk Investigational Site, Coventry, United Kingdom|Novo Nordisk Investigational Site, Darlington, United Kingdom|Novo Nordisk Investigational Site, Dudley, United Kingdom|Novo Nordisk Investigational Site, Durham, United Kingdom|Novo Nordisk Investigational Site, Greenisland, United Kingdom|Novo Nordisk Investigational Site, Halifax, United Kingdom|Novo Nordisk Investigational Site, Hull, United Kingdom|Novo Nordisk Investigational Site, Kettering, United Kingdom|Novo Nordisk Investigational Site, Leicestershire, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, Lincs, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Machester, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Merseyside, United Kingdom|Novo Nordisk Investigational Site, Nuneaton, United Kingdom|Novo Nordisk Investigational Site, Rayleigh, United Kingdom|Novo Nordisk Investigational Site, Rhyl, United Kingdom|Novo Nordisk Investigational Site, South Shields, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom|Novo Nordisk Investigational Site, Walton on Thames, United Kingdom|Novo Nordisk Investigational Site, Watford, United Kingdom|Novo Nordisk Investigational Site, Wellingborough, United Kingdom",,https://ClinicalTrials.gov/show/NCT03876015
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03922750,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,267,NCT03922750,A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Insulin 287|Drug: Insulin glargine U100,"Time in target range 3.9-10.0 mmol/L (70-180 mg/dL) measured using continuous glucose monitoring (CGM)|Change in glycosylated haemoglobin (HbA1c)|Change in fasting plasma glucose (FPG)|Change in body weight|Weekly insulin dose|Number of treatment emergent adverse events (TEAEs)|Number of severe hypoglycaemic episodes (level 3)|Number of clinically significant hypoglycaemic episodes (level 2) (less than 3.0 mmol/L (54 mg/dL), confirmed by blood glucose (BG) meter) or severe hypoglycaemic episodes (level 3)|Number of hypoglycaemic alert episodes (level 1) (greater than or equal to 3.0 mmol/L and less than 3.9 mmol/L (greater than or equal to 54 mg/dL and less than 70 mg/dL, confirmed by BG meter)",Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,154,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1436-4466|U1111-1219-5541|2018-003407-18,"May 9, 2019","December 19, 2019","January 27, 2020","April 22, 2019",,"February 17, 2020","Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Surrey, British Columbia, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Broumov, Czechia|Novo Nordisk Investigational Site, Holešov, Czechia|Novo Nordisk Investigational Site, Hranice, Czechia|Novo Nordisk Investigational Site, Trutnov, Czechia|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Roma, Italy",,https://ClinicalTrials.gov/show/NCT03922750
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04042441,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,268,NCT04042441,"A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice",ARISE,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 2",Drug: Insulin Degludec/Insulin Aspart,"Change in local laboratory measured glycosylated haemoglobin (HbA1c)|HbA1c less than 7% (Yes/No)|HbA1c less than pre-defined individual treatment target (Yes/No)|Change in local laboratory measured fasting plasma glucose (FPG)|Change in local laboratory measured FPG|Change in insulin dose (total, basal, prandial)|Change in body weight|Number of patient recollection of non-severe hypoglycaemic episodes|Number of patient recollection of nocturnal non-severe hypoglycaemic episodes|Number of patient recollection of overall severe hypoglycaemic episodes|Number of weekly self-measured plasma glucose (SMPG) measurements|Reason for initiating Ryzodeg® (pre-specified response option(s))|Discontinue treatment with Ryzodeg® during the treatment period (Yes/No)|Reason for discontinuing treatment with Ryzodeg® during the treatment period, if applicable, (pre-specified response option(s))|Time period from initiation to discontinuation of treatment with Ryzodeg®",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",,1112,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN5401-4525|U1111-1227-8654,"July 29, 2019","November 12, 2020","November 12, 2020","August 2, 2019",,"May 29, 2020","Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Wollongong, New South Wales, Australia|Novo Nordisk Investigational Site, Herston, Queensland, Australia|Novo Nordisk Investigational Site, South Brisbane, Queensland, Australia|Novo Nordisk Investigational Site, Elizabeth Vale, South Australia, Australia|Novo Nordisk Investigational Site, Keswick, South Australia, Australia|Novo Nordisk Investigational Site, Hobart, Tasmania, Australia|Novo Nordisk Investigational Site, Box Hill, Victoria, Australia|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Cooloongup, Western Australia, Australia|Novo Nordisk Investigational Site, Guwahati, Assam, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Delhi, New Delhi, India|Novo Nordisk Investigational Site, Bhubaneswar, Orissa, India|Novo Nordisk Investigational Site, Mohali, Punjab, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Howrah, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Kedah, Malaysia|Novo Nordisk Investigational Site, Kelantan, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuching, Malaysia|Novo Nordisk Investigational Site, Melaka, Malaysia|Novo Nordisk Investigational Site, Melaka, Malaysia|Novo Nordisk Investigational Site, Penang, Malaysia|Novo Nordisk Investigational Site, Perak, Malaysia|Novo Nordisk Investigational Site, Perlis, Malaysia|Novo Nordisk Investigational Site, Putrajaya, Malaysia|Novo Nordisk Investigational Site, Selangor, Malaysia|Novo Nordisk Investigational Site, Selangor, Malaysia|Novo Nordisk Investigational Site, Aklan, Philippines|Novo Nordisk Investigational Site, Cebu City, Philippines|Novo Nordisk Investigational Site, Davao City, Philippines|Novo Nordisk Investigational Site, Iloilo, Philippines|Novo Nordisk Investigational Site, Makati City, Philippines|Novo Nordisk Investigational Site, Manila, Philippines|Novo Nordisk Investigational Site, Manila, Philippines|Novo Nordisk Investigational Site, Quezon City, Philippines|Novo Nordisk Investigational Site, Quezon City, Philippines|Novo Nordisk Investigational Site, Jeddah, Saudi Arabia|Novo Nordisk Investigational Site, Jeddah, Saudi Arabia|Novo Nordisk Investigational Site, Jeddah, Saudi Arabia|Novo Nordisk Investigational Site, Jeddah, Saudi Arabia|Novo Nordisk Investigational Site, Makkah, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Lenasia, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Berea, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Alberton, South Africa|Novo Nordisk Investigational Site, Bloemfontein, South Africa",,https://ClinicalTrials.gov/show/NCT04042441
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03929679,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,269,NCT03929679,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)",SURE NL,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Drug: semaglutide,Change in Glycated Haemoglobin A1c (HbA1c)|Change in body weight|Change in waist circumference|HbA1c level below 8.0% (64 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.5% (59 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.0% (53 mmol/mol) (yes/no)|Reduction in HbA1c of 1.0% point or more (yes/no)|Weight reduction of 3.0% or more (yes/no)|Weight reduction of 5.0% or more (yes/no)|HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)|Patient reported severe or documented hypoglycaemia (yes/no)|Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction|Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction|Change in score for Short Form (SF)-36 v2: Physical summary component|Change in score for SF-36 v2: Mental summary component|Patient completed the study under treatment with semaglutide (yes/no),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",,217,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN9535-4496|U1111-1222-5565,"May 28, 2019","November 26, 2020","November 26, 2020","April 29, 2019",,"May 29, 2020","Novo Nordisk Investigational Site, Alkmaar, Netherlands|Novo Nordisk Investigational Site, Almelo, Netherlands|Novo Nordisk Investigational Site, Almere, Netherlands|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Arnhem, Netherlands|Novo Nordisk Investigational Site, Bladel, Netherlands|Novo Nordisk Investigational Site, Den Bosch, Netherlands|Novo Nordisk Investigational Site, Den Haag, Netherlands|Novo Nordisk Investigational Site, Dordrecht, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Emmen, Netherlands|Novo Nordisk Investigational Site, Enschede, Netherlands|Novo Nordisk Investigational Site, Gemert, Netherlands|Novo Nordisk Investigational Site, Groningen, Netherlands|Novo Nordisk Investigational Site, Heerlen, Netherlands|Novo Nordisk Investigational Site, Hoogeveen, Netherlands|Novo Nordisk Investigational Site, Leiden, Netherlands|Novo Nordisk Investigational Site, Montfort, Netherlands|Novo Nordisk Investigational Site, Nijverdal, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Sint Anthonis, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Warmenhuizen, Netherlands|Novo Nordisk Investigational Site, Zaandam, Netherlands|Novo Nordisk Investigational Site, Zevenbergen, Netherlands|Novo Nordisk Investigational Site, Zwijndrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT03929679
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03951805,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,275,NCT03951805,A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Insulin 287|Drug: Insulin Glargine,"Time in target range 3.9-10.0 mmol/L (70-180 mg/dL) measured using CGM (continuous glucose monitoring)|Change in HbA1c (glycated haemoglobin)|Change in fasting plasma glucose (FPG)|Change in body weight|Weekly insulin dose|Number of treatment emergent adverse events (TEAEs)|Number of severe hypoglycaemic episodes (Level 3)|Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)|Number of hypoglycaemic alert episodes(level 1) (greater than or equal to 3.0 and below 3.9 mmol/L (greater than or equal to 54 and below 70 mg/dL), confirmed by BG meter)",Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,205,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN1436-4465|U1111-1219-5474|2018-003406-11,"May 9, 2019","December 12, 2019","January 17, 2020","May 15, 2019",,"January 23, 2020","Novo Nordisk Investigational Site, Anaheim, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Schertz, Texas, United States|Novo Nordisk Investigational Site, Karlovac, Croatia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Rijeka, Croatia|Novo Nordisk Investigational Site, Varazdin, Croatia|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Pohlheim, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Kaposvár, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, Hungary|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Radom, Poland|Novo Nordisk Investigational Site, Tomaszow Mazowiecki, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Banska Bystrica, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Nitra, Slovakia|Novo Nordisk Investigational Site, Rimavska Sobota, Slovakia|Novo Nordisk Investigational Site, Roznava, Slovakia|Novo Nordisk Investigational Site, Velky Meder, Slovakia|Novo Nordisk Investigational Site, Baracaldo, Spain|Novo Nordisk Investigational Site, La Coruña, Spain|Novo Nordisk Investigational Site, La Roca del Vallés, Spain|Novo Nordisk Investigational Site, Vic (Barcelona), Spain",,https://ClinicalTrials.gov/show/NCT03951805
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04094415,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,288,NCT04094415,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice",SURE ITALY,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 2",Drug: Semaglutide,Change in Glycated Haemoglobin A1c (HbA1c) (measured in percent)|Change in HbA1c (measured in mmol/mol)|Change in body weight (measured in kg)|Change in body weight (measured in percent)|Change in waist circumference|HbA1c level at end of study: below 8.0% (64 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.5% (59 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.0% (53 mmol/mol) (yes/no)|Reduction in HbA1c from baseline to end of study of 1.0% point or more (Y/N)|Weight reduction of 3.0% or more (yes/no)|Weight reduction of 5.0% or more (yes/no)|HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)|Patient reported severe or documented hypoglycaemia (yes/no)|Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction|Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction )|Change in score for Short Form (SF)-36 v2: Physical summary component|Change in score for SF-36 v2: Mental summary component|Patient completed the study under treatment with semaglutide (yes/no),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",,520,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN9535-4549|U1111-1233-2023,"October 28, 2019","June 24, 2021","June 24, 2021","September 19, 2019",,"June 4, 2020","Novo Nordisk Investigational Site, Bagno a Ripoli, Italy|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Brindisi, Italy|Novo Nordisk Investigational Site, Casarano (Lecce), Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Chieri Torino, Italy|Novo Nordisk Investigational Site, Foggia, Italy|Novo Nordisk Investigational Site, Gaeta, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Negrar (VR), Italy|Novo Nordisk Investigational Site, Orbassano, Italy|Novo Nordisk Investigational Site, Pavia, Italy|Novo Nordisk Investigational Site, Prato, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, Rozzano (MI), Italy|Novo Nordisk Investigational Site, Sesto San Giovanni (MI), Italy|Novo Nordisk Investigational Site, Treviglio (Bergamo), Italy|Novo Nordisk Investigational Site, Treviso, Italy|Novo Nordisk Investigational Site, Udine, Italy|Novo Nordisk Investigational Site, Vicenza, Italy|Novo Nordisk Investigational Site, Vicenza, Italy|Novo Nordisk Investigational Site, Vigevano, Italy",,https://ClinicalTrials.gov/show/NCT04094415
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04067999,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,289,NCT04067999,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice",SURE SPAIN,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 2",Drug: Semaglutide,Change in Glycated Haemoglobin A1c (HbA1c) (measured in percent)|Change in Glycated Haemoglobin A1c (HbA1c) (measured in mmol/mol)|Change in body weight (measured in kg)|Change in body weight (measured in percent)|Change in waist circumference|HbA1c level at end of study: below 8.0% (64 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.5% (59 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.0% (53 mmol/mol) (yes/no)|Reduction in HbA1c from baseline to end of study of 1.0% point or more (Y/N)|Weight reduction of 3.0% or more (yes/no)|Weight reduction of 5.0% or more (yes/no)|HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)|Patient reported severe or documented hypoglycaemia (yes/no)|Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction|Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction )|Change in score for Short Form (SF)-36 v2: Physical summary component|Change in score for SF-36 v2: Mental summary component|Patient completed the study under treatment with semaglutide (yes/no),Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",,217,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN9535-4368|U1111-1217-3546,"August 5, 2019","June 22, 2021","June 22, 2021","August 28, 2019",,"April 17, 2020","Novo Nordisk Investigational Site, A Coruña, Spain|Novo Nordisk Investigational Site, Baracaldo, Spain|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Bilbao, Spain|Novo Nordisk Investigational Site, Ferrol, Spain|Novo Nordisk Investigational Site, Galdakao, Spain|Novo Nordisk Investigational Site, Las Palmas de Gran Canaria, Spain|Novo Nordisk Investigational Site, Oviedo, Spain|Novo Nordisk Investigational Site, Pamplona, Spain|Novo Nordisk Investigational Site, Pontevedra, Spain|Novo Nordisk Investigational Site, Ribadeo, Spain|Novo Nordisk Investigational Site, Salamanca, Spain|Novo Nordisk Investigational Site, Valladolid, Spain|Novo Nordisk Investigational Site, Vigo, Spain|Novo Nordisk Investigational Site, Álava, Spain",,https://ClinicalTrials.gov/show/NCT04067999
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03989232,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,292,NCT03989232,A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes,SUSTAIN FORTE,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Placebo (semaglutide),Change in HbA1c|Change in body weight (kg)|Change in fasting plasma glucose (FPG)|Change in body mass index (BMI)|Change in waist circumference|HbA1c below 7%|HbA1c equal to or below 6.5%|Weight loss equal to or above 5%|Weight loss equal to or above 10%|Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes|Change in pulse rate,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,964,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NN9535-4506|U1111-1224-5162|2018-004529-96,"June 19, 2019","September 16, 2020","November 11, 2020","June 18, 2019",,"January 18, 2020","Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Chandler, Arizona, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Mesa, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Spring Valley, California, United States|Novo Nordisk Investigational Site, Van Nuys, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Coral Gables, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Adairsville, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Lake Charles, Louisiana, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Trenton, New Jersey, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Salisbury, North Carolina, United States|Novo Nordisk Investigational Site, Statesville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Corvallis, Oregon, United States|Novo Nordisk Investigational Site, Gaffney, South Carolina, United States|Novo Nordisk Investigational Site, Greenville, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Humble, Texas, United States|Novo Nordisk Investigational Site, Hurst, Texas, United States|Novo Nordisk Investigational Site, Katy, Texas, United States|Novo Nordisk Investigational Site, Plano, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Shavano Park, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Walla Walla, Washington, United States|Novo Nordisk Investigational Site, Wenatchee, Washington, United States|Novo Nordisk Investigational Site, Kozloduy, Bulgaria|Novo Nordisk Investigational Site, Montana, Bulgaria|Novo Nordisk Investigational Site, Petrich, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, Bulgaria|Novo Nordisk Investigational Site, Yambol, Bulgaria|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Stoney Creek, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Ceske Budejovice, Czechia|Novo Nordisk Investigational Site, Praha 10, Czechia|Novo Nordisk Investigational Site, Praha 5, Czechia|Novo Nordisk Investigational Site, Vlasim, Czechia|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Kaposvár, Hungary|Novo Nordisk Investigational Site, Komarom, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Szekszárd, Hungary|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gorzow Wielkopolski, Poland|Novo Nordisk Investigational Site, Katowice, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Manati, Puerto Rico|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Hnusta, Slovakia|Novo Nordisk Investigational Site, Kezmarok, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Krupina, Slovakia|Novo Nordisk Investigational Site, Levice, Slovakia|Novo Nordisk Investigational Site, Nove Zamky, Slovakia|Novo Nordisk Investigational Site, Pezinok, Slovakia|Novo Nordisk Investigational Site, Poprad, Slovakia|Novo Nordisk Investigational Site, Povazska Bystrica, Slovakia|Novo Nordisk Investigational Site, Puchov, Slovakia|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Mykolaiv, Ukraine|Novo Nordisk Investigational Site, Ternopil, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, Ukraine|Novo Nordisk Investigational Site, Zhytomyr, Ukraine",,https://ClinicalTrials.gov/show/NCT03989232
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04109508,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,315,NCT04109508,A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets,,Recruiting,No Results Available,Healthy Volunteers|Type 2 Diabetes,Drug: Oral semaglutide,"AUC0-24h,sema,SS; area under the semaglutide plasma concentration−time curve during a dosing interval at steady state|Cmax,sema,SS; maximum semaglutide plasma concentration at steady state|tmax,sema,SS; time to maximum semaglutide plasma contraction at steady state|t½,sema,SS; terminal half-life of semaglutide at steady state",Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,278,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN9924-4564|U1111-1233-0878|2019-002010-40,"October 2, 2019","January 8, 2021","February 15, 2021","September 30, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT04109508
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04097600,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,316,NCT04097600,A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets,,Recruiting,No Results Available,Healthy Volunteers|Type 2 Diabetes,Drug: Oral semaglutide,"AUC0-24h,sema,SS; area under the semaglutide plasma concentration−time curve during a dosing interval at steady state|Cmax,sema,SS; maximum semaglutide plasma concentration at steady state|tmax,sema,SS; time to maximum semaglutide plasma contraction at steady state|t½,sema,SS; terminal half-life of semaglutide at steady state",Novo Nordisk A/S,All,18 Years to 64 Years   (Adult),Phase 1,274,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN9924-4486|U1111-1226-6257|2019-000279-17,"September 30, 2019","December 20, 2020","January 27, 2021","September 20, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT04097600
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03797885,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,358,NCT03797885,A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal,PICT2RE,Completed,No Results Available,"Diabetes Mellitus, Type 2",Other: No treatment given,"Proportion of type 2 diabetes mellitus (T2DM) patients with cardiovascular risk factors (CVRFs) and/or established cardiovascular disease (CVD), regardless the date of diagnosis|Hypoglycaemic episodes|Hyperglycaemic episodes|Presence of T2DM complications (yes/no)|Types of T2DM complications|Hospital appointments|Hospitalisation episodes|Emergency visits|Change in waist circumference|Change in body mass index|Change in blood pressure|Change in urine albumin|Change in glycosylated hemoglobin (HbA1c)|Change in HbA1c|Change in Estimated Glomerular Filtration Rate (eGFR)|Change in total cholesterol|Change in low-density lipoprotein cholesterol|Change in high-density lipoprotein cholesterol|Change in triglyceride|Type of pharmacological treatment",Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",,737,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,NN2211-4435|U1111-1207-2878,"January 15, 2019","October 15, 2019","October 15, 2019","January 9, 2019",,"November 7, 2019","Novo Nordisk Investigational Site, Almada, Portugal|Novo Nordisk Investigational Site, Caldas da Rainha, Portugal|Novo Nordisk Investigational Site, Leiria, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Matosinhos, Portugal|Novo Nordisk Investigational Site, Portimão, Portugal|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Viana do Castelo, Portugal|Novo Nordisk Investigational Site, Vila Nova de Gaia, Portugal|Novo Nordisk Investigational Site, Vila Real, Portugal|Novo Nordisk Investigational Site, Viseu, Portugal",,https://ClinicalTrials.gov/show/NCT03797885
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04143945,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,359,NCT04143945,"A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",,Completed,No Results Available,"Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity",Drug: Semaglutide (administered by DV3396 pen)|Drug: Semaglutide (administered by PDS290 pen),Intensity of injection site pain,Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,104,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",INS-4603|2019-003654-83|U1111-1239-7955,"October 28, 2019","January 4, 2020","January 4, 2020","October 30, 2019",,"March 6, 2020","Novo Nordisk Investigational Site, Groningen, Netherlands",,https://ClinicalTrials.gov/show/NCT04143945
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04007107,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,360,NCT04007107,"A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",,Completed,No Results Available,"Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity",Drug: Semaglutide (administered by DV3396 pen)|Drug: Semaglutide (administered by PDS290 pen),Intensity of injection site pain as assessed by visual analogue scale,Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,103,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",INS-4582|2019-002284-10|U1111-1233-9590,"June 27, 2019","July 28, 2019","September 4, 2019","July 5, 2019",,"September 9, 2019","Novo Nordisk Investigational Site, Groningen, Netherlands",,https://ClinicalTrials.gov/show/NCT04007107
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT03987802,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,490,NCT03987802,"An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice",,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Drug: Faster-acting insulin aspart,Adverse Events (AEs)|Serious Adverse Events (SAEs)|Adverse Drug Reactions (ADRs)|Serious Adverse Drug Reactions (SADRs)|Patient reported severe hypoglycaemia|Patient reported Blood Glucose (BG) confirmed (below 56 mg/dl) hypoglycaemia|Patient reported Severe or BG confirmed (below 56 mg/dl) hypoglycaemia|Change in HbA1c,Novo Nordisk A/S,All,"18 Years and older   (Adult, Older Adult)",,300,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,NN1218-4489|U1111-1222-9492,"July 15, 2020","July 15, 2021","July 15, 2021","June 17, 2019",,"March 9, 2020",,,https://ClinicalTrials.gov/show/NCT03987802
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04152915,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,501,NCT04152915,A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens,,Completed,No Results Available,"Healthy Volunteers|Diabetes Mellitus, Type 2",Drug: Semaglutide,"AUC0-last,sema,1mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period|Cmax,sema,1mg: Maximum observed semaglutide concentration after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period|AUC0-168h,sema,0.25mg,SS: Area under the semaglutide concentration time curve from time 0 until 168 hours at steady state after the last dose of s.c. semaglutide 0.25 mg administration|Cmax,sema,0.25mg,SS: Maximum observed semaglutide concentration at steady state after the last dose of s.c. semaglutide 0.25 mg administration|AUC0-∞,sema,1mg: Area under the semaglutide concentration time curve from time 0 until infinity after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period|tmax,sema,1mg: Time of maximum observed semaglutide concentration after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period|tmax,sema,0.25mg,SS: Time of maximum observed semaglutide concentration at steady state after the last dose of s.c. semaglutide 0.25 mg administration|t½,sema,1mg: terminal elimination half-life of semaglutide after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period",Novo Nordisk A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,68,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NN9535-4588|U1111-1235-3506|2019-002588-92,"November 25, 2019","May 25, 2020","May 25, 2020","November 5, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Mainz, Germany",,https://ClinicalTrials.gov/show/NCT04152915
Study Director,Clinical Reporting Anchor and Disclosure (1452),Novo Nordisk A/S,,NCT04016974,clinical reporting anchor and disclosure (1452),clinical,female,0.5,4,502,NCT04016974,A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese,,Recruiting,No Results Available,"Healthy Volunteers|Diabetes Mellitus, Type 2",Drug: Oral semaglutide|Drug: Placebo,"AUC0-24h,sema,SS, area under the semaglutide concentration-time curve during a dosing interval (0−24 hours) at steady state|Cmax,sema,SS, maximum observed semaglutide plasma concentration during a dosing interval (0−24 hours) at steady state|tmax,sema,SS, time to maximum observed semaglutide plasma concentration during a dosing interval (0−24 hours) at steady state|CL/Fsema,SS, total apparent clearance of semaglutide at steady state|Ctrough,sema,SS, trough semaglutide plasma concentration at steady state|t½,sema,SS, terminal half-life of semaglutide at steady state|Vss/Fsema, apparent volume of distribution of semaglutide at steady state|MRTsema,SS, mean residence time of semaglutide at steady state|Rtheor,sema,SS, theoretical accumulation index, which is defined as [1/(1-Exp (-λZ,sema,SS*24h))], where λZ,sema,SS=log(2)/t½,sema,SS|Change in body weight from baseline|Change in fasting plasma glucose from baseline|Number of treatment-emergent adverse events|Number of treatment-emergent hypoglycaemic episodes",Novo Nordisk A/S,All,18 Years to 55 Years   (Adult),Phase 1,32,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NN9924-4303|U1111-1186-6753,"October 8, 2019","September 17, 2020","October 27, 2020","July 12, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Beijing, China",,https://ClinicalTrials.gov/show/NCT04016974
Principal Investigator,"Joel Neutel, MD",Orange County Research Center,,NCT04168541,joel neutel,joel,male,0.98,42048,216,NCT04168541,Glycemic Response in Persons With Type 2 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Other: Oral Nutrition Supplement,Area under the blood glucose curve (ACU 0-240 minutes)|Area under the insulin curves (AUC 0-240)|Insulinogenic index [Change in Ins30/Change in Glu30],Nestlé,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,14,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,17.11.US.HCN,"February 5, 2018","April 18, 2018","April 18, 2018","November 19, 2019",,"November 19, 2019","Orange County Research Center, Tustin, California, United States",,https://ClinicalTrials.gov/show/NCT04168541
Principal Investigator,"Ines Banjari, PhD","Department of Food and Nutrition Research, Faculty of Food Technology",,NCT04054284,ines banjari,ines,female,0.98,25430,217,NCT04054284,Safety and Efficacy of Herbal Tea in Type 2 Diabetics,DIABHerbMix,Completed,No Results Available,Type 2 Diabetes|Herbal Medicine Adverse Reaction,Dietary Supplement: Antidiabetic Herbal Tea|Dietary Supplement: Herbal Tea,Number of patients with adverse event|Glycated Hemoglobin|Fasting Glucose,Josip Juraj Strossmayer University of Osijek|Dom zdravlja Osijek (Health Centre Osijek)|Osijek University Hospital,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Screening",JJStrossmayerU-1,"July 1, 2019","February 10, 2020","February 12, 2020","August 13, 2019",,"February 13, 2020","Department of Food and Nutrition Research, Faculty of Food Technology, Osijek, Croatia|Health Centre Osijek, Osijek, Croatia|University Hospital Centre, Osijek, Croatia",,https://ClinicalTrials.gov/show/NCT04054284
Principal Investigator,"Michelle L Redmond, PhD","University of Kansas Medican Center Research Institute, Inc",,NCT03855449,michelle l redmond,michelle,female,0.98,66334,218,NCT03855449,A Task Analysis Study of DECIDE For African American Patients With Type 2 Diabetes,eDECIDE,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Task Analysis Intervention Group,Task Analysis study process chart|Task Analysis Wireframe Development part 1|Task Analysis Wireframe Development part 2,"University of Kansas Medical Center|Wichita State University|National Heart, Lung, and Blood Institute (NHLBI)",All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,4,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,STUDY00141460|1K01HL135472-01A1,"June 5, 2019","July 31, 2020","January 31, 2023","February 26, 2019",,"March 26, 2020","University of Kansas Medical Center, Wichita, Kansas, United States",,https://ClinicalTrials.gov/show/NCT03855449
Principal Investigator,"Michelle L Litchman, PhD, FNP-BC",University of Utah College of Nursing,,NCT03799796,michelle l litchman,michelle,female,0.98,66334,236,NCT03799796,Combining Flash Glucose Monitoring and Online Peer Support to Improve Outcomes in Hispanics With Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Flash Glucose Monitoring with Online Peer Support,Time-in-Range|A1C|Online peer support engagement,University of Utah|La Trobe University,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,ADC-SRR-IIS-18-23,"December 16, 2019",August 2020,September 2020,"January 10, 2019",,"February 7, 2020","University of Utah College of Nursing, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03799796
Principal Investigator,Evrim Koçarslan,researcher,,NCT04064996,evrim koçarslan,evrim,female,0.68,1628,224,NCT04064996,Effectiveness of Foot Exercise People With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Peripheral Neuropathy",Other: Routine rehabilitation program patient education|Other: Routine rehabilitation program + foot exercise training,Pain assessment with Algometry|Pain assessment with The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale|Pain assessment With Visual Analog Scale|Muscle Strength with Hand held dynamometer|Range Of Motion with goniometer|Baseline Tactile Semmes-Weinstein Monofilament|Edema measurement of tape|Evaluation of functional capacity with 6 minutes walking test|Two Point Discrimation Test|The Foot and Ankle Ability Measure|HbA1c|Serum creatinine|Albumin levels,Istanbul University,All,"45 Years to 70 Years   (Adult, Older Adult)",Not Applicable,34,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,199292,"April 1, 2019","July 30, 2019","November 30, 2019","August 22, 2019",,"April 13, 2020","Istanbul University, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT04064996
Principal Investigator,"Jing Ma, professor",RenJi Hospital,,NCT04185662,jing ma,jing,female,0.75,2653,225,NCT04185662,Effects of Artificial Sweeteners on Glucose Metabolism in Patients With Type 2 Diabetes,SWEETS,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: sucralose,Fasting glucose|postprandial blood sugar|HbA1c,"RenJi Hospital|ShiBei Hospital , JingAn District, Shanghai|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|PuNan Hospital ,Shanghai",All,30 Years to 60 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,T2DM20190619,"December 1, 2019","August 30, 2021","September 30, 2021","December 4, 2019",,"December 4, 2019","Renji Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04185662
Principal Investigator,"Alan Schorr, Dr.","Diabetes and Endocrinology Consultants of Pennsylvania, LLC (Decpa LLC)",,NCT04057248,alan schorr,alan,male,0.99,39948,230,NCT04057248,Digital Self-Management and Health Coaching for Type 2 Diabetes - Impact on Diabetes Clinical and Wellness Indicators,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Device: Dario Blood Glucose Monitoring System|Behavioral: CDE,HbA1C taken in blood test,LabStyle Innovations Ltd.,All,"35 Years and older   (Adult, Older Adult)",Not Applicable,14,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CP-0010,"July 9, 2018","June 1, 2019","June 1, 2019","August 15, 2019",,"September 4, 2019","Diabetes and Endocrinology Consultants of Pennsylvania, LLC (Decpa LLC), Feasterville, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04057248
Principal Investigator,"Aline Marcadenti, PhD",Hospital do Coracao,,NCT03793855,aline marcadenti,aline,female,0.97,22311,231,NCT03793855,Nutritional Strategy for Glycemic Control in Patients With Type 2 Diabetes Mellitus (NUGLIC),,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Nutritional Strategy|Behavioral: Dietary Prescription,HbA1C|B-PAID|DSCA,Hospital do Coracao,All,"30 Years and older   (Adult, Older Adult)",Not Applicable,370,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NUGLIC,"May 6, 2019",September 2020,December 2020,"January 4, 2019",,"February 17, 2020","Universidade Federal de Juiz de Fora, Governador Valadares, Brazil|Hospital de Clínicas de Porto Alegre - Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil|Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil|Instituto Estadual de Cardiologia Aloysio de Castro, Rio De Janeiro, Brazil|Universidade Federal da Bahia, Salvador, Brazil|Hospital do Coracao, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03793855
Principal Investigator,"Hanno Pijl, MD, PhD",Leiden Univerity Medical Centre,,NCT03811587,hanno pijl,hanno,male,0.88,499,233,NCT03811587,Clinical Feasibility and Efficacy of Intermittent Use of a Fasting Mimicking Diet in the Treatment of Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Fasting Mimicking diet,Concentration of HbA1c|Dosage of antidiabetic medication used,"Leiden University Medical Center|Dutch Diabetes Research Foundation|Health Holland|IFOM, The FIRC Institute of Molecular Oncology|L-Nutra",All,"18 Years to 74 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NL63892.058.18 - P18.049,"November 5, 2018","September 1, 2021","December 31, 2021","January 22, 2019",,"February 20, 2020","Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT03811587
Principal Investigator,Alvin Mushlin,Weill Cornell Medical College/Memorial Sloan Kettering Cancer Center,,NCT03921242,alvin mushlin,alvin,male,0.99,7714,238,NCT03921242,Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Renal Insufficiency, Chronic",Drug: Metformin|Drug: Sulfonylurea|Drug: DPP-4 inhibitor|Drug: SGLT2 inhibitor|Drug: GLP1 receptor agonist,"Incidence of Severe Hypoglycemia Assessed from EMR|Difference in Glycosylated Hemoglobin (HbA1c) level (mmol/mol)|Heterogeneity of Treatment Effect Via Pre-specified Sub-Group Analyses|Incidence of acidosis, hospitalization for hyperglycemia, acute myocardial infarction, stroke, heart failure hospitalization, and heart failure emergency room visits|Difference in Body-Mass Index Assessed From EMR (BMI) (kg/m2)|Difference in Laboratory-Measured eGFR (mL/min)",Weill Medical College of Cornell University|Patient-Centered Outcomes Research Institute,All,"18 Years and older   (Adult, Older Adult)",,16000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,1809019555,"August 1, 2019","March 1, 2021","March 1, 2021","April 19, 2019",,"September 26, 2019","University of North Carolina, Chapel Hill, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03921242
Study Director,Cristobal Morales Portillo,Hospital Universitario Virgen Macarena,,NCT04149067,cristobal morales portillo,cristobal,male,0.98,4849,239,NCT04149067,Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Dapagliflozin|Drug: Sitagliptin,0.5% in Hb1Ac and 1.5 kg in body weight|Evaluate the results due to the use of SGLT2i/DPP4i|Evaluate the security of the treatment,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|AstraZeneca,All,"18 Years to 75 Years   (Adult, Older Adult)",,1080,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,FIS-DAP-2016-01,"June 5, 2017","March 15, 2019","March 15, 2019","November 4, 2019",,"November 4, 2019","Cristóbal Morales Portillo, Sevilla, Andalucía, Spain",,https://ClinicalTrials.gov/show/NCT04149067
Principal Investigator,"Andreas Pfuetzner, Prof. Dr. Dr.",Pfützner Science & Health Institute GmbH,,NCT04030091,andreas pfuetzner,andreas,male,0.99,71365,242,NCT04030091,Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1",Drug: 3 hours humulin R 100 IU/mL PIT|Drug: 2 hours humulin R 100 IU/mL PIT,Endothelial function|Renal function|nerve function|Retinopathy|HbA1c|Insulin resistance|Diabetes treatment satisfaction questionnaire,Sciema UG|Innovative Diabetes Treatment Studies LLC.,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,16,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCTI-PIT-001,"September 6, 2019",June 2020,July 2020,"July 23, 2019",,"January 18, 2020","NYC Research, Inc., New York, New York, United States|Pfützner Science & Health Institute GmbH, Mainz, Rhineland-Palatinate, Germany",,https://ClinicalTrials.gov/show/NCT04030091
Principal Investigator,"Olga A Miroshnichenko, PhD",Saint Petersburg State Diagnostic Center № 85,,NCT04012775,olga a miroshnichenko,olga,female,0.98,80307,244,NCT04012775,Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Biological: Insulin Humulin® NPH|Biological: Insulin Rinsulin® NPH,Antibody Response|Hypoglycemic episodes (glucose level < 3.9 mmol/l) frequency|Change in BMI from baseline|Occurrence of adverse events|Occurrence of Injection Site Reaction|Change in HbA1c from baseline|Change in fasting plasma glucose level from baseline|Change in basal insulin dose per body weight (U/kg) from baseline|Change in total basal insulin dose (U) from baseline,Geropharm,All,"18 Years and older   (Adult, Older Adult)",Phase 3,201,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RINPH-IM,"April 20, 2017","September 24, 2018","September 24, 2018","July 9, 2019",,"July 9, 2019","Chelyabinsk Railway Clinical Hospital, Chelyabinsk, Russian Federation|Moscow Endocrinological Dispensary, Moscow, Russian Federation|Moscow Clinical Hospital № 71, Moscow, Russian Federation|Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russian Federation|V.A. Baranov Republic Hospital, Petrozavodsk, Russian Federation|City Polyclinic № 6, Saint Petersburg, Russian Federation|City Hospital № 2, Saint Petersburg, Russian Federation|City Polyclinic № 17, Saint Petersburg, Russian Federation|Medical Sanitary Unit № 157, Saint Petersburg, Russian Federation|Institute of Medical Research, Saint Petersburg, Russian Federation|Research Center Eco-Safety, Saint Petersburg, Russian Federation|Saint Petersburg State Diagnostic Center № 85, Saint Petersburg, Russian Federation|Diabetes Center, Samara, Russian Federation|Clinical Hospital № 3, Yaroslavl, Russian Federation",,https://ClinicalTrials.gov/show/NCT04012775
Study Chair,"Kimberly G Brodovicz, (203) 448-1937",kimberly.brodovicz@boehringer-ingelheim.com,,NCT03817463,kimberly g brodovicz,kimberly,female,0.99,17328,245,NCT03817463,"A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes",,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Drug: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor|Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor,"Number of participants hospitalized for heart failure|Number of participants with all-cause mortality|Number of participants with both hospitalization for heart failure and all cause mortality|Number of participants with myocardial infraction (MI), stroke, all cause mortality|Number of participants with Cardiovascular mortality|Number of participants with a composite outcome including hospitalization for heart failure and cardiovascular (CV) mortality|Number of participants with 3-point major adverse cardiovascular (CV) events (MACE), defined as a composite outcome including myocardial infarction (MI),stroke, and cardiovascular (CV) mortality|Number of participants with coronary revascularization procedure|Number of participants with end-stage renal disease (ESRD)|Number of participants with estimated glomerular filtration rate (eGFR) decline|Number of participants with progression from normoalbuminuria to micro- or macroalbuminuria|Number of participants with a composite outcome including eGFR decline and progression to micro- or macroalbuminuria|Number of participants with bone fracture|Number of participants with diabetic ketoacidosis|Number of participants with severe hypoglycemia|Number of participants with lower-limb amputation|Number of participants with acute kidney injury requiring dialysis|Healthcare resource utilization|Cost of care",Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",,150000,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,1245-0195,"April 15, 2019","January 1, 2021","January 1, 2021","January 25, 2019",,"June 4, 2020","Steno Diabetes Center Copenhagen, Department of Clinical Epidemiology, Gentofte, Denmark|Helsinki University Hospital, Helsinki, Finland|University of Ulm, Institute for Epidemiology and medical biometry, Ulm, Germany|Maccabi Healthcare Services, Tel Aviv, Israel|Gifu University, Gifu, Japan|Ajou University Hospital, Suwon, Korea, Republic of|Oslo University Hospital, Department of Clinical Lipidology, Oslo, Norway|Oslo University Hospital, Department of Cardiology, Oslo, Norway|Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain|TFS Trial Form Support International AB, Lund, Sweden|Quantify Research AB, Stockholm, Sweden|Taiwan Society for Pharmacoeconomics and Outcome Research (TaSPOR), Taipei City, Taiwan|Leicester Real World Evidence Unit, Leicester general Hospital, Leicester, United Kingdom",,https://ClinicalTrials.gov/show/NCT03817463
Study Chair,"Samuel Headley, PhD",Springfield College,,NCT04006938,samuel headley,samuel,male,0.99,59464,246,NCT04006938,Effect of Continuous vs Intermittent Aerobic Exercise on Glycemic Control in a Barbadian Population With Type 2 Diabetes,,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Single Bout ('S')|Behavioral: Multiple Bout ('M'),2 hour post prandial blood glucose level after breakfast|2 hour post prandial blood glucose level after lunch|2 hour post prandial blood glucose level after dinner|Fasting blood sugar level,Springfield College,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KCK00000001,July 2019,February 2020,April 2020,"July 5, 2019",,"July 5, 2019",,,https://ClinicalTrials.gov/show/NCT04006938
Principal Investigator,"Aleksandr Yu Mayorov, MD",Endocrinology Research Centre,,NCT04023344,aleksandr yu mayorov,aleksandr,male,0.99,7354,254,NCT04023344,Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus",Drug: Humalog Mix25|Drug: Insulin Lispro Biphasic 25,Antibody Response|Adverse Events frequency and degree|HbA1c|Fasting Plasma Glucose Level|Seven-Point Glucose Testing|Insulin Dose|Body Mass Index|Treatment Satisfaction,Geropharm,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,210,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LISPRO25-IM,"March 14, 2018","January 15, 2019","April 18, 2019","July 17, 2019",,"July 17, 2019","Chelyabinsk Railway Clinical Hospital, Chelyabinsk, Russian Federation|Railway Clinical Hospital N.A. Semashko, Moscow, Russian Federation|Endocrinology Research Centre (Moscow), Moscow, Russian Federation|Moscow Endocrinological Dispensary, Moscow, Russian Federation|Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russian Federation|V.A. Baranov Republic Hospital, Petrozavodsk, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|City Polyclinic № 77, Saint Petersburg, Russian Federation|City Hospital № 2, Saint Petersburg, Russian Federation|City Polyclinic № 117, Saint Petersburg, Russian Federation|City Polyclinic № 17, Saint Petersburg, Russian Federation|Institute of Medical Research, Saint Petersburg, Russian Federation|Research Center Eco-Safety, Saint Petersburg, Russian Federation|City Hospital №40, Saint Petersburg, Russian Federation|Pokrovskaya Municipal Hospital, Saint Petersburg, Russian Federation|Diabetes Center, Samara, Russian Federation|Clinical City Hospital № 9, Saratov, Russian Federation|Siberian State Medical University, Tomsk, Russian Federation",,https://ClinicalTrials.gov/show/NCT04023344
Principal Investigator,"Antonio V Gaddi, MD, PhD","EuroGenLab, Bologna, Italy",,NCT04038528,antonio v gaddi,antonio,male,0.99,328654,256,NCT04038528,Telemedical Devices in the Management of Type 2 Diabetes Mellitus to Improve Diabetic Control and Quality of Life,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Behavioral: telemonitoring of T2DM,glycated hemoglobin (GlyH) level|Quality of life perception|Body mass index (BMI)|Abdominal circumference|Triglyceride|LDL-cholesterol|Systolic Blood Pressure (BP)|Diastolic BP|Compliance|Hyperglycemic events,"Centro Studi Internazionali, Italy|GPI SpA",All,"18 Years and older   (Adult, Older Adult)",,350,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2018-DC-2-0,"March 1, 2018","March 1, 2020","July 31, 2020","July 31, 2019",,"July 31, 2019","ASP Catanzaro, Catanzaro, Italy",,https://ClinicalTrials.gov/show/NCT04038528
Principal Investigator,"Mónica Marazuela Azpíroz, MD PhD",Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,,NCT04191525,mónica marazuela azpíroz,mónica,female,0.98,4087,258,NCT04191525,Phase II Clinical Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: BPL-1 Probiotic capsules|Dietary Supplement: Placebo,Fasting glucose|Glycated haemoglobin|Insulin|HOMA-IR|Total cholesterol|HDL-cholesterol|LDL-cholesterol|Triglycerides|Body Mass Index (BMI)|Body Fat Percentage (%BF)|Blood pressure|Waist perimeter,Mónica Marazuela Azpíroz|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PROBIDEM,"September 10, 2018","June 26, 2019","June 26, 2019","December 9, 2019",,"December 19, 2019","Hospital Universitario de La princesa, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04191525
Principal Investigator,"Courtney Peterson, Ph.D.",University of Alabama at Birmingham,,NCT04155619,courtney peterson,courtney,female,0.79,1805,270,NCT04155619,Using Early Time Restricted Feeding and Timed Light Therapy to Improve Glycemic Control in Adults With Type 2 Diabetes,,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Time Restricted Feeding|Light; Therapy, Complications",Behavioral: No change in meal timing|Behavioral: No change in light exposure|Behavioral: Early Time-Restricted Feeding|Behavioral: Timed Light Therapy,"24-hour glucose levels|24-hour insulin levels|24-hour C-peptide levels|Hemoglobin A1C|Insulin sensitivity|Beta-cell responsivity index (a measure of beta-cell function)|Insulin secretion|Melatonin Amplitude|Cortisol Amplitude|Melatonin Phase|Cortisol Phase|Glycemic (""Peripheral"") Rhythm Amplitude|Glycemic (""Peripheral"") Rhythm Phase",University of Alabama at Birmingham,All,"30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,344,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,IRB-300003964,July 2020,July 2023,July 2023,"November 7, 2019",,"April 21, 2020","University of Alabama at Birmingham; Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT04155619
Principal Investigator,"Hana Kahleova, MD",Physicians Committee for Responsible Medicine,,NCT04088981,hana kahleova,hana,female,0.98,33128,271,NCT04088981,"Effect of a Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes",,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Dietary intervention,Intramyocellular concentrations|Hepatocellular lipid concentrations|Insulin sensitivity|Concentration of glucose|Concentration of immunoreactive insulin|Concentration of C-peptide|Rate of glycemic control|Resting energy expenditure|Postprandial metabolism|Body Composition|Gut microbiome composition|Concentration of plasma lipids|Body weight,Physicians Committee for Responsible Medicine|Yale University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Pro00037991,September 2020,July 2023,July 2023,"September 13, 2019",,"September 18, 2019",,,https://ClinicalTrials.gov/show/NCT04088981
Principal Investigator,"María Trinidad García Vázquez, Dentist, PhD",Gerencia de Atención Primaria,,NCT04051866,maría trinidad garcía vázquez,maría,female,0.99,232436,272,NCT04051866,Effectiveness of Non-surgical Periodontal Treatment on HbA1c Levels in a Patient With Type 2 Diabetes Mellitus,,Not yet recruiting,No Results Available,"Chronic Periodontitis|Diabetes Mellitus, Type 2",Procedure: Non-surgical periodontal treatment: Scaling and root planing (SRP)|Other: Oral hygiene instructions,Glycated Hemoglobin A (HbA1c)|Probing depth|Glomerular filtration|Quality of life of patients: EuroQol 5D-5L questionnaire|Physical activity (IPAQ questionnaire)|Diet questionnaire (MEDAS)|Therapeutic adherence questionnaire (Morisky-Green)|Cost-utility|Gingival Recession|Clinical attachment level|Gingival Probing bleeding,"Gerencia de Atención Primaria, Madrid",All,"35 Years and older   (Adult, Older Adult)",Not Applicable,288,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCI 20/18,"March 2, 2020","April 1, 2022","December 15, 2022","August 9, 2019",,"February 6, 2020","Gerencia de Atención Primaria, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04051866
Principal Investigator,"camille Marciniak, MD","University Hospital, Lille",,NCT04018105,camille marciniak,camille,female,0.9,51457,274,NCT04018105,Influence of Preprandial Metformin Administration on Carbohydrate Absorption,METTIME,Not yet recruiting,No Results Available,Impaired Glucose Tolerance|Type2 Diabetes,Other: Oral glucose tolerance test (OGTT) with or without metformin,Area under the curve of D-Xylose|Number of Participants with gastrointestinal side effects|Area under the curve of blood glucose|Area under the curve of insulin|Area under the curve of GLP-1,"University Hospital, Lille",Female,18 Years to 60 Years   (Adult),Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018_35|2019-001175-36,March 2020,March 2022,March 2022,"July 12, 2019",,"December 4, 2019",,,https://ClinicalTrials.gov/show/NCT04018105
Principal Investigator,"Pierre Ernst, MD, MSc, FRCPC","Lady Davis Institute for Medical Research, Jewish General Hospital",,NCT04017221,pierre ernst,pierre,male,0.99,91174,276,NCT04017221,Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Urosepsis|Diabetic Ketoacidosis|Lower Extremity Amputation",Drug: Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Drug: Dipeptidyl peptidase-4 (DPP-4) inhibitors|Drug: Other treatment combinations,Incidence rate of urosepsis|Incidence rate of diabetic ketoacidosis (DKA)|Incidence rate of lower extremity amputation|Incidence rate of Fournier's gangrene,"Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR)",All,"18 Years and older   (Adult, Older Adult)",,1249636,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Q18-09/10/11,"October 1, 2018","December 1, 2019","December 1, 2019","July 12, 2019",,"January 14, 2020","Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT04017221
Principal Investigator,"Pierre Ernst, MD, MSc, FRCPC","Lady Davis Institute for Medical Research, Jewish General Hospital",,NCT03939624,pierre ernst,pierre,male,0.99,91174,326,NCT03939624,Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events,,Completed,No Results Available,Type2 Diabetes|Myocardial Infarction|Ischemic Stroke|Cardiovascular Death|Heart Failure|All-Cause Mortality,Drug: Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Drug: Dipeptidyl peptidase-4 (DPP-4) inhibitors,Myocardial infarction|Ischemic stroke|Cardiovascular death|All-cause mortality|Heart failure,"Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR)",All,"18 Years and older   (Adult, Older Adult)",,419734,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Q18-06,"October 1, 2018","October 1, 2019","October 1, 2019","May 7, 2019",,"January 14, 2020","Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03939624
Study Director,"Vincent Prévot, PhD","Institut National de la Santé Et de la Recherche Médicale, France",,NCT03974139,vincent prévot,vincent,male,0.99,79107,277,NCT03974139,Impact of Metformin on Leptin Transport in Cerebrospinal Fluid of Obese Patients,LEPTOB,Recruiting,No Results Available,"Obesity Without Type 2 Diabetes, With BMI>30",Drug: Metformin Oral Tablet,cerebrospinal fluid /plasma leptin ratio|cerebrospinal fluid /plasma glucose ratio|cerebrospinal fluid /plasma glucagon like peptide 1 (GLP1) ratio|cerebrospinal fluid /plasma insulin ratio|cerebrospinal fluid /plasma ghrelin ratio|Cerebrospinal fluid levels of Agouti-Related Peptide (AgRP)|Plasma levels of Agouti-Related Peptide (AgRP)|Cerebrospinal fluid levels of proopiomelanocortin (POMC)|Plasma levels of proopiomelanocortin (POMC)|Cerebrospinal fluid levels of neuropeptide Y (NPY)|Plasma levels of neuropeptide Y (NPY)|Cerebrospinal fluid levels of leptin soluble receptor|Plasma levels of leptin soluble receptor|Apparent diffusion coefficient (ADC)|Hypothalamic concentration of N-acetyl-aspartate (NAA)|Hypothalamic concentration of creatine|Hypothalamic concentration of Choline|Hypothalamic concentration of Glutamine / glutamate|Hypothalamic concentration of gamma-aminobutyric acid (GABA)|Weight|Abdominal circumference|Percentage of body fat|Fat free mass (Kg)|Energy expenditure|Score of the Three Factor Eating Questionnaire (TFEQ)|Score of the Dutch Eating Behaviour Questionnaire (DEBQ),Lille Catholic University|Centre Hospitalier Arras,All,18 Years to 40 Years   (Adult),Phase 2,31,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RC-P0054,"September 10, 2019","August 31, 2021","May 31, 2022","June 4, 2019",,"October 24, 2019","Centre hospitalier d'Arras, Arras, France",,https://ClinicalTrials.gov/show/NCT03974139
Principal Investigator,"Vincent Florent, MD, MSc, PhD","Centre Hospitalier d'Arras, INSERM",,NCT03974139,vincent florent,vincent,male,0.99,79107,277,NCT03974139,Impact of Metformin on Leptin Transport in Cerebrospinal Fluid of Obese Patients,LEPTOB,Recruiting,No Results Available,"Obesity Without Type 2 Diabetes, With BMI>30",Drug: Metformin Oral Tablet,cerebrospinal fluid /plasma leptin ratio|cerebrospinal fluid /plasma glucose ratio|cerebrospinal fluid /plasma glucagon like peptide 1 (GLP1) ratio|cerebrospinal fluid /plasma insulin ratio|cerebrospinal fluid /plasma ghrelin ratio|Cerebrospinal fluid levels of Agouti-Related Peptide (AgRP)|Plasma levels of Agouti-Related Peptide (AgRP)|Cerebrospinal fluid levels of proopiomelanocortin (POMC)|Plasma levels of proopiomelanocortin (POMC)|Cerebrospinal fluid levels of neuropeptide Y (NPY)|Plasma levels of neuropeptide Y (NPY)|Cerebrospinal fluid levels of leptin soluble receptor|Plasma levels of leptin soluble receptor|Apparent diffusion coefficient (ADC)|Hypothalamic concentration of N-acetyl-aspartate (NAA)|Hypothalamic concentration of creatine|Hypothalamic concentration of Choline|Hypothalamic concentration of Glutamine / glutamate|Hypothalamic concentration of gamma-aminobutyric acid (GABA)|Weight|Abdominal circumference|Percentage of body fat|Fat free mass (Kg)|Energy expenditure|Score of the Three Factor Eating Questionnaire (TFEQ)|Score of the Dutch Eating Behaviour Questionnaire (DEBQ),Lille Catholic University|Centre Hospitalier Arras,All,18 Years to 40 Years   (Adult),Phase 2,31,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RC-P0054,"September 10, 2019","August 31, 2021","May 31, 2022","June 4, 2019",,"October 24, 2019","Centre hospitalier d'Arras, Arras, France",,https://ClinicalTrials.gov/show/NCT03974139
Principal Investigator,"David Kerr, M.D.",Sansum Diabetes Research Institute,,NCT03940300,david kerr,david,male,0.99,501011,279,NCT03940300,Farming for Life - Health Impact of Organic Vegetable Prescriptions for Adults Living With or at Risk of Type 2 Diabetes,FFL,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Food Supply|Poverty|Minority Health|Obesity",Dietary Supplement: Fresh organic vegetables,Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by blood pressure.|Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by body mass index.|Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by waist circumference .|Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by hemoglobin A1c.|Improve food security for adults with or at risk for type 2 diabetes assessed by U.S. Household Food Security Survey Module: Six-item short form|Improve glycemic control measured by continuous glucose monitoring (CGM),Sansum Diabetes Research Institute|United States Department of Agriculture (USDA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,440,Other|U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018-01793,"January 28, 2019",December 2023,May 2024,"May 7, 2019",,"May 10, 2019","Sansum Diabetes Research Institute, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT03940300
Principal Investigator,"David Kerr, M.D.",Sansum Diabetes Research Institute,,NCT03830840,david kerr,david,male,0.99,501011,301,NCT03830840,Mil Familias Cohort Establishment: a Study to Understand Determinants of Diabetes and Its Complications Among US Latinos,,Enrolling by invitation,No Results Available,Type2 Diabetes Mellitus|Cardiovascular Diseases,,"Success (evaluated by Yes/No format) recruiting and establishing an observational cohort of 1,000 Latino families with at least one family member living with type 2 diabetes by deploying the methods proven feasible by Mil Familias Operational Pilot.|Socio-demographics assessed by questionnaire.|Number of healthcare visits and the difficulty in traveling to the healthcare provider assessed by questionnaire|Questions regarding personal opinions regarding the burden of diabetes on Latinos measured by specific questions|Total daily tortilla consumption|Daily sugary drink consumption|Number of times per week eating meals prepared away from home|Laboratory blood draw for evaluation of C-Peptide related to diabetes|Laboratory blood draw for evaluation of C-Reactive protein related to diabetes|Laboratory blood draw for evaluation of Complete Blood Count|Laboratory blood draw for evaluation of Comprehensive Metabolic Panel|Laboratory blood draw for evaluation of Glutamic Acid Decarboxylase (GAD) antibodies related to diabetes|Laboratory blood draw for evaluation of HbA1c related to diabetes|Laboratory blood draw for evaluation of Insulin autoantibody related to diabetes|Laboratory blood draw for evaluation of Islet antigen 2 (IA-2) antibody related to diabetes|Laboratory blood draw for evaluation of lipids|Laboratory blood draw for evaluation of Insulin|Laboratory blood draw for evaluation of thyroid function|Microalbumin measured in a urine sample|Creatinine measured in a urine sample|Microalbumin/creatinine ratio measured in a urine sample|Cheek cells and saliva for genomic analysis|Stool samples for microbiome analysis|Height measured by Physical exam|Weight measured by Physical exam|Waist circumference measured by Physical exam|Blood pressure measured by Physical exam|Temperature measured by Physical exam|Heart rate measured by Physical exam|Foot examination evaluated by Questions and Physical exam|Neuropathy Questions during Physical exam|Retinopathy questions during Physical exam|Dental exam Questions during Physical exam|Eye exam Questions during Physical exam|Medical history, family medical history, and medication status and history assessed by interview|Menopausal status, pregnancy status, and gestational diabetes history for women determined by interview|Determination of diabetes related foot disease|Acculturation measured by the Brief Acculturation Scale for Hispanics (BASH)|Quality of life measured by the Short Form Health Survey (SF-12)|Depression measured by the Patient Health Questionnaire-9|Perceived Ethnic Discrimination measured by the Brief Perceived Ethnic Discrimination Questionnaire - Community version (PEDQ-CV)|Adverse Childhood Experiences (ACE) quantified by ACE questionnaire|Spirituality measured by a Spiritual Well Being Scale|Risk Perception Survey For Developing Diabetes (RPS-DD)|Sleep quality measured by the Oviedo Sleep Questionnaire (OSQ)|Stress measured by the 4 item Perceived Stress Scale (PSS)|Drug abuse measured by the Drug Abuse Screening Test (DAST) - 20|Diabetes management measured by the Diabetes Symptom Self-Care Inventory|Family diabetes management measured by questionnaire|Foot self care confidence measured by questionnaire|Health literacy measured by the Short Assessment of Health Literacy (SAHL)|Measurement of health numeracy|Trust in physician measured by the Trust in Physician (TPS) questionnaire|Social needs screening assessed by the Health Leads Screening toolkit|Food security assessed by U.S. Household Food Security Survey Module: Six-item short form|Functional support measured by the SSQ6|Support structure measured by Medical Outcomes Study Social Support Survey (mMOS-SS)|National survey of children's health (NSCH) for all children and youth",Sansum Diabetes Research Institute|Eli Lilly and Company,All,"7 Years and older   (Child, Adult, Older Adult)",,5000,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2017 - 6004,"February 1, 2019",November 2021,December 2021,"February 5, 2019",,"March 20, 2020","Sansum Diabetes Research Institute, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT03830840
Principal Investigator,"David Chung-Wah SIU, Prof",The University of Hong Kong,,NCT04200586,david chung-wah siu,david,male,0.99,501011,309,NCT04200586,The Effects of SGLTi on Diabetic Cardiomyopathy,SGLTi,Recruiting,No Results Available,Type2 Diabetes|Heart Failure With Reduced Ejection Fraction,Drug: Dapagliflozin,Change in myocardial perfusion reserve index,The University of Hong Kong,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 4,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Version no.3,"April 9, 2020","September 30, 2021","September 30, 2021","December 16, 2019",,"June 9, 2020","Queen Mary Hospital, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT04200586
Principal Investigator,"David Han, MD",PAREXEL Early Phase Clinical Unit-Los Angeles,,NCT04155645,david han,david,male,0.99,501011,397,NCT04155645,"To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia",,Recruiting,No Results Available,Dyslipidemia,Drug: AZD8233 subcutaneous injection|Drug: Placebo,Number of subjects with adverse events (AEs) due to AZD8233 SC multiple ascending dose treatment.|Vital sign: Systolic blood pressure (SBP)|Vital sign: Pulse rate|Vital sign: Oral body temperature|Number of patients with abnormal findings in resting 12-lead Electrocardiogram (ECG) and digital ECG (dECG).|Number of subject with abnormal findings in cardiac telemetry|Physical examination|Injection site reaction examinations|Laboratory assessments: Hematology - Blood cells count|Laboratory assessments: Hematology - Hemoglobin (Hb)|Laboratory assessments: Hematology - Hematocrit (HCT)|Laboratory assessments: Hematology - Mean corpuscular volume (MCV)|Laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH)|Laboratory assessments: Hematology - Mean corpuscular hemoglobin concentration (MCHC)|Laboratory assessments: Hematology - Differential WBC count|Laboratory assessments: Hematology - Platelet count and platelet function assessment.|Laboratory assessments: Hematology - Reticulocytes absolute count|Laboratory assessments: Serum clinical chemistry - Electrolytes|Laboratory assessments: Serum clinical chemistry - Blood urea nitrogen (BUN)|Laboratory assessments: Serum clinical chemistry - Creatinine|Laboratory assessments: Serum clinical chemistry - Glucose (fasting)|Laboratory assessments: Serum clinical chemistry - Creatine kinase|Laboratory assessments: Serum clinical chemistry - Direct bilirubin|Laboratory assessments: Serum clinical chemistry - Hemoglobin A1c (HbA1c)|Laboratory assessments: Serum clinical chemistry - Liver enzymes|Laboratory assessments: Serum clinical chemistry - Total bilirubin|Laboratory assessments: Serum clinical chemistry - Cell enzymes|Laboratory assessments: Serum clinical chemistry - Bicarbonate|Laboratory assessments: Serum clinical chemistry - Uric acid|Laboratory assessments: Coagulation|Renal safety biomarkers - Urine clusterin|Renal safety biomarkers - Urine cystatin-C|Renal safety biomarkers - Urine N-acetyl-beta-D-glucosaminidase (NAG)|Renal safety biomarkers - Urine albumin|Renal safety biomarkers - Urine creatinine|Renal safety biomarkers - Urine Kidney injury molecule1 (KIM-1)|Renal safety biomarkers - Urine Neutrophil gelatinase-associated lipocalin (NGAL)|Renal safety biomarkers - Urine Osteopontin|Renal safety biomarkers - Urine total protein|Immune Activation Response - High-sensitivity C-reactive protein (hs-CRP)|Complement Activation panel|Laboratory assessments: Clinical urinalysis|Plasma PK analysis: Time delay between drug administration and the first observed concentration in plasma (tlag).|Plasma PK analysis: Time to reach peak or maximum observed concentration or response following drug administration (tmax).|Plasma PK analysis: Observed maximum plasma concentration (Cmax).|Plasma PK analysis: Area under the plasma concentration-curve from time zero to time last value above the limit of quantification (AUC[0-last]).|Plasma PK analysis: Area under the concentration-time curve from time zero to 24 hours post-dose (AUC[0-24]).|Plasma PK analysis: Area under the concentration-time curve from time zero to 48 hours post-dose (AUC[0-48]).|Plasma PK analysis: Area under the concentration-time curve from time zero extrapolated to infinity (AUC).|Plasma PK analysis: Area under the plasma concentration-time curve from time during the dosing interval (AUCt).|Plasma PK analysis: Observed trough plasma drug concentration (Ctrough).|Plasma PK analysis: Apparent total body clearance of drug from plasma after extravascular administration (CL/F).|Plasma PK analysis: Apparent volume of distribution for parent drug at terminal phase (extravascular administration) (Vz/F).|Plasma PK analysis: Half-life associated with the terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2).|Plasma PK analysis: Mean Residence Time (MRT).|Urine PK analysis: Amount excreted in urine (Ae).|Urine PK analysis: Fraction excreted unchanged in urine (Fe).|Urine PK analysis: Renal clearance (CLR).|PD analysis: Levels of dyslipidemia related biomarkers.,AstraZeneca|Parexel,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,33,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,D7990C00002,"November 21, 2019","April 30, 2021","April 30, 2021","November 7, 2019",,"June 9, 2020","Research Site, Glendale, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04155645
Principal Investigator,"David A Hess, PhD","Robart's Research Institute, London, Ontario",,NCT04132531,david a hess,david,male,0.99,501011,426,NCT04132531,Effect of Weight Loss Surgery on Stem Cells.,,Completed,No Results Available,"Obesity, Morbid|Stem Cells|Cardiovascular Morbidity",Procedure: Bariatric (weight loss) surgery,Change in the frequency of circulating cells with aldehyde dehydrogenase activity.|Change in the frequency of circulating cells with aldehyde dehydrogenase activity and cell surface marker expression.,"St. Michael's Hospital, Toronto|Humber River Hospital|University of Western Ontario, Canada",All,19 Years to 60 Years   (Adult),,38,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,PRO_B_001,"May 1, 2018","June 25, 2019","August 13, 2019","October 18, 2019",,"October 18, 2019","St. Michael's Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04132531
Principal Investigator,"Subodh Verma, MD","St. Michael's Hospital, Toronto",,NCT04132531,subodh verma,subodh,male,0.98,228,426,NCT04132531,Effect of Weight Loss Surgery on Stem Cells.,,Completed,No Results Available,"Obesity, Morbid|Stem Cells|Cardiovascular Morbidity",Procedure: Bariatric (weight loss) surgery,Change in the frequency of circulating cells with aldehyde dehydrogenase activity.|Change in the frequency of circulating cells with aldehyde dehydrogenase activity and cell surface marker expression.,"St. Michael's Hospital, Toronto|Humber River Hospital|University of Western Ontario, Canada",All,19 Years to 60 Years   (Adult),,38,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,PRO_B_001,"May 1, 2018","June 25, 2019","August 13, 2019","October 18, 2019",,"October 18, 2019","St. Michael's Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT04132531
Principal Investigator,David B Savage,University of Cambridge,,NCT04190849,david b savage,david,male,0.99,501011,433,NCT04190849,European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD),EU-PNAFLD,Recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease|Non-alcoholic Fatty Liver|Non-alcoholic Steatohepatitis,,Survival|Cardiovascular morbidity|Liver morbidity|Asymptomatic progression of liver disease,Cambridge University Hospitals NHS Foundation Trust|The European Association for the Study of the Liver|Children's Liver Disease Foundation,All,"up to 18 Years   (Child, Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,A094204|174534,"November 14, 2017",November 2047,November 2047,"December 9, 2019",,"December 9, 2019","Maastricht UMC, Maastricht, Netherlands|Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|Birmingham Children's Hospital, Birmingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT04190849/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04190849
Study Director,"Joao Raposo, MD PhD",Associacao Protectora dos Diabeticos de Portugal,,NCT04141111,joao raposo,joao,male,0.98,12849,280,NCT04141111,Retrospective and Prospective Study on Professional Continuous Glucose Monitoring in Insulin-treated Type 2 Diabetes,ADJUST,Completed,No Results Available,"Diabetes Mellitus, Type 2",Device: Continuous Glucose Monitoring (CGM),Glycemic control|Health status|Treatment satisfaction|Therapeutic changes,Associacao Protectora dos Diabeticos de Portugal|Medtronic,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,102,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,639/2015,"March 22, 2015","January 24, 2017","March 1, 2018","October 28, 2019",,"October 28, 2019","APDP, Lisboa, Portugal",,https://ClinicalTrials.gov/show/NCT04141111
Principal Investigator,"Eric Benamo, MD",Centre Hospitalier Avignon,,NCT03847779,eric benamo,eric,male,0.99,135071,281,NCT03847779,Microcirculatory Vasomotor Changes in Type 2 Diabetes With Peripheral Neuropathy,NEUROMICRO,Recruiting,No Results Available,Diabetic Neuropathy Peripheral|Small Vessel Disease of Diabetes Mellitus|Vasodilation|Vasoconstriction,"Other: ""Rest""|Other: ""Exercise""|Other: ""Foot lowering""|Other: ""Hyperthermia""",Changes in average spectral amplitude of the entire frequency range between baseline and after stimulus,University of Avignon,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,110,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,UAPV-012019-AVJ,"February 4, 2019","June 30, 2020","June 30, 2020","February 20, 2019",,"February 20, 2019","Centre Hospitalier Henri Duffaut, Avignon, France",,https://ClinicalTrials.gov/show/NCT03847779
Principal Investigator,"Eric A Finkelstein, PhD, MHA",Duke-NUS Graduate Medical School,,NCT03800680,eric a finkelstein,eric,male,0.99,135071,451,NCT03800680,A Randomized Trial to Slow the Progression of Diabetes,TRIPOD,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Diabetes Management Package (DMP)|Behavioral: M-POWER Rewards,Change in HbA1c levels at Month 12|Change in HbA1c levels at Month 6|Change in weight at Months 6 and 12|Change in blood pressure at Months 6 and 12|Proportion of participants that had insulin treatment initiated by Months 6 and 12|Change in self-reported physical activity at Months 6 and 12|Change in self-reported weight monitoring at Months 6 and 12|Change in self-reported blood glucose monitoring at Months 6 and 12|Change in self-reported medication adherence at Months 6 and 12|Change in self-reported diabetes self-management at Months 6 and 12|Change in self-reported sleep quality at Months 6 and 12|Change in self-reported work productivity and daily activity impairment at Months 6 and 12|Change in self-reported health utility index at Months 6 and 12|Incremental cost-effectiveness ratios based on HbA1c at Month 12|Incremental cost-effectiveness ratios based on QALY at Month 12,"Duke-NUS Graduate Medical School|National Medical Research Council (NMRC), Singapore|SingHealth Polyclinics|Singapore General Hospital|Changi General Hospital",All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,339,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,HSRGDB16Dec003,"October 19, 2019",April 2022,April 2022,"January 11, 2019",,"May 18, 2020","Duke-NUS Medical School, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT03800680
Principal Investigator,"Hye Seung Jung, MD",Seoul National University Hospital,,NCT04123587,hye seung jung,hye,female,0.94,2026,282,NCT04123587,Genetic Variants Replication Study Associated With Dependence on Sulfonylurea in Participants With Type 2 Diabetes,,Recruiting,No Results Available,Diabetes Mellitus,Drug: discontinuation of Sulfonylureas,the list of previously found candidate variants which are observed in the slufonylurea-dependent patients but not in the non-dependent patients,Seoul National University Hospital,All,"19 Years and older   (Adult, Older Adult)",Phase 4,58,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SU,"September 10, 2019",August 2020,August 2021,"October 11, 2019",,"October 11, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT04123587
Principal Investigator,"Xiang Zhu, Dorctor","Third Affiliated Hospital, Sun Yat-Sen University",,NCT03970161,xiang zhu,xiang,male,0.71,763,284,NCT03970161,Evaluation of Early Retinal Nerve Injury in Type 2 Diabetes Patients Without Diabetic Retinopathy,,Recruiting,No Results Available,Diabetes Mellitus|Diabetic Retinopathy|Nerve Injury,Device: routine ophthalmic examination,Peripapillary RNFL thickness|GCL+ in the macular area obtained using the 3D wide mode|Retinal thickness in all macular regions|RNFL thickness in the macular area obtained using the 3D Macula (v) mode|GCL+ thickness in the macular region obtained using the 3D Macula (v) mode,"Third Affiliated Hospital, Sun Yat-Sen University",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,720,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Retinal nerve injury in T2DM,"May 29, 2019","June 1, 2021","June 1, 2021","May 31, 2019",,"May 31, 2019","The third affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03970161
Principal Investigator,Ebaa AlOzairi,Dasman Diabetes Institute,,NCT04136730,ebaa alozairi,ebaa,male,0.55,29,290,NCT04136730,"Effects of Home- and Gym-based Resistance Exercise on Body Composition, Muscle Strength and Glycemic Control in People With Type 2 Diabetes.",,Recruiting,No Results Available,Diabetes,Behavioral: Home-based|Behavioral: Gym-based,HbA1c|Fat-free mass|SPPB,Dasman Diabetes Institute|University of Glasgow,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HM-2019-021,"August 1, 2019",August 2020,August 2020,"October 23, 2019",,"October 23, 2019","Dasman Diabetes Institute, Kuwait City, Kuwait",,https://ClinicalTrials.gov/show/NCT04136730
Principal Investigator,"Ebaa AlOzairi, MD, PhD",Dasman Diabetes Institute,,NCT04135287,ebaa alozairi,ebaa,male,0.55,29,472,NCT04135287,Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients,,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: GLP-1 receptor agonist,HbA1c|Beta cell function|Weight loss|Fasting Plasma Glucagon,Dasman Diabetes Institute,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 4,315,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RA HM-2019-004,"March 1, 2020","March 1, 2023","July 15, 2023","October 22, 2019",,"February 17, 2020","Dasman Diabetes Institute, Kuwait, Kuwait",,https://ClinicalTrials.gov/show/NCT04135287
Principal Investigator,"Kristine Færch, PhD",Steno Diabetes Center Copenhagen,,NCT03854656,kristine færch,kristine,female,0.98,6020,296,NCT03854656,Effect of Time-restricted Eating on Behaviour and Metabolism in Overweight Individuals at High Risk of Type 2 Diabetes,RESET,Recruiting,No Results Available,Overweight and Obesity|PreDiabetes,Other: Time-restricted eating,"Change in body weight (kg)|Body weight (kg)|Body mass index (kg/m^2)|Fat mass (kg)|Fat free mass (kg)|Fat percentage (%)|Waist circumference (cm)|Hip circumference (cm)|HbA1c (mmol/mol and %)|Systolic blood pressure (mmHg)|Diastolic blood pressure (mmHg)|Heart rate (bpm)|Resting energy expenditure (kcal/day)|Substrate oxidation (respiratory exchange ratio)|Metabolites|Hormones|Circulating proteins that associate with low-grade inflammation and lipid metabolism|Respiratory and glycolytic capacities of isolated peripheral blood mononuclear cells (PBMCs)|Heart rate response to standing up from the supine position|Heart rate response to inhalation and exhalation|Heart rate response to forced exhalation during rest (valsalva maneuver)|Gastric emptying time (hours and minutes)|Small bowel transit time (hours and minutes)|Large bowel transit time (hours and minutes)|Total gastrointestinal transit time (hours and minutes)|Motility index|Attention measured using eye tracking|Emotions measured using facial expression analyses|Arousal measured using galvanic skin response|Food choice|Implicit wanting|Explicit liking|Explicit wanting|Insulin sensitivity (indices)|Insulin resistance (indices)|Subjective appetite|Mean amplitude of glycaemic excursions (MAGE)|Continuous overall net glycaemic action (CONGA)|Daily time spent above different glucose concentrations (e.g. >6.1 mmol/L, >7.0 mmol/L, >7.8 mmol/L, and >11.1 mmol/L)|Mean glucose concentrations|Standard deviation of glucose concentrations|Variation coefficients of glucose concentrations|Physical activity (time spent at different intensities)|Physical activity (counts/min)|Physical activity energy expenditure (kcal/day)|Physical activity (MET hours)|Timing of physical activity (hh:mm)|Energy intake (kcal/day)|Macronutrient intake (energy percentage)|Timing of dietary intake (hh:mm)|Sleep timing (hh:mm)|Sleep duration (min)|Sleep variability (min)|Sleep onset latency (min)|Sleep efficiency (%)|Wakefulness (min)|Self-reported gastrointestinal symptoms (part 1)|Self-reported gastrointestinal symptoms (part 2)|Self-reported gastrointestinal symptoms (part 3)|Self-reported autonomic symptoms|Self-reported control over eating|Self-reported sleepiness|Self-reported sleep quality|Self-reported chronotype|Self-reported physical activity|Self-reported overall health and wellbeing|Self-reported eating behavior|Self-reported night eating|Daily eating/drinking window (hh:min)|Microbiome content and diversity|Motivation for participation (qualitative methods)|Feasibility of the intervention (qualitative methods)|Satisfaction with the intervention (qualitative methods)",Kristine Færch|University of Copenhagen|Aalborg University Hospital|iMotions A/S|University of Leeds|Salk Institute for Biological Studies|Steno Diabetes Center Copenhagen,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,NNF17OC0027822,"February 25, 2019",June 2020,August 2020,"February 26, 2019",,"November 25, 2019","Steno Diabetes Center Copenhagen, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT03854656
Principal Investigator,"Steen B Haugaard, Professor","Dept. of Endocrinology, Copenhagen University Hospital Bispebjerg",,NCT03814694,steen b haugaard,steen,male,0.99,1027,297,NCT03814694,Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes. The Hypo-energetic Study,CutDM-Hypo,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Overweight and Obesity",Dietary Supplement: CRHP Diet|Dietary Supplement: CD Diet,Change in glycated hemoglobin (HbA1c) during 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.|Change in hepatic fat content after 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.|Change in fasting plasma triglycerides during 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.,"Bispebjerg Hospital|University of Copenhagen|University of Aarhus|The Danish Dairy Research Foundation, Denmark|Arla Foods",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CUTDM-HYPO,"January 29, 2019",July 2020,December 2020,"January 24, 2019",,"August 13, 2019","Bispebjerg Hospital, Copenhagen, Copenhagen NV, Denmark",,https://ClinicalTrials.gov/show/NCT03814694
Principal Investigator,"Daniel A Bottino, PhD",State University of Rio de Janeiro,,NCT04112875,daniel a bottino,daniel,male,0.99,317409,300,NCT04112875,"Effect of L-arginine on Microcirculation, Myogenesis and Angiogenesis Associated With Aging, Sarcopenia and Diabetes",,Completed,No Results Available,Aging|Sarcopenia|Type 2 Diabetes|Microcirculation,Dietary Supplement: L-arginine|Dietary Supplement: Maltodextrin,Changes in Microcirculation|Changes in Endothelium-dependent and endothelium-independent vasodilation|Change in metabolic markers|change in circulating muscle growth and degradation factors|Body composition by DXA,Rio de Janeiro State University|Laboratory for Clinical and Experimental Research on Vascular Biology,Female,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Arginine,April 2016,April 2019,September 2019,"October 2, 2019",,"October 2, 2019","State University of Rio de Janeiro, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT04112875
Principal Investigator,"Gerusa M Costa, MSc",State University of Rio de Janeiro,,NCT04112875,gerusa m costa,gerusa,female,1.0,39,300,NCT04112875,"Effect of L-arginine on Microcirculation, Myogenesis and Angiogenesis Associated With Aging, Sarcopenia and Diabetes",,Completed,No Results Available,Aging|Sarcopenia|Type 2 Diabetes|Microcirculation,Dietary Supplement: L-arginine|Dietary Supplement: Maltodextrin,Changes in Microcirculation|Changes in Endothelium-dependent and endothelium-independent vasodilation|Change in metabolic markers|change in circulating muscle growth and degradation factors|Body composition by DXA,Rio de Janeiro State University|Laboratory for Clinical and Experimental Research on Vascular Biology,Female,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Arginine,April 2016,April 2019,September 2019,"October 2, 2019",,"October 2, 2019","State University of Rio de Janeiro, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT04112875
Study Director,"Adam Bataineh, MD MSc","Span Health, East Suffolk and North Essex NHS Foundation Trust",,NCT04198935,adam bataineh,adam,male,0.98,116396,454,NCT04198935,Evaluating a Digital Diabetes Education Program,,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Device: Span Health Mobile Application,Change in weight|Blood pressure|Hemoglobin A1C (HbA1C) level|Lipid profile|Participant's experience|Adherence to the the program,Adam Bataineh|Span Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0000001,May 2020,July 2020,August 2020,"December 13, 2019",,"December 23, 2019",,,https://ClinicalTrials.gov/show/NCT04198935
Principal Investigator,"Sumbal Babar, MBBS",East Tennessee State University,,NCT04198935,sumbal babar,sumbal,female,0.95,38,454,NCT04198935,Evaluating a Digital Diabetes Education Program,,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Device: Span Health Mobile Application,Change in weight|Blood pressure|Hemoglobin A1C (HbA1C) level|Lipid profile|Participant's experience|Adherence to the the program,Adam Bataineh|Span Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0000001,May 2020,July 2020,August 2020,"December 13, 2019",,"December 23, 2019",,,https://ClinicalTrials.gov/show/NCT04198935
Principal Investigator,"Caroline A Presley, MD, MPH",University of Alabama at Birmingham,,NCT03987841,caroline a presley,caroline,female,0.98,64753,303,NCT03987841,Intervention Mapping to Adapt a Mindfulness-based Intervention for Adults With Diabetes and Emotional Distress,,Not yet recruiting,No Results Available,Type 2 Diabetes|Stress,Behavioral: Integrated MBSR/DSME intervention,Diabetes distress|Hemoglobin A1c (A1C)|Diabetes self-management behaviors|Medication adherence|Acceptability of the intervention to participants: semi-structured interviews|Feasibility: percentage of screened participants who are eligible|Feasibility: percentage of eligible participants who enroll|Feasibility: distribution of participants by demographics|Feasibility: percentage of sessions attended,University of Alabama at Birmingham,All,19 Years to 64 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-300003578,"June 1, 2020","January 1, 2021","January 1, 2022","June 17, 2019",,"June 18, 2019","Cooper Green Mercy Health Systems, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT03987841
Principal Investigator,"Weiping Jia, MD, PhD",Shanghai 6th People's Hospital,,NCT03958838,weiping jia,weiping,male,0.71,55,304,NCT03958838,Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Dissemination To 12 Communities,,Recruiting,No Results Available,Type2 Diabetes|PreDiabetes,Behavioral: Peer Support Integrated with Primary Care,Change from Baseline HbA1c and at 12 months|Change from Baseline Fasting Blood Glucose and at 12 months|Change from Baseline Blood Pressure and at 12 months|Change from Baseline BMI and at 12 months|Change from Baseline Blood Lipids and at 12 months|Change from Baseline Waist circumference and at 12 months|Change from Baseline Hemoglobin and at 12 months|Change from Baseline Red Blood Cell Count and at 12 months|Change from Baseline Mean Corpuscular Volume and at 12 months|Change from Baseline Mean Corpuscular Hemoglobin and at 12 months|Change from Baseline Liver Functioning and at 12 months|Change from Baseline Bilirubin and at 12 months|Change from Baseline Blood Urea and at 12 months|Change from Baseline Serum Creatinine and at 12 months|Change from Baseline Uric Acid and at 12 months|Change from Baseline Urine Albumin/Creatinine Ratio and at 12 months|Change in Insulin Functioning at 6 and 12 months|Change in C-peptides at 6 and 12 months|Change in CRP at 6 and 12 months|Change from Baseline Diabetes Self Care Behaviors and 12 months|Change from Baseline General Quality of Life and 12 months|Change from Baseline Diabetes Quality of Life and 12 months|Change from Baseline Depression and 12 months|Change from Baseline Insulin Attitudes and 12 months|Change in Neighborhood Interactions and 12 months|Change in Peer Support Engagement and Health Care Utilization and 12 months,"Shanghai 6th People's Hospital|University of North Carolina, Chapel Hill|Merck Foundation",All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,2160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019-028,"May 25, 2019","July 31, 2020","October 31, 2020","May 22, 2019",,"July 8, 2019","Anting Huangdu Community Health Center, Shanghai, Shanghai, China|Baihe Community Health Center, Shanghai, Shanghai, China|Dachang Qilian Community Health Center, Shanghai, Shanghai, China|Fangsong Community Health Center, Shanghai, Shanghai, China|Guangzhong Community Health Center, Shanghai, Shanghai, China|Huamu Community Health Center, Shanghai, Shanghai, China|Liantang Community Health Center, Shanghai, Shanghai, China|Luodian Community Health Center, Shanghai, Shanghai, China|Nanxiang Community Health Center, Shanghai, Shanghai, China|Nicheng Community Health Center, Shanghai, Shanghai, China|Ouyang Community Health Center, Shanghai, Shanghai, China|Waigang Community Health Center, Shanghai, Shanghai, China|Xiao Kunshan Community Health Center, Shanghai, Shanghai, China|Xuhang Community Health Center, Shanghai, Shanghai, China|Yichuan Community Health Center, Shanghai, Shanghai, China|Zhaoxiang Community Health Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03958838
Principal Investigator,"Edwin B Fisher, PhD","University of North Carolina, Chapel Hill",,NCT03958838,edwin b fisher,edwin,male,0.99,17259,304,NCT03958838,Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Dissemination To 12 Communities,,Recruiting,No Results Available,Type2 Diabetes|PreDiabetes,Behavioral: Peer Support Integrated with Primary Care,Change from Baseline HbA1c and at 12 months|Change from Baseline Fasting Blood Glucose and at 12 months|Change from Baseline Blood Pressure and at 12 months|Change from Baseline BMI and at 12 months|Change from Baseline Blood Lipids and at 12 months|Change from Baseline Waist circumference and at 12 months|Change from Baseline Hemoglobin and at 12 months|Change from Baseline Red Blood Cell Count and at 12 months|Change from Baseline Mean Corpuscular Volume and at 12 months|Change from Baseline Mean Corpuscular Hemoglobin and at 12 months|Change from Baseline Liver Functioning and at 12 months|Change from Baseline Bilirubin and at 12 months|Change from Baseline Blood Urea and at 12 months|Change from Baseline Serum Creatinine and at 12 months|Change from Baseline Uric Acid and at 12 months|Change from Baseline Urine Albumin/Creatinine Ratio and at 12 months|Change in Insulin Functioning at 6 and 12 months|Change in C-peptides at 6 and 12 months|Change in CRP at 6 and 12 months|Change from Baseline Diabetes Self Care Behaviors and 12 months|Change from Baseline General Quality of Life and 12 months|Change from Baseline Diabetes Quality of Life and 12 months|Change from Baseline Depression and 12 months|Change from Baseline Insulin Attitudes and 12 months|Change in Neighborhood Interactions and 12 months|Change in Peer Support Engagement and Health Care Utilization and 12 months,"Shanghai 6th People's Hospital|University of North Carolina, Chapel Hill|Merck Foundation",All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,2160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019-028,"May 25, 2019","July 31, 2020","October 31, 2020","May 22, 2019",,"July 8, 2019","Anting Huangdu Community Health Center, Shanghai, Shanghai, China|Baihe Community Health Center, Shanghai, Shanghai, China|Dachang Qilian Community Health Center, Shanghai, Shanghai, China|Fangsong Community Health Center, Shanghai, Shanghai, China|Guangzhong Community Health Center, Shanghai, Shanghai, China|Huamu Community Health Center, Shanghai, Shanghai, China|Liantang Community Health Center, Shanghai, Shanghai, China|Luodian Community Health Center, Shanghai, Shanghai, China|Nanxiang Community Health Center, Shanghai, Shanghai, China|Nicheng Community Health Center, Shanghai, Shanghai, China|Ouyang Community Health Center, Shanghai, Shanghai, China|Waigang Community Health Center, Shanghai, Shanghai, China|Xiao Kunshan Community Health Center, Shanghai, Shanghai, China|Xuhang Community Health Center, Shanghai, Shanghai, China|Yichuan Community Health Center, Shanghai, Shanghai, China|Zhaoxiang Community Health Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03958838
Principal Investigator,Alfredo Franco-Obregon,"National University, Singapore",,NCT04183543,alfredo franco-obregon,alfredo,male,0.99,28805,308,NCT04183543,Pemf Therapy for the Management of Diabetes in Obese Patients,PROMISE,Recruiting,No Results Available,Obesity|Type 2 Diabetes,Device: Pulsed Electromagnetic Fields|Device: Sham Therapy,Change in baseline HbA1c at 17 weeks.|Change in baseline fasting blood glucose level at 17 weeks.|Change in baseline serum triglycerides at 17 weeks.|Change in baseline serum HDL at 17 weeks.|Change in baseline serum LDL at 17 weeks.|Change in baseline serum cholesterol at 17 weeks.|Change in baseline BMI at 17 weeks.|Change in baseline body weight at 17 weeks.|Change in baseline waist-hip ratio at 17 weeks.|Change in baseline serum C-Peptide at 17 weeks.|Change in baseline blood pressure at 17 weeks.,"National University Hospital, Singapore|National University, Singapore",All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",PROMISE,"December 2, 2019",June 2021,December 2021,"December 3, 2019",,"December 3, 2019","National University Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04183543
Principal Investigator,Asim Shabbir,"National University Hospital, Singapore",,NCT04183543,asim shabbir,asim,male,0.98,3463,308,NCT04183543,Pemf Therapy for the Management of Diabetes in Obese Patients,PROMISE,Recruiting,No Results Available,Obesity|Type 2 Diabetes,Device: Pulsed Electromagnetic Fields|Device: Sham Therapy,Change in baseline HbA1c at 17 weeks.|Change in baseline fasting blood glucose level at 17 weeks.|Change in baseline serum triglycerides at 17 weeks.|Change in baseline serum HDL at 17 weeks.|Change in baseline serum LDL at 17 weeks.|Change in baseline serum cholesterol at 17 weeks.|Change in baseline BMI at 17 weeks.|Change in baseline body weight at 17 weeks.|Change in baseline waist-hip ratio at 17 weeks.|Change in baseline serum C-Peptide at 17 weeks.|Change in baseline blood pressure at 17 weeks.,"National University Hospital, Singapore|National University, Singapore",All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",PROMISE,"December 2, 2019",June 2021,December 2021,"December 3, 2019",,"December 3, 2019","National University Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT04183543
Principal Investigator,"Matthew Budoff, MD",Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,,NCT03985384,matthew budoff,matthew,male,1.0,35521,310,NCT03985384,Semaglutide Treatment On Coronary Progression,STOP,Recruiting,No Results Available,Type 2 Diabetes|Coronary Artery Disease,Drug: Semaglutide 2 MG/1.5 ML Subcutaneous Solution|Drug: Placebo,Rate of change in non-calcified plaque volume|Rate of change in total plaque volume,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,All,"40 Years and older   (Adult, Older Adult)",Phase 4,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",22174-01,"April 30, 2019",September 2020,September 2020,"June 13, 2019",,"April 9, 2020","Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, United States",,https://ClinicalTrials.gov/show/NCT03985384
Principal Investigator,"Cynthia Fritschi, PhD, RN","University of Illinois at Chicago, College of Nursing",,NCT04083248,cynthia fritschi,cynthia,female,0.99,31660,311,NCT04083248,Building Self-regulation Capacity in AA T2DM Women: Feasibility of EMI,,Recruiting,No Results Available,Type 2 Diabetes|Self-regulation,Behavioral: Feasibility group,Hours of CGM data|Number of times participants accessed their CGM data|Wear time of Fitbit activity monitor|Interrelationships between real-time interstitial glucose levels (mg/dL) and activity levels (active minutes (correlation coefficients).|Interrelationships between real-time interstitial glucose levels (mg/dL) and activity levels (step counts).|Acceptability of intervention: Semi-structured Diabetes Study Acceptability Interview Guide,University of Illinois at Chicago|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Chicago,Female,"40 Years and older   (Adult, Older Adult)",Not Applicable,26,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2019-0922|P30DK092949,"September 20, 2019","July 31, 2020","July 31, 2020","September 10, 2019",,"April 24, 2020","University of Illinois at Chicago, College of Nursing, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04083248
Principal Investigator,"Reina C. Villareal, MD","Michael E. DeBakey VA Medical Center, Houston, TX",,NCT03887936,reina c. villareal,reina,female,0.95,2063,318,NCT03887936,Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism,,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Hypogonadism,Drug: Testosterone gel 1.62%|Drug: Placebo,Finite element analysis of bone to measure bone strength|Markers of bone turnover to measure bone metabolism|Osteoblast and osteoclast progenitor cells which are cells found in bone,VA Office of Research and Development,Male,"40 Years to 65 Years   (Adult, Older Adult)",Phase 4,166,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ENDB-009-18F|1I01CX001665-01A2,"October 1, 2019","September 30, 2024","September 30, 2025","March 25, 2019",,"March 4, 2020","Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03887936
Study Chair,"Alexey Medvedchikov, +43180105-7896",Alexey.Medvedchikov@Boehringer-Ingelheim.com,,NCT03807440,alexey medvedchikov,alexey,male,1.0,7556,322,NCT03807440,DIA_CENTRAL:T2D Treatment Pattern in Central Europe,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Drug: Empagliflozin|Drug: Sodium Glucose Transporter 2 inhibitor|Drug: Dipeptidyl-peptidase 4 inhibitor|Drug: Glucagon-like peptide 1 agonist,"T2D patients' baseline characteristics when initiating either empagliflozin - or other SGLT2i, DPP4i or GLP1a on top of current antidiabetic treatment by different HCP specialties in CEE countries|Burden of comorbidities (prevalence of cardiovascular disease (CVD), chronic kidney disease (CKD) and CVD/CKD risk factors) in this T2D patient population|Actual treatment use in patients with and without established CVD|Association of socioeconomic parameters with treatment decisions|Discontinuation rate for GLP1a, DPP4i and SGLT2i after a follow up of approximately one year from the initial time point|Reasons for discontinuation for GLP1a, DPP4i and SGLT2i after a follow up of approximately one year from the initial time point|Average duration of treatment for GLP1a, DPP4i and SGLT2i after a follow up of approximately one year from the initial time point",Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",,4000,Industry,Observational,Observational Model: Other|Time Perspective: Retrospective,1245-0187,"August 26, 2019","January 31, 2021","January 31, 2021","January 17, 2019",,"June 4, 2020","Practice Dr. Alice Sýkorová, Bilina, Czechia|Marie Horňáčková, Brno, Czechia|Michal Brada, Břeclav, Czechia|Barbara Buzová, Havířov, Czechia|Zaviatičová, Petra, Havířov, Czechia|Barbora Doležalová, Heřmanův Městec, Czechia|Radana Syslová, Hlušovice, Czechia|Pavel Kasík, Hořovice, Czechia|Practice Dr. Petr Maule, Humpolec, Czechia|Practice Dr. Petra Vrbová, Jilemnice, Czechia|Practice MUDr. Gita Markofová, Karlovy Vary, Czechia|MUDr.Tomáš Edelsberger, Krnov, Czechia|Śárka Drinková, Ledeč nad Sázavou, Czechia|Martina Košková, Mladá Boleslav, Czechia|Jitka Kuchařová, Mělník, Czechia|Karel Churavý, Nový jičín, Czechia|Śárka Kubánková, Nymburk, Czechia|Dobromila Vykoupilová, Němčice nad Hanou, Czechia|Agentura Science Pro spol. s.r.o., Olomouc, Czechia|Anna Rancová, Olomouc, Czechia|MUDr.Tomáš Hrdina, Opočno, Czechia|Radka Nágelová, Ostrava Poruba, Czechia|Practice Dr. René Turčínek, Ostrava, Czechia|Zdeněk Jankovec, Plzeň, Czechia|Diabetologická a interní ambulance, Poděbrady, Czechia|Practice Dr. Milena Peterková, Praha 2, Czechia|MUDr.Michala Pelikánová s.r.o., Praha 4, Czechia|Markéta Hovorková, Praha 4, Czechia|Jakub Hron, Praha 4, Czechia|Milan Flekač, Praha 5, Czechia|Jiří Jón, Praha 5, Czechia|Practice Dr. Lucie Kufová, Praha 5, Czechia|Barbora Diepoltová, Praha 9, Czechia|AIDIN VK s.r.o., Přerov, Czechia|Martin Střelka, Příbor, Czechia|Practice Dr. Petronela Janečková, Rumburk, Czechia|Practice Dr. Miroslav Lindovský, Sokolov, Czechia|Dana Fialkovičová, Strakonice, Czechia|Marek Frydrych, Třebíč, Czechia|Lubomír Kudlej, Vrchlabí, Czechia|Robin Urbánek, Zlín, Czechia|Practice MUDr. Marie Löblová, České Budějovice, Czechia|Lékařský dům Géčko, České Budějovice, Czechia",,https://ClinicalTrials.gov/show/NCT03807440
Principal Investigator,"Nazarii Kobyliak, PhD",Bogomolets National Medical University,,NCT04201938,nazarii kobyliak,nazarii,male,1.0,6,323,NCT04201938,Effect of Probiotic Co-administration With Omega-3 Fatty Acids on Obesity Parameters and Insulin Resistance,ENDO-5,Completed,No Results Available,Obesity|Insulin Resistance|Insulin Sensitivity|Type2 Diabetes|Visceral Obesity,Combination Product: Symbiter-Omega|Dietary Supplement: Placebo,HOMA-2IR|insulin sensitivity (%S)|HbA1c|fasting plasma insulins (FPI)|fasting plasma glucose (FPG)|β-cell function (%B)|C-peptide|weight|waist circumferences (WC)|body mass index (BMI)|cytokines levels,Bogomolets National Medical University|Taras Shevchenko National University of Kyiv,,"Child, Adult, Older Adult",Not Applicable,56,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ENDO-5,"February 1, 2018","March 1, 2018","January 15, 2019","December 17, 2019",,"December 17, 2019","Bogomolets National Medical University, Kyiv, Ukraine",,https://ClinicalTrials.gov/show/NCT04201938
Study Chair,"Kirsi Pietiläinen, Prof.",Gyllenberg Professor in Clinical Metabolism Obesity Research Unit University of Helsinki,,NCT03823027,kirsi pietiläinen,kirsi,female,0.93,1706,325,NCT03823027,STAR Study Investigating Performance and Safety of the Medical Device SiPore15™,,Completed,No Results Available,PreDiabetes|Pre Diabetes|Prediabetic State|Type2 Diabetes|Type2 Diabetes Mellitus|Overweight|Obese,Device: SiPore15™,Performance measured as changes in HbA1c|Tolerability measured as evaluation of Adverse Events|Performance measured as changes in LDL-C|Performance measured as changes in body fat %,Sigrid Therapeutics AB,All,"18 Years to 105 Years   (Adult, Older Adult)",Not Applicable,43,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STAR01,"January 28, 2019","October 2, 2019","October 2, 2019","January 30, 2019",,"November 5, 2019","Pihlajalinna Ite, Satucon OY, Kuopio, Finland|Clinical Trial Consultants, Uppsala, Uppland, Sweden",,https://ClinicalTrials.gov/show/NCT03823027
Study Director,"Niels Jessen, Professor","Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital",,NCT04166760,niels jessen,niels,male,0.99,7479,327,NCT04166760,Metabolic Effects of Whey Compounds in Patients With Diabetes Mellitus Type 2.,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: speWHE|Dietary Supplement: WHE,Difference in iAUC for insulin between WHE and speWHE|Differences in iAUC and concentration differences for GIP|Differences in iAUC and concentration differences for GLP-1|Differences in iAUC and concentration differences for glucagon|Differences in iAUC and concentration differences for glucose|Differences in iAUC and concentration differences for C-peptid|Differences in iAUC and concentration differences for FFA|Activity measurements|continuous glucose measurement (CGM),University of Aarhus,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAKE4,"January 6, 2020","October 1, 2020","October 31, 2020","November 18, 2019",,"January 7, 2020","Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT04166760
Principal Investigator,"Charles Zerez, MD, PhD",Straub Medical Center,,NCT03947879,charles zerez,charles,male,0.99,49331,328,NCT03947879,The Effect of Pharmaceutical Grade L-glutamine (Endari) on Glycemic Control in Patients With Diabetes Mellitus Type II,,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: L-glutamine|Other: No L-glutamine,Change in fasting glucose|Change in hemoglobin A1c|Change in fructosamine|Change in complete blood count|Change in blood chemistry|Change in hepatic function|Change in microablbumin|Change in weight|Change in waist circumference,Hawaii Pacific Health,All,"18 Years and older   (Adult, Older Adult)",Phase 1,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018-119,May 2019,May 2021,May 2022,"May 13, 2019",,"May 13, 2019",,,https://ClinicalTrials.gov/show/NCT03947879
Study Chair,"Suhendro Suhendro, Doctor",Indonesia University,,NCT03815305,suhendro suhendro,suhendro,male,0.96,23,329,NCT03815305,Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2,,"Active, not recruiting",No Results Available,"Xerosis Cutis|Diabetes Mellitus, Type 2",Drug: Centella Asiatica Extract|Drug: Topical CA|Drug: Petroleum jelly,Change in Skin Capacitance|Change in SOD|Change in IL-1α|Change in AGEs CML|Change in SRRC,Indonesia University,All,"up to 60 Years   (Child, Adult)",Phase 4,159,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",441/UN2.F1/ETIK/2018/,"July 30, 2018","January 12, 2019","June 30, 2019","January 24, 2019",,"January 24, 2019","Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT03815305
Principal Investigator,"Mostafa O El Mokadem, M.D.","Cardiology department,Faculty of Medicine, Beni-Suef University",,NCT04143412,mostafa o el mokadem,mostafa,male,0.98,14950,330,NCT04143412,"Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination",,Recruiting,No Results Available,Diabetic Nephropathy Type 2|Microalbuminuria Due to Type 2 Diabetes Mellitus,Drug: Tritace (Ramipril 10 mg),Urinary albumin/creatinin ratio (UACR)|Blood pressure|estimated Glomerular Filtration Rate (e GFR)|Serum K,Beni-Suef University,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,RAAS blockers in albuminuria,"February 4, 2019",February 2020,March 2020,"October 29, 2019",,"January 18, 2020","Faculty of Medicine,Beni-Suef University, Banī Suwayf, Egypt",,https://ClinicalTrials.gov/show/NCT04143412
Principal Investigator,"Harry Prapavessis, PhD","University of Western Ontario, Canada",,NCT03815955,harry prapavessis,harry,male,0.98,24264,331,NCT03815955,Reducing Sedentary Behaviour in Patients With Type II Diabetes,,Completed,No Results Available,"Diabetes|Diabetes Mellitus, Type 2|Sedentary Lifestyle",Behavioral: Non-Sedentary Behaviour Modelling,Frequency of Non-Sedentary Behaviour Breaks|Non-Sedentary Behaviour Break Time|Capillary Blood Glucose|Self-efficacy|Goal Intentions|Positive and Negative Affect,"Western University, Canada|St. Joseph's Health Care London",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,112907,"March 14, 2019","April 25, 2019","April 25, 2019","January 25, 2019",,"October 1, 2019","University of Western Ontario, London, Ontario, Canada|St. Joseph's Family Medical and Dental Centre, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03815955
Study Director,Laura Wilkes,Banner University Medical Center,,NCT03946631,laura wilkes,laura,female,0.98,288403,511,NCT03946631,GDM Post Partum Screening,,Recruiting,No Results Available,"Diabetes|Gestational Diabetes|Diabetes Mellitus, Type 2",Diagnostic Test: 2 hour glucose tolerance test using 75g glucose drink,Sensitivity of early postpartum overt diabetes screening by 2-hour glucose tolerance testing in postpartum women.,"Mednax Center for Research, Education, Quality and Safety|Banner University Medical Center",Female,18 Years to 60 Years   (Adult),Not Applicable,150,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,GDM 2019 iris 01-18-0028,"August 20, 2019","June 1, 2021","September 1, 2021","May 10, 2019",,"August 22, 2019","Banner - University Medical Center Phoenix, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03946631
Principal Investigator,"Kisti Fuller, MD","Phoenix Perinatal Associates, Mednax",,NCT03946631,kisti fuller,kisti,female,0.6,10,511,NCT03946631,GDM Post Partum Screening,,Recruiting,No Results Available,"Diabetes|Gestational Diabetes|Diabetes Mellitus, Type 2",Diagnostic Test: 2 hour glucose tolerance test using 75g glucose drink,Sensitivity of early postpartum overt diabetes screening by 2-hour glucose tolerance testing in postpartum women.,"Mednax Center for Research, Education, Quality and Safety|Banner University Medical Center",Female,18 Years to 60 Years   (Adult),Not Applicable,150,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,GDM 2019 iris 01-18-0028,"August 20, 2019","June 1, 2021","September 1, 2021","May 10, 2019",,"August 22, 2019","Banner - University Medical Center Phoenix, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03946631
Principal Investigator,"Gihane G Madkour, Ass Prof",Cairo University,,NCT03807596,gihane g madkour,gihane,female,0.97,60,337,NCT03807596,Hyaluronic Acid With Scaling & Root Planing In Chronic Periodontitis Patients With Diabetes Mellitus Type 2,,Completed,No Results Available,Chronic Periodontitis,Procedure: Periodontal treatment with Hyaluronic acid associated with SRP|Procedure: Scaling & root planning alone,Gain in clinical attachment level,Cairo University,All,38 Months to 56 Months   (Child),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15062011,"March 16, 2017","June 29, 2017","June 29, 2017","January 17, 2019",,"January 18, 2019","Faculty of Dentistry, Cairo University, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT03807596
Study Director,"Gihane Madkour, Prof",Cairo University,,NCT03908606,gihane madkour,gihane,female,0.97,60,371,NCT03908606,Serum Hs-CRP in Periodontitis Patients With or Without Diabetes,,Completed,No Results Available,"Periodontal Disease|Diabetes Mellitus, Type 2",Procedure: Scaling and root planing,clinical attachment level,Cairo University,All,"Child, Adult, Older Adult",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,1281976,"April 11, 2018","January 2, 2019","January 2, 2019","April 9, 2019",,"April 9, 2019","Cairo University, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT03908606
Principal Investigator,"Shannon Rose, PhD",Arkansas Children's Research Institute,,NCT03960333,shannon rose,shannon,female,0.78,5669,339,NCT03960333,Immunometabolism in Pediatric Obesity,IPO,Recruiting,No Results Available,Obesity|Type 2 Diabetes Mellitus|Insulin Resistance,,circulating CD4+T cells in Overweight/Obese vs Lean|circulating CD4+T cells in Type 2 Diabetic pre/post Metformin,Arkansas Children's Hospital Research Institute|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS)|University of Arkansas,All,5 Years to 17 Years   (Child),,110,Other|NIH,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,228816|P20GM109096,"April 25, 2019","February 28, 2021","February 28, 2021","May 23, 2019",,"May 23, 2019","Arkansas Children's Research Institute, Little Rock, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03960333/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03960333/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03960333
Principal Investigator,"Helle Terkildsen Maindal, MPH, PhD",Steno Diabetes Center Copenhagen,,NCT03997773,helle terkildsen maindal,helle,female,0.96,2707,340,NCT03997773,Face-it: Health Promotion for Women With Prior Gestational Diabetes,Face-it,Recruiting,No Results Available,Gestational Diabetes|Type 2 Diabetes Mellitus|Quality of Life,Behavioral: Face-it Intervention,"Change in Body Mass Index (BMI) in women with prior GDM|Change in glucose in women with prior GDM and their partner|Change in HbA1c in women with prior GDM and their partner|Change in insulin in women with prior GDM and their partner|Change in blood pressure in women with prior GDM and their partner|Change in waist- and hip circumference in women with prior GDM and their partner|Change in body fat% in women with prior GDM and their partner|Change in Body Mass Index (BMI) in partners|Change in plasma lipids/triglycerides, total cholesterol, HDL, LDL|Change in quality of life in women with prior GDM and their partner|Change in well-being in women with prior GDM and their partner|Change in self-perceived health in women with prior GDM and their partner|Change in stress in women with prior GDM and their partner|Change in dietary patterns in women with prior GDM and their partner|Change in physical activity patterns in women with prior GDM and their partner","Steno Diabetes Center Copenhagen|Steno Diabetes Center Odense|Steno Diabetes Center Aarhus|Rigshospitalet, Denmark|Odense University Hospital|Aarhus University Hospital|Aarhus Municipality|Odense Municipality|Copenhagen Municipality|Liva Healthcare A/S",All,"Child, Adult, Older Adult",Not Applicable,460,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,StenoDC,"May 21, 2019","January 30, 2023","January 30, 2023","June 25, 2019",,"June 28, 2019","Aarhus University Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark",,https://ClinicalTrials.gov/show/NCT03997773
Principal Investigator,"Melchor Alpizar, MD, PhD","Centro Especializado en Diabetes, Obesidad, Prevención y Enfermedades Cardiovasculares, S.C.",,NCT04053621,melchor alpizar,melchor,male,1.0,707,341,NCT04053621,Co-administration of Thiamine Pyrophosphate and Metformin in Type 2 Diabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Thiamine pyrophosphate|Other: Placebo|Drug: Metformin,hemoglobin A1c|fasting plasma glucose|Lipids profile|inflammation markers|Lifestyle measurement|heart rate variability|arterial elasticity,Laboratorios Manuell SA|Universidad Nacional Autonoma de Mexico,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,92,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2336732,August 2019,May 2020,June 2020,"August 12, 2019",,"August 12, 2019","Centro Especializado en Diabetes, Obesidad, Prevención y Enfermedades Cardiovasculares, S.C., Mexico City, Cdmx, Mexico",,https://ClinicalTrials.gov/show/NCT04053621
Principal Investigator,"Olayinka Shiyanbola, PhD","University of Wisconsin, Madison",,NCT04028076,olayinka shiyanbola,olayinka,male,0.77,1647,342,NCT04028076,Improving Diabetes Medication Adherence for African Americans in Madison and Milwaukee Through Peer Support,,Recruiting,No Results Available,Type2 Diabetes|Medication Adherence|Medication Nonadherence|Peer Support,"Behavioral: Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence",Change in Hemoglobin A1c|Beliefs about Medicines Questionnaire|Culturally adapted illness perception questionnaire|Self-Efficacy for Appropriate Medication Use Scale (SEAMS)|Newest Vital Sign|Adherence to Refills and Medications Scale for Diabetes (ARMS-D),"University of Wisconsin, Madison",All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2019-0721,"July 10, 2019","October 31, 2020","December 31, 2020","July 22, 2019",,"April 24, 2020","University of Wisconsin - Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT04028076
Study Director,"Hong Qi, MD",Peking University Third Hospital,,NCT03903965,hong qi,hong,male,0.65,3894,345,NCT03903965,Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.,,Recruiting,No Results Available,Diabetes Mellitus Type 2|Age Related Cataracts,,OCT Angiography parameters|aqueous humor cytokines levels,Peking University Third Hospital,All,"50 Years to 80 Years   (Adult, Older Adult)",,120,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2019032501,"September 1, 2018","December 1, 2019","December 1, 2019","April 4, 2019",,"December 3, 2019","Peking University Third Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03903965
Principal Investigator,"Robert Rosenson, MD",Icahn School of Medicine at Mount Sinai,,NCT03829046,robert rosenson,robert,male,0.99,177418,347,NCT03829046,The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease,,Recruiting,No Results Available,Atherosclerotic Vascular Disease|Type2 Diabetes|Microvascular Dysfunction,Drug: Placebo|Drug: Evolocumab,Number of Adverse Events|Seattle Angina Questionnaire|MDA Level|MPO Level|IL-6 Level|IL-18 Level|TNF-α Level|PECAM Level|ICAM Level|VCAM Level|Alpha5/Beta3 Activation Levels,Robert Rosenson|Amgen|University of Toronto|University of Michigan|Icahn School of Medicine at Mount Sinai,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",GCO 18-1412|20167719,"June 3, 2019",October 2020,October 2020,"February 4, 2019",,"October 8, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States|St. Michael's - University of Toronto, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03829046
Principal Investigator,"Kim A Connelly, MD",St. Michael's Hospital at University of Toronto,,NCT03829046,kim a connelly,kim,female,0.56,51609,347,NCT03829046,The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease,,Recruiting,No Results Available,Atherosclerotic Vascular Disease|Type2 Diabetes|Microvascular Dysfunction,Drug: Placebo|Drug: Evolocumab,Number of Adverse Events|Seattle Angina Questionnaire|MDA Level|MPO Level|IL-6 Level|IL-18 Level|TNF-α Level|PECAM Level|ICAM Level|VCAM Level|Alpha5/Beta3 Activation Levels,Robert Rosenson|Amgen|University of Toronto|University of Michigan|Icahn School of Medicine at Mount Sinai,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",GCO 18-1412|20167719,"June 3, 2019",October 2020,October 2020,"February 4, 2019",,"October 8, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States|St. Michael's - University of Toronto, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03829046
Principal Investigator,"Joshua J Joseph, MD",The Ohio State University Wexner Medical Center,,NCT04152811,joshua j joseph,joshua,male,0.99,20919,348,NCT04152811,Cooking Matters for Diabetes - A 6-Week Program for Practical Application of Diabetes Self-Management Education,,"Active, not recruiting",No Results Available,Diabetes Mellitus|Type 1 Diabetes|Type 2 Diabetes,Behavioral: Cooking Matters for Diabetes|Other: Usual Diabetes Care,Change in Hemoglobin A1c over 4.5 months|Change in Health Related Quality of Life over 4.5 months using SF-12 Survey,Ohio State University|Academy of Nutrition and Dietetics,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,2019H0095,"July 5, 2019","July 1, 2021","July 1, 2021","November 5, 2019",,"January 27, 2020","The Ohio State University Wexner Medical Center - Outpatient Care East, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04152811
Principal Investigator,"Mariana G Figueiro, PhD",Rensselaer Polytechnic Institute,,NCT03933696,mariana g figueiro,mariana,female,0.98,28214,351,NCT03933696,"Light, Metabolic Syndrome and Alzheimer's Disease",,Recruiting,No Results Available,Mild Cognitive Impairment|Alzheimer Disease|Type2 Diabetes,Device: Tailored Lighting Intervention,Sleep disturbance|Metabolic control|Depression|Cognition|Sleep disturbance using actigraphy|Light measurements|Melatonin Levels,Rensselaer Polytechnic Institute|Icahn School of Medicine at Mount Sinai,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",Aim 2,"April 1, 2019","September 1, 2022","September 1, 2022","May 1, 2019",,"May 13, 2019","Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03933696
Principal Investigator,"Markus Schlaich, MD,FAHA,FESC",Royal Perth Hospital,,NCT03912909,markus schlaich,markus,male,1.0,47703,354,NCT03912909,Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans,EMPA-SNS,Recruiting,No Results Available,Metabolic Syndrome|Type 2 Diabetes Mellitus|Obesity,Drug: Empagliflozin Oral Tablet [Jardiance]|Drug: Placebo Oral Tablet,Reduction in cardiac sympathetic nerve activity|Reduction in renal sympathetic nerve activity|Reduction in muscle sympathetic nerve activity|Reduction in ambulatory BP (blood pressure)|Reduction in central Blood Pressure|Change in urinary sodium excretion|Change in glycemic control,Royal Perth Hospital,All,"25 Years to 65 Years   (Adult, Older Adult)",Phase 4,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",REG 16-157,"August 1, 2018","March 31, 2022","December 30, 2022","April 11, 2019",,"June 11, 2020","Royal Perth Hospital, Perth, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT03912909
Principal Investigator,"Sunit Jariwala, MD",Albert Einstein College of Medicine and Montefiore Medical Center,,NCT03890900,sunit jariwala,sunit,male,0.88,94,362,NCT03890900,T2DXcel Mobile Application,T2DXcel,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: T2DXcel mobile application,Change from baseline hemoglobin A1c to 3 and 6 months|Patient satisfaction measured by the Client Satisfaction Questionnaire-8|Change from baseline diabetes knowledge to 3 months and 6 months|Change from baseline diabetes self-management capabilities to 3 months and 6 months|Change from baseline diabetes self-efficacy to 3 months and 6 months|Change from baseline diabetes quality of life to 3 months and 6 months|Change from baseline LDL cholesterol to 3 months and 6 months,Montefiore Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2018-9590,"March 1, 2020","June 30, 2020","June 30, 2020","March 26, 2019",,"May 4, 2020","Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT03890900
Principal Investigator,"Thomas E Dorner, MD, MPH",Medical University of Vienna,,NCT04125784,thomas e dorner,thomas,male,0.99,176440,468,NCT04125784,Lipid Profile and Diabetes Mellitus in People With HIV,,Not yet recruiting,No Results Available,HIV Infections|Dyslipidemias|Diabetes Mellitus|Cardiovascular Risk Factor,,Changes in dyslipidemia prevalence from baseline - total cholesterol|Changes in dyslipidemia prevalence from baseline- triglycerides|Changes in dyslipidemia prevalence from baseline - HDL-cholesterol|Changes in dyslipidemia prevalence from baseline - Apolipoprotein B|Changes in dyslipidemia prevalence from baseline - LDL-cholesterol|Changes in dyslipidemia prevalence from baseline - Non-HDL-Cholesterol|Changes from baseline in diabetes mellitus type II prevalence|Description of risk profile for cardiovascular events in the sample population|Changes from baseline in drug utilization for PLWHIV|Prevalence of diabetes mellitus type 2 in correlation to the prescribed antiretroviral regime during the follow up time|Changes from baseline in the lipid profile of patients in correlation to prescribed antiretroviral regime|Changes from baseline in therapy prescriptions of patients who were found to have hyperlipidaemia during first study in 2014|Documentation of any major cardiovascular events (stroke or heart attack)|Incidence of diabetes mellitus type 2 in patients who were diagnosed found to be insulin resistant in the first study in 2014|Changes from baseline in therapeutic regimes within those patients who were identified as having diabetes mellitus type 2 in the first study in 2014,"Igor Grabovac|Merck Gesellschaft mbH, Austria|Medical University of Vienna",All,"18 Years and older   (Adult, Older Adult)",,450,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,V2_02082019,"September 7, 2020","September 30, 2021","January 30, 2022","October 14, 2019",,"June 2, 2020",,,https://ClinicalTrials.gov/show/NCT04125784
Study Chair,"Ignatios Ikonomidis, AssProfessor",University of Athens,,NCT04027712,ignatios ikonomidis,ignatios,male,0.98,62,383,NCT04027712,"Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD",,"Active, not recruiting",No Results Available,Diabetes|Clopidogrel Resistance|Amyloid|Insulin Resistance,,mots-c predicts cardiovascular mortality in diabetic with coronary artery disease|b amyloid predicts cardiovascular mortality in diabetic with coronary artery disease|b amyloid predicts cardiovascular mortality in diabetic with coronary artery,University of Athens,All,"18 Years and older   (Adult, Older Adult)",,120,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,LTA_MOTS-c_bamyloid_DM_CAD,"January 1, 2014","December 31, 2019","December 31, 2021","July 22, 2019",,"July 23, 2019","General & University Hospital ""Attikon"", Chaidari, Attiki, Greece",,https://ClinicalTrials.gov/show/NCT04027712
Principal Investigator,"Alexandra Kautzky-Willer, Univ.Prof.Dr.","Department of Internal Medicine III, Clinical Division of Endocrinology and Metabolism, Unit of Gender Medicine, Medical University of Vienna",,NCT04011228,alexandra kautzky-willer,alexandra,female,0.98,122985,373,NCT04011228,Epigenetics Based Diagnosis of Diabetes in Saliva and Blood Samples,,Recruiting,No Results Available,"Prediabetic State|Diabetes Mellitus, Type 2|Ectopic Lipids|Epigenetics Based Modifications",Diagnostic Test: Blood sampling|Diagnostic Test: Saliva and blood samples|Diagnostic Test: Magnet Resonance Spectroscopy,Specifying the microRNAs in saliva in diabetic patients|Correlation of the percentage of liver fat with miRNA´s in diabetic patients.|Correlation of the percentage of heart fat with miRNA´s in diabetic patients|Correlation of the percentage of the content of fat in the skeletal muscle with miRNA´s in diabetic patients.,Medical University of Vienna,All,"18 Years to 75 Years   (Adult, Older Adult)",,224,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EPI-1090,"February 29, 2016","December 11, 2019","January 1, 2020","July 8, 2019",,"September 3, 2019","Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT04011228
Principal Investigator,"Alexandra Kautzky-Willer, MD",Medical University Vienna,,NCT03851627,alexandra kautzky-willer,alexandra,female,0.98,122985,403,NCT03851627,Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese Men With T2DM and Hypogonadism,Test2Func,Not yet recruiting,No Results Available,"Fatty Liver|Obesity|Type2 Diabetes Mellitus|Hypogonadism, Male",Drug: Testosterone Undecanoate|Drug: Placebo,"Liver fat|body weight|waist, hip and neck circumference|insulin sensitivity|Level of HbA1c|Concentration of lipids|quality of live questionnaire|blood pressure|sexual function questionnaire|diabetes management satisfaction questionnaire",Alexandra Kautzky-Willer|Bayer|Medical University of Vienna,Male,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,32,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",T2F12017|2017-001611-37,April 2020,April 2023,December 2023,"February 22, 2019",,"February 28, 2020","Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III, Wien, Austria",,https://ClinicalTrials.gov/show/NCT03851627
Principal Investigator,"Alexandra Stamperna, MD","UNIVERSITY OF THESSALY, SCHOOL OF PHYSICAL EDUCATION & SPORTS SCIENCES",,NCT03889977,alexandra stamperna,alexandra,female,0.98,122985,408,NCT03889977,Resistance Exercise on Postprandial Hyperglycemia in Patients With B-thalassemia Exhibiting Resistance to Insulin,,Completed,No Results Available,"Beta-Thalassemia|Insulin Resistance|PreDiabetes|Diabetes Mellitus, Type 2",Other: Resistance exercise,Changes in blood glucose|Changes in blood insulin|Changes in blood triglycerides|Body mass|Body height|Body fat|Resting heart rate|Heart rate during exercise|Changes in total antioxidant capacity|Changes in reduced glutathione (GSH)|Changes in catalase|Changes in uric acid|Changes in protein carbonyls|Changes in substances that react with thiobarbituric acid (TBARS),University of Thessaly,All,30 Years to 55 Years   (Adult),Not Applicable,6,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B-Thalassemia ResEx Glucose,"February 11, 2019","August 30, 2019","October 30, 2019","March 26, 2019",,"January 18, 2020","Exercise Biochemistry Laboratory, School of Physical Education & Sports Sciences, University of Thessaly, Tríkala, Greece",,https://ClinicalTrials.gov/show/NCT03889977
Study Chair,Shu-Ming Chen,Fooyin University,,NCT03950713,shu-ming chen,shu-ming,male,1.0,1,375,NCT03950713,Mindfulness Program for Older-Diabetes,,Completed,No Results Available,Mental Health Wellness 1,Behavioral: Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T),HbA1c values|Relocation Stress Scale|Depression and Anxiety Stress Scale (DASS-21),Fooyin University,All,65 Years to 85 Years   (Older Adult),Not Applicable,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FYH-IRB-1040602,"January 1, 2017","July 31, 2017","July 31, 2017","May 15, 2019",,"May 15, 2019","Fooyin University, Kaohsiung City, Taiwan",,https://ClinicalTrials.gov/show/NCT03950713
Principal Investigator,"Mauro M Maccario, MD","Endocrinology, Diabetology and Metabolism; University of Turin",,NCT03917758,mauro m maccario,mauro,male,0.99,48289,377,NCT03917758,Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors,GliRACo1,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Arterial Hypertension|Body Weight Changes",Drug: SGLT2 inhibitor,Changes from baseline of antidiuretic function parameters (BNP)|Changes from baseline of antidiuretic function parameters (vasopressin)|Changes from baseline of antidiuretic function parameters (osmolality)|Changes from baseline of antidiuretic function parameters (sodium balance)|Changes from baseline of antidiuretic function parameters (potassium balance)|Changes from baseline of renin-angiotensin-aldosterone system parameters (renin)|Long term changes from baseline of renin-angiotensin-aldosterone system parameters aldosterone)|Long term changes from baseline of renin-angiotensin-aldosterone system parameters|Changes from baseline of blood pressure values (ABPM)|Changes from baseline of body composition|Changes in basal glicemic control|Changes in long term glicemic control,"University of Turin, Italy",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,GliRACo 1,"October 10, 2018","July 30, 2020","October 30, 2020","April 17, 2019",,"January 2, 2020","Mauro Maccario, Torino, Piemonte, Italy",,https://ClinicalTrials.gov/show/NCT03917758
Study Chair,"Ezio E Ghigo, MD","Endocrinology, Diabetology and Metabolism; University of Turin",,NCT03917758,ezio e ghigo,ezio,male,0.99,4048,377,NCT03917758,Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors,GliRACo1,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Arterial Hypertension|Body Weight Changes",Drug: SGLT2 inhibitor,Changes from baseline of antidiuretic function parameters (BNP)|Changes from baseline of antidiuretic function parameters (vasopressin)|Changes from baseline of antidiuretic function parameters (osmolality)|Changes from baseline of antidiuretic function parameters (sodium balance)|Changes from baseline of antidiuretic function parameters (potassium balance)|Changes from baseline of renin-angiotensin-aldosterone system parameters (renin)|Long term changes from baseline of renin-angiotensin-aldosterone system parameters aldosterone)|Long term changes from baseline of renin-angiotensin-aldosterone system parameters|Changes from baseline of blood pressure values (ABPM)|Changes from baseline of body composition|Changes in basal glicemic control|Changes in long term glicemic control,"University of Turin, Italy",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,GliRACo 1,"October 10, 2018","July 30, 2020","October 30, 2020","April 17, 2019",,"January 2, 2020","Mauro Maccario, Torino, Piemonte, Italy",,https://ClinicalTrials.gov/show/NCT03917758
Principal Investigator,"Soo N Lim, MD, PHD",Seoul National University Bundang Hospital,,NCT03877406,soo n lim,soo,female,0.58,2690,379,NCT03877406,Effect of Empagliflozin on Body Composition and Ketones,,Recruiting,No Results Available,"Diabetes Mellitus|Fat; Intolerance, Pancreas",Drug: Empagliflozin 10 MG|Drug: Hypoglycemics Oral,HbA1c|Biochemical parameters|Body weight|Body fat|Systolic and diastolic blood pressures|Lipid profile|Insulin resistance,Seoul National University Bundang Hospital,All,"20 Years and older   (Adult, Older Adult)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,B-1507/307-007,"August 1, 2018","December 31, 2020","December 31, 2021","March 15, 2019",,"April 8, 2020","Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03877406
Principal Investigator,"Gregory A Talavera, MD/MPH",SDSU,,NCT03983499,gregory a talavera,gregory,male,0.99,25701,382,NCT03983499,Latinos Understanding the Need for Adherence in Diabetes,LUNA-D,Completed,No Results Available,Type 2 Diabetes|Glycemic Control|Cardiovascular Risk Factors|Psychological Distress,Behavioral: Special Intervention,HbA1c Blood Value|Body Mass Index (BMI)|Total Cholesterol|Blood Pressure (BP)|Patient Health Questionnaire (PHQ-8)|Generalized Anxiety Disorder 7-item (GAD-7),San Diego State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,456,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NR014866,"July 16, 2015","December 18, 2018","December 31, 2018","June 12, 2019",,"June 12, 2019","South Bay Latino Research Center, Chula Vista, California, United States",,https://ClinicalTrials.gov/show/NCT03983499
Principal Investigator,"Gregory Tracey, MD","Frontage Clinical Services, Inc.",,NCT03790839,gregory tracey,gregory,male,0.99,25701,388,NCT03790839,Drug Interaction Study Between Dorzagliatin and Sitagliptin,,Completed,No Results Available,Patients,Drug: Sitagliptin|Drug: Dorzagliatin,"Cmax,ss|AUCτ,ss",Hua Medicine Limited,All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,15,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMM0111,"January 31, 2019","August 30, 2019","August 30, 2019","January 2, 2019",,"September 24, 2019","Frontage Clinical Services Inc., Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT03790839
Principal Investigator,"Gregory J Tracey, MD","Frontage Clinical Services, Inc.",,NCT03790787,gregory j tracey,gregory,male,0.99,25701,389,NCT03790787,Drug Interaction Study Between Dorzagliatin and Empagliflozin,,Completed,No Results Available,Patients,Drug: Empagliflozin|Drug: Dorzagliatin,"Cmax,ss|AUCτ,ss",Hua Medicine Limited,All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,16,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMM0112,"April 18, 2019","March 15, 2020","March 15, 2020","January 2, 2019",,"March 25, 2020","Frontage Clinical Services Inc., Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT03790787
Principal Investigator,"Gianluca Iacobellis, MD PhD",University of Miami,,NCT04200625,gianluca iacobellis,gianluca,male,0.99,41833,384,NCT04200625,Semaglutide vs Dulaglutide on Epicardial Adipose Tissue,,Completed,No Results Available,Epicardial Fat,,Epicardial Fat thickness,University of Miami,All,"18 Years and older   (Adult, Older Adult)",,80,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,20190944,"September 24, 2019","December 9, 2019","December 9, 2019","December 16, 2019",,"December 16, 2019","University of Miami, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT04200625
Study Director,"Salah Abdelazeem Argoon, professor",Assiut University,,NCT03891927,salah abdelazeem argoon,salah,male,0.97,18411,385,NCT03891927,"Extra Virgin Olive Oil on Glycemic Control ,Insulin Resistance and Insulin Secretion",,Not yet recruiting,No Results Available,Insulin Resistance,Dietary Supplement: extra virgin olive oil,"change of HBa1c (glycated hemoglobin) after intervention by extra virgin olive oil|change of fasting glucose after intervention by extra virgin olive oil|calculating of insulin resistance and insulin secretion after intervention by extra virgin olive oil|reduction of systolic and diastolic blood pressure after intervention by extra virgin olive oil .|reduction of body mass index .|changing in waist circumference .|change at Lipid profile (cholesterol, TG, LDL, HDL) after intervention .",Assiut University,All,30 Years to 60 Years   (Adult),Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,olive oil on glycemic control,"May 1, 2019","November 1, 2020","December 1, 2020","March 27, 2019",,"April 1, 2019",,,https://ClinicalTrials.gov/show/NCT03891927
Principal Investigator,"Sara Rosenkranz, PhD",Kansas State University,,NCT04118257,sara rosenkranz,sara,female,0.98,244324,386,NCT04118257,Short-term Sugary Beverage Consumption on Glucose Control and Cardiovascular Disease Risk Factors,,Completed,No Results Available,Metabolic Syndrome,Dietary Supplement: Sugary beverage: Fruit juice|Dietary Supplement: Sugary beverage: Soda|Dietary Supplement: Control: Water,Change in glucose iAUC|Change in plasma lipids|Change in homeostatic model assessment for insulin resistance|Change in blood pressure|Change in BMI|Change in pulmonary function|Change in insulin iAUC|Change in serum fructosamine,Kansas State University,All,18 Years to 30 Years   (Adult),Not Applicable,37,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,Pro8531,"February 10, 2017","November 14, 2018","November 14, 2018","October 8, 2019",,"October 8, 2019","Lafene Health Center, Manhattan, Kansas, United States",,https://ClinicalTrials.gov/show/NCT04118257
Principal Investigator,"Guillermo Umpierrez, MD",Emory University,,NCT03832907,guillermo umpierrez,guillermo,male,0.99,15173,387,NCT03832907,Dexcom G6 Observational Study,,Completed,No Results Available,Diabetes,Device: Dexcom G6 CGM - Continues Glucose Monitoring sensor system|Diagnostic Test: POC BG - Point-of-Care Blood Glucose monitoring,"Mean daily blood glucose by POC reading compared to CGM reading|Number of clinical significant hypoglycemia (<54 mg/dl) events by POC reading compared to CGM reading|Number of severe hyperglycemia (>240 mg/dl) events by POC reading compared to CGM reading|Number of clinical significant severe hyperglycemia (>240 mg/dl) events by POC reading compared to CGM reading|Number of nocturnal hypoglycemic events < 70 mg/dl and < 54 mg/dl (between 22:00 and 06:00) by POC reading compared to CGM reading|Number of of hypoglycemic events (< 70 and 54 mg/dl) in POC group by POC reading compared to CGM reading|Number of hypoglycemic events (< 70 and 54 mg/dl) by POC reading compared to CGM reading|Time in hypoglycemia (minutes) during the day and night by POC reading compared to CGM reading|Time in hyperglycemia (minutes) during the day and night> 240 mg/dl by POC reading compared to CGM reading|Number of hyperglycemic events > 240 mg/dl by POC reading compared to CGM reading|Percentage of BG readings within target BG of 70 and 180 mg/dl by POC reading compared to CGM reading|Percentage of patients with greater than 5%-time below glucose target (<70 and 54 mg/dl) by POC reading compared to CGM reading|Percentage of patients with greater than 5%-time above glucose target (>180 and 240 mg/dl) by POC reading compared to CGM reading|Glycemic variability calculated by Standard Deviation and MAGE by POC reading compared to CGM reading|Glycemic variability calculated by Standard Deviation, and MAGE by POC reading compared to CGM reading|Number of sensor removal/failures/dislodgments by POC reading compared to CGM reading|Mean absolute relative difference (MARD) by POC reading compared to CGM reading|Number of Dexcom G6 CGM sensor values within 30/30%, 20/20%, 15/15% for values < 70 mg/dl, 70-140 mg/dl, >140-180 mg/dl and > 180 mg/dl), compared to the standard-of-care POC BG|Differences in accuracy between G6 CGM in the abdomen and upper arm insertion sites|Percentage of values within Zone A, B, C of the Clarke Error Grid",Emory University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,101,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IRB00107627,"February 21, 2019","March 31, 2020","March 31, 2020","February 6, 2019",,"May 18, 2020","Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03832907
Principal Investigator,"Kate Millar, MBChB",Portsmouth Hospitals NHS Trust,,NCT04033705,kate millar,kate,female,0.98,38791,390,NCT04033705,DRIVE - Perioperative Period,DRIVE-Periop,Recruiting,No Results Available,"Diabetes Mellitus|Surgical Procedure, Unspecified",Device: Freestyle Libre Pro glucose sensor,"The time spent within, above and below the target glucose range (4-10mmol/L) in the preoperative period|The time spent within, above and below the target glucose range (4-10mmol/L) in the post operative period|Length of hospital stay|Post operative infections",Portsmouth Hospitals NHS Trust,All,"18 Years and older   (Adult, Older Adult)",,30,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PHT/2019/23,"June 11, 2019","August 1, 2020","August 1, 2020","July 26, 2019",,"July 26, 2019","Portsmouth Hospitals NHS Trust, Portsmouth, Hampshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT04033705
Principal Investigator,"Lucio Gnessi, MD PhD",Sapienza University of Rome,,NCT04019431,lucio gnessi,lucio,male,0.99,11226,393,NCT04019431,Effect of a Very Low-Calorie Ketogenic Diet on Gut Microbiota and Fat Distribution,,Recruiting,No Results Available,Obesity,"Dietary Supplement: Whey protein, vegetable protein or animal protein",Body Mass Index change from baseline|Fat mass percentage (%) change from baseline|Visceral adipose tissue (gr) change from baseline|Microbiome taxonomic composition change from baseline|Fasting glucose level (mg/dL) change from baseline|Fasting Insulin level (mcU/mL) change from baseline|Fasting Cholesterol level (mg/dL) change from baseline|Muscle strength (kg) change from baseline|Quality of life (subjective unit) change from baseline|Safety (subjective unit) change from baseline,University of Roma La Sapienza,All,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1236-5158,July 2019,October 2019,November 2019,"July 15, 2019",,"July 15, 2019","Sapienza University of Rome, Roma, RM, Italy",,https://ClinicalTrials.gov/show/NCT04019431
Study Director,Suelen Dallanora,Instituto de Cardiologia,,NCT03904901,suelen dallanora,suelen,female,0.98,299,396,NCT03904901,Influence of Probiotics in Diabetic Cardiopathies With Excessive Weight,,Recruiting,No Results Available,Diabetes Mellitus Type 2 in Obese|Anxiety|Cardiopathy,Dietary Supplement: Probiotics|Dietary Supplement: Placebo,Control of DM2|Anxety|Alteration of serum lipids|Weight|Height|BMI,Instituto de Cardiologia do Rio Grande do Sul,All,20 Years to 60 Years   (Adult),Not Applicable,4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SDallanora,"July 20, 2018",May 2019,June 2019,"April 5, 2019",,"April 5, 2019","Suelen Dallanora, Porto Alegre, RS, Brazil",,https://ClinicalTrials.gov/show/NCT03904901
Principal Investigator,"Carl Hulston, PhD",Loughborough University,,NCT03863431,carl hulston,carl,male,0.98,17561,398,NCT03863431,The Influence of Overfeeding Different Macronutrients on Whole-body Insulin Sensitivity,,Recruiting,No Results Available,Insulin Resistance|Type 2 Diabetes|Glucose Metabolism Disorders|Metabolic Disease,Other: High-fat diet|Other: High-carbohydrate diet,Whole-body insulin sensitivity index|Body Mass Index|Fasting plasma glucose concentration|Fasting serum insulin concentration|Fasting plasma lipid profile (for example total and HDL cholesterol and TAG concentrations; all measured in mmol/L)|Indirect calorimetry|Subjective appetite ratings,Loughborough University,All,18 Years to 40 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,R18-P222,"May 22, 2019",September 2020,September 2020,"March 5, 2019",,"September 4, 2019","School of Sport, Exercise and Health Sciences, Loughborough, Leicestershire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03863431
Principal Investigator,"Tracey McLaughlin, MD",Stanford University,,NCT04167761,tracey mclaughlin,tracey,female,0.96,7299,399,NCT04167761,Ertugliflozin: Cardioprotective Effects on Epicardial Fat,,Not yet recruiting,No Results Available,Cardiovascular Diseases|Atherosclerosis|Type 2 Diabetes|Insulin Resistance,Drug: Ertugliflozin|Drug: Glipizide,Rate of isoproterenol-stimulated lipolysis to measure metabolic flexibility in epicardial adipose tissue samples.|Average insulin mediated glucose uptake (IMGU) to measure insulin sensitivity in epicardial adipose tissue samples.|Characterization of the inflammatory cytokine expression profile in epicardial adipose tissue samples.|Distribution of adipose cell size in epicardial tissue.,Stanford University|Merck Sharp & Dohme Corp.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,36,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,52647,"December 1, 2019","July 31, 2022","July 31, 2022","November 19, 2019",,"November 19, 2019","Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04167761
Principal Investigator,"Andrei C Sposito, MD,Phd","University of Campinas, Brazil",,NCT03932721,andrei c sposito,andrei,male,0.97,21506,400,NCT03932721,EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial,EXCEED-BHS3,Recruiting,No Results Available,"Dyslipidemia Associated With Type II Diabetes Mellitus|Diabetes Mellitus, Type 2|Hypertension Arterial",Drug: Evolocumab 140 MG/ML,Difference in the percentage change in flow mediated dilation (FMD)|Difference in the percentage change in FMD reserve,"University of Campinas, Brazil",All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 4,110,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,Exceed,"October 1, 2018","June 30, 2020","October 30, 2020","May 1, 2019",,"May 10, 2019","Centro de Pesquisa Clinica - FCM/Unicamp, Campinas, SP, Brazil",,https://ClinicalTrials.gov/show/NCT03932721
Principal Investigator,"Mattias Ekstedt, MD, PhD",LiU,,NCT03864510,mattias ekstedt,mattias,male,0.99,5560,404,NCT03864510,NAFLD in Diabetes Type 2 in Primary Care,EPSONIP,Recruiting,No Results Available,NAFLD,,Prevalence of fatty liver|Prevalence of advanced liver disease|The association between physical activity and advanced liver disease (fibrosis >2)|The association between fitness and advanced liver disease (fibrosis >2)|Genetic factors associated with advanced liver disease (fibrosis >2)|Health economic model for disease management|Number of patients that develop symptoms of end-stage liver disease,Linkoeping University,All,"35 Years to 75 Years   (Adult, Older Adult)",,400,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2018:176-31,"April 1, 2019",December 2020,December 2023,"March 6, 2019",,"August 14, 2019","Ekholmen primary health care centre, Linköping, Swedish, Sweden|Åby primary health care centre, Norrköping, Sweden",,https://ClinicalTrials.gov/show/NCT03864510
Principal Investigator,"Julia C Greve, Professor",University of São Paulo,,NCT03792646,julia c greve,julia,female,0.97,106666,407,NCT03792646,"Protein Supplementation: Body Composition, Muscle Strength and Postural Balance",,Unknown status,No Results Available,"Diabetes Mellitus, Type 2|Protein Supplementation|Body Composition|Inflammation Biomarkers|Resistance Training",Dietary Supplement: Whey protein|Other: Exercise training,Muscular strength (hand grip) change from baseline|Muscular strength (peak of torque) change from baseline|Muscular strength (total work) change from baseline|Postural Balance (weight transfer) change from baseline|Postural Balance (sway velocity) change from baseline|Inflammatory biomarkers - plasma concentration change from baseline (Interleukin 6)|Portable Bioelectrical Impedance change from baseline|Inflammatory biomarkers - plasma concentration change from baseline (Tumor necrosis factor-alpha),University of Sao Paulo General Hospital,Male,65 Years to 79 Years   (Older Adult),Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Diabéticos,"May 1, 2018","March 1, 2020","March 1, 2020","January 3, 2019",,"January 3, 2019","Julia Maria DÀndrea Greve, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03792646
Study Director,"Onno CP van Schayck, Prof.",Maastricht University,,NCT04127383,onno cp van schayck,onno,male,0.97,462,409,NCT04127383,Effectiveness and Implementation of the Assessment of Burden of Chronic Conditions (ABCC)-Tool,,Recruiting,No Results Available,"Chronic Obstructive Pulmonary Disease|Asthma|Diabetes Mellitus, Type 2|Heart Failure",Device: Assessment of Burden of Chronic Conditions (ABCC)-tool,Perceived quality of care (PACIC): Patient Assessment of Chronic Illness Care|Quality of life (EQ-5D-5L)|Capability well-being (ICECAP-A)|Patients' activation (PAM)|Medical Consumption within Health Care|Productivity losses,Maastricht University|Netherlands Instititute for Health Services Research|TNO|University of Twente,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,10-10400-98-001,"November 1, 2019","October 1, 2021","October 1, 2021","October 15, 2019",,"February 20, 2020","Maastricht University, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT04127383
Principal Investigator,"Ayeesha Kamal, MD",Aga Khan University,,NCT04082091,ayeesha kamal,ayeesha,female,0.94,63,410,NCT04082091,"Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention",SELECT,Not yet recruiting,No Results Available,"Cardiovascular Diseases|Cerebral Infarction|Type2 Diabetes Mellitus|Hypertension,Essential|Prevention",Behavioral: SELECT mHealth Program,Health Service Delivery of Intervention Outreach via Short Text Messages|Health Service Delivery of Intervention Outreach via Interactive Voice Recording|Health Service Measures of Intervention Uptake|Community Participation and Uptake of Intervention|Early Impact Measure of Intervention for Prompt Referral|Early Impact Measure of Intervention for Detection|Change in Physiological Characteristics of Intervention Participants - Blood Pressure|Change in Physiological Characteristics of Intervention Participants - Weight|Change in Physiologic Characteristics of Intervention Participants- Height|Change in Physiological Characteristics of Intervention Participants - BMI|Change in Physiological Characteristics of Intervention Participants - Physical Activity,Aga Khan University|The George Institute,All,"18 Years to 90 Years   (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,2019-0599-2619,September 2019,September 2020,September 2020,"September 9, 2019",,"September 9, 2019",,,https://ClinicalTrials.gov/show/NCT04082091
Study Director,"Kai Zhang, MD","Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.",,NCT04187443,kai zhang,kai,male,0.93,17357,411,NCT04187443,MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema,,Not yet recruiting,No Results Available,Diabetic Macular Edema|Macular Edema|Type 2 Diabetes With Diabetic Macular Edema|Type 1 Diabetes With Diabetic Macular Edema|Diabetic Retinopathy,Drug: MS-553,Treatment-emergent adverse events|Mean change in the central retina subfield thickness (CRT)|Mean change in the retinal volume|Proportion of patients with >20% reduction in CRT|Proportion of patients with resolution of central involved macular edema|Average mean change in best corrected visual acuity,"Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.|Fountain Medical Development Co., Ltd.|MingSight Pharmaceuticals Pty Limited",All,"18 Years and older   (Adult, Older Adult)",Phase 1,45,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019-001-CN,"March 4, 2020","August 18, 2021","October 18, 2021","December 5, 2019",,"December 24, 2019","Shanghai General Hospital, Shanghai, China",,https://ClinicalTrials.gov/show/NCT04187443
Principal Investigator,"Marc Y Donath, Prof.","University Hospital, Basel, Switzerland",,NCT03827382,marc y donath,marc,male,0.99,116213,412,NCT03827382,Bicycle Exercise and Lifestyle Intervention in Newly Diagnosed Diabetes,BELIFE,Recruiting,No Results Available,Life Style,Behavioral: Lifestyle Intervention,metabolic control|Absolute HbA1c reduction per stratification group|Proportion of patients achieving HbA1c target in each stratification group|Feasibility of bicycle exercise at study enrollment in the ER|Changes in heart rate after bicycle intervention|Changes in respiratory rate after bicycle intervention|Changes in blood pressure after bicycle intervention|Changes in blood glucose after bicycle intervention|Changes in pH after bicycle intervention|Changes in base excess after bicycle intervention|Changes in bicarbonate after bicycle intervention|Incidence of exercise related Adverse Events (Safety) during bicycle exercise in the ER|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Re-hospitalization rate|Re-consultation rate|Changes in HbA1c at 6 months|Changes in physical activity at 6 months|Number of antidiabetic medication at 30 days|Number of antidiabetic medication 60 days|Number of antidiabetic medication at 90 days|Dosage of antidiabetic medication at 30|Dosage of antidiabetic medication at 60 days|Dosage of antidiabetic medication at 90 days|Quality of life by SF-36 Questionnaire,"University Hospital, Basel, Switzerland|Kantonsspital Olten|Kantonsspital Aarau|Luzerner Kantonsspital",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018-01920,"February 1, 2019",June 2021,December 2021,"February 1, 2019",,"May 27, 2020","Cantonal Hospital Aarau, Aarau, Aargau, Switzerland|University Hospital Basel, Basel, Basel-Stadt, Switzerland|Cantonal Hospital Olten, Olten, Solothurn, Switzerland|Cantonal Hospital Lucerne, Lucerne, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03827382/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03827382
Principal Investigator,Sofa D Alfian,University of Groningen,,NCT04023734,sofa d alfian,sofa,female,0.94,1553,413,NCT04023734,A Targeted and Tailored Pharmacist Intervention to Improve Adherence to Antihypertensive Drugs Among Diabetes Patients,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Hypertension|Medication Nonadherence","Behavioral: Reminders, habit-based strategies and/or involvement of family member|Behavioral: Counselling to increase knowledge|Behavioral: Counselling to increase motivation|Behavioral: Explore/address other drug related problems|Behavioral: Usual care based on the Indonesian guideline",Medication adherence|Blood pressure level|Medication beliefs|Reach|Pharmacists' adoption of the intervention|Patients' adoption of the intervention|Pharmacists' suggestions for future implementation|Patients' suggestions for future implementation|Pharmacists' willingness to maintain the intervention|Patients' willingness to maintain the intervention,University of Groningen|Universitas Padjadjaran,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,113,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,PharIndo2019,"August 16, 2019","December 30, 2019","January 30, 2020","July 17, 2019",,"March 24, 2020","Community Health Centers, Bandung, West Java, Indonesia",,https://ClinicalTrials.gov/show/NCT04023734
Study Chair,Theodoros N. Arvanitis,University of Warwick,,NCT03834207,theodoros n. arvanitis,theodoros,male,0.99,886,418,NCT03834207,A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy,C3-Cloud,Recruiting,No Results Available,Diabetes Type 2|Renal Failure|Heart Failure|Depression|Chronic Disease|Aging,Device: Use of the C3-Cloud IT system,Acceptability & usefulness of the C3-Cloud system,"Dr Christopher Marguerie|University of Warwick|Kronikgune|Medixine|SRDC|Institut National de la Santé Et de la Recherche Médicale, France|Eurorec|Empirica|Örebro University, Sweden|Osakidetza|Region Jamtland Harjedalen|Cambio Healthcare|South Warwickshire NHS Foundation Trust",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,672,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,689181,"October 1, 2018","January 31, 2020","April 30, 2020","February 7, 2019",,"February 7, 2019","Osakidetza, Vitoria-Gasteiz, Araba, Spain|Region Jamtland Harjedalen, Ostersund, Sweden|South Warwickshire NHS Foundation Trust, Warwick, Warwickshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03834207
Principal Investigator,"Esben Stistrup Lauritzen, MD",Medical Research Laboratory,,NCT03859934,esben stistrup lauritzen,esben,male,0.99,219,419,NCT03859934,Metabolic Effects of Melatonin Treatment,,Recruiting,No Results Available,Metabolic Disease|Insulin Sensitivity|Glucose Metabolism Disorders (Including Diabetes Mellitus)|Type 2 Diabetes Mellitus|Blood Pressure|Inflammation,Drug: Melatonin|Drug: Placebo Oral Tablet,Change of insulin sensitivity|Change of insulin secretion change|MTNR1a rs10830963 influence on change in insulin sensitivity and insulin secretion|Change of insulin signalling|Change of ambulatory blood pressure|Change of arterial stiffness|Change of gut microbiome|Change of sleep evaluation 1|Change of sleep evaluation 2|Change of psychological health 1|Change of psychological health 2|Hormonal changes|Change of glucose and palmitate kinetics|Change of regional glucose and palmitate uptake|Change of DEXA-scans|Change of assessment of respiratory quotient (RQ)|Change of assessment of resting energy expenditure (REE),University of Aarhus|University of Copenhagen,Male,"40 Years to 70 Years   (Adult, Older Adult)",Phase 1,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2019-000213-37,"September 26, 2019","September 1, 2021","September 1, 2022","March 1, 2019",,"September 30, 2019","Medical Research Laboratory, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT03859934
Principal Investigator,"Ulla Kampmann Opstrup, MD, PhD",Aarhus University Hospital,,NCT03859934,ulla kampmann opstrup,ulla,female,0.96,3179,419,NCT03859934,Metabolic Effects of Melatonin Treatment,,Recruiting,No Results Available,Metabolic Disease|Insulin Sensitivity|Glucose Metabolism Disorders (Including Diabetes Mellitus)|Type 2 Diabetes Mellitus|Blood Pressure|Inflammation,Drug: Melatonin|Drug: Placebo Oral Tablet,Change of insulin sensitivity|Change of insulin secretion change|MTNR1a rs10830963 influence on change in insulin sensitivity and insulin secretion|Change of insulin signalling|Change of ambulatory blood pressure|Change of arterial stiffness|Change of gut microbiome|Change of sleep evaluation 1|Change of sleep evaluation 2|Change of psychological health 1|Change of psychological health 2|Hormonal changes|Change of glucose and palmitate kinetics|Change of regional glucose and palmitate uptake|Change of DEXA-scans|Change of assessment of respiratory quotient (RQ)|Change of assessment of resting energy expenditure (REE),University of Aarhus|University of Copenhagen,Male,"40 Years to 70 Years   (Adult, Older Adult)",Phase 1,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2019-000213-37,"September 26, 2019","September 1, 2021","September 1, 2022","March 1, 2019",,"September 30, 2019","Medical Research Laboratory, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT03859934
Principal Investigator,"Julie Støy, MD, PhD",Aarhus University Hospital,,NCT03859934,julie støy,julie,female,0.98,116926,419,NCT03859934,Metabolic Effects of Melatonin Treatment,,Recruiting,No Results Available,Metabolic Disease|Insulin Sensitivity|Glucose Metabolism Disorders (Including Diabetes Mellitus)|Type 2 Diabetes Mellitus|Blood Pressure|Inflammation,Drug: Melatonin|Drug: Placebo Oral Tablet,Change of insulin sensitivity|Change of insulin secretion change|MTNR1a rs10830963 influence on change in insulin sensitivity and insulin secretion|Change of insulin signalling|Change of ambulatory blood pressure|Change of arterial stiffness|Change of gut microbiome|Change of sleep evaluation 1|Change of sleep evaluation 2|Change of psychological health 1|Change of psychological health 2|Hormonal changes|Change of glucose and palmitate kinetics|Change of regional glucose and palmitate uptake|Change of DEXA-scans|Change of assessment of respiratory quotient (RQ)|Change of assessment of resting energy expenditure (REE),University of Aarhus|University of Copenhagen,Male,"40 Years to 70 Years   (Adult, Older Adult)",Phase 1,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2019-000213-37,"September 26, 2019","September 1, 2021","September 1, 2022","March 1, 2019",,"September 30, 2019","Medical Research Laboratory, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT03859934
Principal Investigator,"Asbjørn M Drewes, Professor",Aalborg University Hospital,,NCT04143269,asbjørn m drewes,asbjørn,male,1.0,46,421,NCT04143269,Treatment of Complications to Diabetic Autonomic Neuropathy With Vagus Nerve Stimulation,DAN-VNS,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Gastrointestinal Dysfunction",Device: Non-invasive transcutaneous vagus nerve stimulation|Device: Sham vagus nerve stimulation,Subjective gastrointestinal symptoms|Holter monitoring|Cardiac vagal tone|Cardiovascular reflex testing|Sudomotor function|Pan-intestinal imaging|Functional brain scan|Intestinal transit|EEG spectral analysis|Pain tolerance threshold|Cold pressor test|Glycaemic control|Level of inflammation,Aalborg University Hospital|ElectroCore INC,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DAN-VNS|CIV-19-07-029105|N-20190020,November 2019,June 2021,June 2021,"October 29, 2019",,"October 29, 2019",,,https://ClinicalTrials.gov/show/NCT04143269
Principal Investigator,"Ton J. Rabelink, Prof.",Leiden University Medical Center,,NCT03889236,ton j. rabelink,ton,male,0.95,6381,422,NCT03889236,Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.,Glycotreat,Recruiting,No Results Available,Diabetic Nephropathy Type 2|Albuminuria|Type2 Diabetes Mellitus|Glucose Metabolism Disorders|Microalbuminuria|Diabetic Nephropathies|Diabetic Complications Renal|Diabetes Mellitus|Kidney Diseases|South Asian,Other: Fasting mimicking diet Prolon|Dietary Supplement: Food supplement Endocalyx|Dietary Supplement: Placebo,Percentage change from baseline in the Microvascular Health Index in the fasting mimicking diet or food supplement group compared to the placebo group|Percentage change from baseline in Urine albumin-to-creatinine ratio (UACR) in the fasting mimicking diet or food supplement group compared to the placebo|Percentage change from baseline in urinary heparanase levels in the fasting mimicking diet or food supplement group compared to the placebo|Percentage change from baseline in urinary MCP-1 levels in the fasting mimicking diet or food supplement group compared to the placebo|Percentage change from baseline in specific urinary heparan sulfate domains in the fasting mimicking diet or food supplement group compared to the placebo,Leiden University Medical Center|Dutch Kidney Foundation|Health Holland|Radboud University,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P17.249,"May 3, 2018","December 31, 2019","December 31, 2019","March 26, 2019",,"March 26, 2019","Leiden Universitiy Medical Center (LUMC), Leiden, Noord Holland, Netherlands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03889236/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03889236
Study Chair,"Péter Hegyi, MD, PhD, DSc","Insitute for Translational Medicine, Medical School, University of Pécs, HU",,NCT04164602,péter hegyi,péter,male,0.95,88,423,NCT04164602,The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly,NODES,Not yet recruiting,No Results Available,"Diabetes Mellitus|Diabetes|Diabetes Mellitus, Type 2|Diabetes type2|Cancer of Pancreas|Pancreas Neoplasm|Pancreas Adenocarcinoma|Pancreatic Cancer",,"incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes|mortality of pancreatic ductal adenocarcinoma in new-onset diabetic patients|the proportion of localised and resectable pancreatic ductal adenocarcinoma|change in body weight|Change in fasting blood glucose and HbA1c|Antidiabetic medications and the risk of pancreatic ductal adenocarcinoma|presence of concomitant diseases|smoking and alcohol intake|The sensitivity, specificity, positive and negative predictive values, and accuracy of the biomarker test|Cost-benefit analysis",University of Pecs|Hungarian Pancreatic Study Group (HPSG),All,"60 Years and older   (Adult, Older Adult)",,2522,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,41085-6/2019EÜIG,"September 11, 2020","December 31, 2022","June 30, 2023","November 15, 2019",,"June 9, 2020",,,https://ClinicalTrials.gov/show/NCT04164602
Principal Investigator,"László Czakó, MD, PhD, DSc","First Department of Medicine University of Szeged, HU",,NCT04164602,lászló czakó,lászló,male,0.96,90,423,NCT04164602,The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly,NODES,Not yet recruiting,No Results Available,"Diabetes Mellitus|Diabetes|Diabetes Mellitus, Type 2|Diabetes type2|Cancer of Pancreas|Pancreas Neoplasm|Pancreas Adenocarcinoma|Pancreatic Cancer",,"incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes|mortality of pancreatic ductal adenocarcinoma in new-onset diabetic patients|the proportion of localised and resectable pancreatic ductal adenocarcinoma|change in body weight|Change in fasting blood glucose and HbA1c|Antidiabetic medications and the risk of pancreatic ductal adenocarcinoma|presence of concomitant diseases|smoking and alcohol intake|The sensitivity, specificity, positive and negative predictive values, and accuracy of the biomarker test|Cost-benefit analysis",University of Pecs|Hungarian Pancreatic Study Group (HPSG),All,"60 Years and older   (Adult, Older Adult)",,2522,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,41085-6/2019EÜIG,"September 11, 2020","December 31, 2022","June 30, 2023","November 15, 2019",,"June 9, 2020",,,https://ClinicalTrials.gov/show/NCT04164602
Principal Investigator,"Hae-Ra Han, PhD, RN",Johns Hopkins University,,NCT03925948,hae-ra han,hae-ra,female,1.0,1,429,NCT03925948,Health Literacy Intervention for African Americans With Diabetes,,Completed,No Results Available,Uncontrolled Diabetes,Behavioral: PLAN 4 Success-Diabetes,Change in Health literacy as assessed by Literacy Assessment in Diabetes (LAD).|Change in Health literacy as assessed by the Newest Vital Sign|Change in Diabetes knowledge measured with the validated Diabetes Knowledge Test|Change in Diabetes self-efficacy measured with Stanford Diabetes Self-Efficacy scale,Johns Hopkins University|Brancati Center for the Advancement of Community Care|Center for Community Innovation and Scholarship at the Johns Hopkins University|East Baltimore Medical Center|Shepherds Clinic|John Hopkins Aftercare Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,19,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,IRB00061339,"May 6, 2015","February 1, 2019","February 1, 2019","April 24, 2019",,"April 24, 2019","Wald Community Nursing Center, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03925948
Principal Investigator,"Benjamin J Renquist, PhD",University of Arizona,,NCT04062890,benjamin j renquist,benjamin,male,0.99,62465,430,NCT04062890,Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance,,Not yet recruiting,No Results Available,Hyperinsulinism|Insulin Resistance|Insulin Sensitivity|Glucose Intolerance|Hypertension,Drug: Vigabatrin Pill|Drug: Placebo oral tablet,Fasted serum glucose and insulin|Glucose Clearance|Insulin Sensitivity|Blood Pressure,University of Arizona|Arizona Department of Health Services,All,18 Years to 60 Years   (Adult),Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ADHS18-201472b,"December 15, 2019","December 30, 2021","December 30, 2022","August 20, 2019",,"August 20, 2019",,,https://ClinicalTrials.gov/show/NCT04062890
Study Director,"Ebru Calik-Kutukcu, PhD",Hacettepe University,,NCT03823664,ebru calik-kutukcu,ebru,female,0.97,24743,432,NCT03823664,"Cardiorespiratory Fitness in Prediabetic,Type 2 Diabetic and Healthy Individuals",,Recruiting,No Results Available,"Prediabetic State|Diabetes Mellitus, Type 2|Cardiorespiratory Fitness|Inflammation|Exercise Test",Diagnostic Test: Cardiorespiratory Fitness,Cardiorespiratory fitness|Functional Exercise Capacity|Pulmonary functions|Respiratory Muscle Strength|Maximal Exercise Capacity|Physical Activity Level,Hacettepe University,All,"18 Years to 65 Years   (Adult, Older Adult)",,36,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,GO 17/793,"November 1, 2018","June 1, 2019","November 1, 2019","January 30, 2019",,"January 30, 2019","Hacettepe University, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT03823664
Study Chair,"Hulya Arikan, Professor",Hacettepe University,,NCT03823664,hulya arikan,hulya,female,0.97,3317,432,NCT03823664,"Cardiorespiratory Fitness in Prediabetic,Type 2 Diabetic and Healthy Individuals",,Recruiting,No Results Available,"Prediabetic State|Diabetes Mellitus, Type 2|Cardiorespiratory Fitness|Inflammation|Exercise Test",Diagnostic Test: Cardiorespiratory Fitness,Cardiorespiratory fitness|Functional Exercise Capacity|Pulmonary functions|Respiratory Muscle Strength|Maximal Exercise Capacity|Physical Activity Level,Hacettepe University,All,"18 Years to 65 Years   (Adult, Older Adult)",,36,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,GO 17/793,"November 1, 2018","June 1, 2019","November 1, 2019","January 30, 2019",,"January 30, 2019","Hacettepe University, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT03823664
Study Chair,"Cemile Bozdemir-Ozel, MsC",Hacettepe University,,NCT03823664,cemile bozdemir-ozel,cemile,female,0.97,2959,432,NCT03823664,"Cardiorespiratory Fitness in Prediabetic,Type 2 Diabetic and Healthy Individuals",,Recruiting,No Results Available,"Prediabetic State|Diabetes Mellitus, Type 2|Cardiorespiratory Fitness|Inflammation|Exercise Test",Diagnostic Test: Cardiorespiratory Fitness,Cardiorespiratory fitness|Functional Exercise Capacity|Pulmonary functions|Respiratory Muscle Strength|Maximal Exercise Capacity|Physical Activity Level,Hacettepe University,All,"18 Years to 65 Years   (Adult, Older Adult)",,36,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,GO 17/793,"November 1, 2018","June 1, 2019","November 1, 2019","January 30, 2019",,"January 30, 2019","Hacettepe University, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT03823664
Study Chair,"Selcuk Dagdelen, Professor",Hacettepe University,,NCT03823664,selcuk dagdelen,selcuk,male,0.97,7398,432,NCT03823664,"Cardiorespiratory Fitness in Prediabetic,Type 2 Diabetic and Healthy Individuals",,Recruiting,No Results Available,"Prediabetic State|Diabetes Mellitus, Type 2|Cardiorespiratory Fitness|Inflammation|Exercise Test",Diagnostic Test: Cardiorespiratory Fitness,Cardiorespiratory fitness|Functional Exercise Capacity|Pulmonary functions|Respiratory Muscle Strength|Maximal Exercise Capacity|Physical Activity Level,Hacettepe University,All,"18 Years to 65 Years   (Adult, Older Adult)",,36,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,GO 17/793,"November 1, 2018","June 1, 2019","November 1, 2019","January 30, 2019",,"January 30, 2019","Hacettepe University, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT03823664
Principal Investigator,"Beyza Nur Karaduz, PT",Hacettepe University,,NCT03823664,beyza nur karaduz,beyza,female,0.97,5285,432,NCT03823664,"Cardiorespiratory Fitness in Prediabetic,Type 2 Diabetic and Healthy Individuals",,Recruiting,No Results Available,"Prediabetic State|Diabetes Mellitus, Type 2|Cardiorespiratory Fitness|Inflammation|Exercise Test",Diagnostic Test: Cardiorespiratory Fitness,Cardiorespiratory fitness|Functional Exercise Capacity|Pulmonary functions|Respiratory Muscle Strength|Maximal Exercise Capacity|Physical Activity Level,Hacettepe University,All,"18 Years to 65 Years   (Adult, Older Adult)",,36,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,GO 17/793,"November 1, 2018","June 1, 2019","November 1, 2019","January 30, 2019",,"January 30, 2019","Hacettepe University, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT03823664
Principal Investigator,"Jean-Louis PEPIN, MD, PhD",Grenoble Alpes University Hospital,,NCT03857191,jean-louis pepin,jean-louis,male,0.99,5131,434,NCT03857191,Nutritional Rehabilitation and Sleep Apnea in the Obese,DIETSLEEP,Recruiting,No Results Available,"Obese|Sleep Apnea, Obstructive",Dietary Supplement: Nutritional psychocomportemental rehabilitation,Difference in OSA risk before and after nutritional and psychocomportemental rehabilitation|Difference in daytime sleepiness before and after nutritional and psychocomportemental rehabilitation|Weight loss according to OSA status|Change in Blood pressure according to OSA status|Change in Medication use according to OSA status|To assess the effect of Weight loss on OSA,"University Hospital, Grenoble|Groupe Ethique & santé",All,"18 Years and older   (Adult, Older Adult)",,396,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,38RC18.267|2018-A02617-48,"March 22, 2019","September 25, 2021","September 25, 2021","February 27, 2019",,"January 27, 2020","Chu Grenoble Alpes, Grenoble Cedex 9, France",,https://ClinicalTrials.gov/show/NCT03857191
Study Director,"Filiz Demircik, PhD",Sciema UG,,NCT03840161,filiz demircik,filiz,female,0.97,12544,436,NCT03840161,Use of CoG by Patients With Diabetes Mellitus,,Completed,No Results Available,Diabetes Mellitus,Device: non-invasive tissue glucose prediction,CoG accuracy in measuring glucose levels (non-invasively) during a standardized meal experiment.|CoG accuracy in monitoring glucose levels (invasively) during a standardized meal experiment.|Impact of the CoG on long-term (three month) glycemic control (HbA1c using standard laboratory procedures) in patients with type 1 and 2 diabetes|Treatment satisfaction questionnaire,Sciema UG|Cnoga Medical Ltd.,All,"18 Years to 90 Years   (Adult, Older Adult)",,40,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,CNG-NGM-003,"July 16, 2018","February 28, 2019","March 31, 2019","February 15, 2019",,"January 18, 2020","Mills-Penisnsula Medical Center, San Mateo, California, United States",,https://ClinicalTrials.gov/show/NCT03840161
Principal Investigator,"Cristina García Serrano, Nurse",Institut Català de la Salut,,NCT03857802,cristina garcía serrano,cristina,female,0.99,140931,437,NCT03857802,Efficiency of a Nursing Intervention in Sleep Hygiene,ENISH,Recruiting,No Results Available,Sleep Disorder|Metabolic Glucose Disorders,Behavioral: Sleep hygiene intervention,Change of glycated hemoglobin levels.|Change in sleep quality: Pittsburgh Sleep Quality Index,Jordi Gol i Gurina Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,JordiGol,"September 1, 2017",April 2019,April 2019,"February 28, 2019",,"March 7, 2019","Centro Atención Primaria - Institut Català de la Salut, Balaguer, Lleida, Spain",,https://ClinicalTrials.gov/show/NCT03857802
Principal Investigator,"Suzanne E Mitchell, MD",Boston Medical Center,,NCT03889600,suzanne e mitchell,suzanne,female,0.98,9856,438,NCT03889600,Re-Engineered Discharge for Diabetes-Computer Adaptive Testing (REDD-CAT),,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: REDD-CAT,Feasibility - Recruitment potential: percentage of eligible patients willing to enroll in the study|Feasibility - Participant burden: time required for participants to complete data collection measures|Feasibility - Subject retention: percentage of patients who complete the 30-day follow-up time point|Feasibility - Implementation fidelity: percentage of indicated referrals that are made|Limited Efficacy - Change in coping: Ways of Coping scale|Limited Efficacy - Change in diabetes related distress: Diabetes Distress scale|Limited Efficacy - Change in depression: Patient Health Questionnaire (PHQ-9)|Limited Efficacy - Change in anxiety: The Generalized Anxiety Disorder 7 (GAD-7)|Limited Efficacy - 30-Day readmission rate,Boston Medical Center|University of Michigan,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,H-38545,September 2020,March 2021,March 2021,"March 26, 2019",,"October 29, 2019",,,https://ClinicalTrials.gov/show/NCT03889600
Principal Investigator,"Dr Momina Abid, MBBS,M Phil (ongoing)",Ziauddin University,,NCT04120259,momina abid,momina,female,0.99,80,440,NCT04120259,Effect of Apple Cider Vinegar and Metformin Combination vs Metformin Alone in Type 2 Diabetics,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Metformin Oral Tablet|Dietary Supplement: Vinegar,BMI (Anthropometric Measurement)|Measurement of Hemoglobin A1c|Measurement of Fasting Blood Sugar,Ziauddin University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,126,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,002,"April 22, 2019","August 26, 2019","August 26, 2019","October 9, 2019",,"October 21, 2019","Ziauddin University, Karachi, Sindh, Pakistan",,https://ClinicalTrials.gov/show/NCT04120259
Principal Investigator,"Dr Zahida Memon, MBBS,M Phil,PhD",Ziauddin University,,NCT04120259,zahida memon,zahida,female,0.97,199,440,NCT04120259,Effect of Apple Cider Vinegar and Metformin Combination vs Metformin Alone in Type 2 Diabetics,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Metformin Oral Tablet|Dietary Supplement: Vinegar,BMI (Anthropometric Measurement)|Measurement of Hemoglobin A1c|Measurement of Fasting Blood Sugar,Ziauddin University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,126,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,002,"April 22, 2019","August 26, 2019","August 26, 2019","October 9, 2019",,"October 21, 2019","Ziauddin University, Karachi, Sindh, Pakistan",,https://ClinicalTrials.gov/show/NCT04120259
Principal Investigator,"Licia iacoviello, MD, PhD",IRCCS Neuromed,,NCT03949504,licia iacoviello,licia,female,0.99,2212,442,NCT03949504,Diabetes Risk Diagnosis and Management,DIARIO,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Procedure: New Find-risk questionnaire software,Number of subjects at high risk for Diabetes|Number of subjects with diabetes|Concentration of glucose in plasma,Neuromed IRCCS,All,"34 Years to 100 Years   (Adult, Older Adult)",,1500,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,DEP3_2019,"January 9, 2019","July 30, 2021","December 31, 2021","May 14, 2019",,"May 17, 2019","IRCCS INM Neuromed, Department of Epidemiology and Prevention, Pozzilli, IS, Italy",,https://ClinicalTrials.gov/show/NCT03949504
Principal Investigator,"Nana F Hempler, PhD",Steno Diabetes Center Copenhagen,,NCT03950219,nana f hempler,nana,female,0.82,32306,445,NCT03950219,CUlturally Sensitive TOols for Ethnic Minorities in Diabetes Self-management Education and Support,CUSTOM,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Group course,Well-being|diabetes self-management|HbA1c,"Steno Diabetes Center Copenhagen|Centre for Diabetes, Copenhagen municipality",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,309,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,CUSTOM,"March 1, 2019","December 31, 2020",October 2022,"May 15, 2019",,"May 16, 2019","Centre for Diabetes, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT03950219
Principal Investigator,"Sanjay Kinra, MD, PhD",London School of Hygiene and Tropical Medicine,,NCT03938233,sanjay kinra,sanjay,male,0.99,4711,446,NCT03938233,Diabetes Self Management Education Programme in Thailand,DSMET,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system,Hemoglobin A1c levels (HbA1c)|Total cardiovascular risk|EQ-5D|Hospital Anxiety and Depression scale (HADS)|Perceived Stress Questionnaire (PSQ)|Summary of Diabetes Self-Care Activities Assessment (SDSCA)|International Physical Activity Questionnaire|Body mass index (BMI),London School of Hygiene and Tropical Medicine|Medical Research Council|Chiang Mai University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,693,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,1,"March 1, 2020","September 1, 2022","March 1, 2023","May 6, 2019",,"January 18, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03938233/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03938233/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03938233
Principal Investigator,"William Martinez, MD, MS",Vanderbilt University Medical Center,,NCT03947333,william martinez,william,male,0.99,64097,447,NCT03947333,Evaluation of a Patient Portal Intervention for Diabetes: A Randomized Controlled Trial,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Other: My Diabetes Care,Change in Patient Activation at 6 months|Change in Patient Activation at 3 months|Change in Diabetes Knowledge|Change in Diabetes Self-Care|Change in Diabetes Medication Adherence|Change in Diabetes Self-Efficacy|Change in Diabetes Distress|Satisfaction/Usability of My Health at Vanderbilt (for control group) and My Diabetes Care (for intervention group)|System Usage Data for My Health at Vanderbilt (for control group) and My Diabetes Care (for intervention group)|Change in Blood Glucose Control|Change in Blood Pressure Control|Treatment Intensification|Change in Flu Vaccination Status for 2019-20 Flu Season|Change in Low Density Lipoprotein,Vanderbilt University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,300,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,190825|5K23DK106511,"March 9, 2020",December 2020,December 2020,"May 13, 2019",,"May 18, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03947333
Principal Investigator,"Amit Majithia, MD",Onduo,,NCT03865381,amit majithia,amit,male,0.99,8292,450,NCT03865381,Onduo Virtual Diabetes Clinic Study,VDC,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Device: Onduo App,"Mean change in hemoglobin A1c|Change in weight from enrollment|Time to first change in diabetes medication or dosage from enrollment|Change in CGM summary measures from the first wear period versus the final wear period including glycemic variability, time spent in glycemic range, and mean glucose.|Mean Change in A1c",Verily Life Sciences LLC,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,100901,"February 8, 2019","February 12, 2020","October 15, 2020","March 6, 2019",,"May 6, 2020","Palo Alto Medical Foundation, Palo Alto, California, United States|Premier Medical Associates, Monroeville, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03865381
Principal Investigator,"Nallely Mora, MD, MPH",Loyola University Chicago,,NCT04052815,nallely mora,nallely,female,0.98,110,452,NCT04052815,Community Based DPP Program for Hispanic/Latino Females,,Recruiting,No Results Available,Pre Diabetes|Obesity,Behavioral: Diabetes prevention program culturally tailored,Change from Baseline Weight at 12 month|Change from Baseline waist circumference at 12 months|Change from Baseline Glycated hemoglobin at 12 months|Change from Baseline low density lipoprotein (LDL) at 12 months|Change from baseline High-density lipoprotein (HDL) at 12 months|Dietary assessment for fruits and vegetables|Dietary assessment of fat consumption,Loyola University,Female,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,212259,"January 1, 2020","December 30, 2020","April 30, 2021","August 12, 2019",,"February 21, 2020","Quinn Center, Maywood, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04052815
Principal Investigator,"Manju R Mamtani, MD",Treasurer,,NCT03918525,manju r mamtani,manju,female,0.51,452,453,NCT03918525,Diabetes In Sindhi Families In Nagpur (DISFIN),DISFIN,Completed,No Results Available,"Diabetes Mellitus, Type 2",Other: Sindhi families,Type 2 diabetes|Insulin resistance|Hypertension|Obesity|Central obesity|Dyslipidemia,"Lata Medical Research Foundation, Nagpur",All,"20 Years and older   (Adult, Older Adult)",,1462,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,RPC#23A,"February 20, 2017","February 20, 2018","February 20, 2018","April 17, 2019",,"April 17, 2019","Lata Medical Research Foundation, Nagpur, Maharashtra, India",,https://ClinicalTrials.gov/show/NCT03918525
Principal Investigator,"Scott Sittig, PhD",University of South Alabama,,NCT04132089,scott sittig,scott,male,0.99,31815,455,NCT04132089,Mobile Health Application for Diabetes,,Completed,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: capABILITY,20 participants baseline self-efficacy score will be measured at baseline and after the utilization (9 weeks) of the mHealth application capABILITY.|20 participants baseline diabetes knowledge score will be measure at baseline and after the utilization (9 weeks) of the mHealth application capABILITY.|20 participants baseline diabetes self-management score will be measured at baseline and after the utilization (9 weeks) of the mHealth application capABILITY.|Participants will login and use capABILITY quicker (time measured in seconds) after receiving a behavioral trigger message than those participants who don't receive a behavioral trigger.|Participants who receive a Spark trigger message will login and use capABILITY quicker (time measured in seconds) than those participants who receive Facilitator trigger message.,University of South Alabama,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other,1122,"January 1, 2015","January 1, 2017","April 1, 2017","October 18, 2019",,"October 18, 2019",,,https://ClinicalTrials.gov/show/NCT04132089
Principal Investigator,"Raquel C Greer, MD, MHS",Johns Hopkins University,,NCT04034511,raquel c greer,raquel,female,0.98,50152,456,NCT04034511,Food and Education Effects on Diabetes Study,FEED,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Medically-tailored meal delivery and medical nutrition therapy,Change in hemoglobin A1c|Change in Hemoglobin A1c,Johns Hopkins University|Moveable Feast|Priority Partners MCO|Leonard & Helen R. Stulman Charitable Foundation|France-Merrick Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB00200526,"January 21, 2020",September 2020,March 2021,"July 26, 2019",,"January 28, 2020","Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04034511
Principal Investigator,"Sue Dahl-Popolizio, DBH, OTR/L",Arizona State University,,NCT03821662,sue dahl-popolizio,sue,female,0.97,12000,459,NCT03821662,OT-Led Interdisciplinary Diabetes Self-Management Prgm,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus",Behavioral: OT Diabetes Self-Management Intervention,Change from Baseline Glycated hemoglobin (HbA1C)|Canadian Occupational Therapy Measure (COPM)|Change from Baseline Patient-Reported Outcomes Measurement Information SystemⓇ (PROMIS) 29|Change from Baseline Diabetes Empowerment Scale (DES-SF)|Change from Baseline Medication Adherence Assessment Scale,Arizona State University|Hand Therapy Partners,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,00009334,"April 11, 2019","July 30, 2019","July 30, 2019","January 30, 2019",,"June 9, 2020","Hand Therapy Partners, Mesa, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03821662
Principal Investigator,"Dayna Johnson, PhD",Emory University,,NCT04160078,dayna johnson,dayna,female,0.86,290,460,NCT04160078,Mindfulness IN-home for Diabetes and Sleep Health,MINDS,Suspended,No Results Available,"Diabetes|Diabetes Mellitus, Type 2",Behavioral: Mindfulness-based stress reduction (MBSR) Intervention,Change in average nightly sleep duration from baseline|Change in sleep timing from baseline|Change in sleep quality from baseline|Change in average high-density lipoproteins (HDL) Cholesterol from baseline|Change in triglycerides from baseline|Change in fasting blood glucose|Change in hemoglobin A1c (HbA1c) from baseline|Change in Blood pressure from baseline|Change in C-reactive protein from baseline,Emory University|Georgia Center for Diabetes Translation Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IRB00112861|P30DK111024,"December 18, 2019",May 2020,May 2020,"November 12, 2019",,"May 4, 2020","Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04160078
Principal Investigator,"Biraj M Karmacharya, PhD",Kathmandu University School of Medical Sciences,,NCT04131257,biraj m karmacharya,biraj,male,0.97,30,461,NCT04131257,Nurse-led Continuum of Care for People With Diabetes and Pre-diabetes in Nepal,NUCOD,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Nurse-led Continuum of Care,"Change in Glycated Hemoglobin (HbA1c) level|Change in the incidence of diabetes among individuals with pre-diabetes|Change in Blood Pressure|Change in lipid profile levels (HDL, LDL, Triglycerides, Total cholesterol)|Change in Body Mass Index|Change in the ""Reach"" of people participating in the program|Change in the ""Adoption at the patient level"" measured by the Summary of Diabetes Self-Care Activities Scale|Change in the ""Adoption at the patient level"" measured by the Diabetes Treatment Satisfaction Questionnaire|Change in the ""Adoption at the clinic level""",Kathmandu University School of Medical Sciences,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1236,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",KathmanduUSMS,December 2019,December 2020,December 2020,"October 18, 2019",,"October 18, 2019",,,https://ClinicalTrials.gov/show/NCT04131257
Principal Investigator,"Sabine Hazan, MD",ProgenaBiome,,NCT04213651,sabine hazan,sabine,female,0.98,43397,462,NCT04213651,A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Diabetes Mellitus,,Recruiting,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 2",Other: No intervention,Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing,ProgenaBiome,All,"Child, Adult, Older Adult",,100,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ProgenaBiome-032,"March 2, 2020",March 2023,July 2023,"December 30, 2019",,"March 6, 2020","ProgenaBiome, Ventura, California, United States",,https://ClinicalTrials.gov/show/NCT04213651
Principal Investigator,"Kensaku Kawamoto, MD, PhD, MHS",University of Utah,,NCT03826290,kensaku kawamoto,kensaku,male,1.0,62,463,NCT03826290,Evaluation of a Dashboard for Diabetes Care Integrated With the Electronic Health Record,,Recruiting,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 2",Other: EHR-integrated diabetes dashboard,Per-patient change in Hemoglobin A1c (HbA1c) levels from beginning to end of evaluation period|Per-patient change in body mass index (BMI) from beginning to end of evaluation period|Cost of diabetes medications prescribed,"University of Utah|Hitachi, Ltd.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,17000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UUtah_00109162,"January 9, 2019",January 2020,May 2020,"February 1, 2019",,"February 1, 2019","University of Utah Health, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT03826290
Principal Investigator,"Linda Siminerio, RN, PhD, CDE",Professor,,NCT03999268,linda siminerio,linda,female,0.98,99198,464,NCT03999268,Insulin Start Therapy Application With Resources and Training,I-START,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: I-START|Behavioral: Standard Insulin Administration Education,Change from baseline in psychological insulin resistance at 2 weeks|Change from baseline in psychological insulin resistance at 3 months|Change from baseline in psychological insulin resistance at 6 months|Change from baseline in glycemic control at 3 months|Change from baseline in glycemic control at 6 months|Change from baseline in medication adherence at 3 months|Change from baseline in medication adherence at 6 months|Change from baseline in diabetes empowerment at 3 months|Change from baseline in diabetes empowerment at 6 months|Change from baseline in diabetes distress at 3 months|Change from baseline in diabetes distress at 6 months|Patient Satisfaction|Provider Satisfaction,University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY19040017,"November 25, 2019","December 31, 2020","December 31, 2020","June 26, 2019",,"December 17, 2019","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03999268
Principal Investigator,Given Chipili,"Mukuba University, Kitwe, Zambia",,NCT04016012,given chipili,given,male,0.8,300,465,NCT04016012,Overweight and Obesity in Relation to Type ll Diabetes Melitus,,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Overweight and Obesity",Dietary Supplement: Local Zambian Foods,Change in Blood glucose levels|Change in Body weight|Change of Body Mass Index (BMI),"Mukuba University|University of Zambia|Afe Babalola University, Nigeria|National Food and Nutrition Commission, Zambia|University of Ghana|Sokoine University of Agriculture|Kitwe Teaching Hospital, Zambia",All,18 Years to 55 Years   (Adult),Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MU0619,"January 5, 2020","June 5, 2020","June 15, 2020","July 11, 2019",,"July 11, 2019","Kitwe Teaching Hospital, Kitwe, Copperbelt, Zambia",,https://ClinicalTrials.gov/show/NCT04016012
Principal Investigator,Katarina T Borer,Professor Emerita,,NCT03930758,katarina t borer,katarina,female,0.98,12712,466,NCT03930758,Preventing Diabetic Osteoporosis With Exercise,DIABETICBONE,Completed,No Results Available,"Diabetes Mellitus, Type 2",Combination Product: Behavior intervention of uphill exercise|Combination Product: Dietary intervention of exercise before the meal|Combination Product: Dietary intervention of uphill exercise|Combination Product: Dietary intervention of exercise after the meal|Combination Product: Behavior intervention of downhill exercise|Combination Product: Behavioral intervention of downhill exercise|Combination Product: Behavioral intervention of sedentary no-exercise trial|Combination Product: Dietary intervention of eating two meals,C-terminal propeptide of type I collagen|C-terminal telopeptide of type 1 collagen|Osteocalcin|Bone-specific alkaline phosphatase|Insulin|Parathyroid hormone|Cortisol|Growth hormone|Glucose|Dual-energy X-ray radiography|Novel Pedar,"University of Michigan|University of Wisconsin, La Crosse|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",Female,"50 Years to 65 Years   (Adult, Older Adult)",Not Applicable,15,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,HUM32227/ HUM32700|R15DK082800|M01RR024986,"October 8, 2009","December 5, 2012","December 20, 2012","April 29, 2019",,"April 29, 2019",,,https://ClinicalTrials.gov/show/NCT03930758
Principal Investigator,"Tricia Tan, MB ChB",Imperial College London,,NCT03842475,tricia tan,tricia,female,0.98,1792,467,NCT03842475,Who Will Benefit From Bariatric Surgery for Diabetes?,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Obesity",Procedure: Roux-en-Y gastric bypass (RYGB),"Diabetes remission (partial or complete)|Diabetes remission (complete)|Waist circumference, waist/hip ratio (cm)|Body mass index (kg/m2)|Weight loss|Change in visceral adipose tissue|Change in ectopic fat","Imperial College London|National Institute for Health Research, United Kingdom",All,"18 Years to 80 Years   (Adult, Older Adult)",,210,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRAS:231300,"October 1, 2018","December 1, 2021","June 5, 2028","February 15, 2019",,"February 15, 2019","Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03842475
Principal Investigator,"Tanja Dujic, PhD",University of Sarajevo,,NCT04198948,tanja dujic,tanja,female,0.98,35007,470,NCT04198948,Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers,INTERGLIKOM,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Omeprazole|Drug: Placebo oral tablet|Drug: Gliclazide,Gliclazide AUC|Glucose|Insulin,University of Sarajevo|General Hospital Prim. Dr. Abdulah Nakas|University of Dundee,Male,18 Years to 30 Years   (Adult),Phase 1,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,0101-3678/18,"March 4, 2019","August 5, 2019","August 5, 2019","December 13, 2019",,"February 5, 2020","General Hospital Prim. Dr. Abdulah Nakas, Sarajevo, Bosnia and Herzegovina",,https://ClinicalTrials.gov/show/NCT04198948
Principal Investigator,"Aida Kulo Cesic, PhD",University of Sarajevo,,NCT04198948,aida kulo cesic,aida,female,0.98,14496,470,NCT04198948,Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers,INTERGLIKOM,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Omeprazole|Drug: Placebo oral tablet|Drug: Gliclazide,Gliclazide AUC|Glucose|Insulin,University of Sarajevo|General Hospital Prim. Dr. Abdulah Nakas|University of Dundee,Male,18 Years to 30 Years   (Adult),Phase 1,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,0101-3678/18,"March 4, 2019","August 5, 2019","August 5, 2019","December 13, 2019",,"February 5, 2020","General Hospital Prim. Dr. Abdulah Nakas, Sarajevo, Bosnia and Herzegovina",,https://ClinicalTrials.gov/show/NCT04198948
Principal Investigator,"Albert Tejada, MD, PI",Synexus,,NCT04094649,albert tejada,albert,male,0.98,41504,473,NCT04094649,Acute Study of Effect of Ultrasound Vagus Nerve Stimulation on Glycemia,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Device: Ultrasound Vagus Nerve Stimulation (DECIMA),"Change in blood glucose Area Under the Curve (AUC, mg/dL ● hours) from baseline to 3 hours after an Oral Glucose Tolerance Test (OGTT) with Ultrasonic Vagus Nervous Stimulation (uVNS).hyperglycemia|Change in whole blood lipospolysaccharide-induced TNF-Alpha (pg/mL) production from base line to 4 hours post stimulation.","Aucta Technologies, Inc.|STATKING Clinical Services",All,21 Years to 60 Years   (Adult),Not Applicable,10,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Device Feasibility",AT-C-19-01,"August 1, 2019",January 2020,February 2020,"September 19, 2019",,"September 19, 2019","Synexus, Tempe, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04094649
Principal Investigator,Mei Hui Liu,"National University, Singapore",,NCT03989908,mei hui liu,mei,female,0.94,3347,477,NCT03989908,Effects of Microfluidic Noodle on Blood Glucose Levels of Healthy Volunteers.,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Microfludic noodle|Other: Control noodle,Change in glucose response|Change in insulin response|Change in ghrelin level|Change in glucagon-like peptide 1 (GLP-1) level|Change in satiety rating,"National University, Singapore|National University Health System",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,2018/01062,"January 13, 2019","December 30, 2019","December 30, 2019","June 18, 2019",,"June 18, 2019","National University of Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT03989908
Principal Investigator,Mei Hui Liu,"National University, Singapore",,NCT03985566,mei hui liu,mei,female,0.94,3347,478,NCT03985566,Effects of Fixed Meals With Special Formulated Rice on Blood Glucose Levels of Healthy Volunteers.,,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Fibre Grain|Dietary Supplement: Jasmine white rice,Change in glucose response|Change in insulin response|Change in ghrelin level|Change in glucagon-like peptide 1 (GLP-1) level|Change in satiety rating|Change in glucose trajectories over 14 days of continous glucose monitoring,"National University, Singapore|Alchemy Foodtech Pte Ltd",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,2017/01126,"July 3, 2018","December 30, 2020","December 30, 2020","June 13, 2019",,"February 26, 2020","National University of Singapore, Singapore, Singapore","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03985566/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03985566
Principal Investigator,Mats Rudling,Karolinska Institutet,,NCT03921203,mats rudling,mats,male,0.99,4555,482,NCT03921203,ApoB48 Metabolism in Plasma and Interstitial Fluid,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",,ApoB48 levels in blood and interstitial fluid,Karolinska University Hospital,All,"18 Years and older   (Adult, Older Adult)",,10,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,ApoB48IC2,"April 17, 2019","June 1, 2020","December 31, 2021","April 19, 2019",,"April 19, 2019","Patient research centre, Clinic of endocrinology, Karolinska University Hospital, Stockholm, Huddinge, Sweden",,https://ClinicalTrials.gov/show/NCT03921203
Principal Investigator,"Rehab H Werida, Lecturer",Damanhour University,,NCT03907423,rehab h werida,rehab,female,0.92,530,483,NCT03907423,Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Rosuvastatin10 mg tablet|Drug: Placebo Oral Tablet,serum levels of fetuin A|serum levels of Sortilin,Damanhour University,All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Rosuvastatin on diabetics,"April 1, 2019","October 1, 2019","November 1, 2019","April 9, 2019",,"April 16, 2019","Damanhour Medical National Institute, Damanhūr, N/A = Not Appُlicable, Egypt",,https://ClinicalTrials.gov/show/NCT03907423
Principal Investigator,"Daphne SL Gardner, MD","Singapore General Hospital, SingHealth",,NCT03837262,daphne sl gardner,daphne,female,0.98,3275,486,NCT03837262,GLucose Monitoring Programme SingaporeE (GLiMPSE),GLiMPSE,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Combination Product: Flash Glucose Monitoring and structured education,Recruitment and retention|Questionnaire|HbA1c|DSS questionnaire|EQ-5D-5L Questionnaire|WPAI questionnaire,Singapore General Hospital|KK Women's and Children's Hospital|SingHealth Polyclinics,All,"12 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,GLiMPSE-POC1,"March 25, 2019","October 31, 2019","October 31, 2019","February 12, 2019",,"April 5, 2019","Singapore General Hospital, Singapore, Singapore|KKH, Singapore, Singapore|Pasir Ris Polyclinic, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT03837262
Study Director,"Naji Abumrad, MD",Vanderbilt University Medical Center,,NCT03991299,naji abumrad,naji,male,0.92,1594,489,NCT03991299,"Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects",,Not yet recruiting,No Results Available,"Obese|Diabetes Mellitus, Type 2",Drug: Botox 200 UNT Injection,Change in body weight at 6 months|Change in body weight at 3 months|Change in body weight at 1 month|Change in glucose tolerance at 6 months|Change in glucose tolerance at 3 months|Change in glucose tolerance at 1 month|Change in insulin tolerance|Change in C-peptide tolerance|Change in ghrelin tolerance|Change in GIP tolerance|Change in GLP-1 tolerance|Change in PP tolerance|Change in PYY tolerance,Vanderbilt University Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,181978,"February 2, 2020","August 31, 2020","December 31, 2020","June 19, 2019",,"December 18, 2019",,,https://ClinicalTrials.gov/show/NCT03991299
Principal Investigator,"Belinda M. Reininger, DrPH","The University of Texas Health Science Center, Houston",,NCT04035395,belinda m. reininger,belinda,female,0.98,8786,491,NCT04035395,Salud y Vida 2.0: Enhancing Integrated Behavioral Health for Diabetics in the Rio Grande Valley,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Behavior, Health","Other: Peer-led Support Group|Other: Behavioral Health Consult|Other: Medication Therapy Management Consult|Other: La Cocina Alegre/ The Happy Kitchen|Other: Mind, Exercise, Nutrition, Do it!",Rate of Change in Hemoglobin A1c|Rate of Change in Blood Pressure|Rate of Change in BMI|Rate of Change in Depressive Symptoms|Rate of Change in Quality of Life: Duke Health Profile|Rate of Change in Total Cholesterol|Rate of Change in Self-efficacy: Diabetes Self-Efficacy Scale,"The University of Texas Health Science Center, Houston|Health Resources in Action, Inc.",All,"18 Years to 74 Years   (Adult, Older Adult)",Not Applicable,353,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,HSC-SPH-16-0044,"September 29, 2016","June 13, 2018","June 13, 2018","July 29, 2019",,"August 2, 2019",,,https://ClinicalTrials.gov/show/NCT04035395
Principal Investigator,"Dilay AÇIL, Asst.Prof.",Manisa Celal Bayar University,,NCT04104711,dilay açil,dilay,female,0.97,838,495,NCT04104711,Home-Based Intervention to the Diabetics,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Home Visit","Other: Home visits, health education",Health Belief Model Scale in Patients with Diabetes|Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes|Fasting plasma glucose level (mg/dl)|Postprandial glucose level (mg/dl)|Hemoglobin A1c level (%)|Body mass index (kg/m2)|Blood pressure level (mmHg)|Costs via frequency of complication-related hospital admissions,"Dilay AÇIL,PhD|Dokuz Eylul University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,81,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"970-GOA, 2014 / 07-20","January 1, 2015","March 30, 2017","July 14, 2017","September 26, 2019",,"September 30, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04104711/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04104711
Study Director,"Zuhal BAHAR, Prof.",Koç University,,NCT04104711,zuhal bahar,zuhal,female,0.97,3609,495,NCT04104711,Home-Based Intervention to the Diabetics,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Home Visit","Other: Home visits, health education",Health Belief Model Scale in Patients with Diabetes|Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes|Fasting plasma glucose level (mg/dl)|Postprandial glucose level (mg/dl)|Hemoglobin A1c level (%)|Body mass index (kg/m2)|Blood pressure level (mmHg)|Costs via frequency of complication-related hospital admissions,"Dilay AÇIL,PhD|Dokuz Eylul University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,81,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"970-GOA, 2014 / 07-20","January 1, 2015","March 30, 2017","July 14, 2017","September 26, 2019",,"September 30, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04104711/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04104711
Study Chair,"Abdurrahman ÇÖMLEKÇİ, MD,Prof.",Dokuz Eylul University,,NCT04104711,abdurrahman çömlekçi̇,abdurrahman,male,0.97,5580,495,NCT04104711,Home-Based Intervention to the Diabetics,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Home Visit","Other: Home visits, health education",Health Belief Model Scale in Patients with Diabetes|Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes|Fasting plasma glucose level (mg/dl)|Postprandial glucose level (mg/dl)|Hemoglobin A1c level (%)|Body mass index (kg/m2)|Blood pressure level (mmHg)|Costs via frequency of complication-related hospital admissions,"Dilay AÇIL,PhD|Dokuz Eylul University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,81,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"970-GOA, 2014 / 07-20","January 1, 2015","March 30, 2017","July 14, 2017","September 26, 2019",,"September 30, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04104711/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04104711
Principal Investigator,"Christophe De Block, MD","University Hospital, Antwerp",,NCT04007003,christophe de block,christophe,male,0.99,90978,506,NCT04007003,An Audit of the Impact of Tailored Information Delivered Via a Digital Learning Platform,,Terminated,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1",Behavioral: training in optimal insulin injection technique,Change in Insulin Use|Change in Glycemic Control|Incidence of Hypoglycemic Events|Change in Needle Re-Use,"Becton, Dickinson and Company",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,170,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,LiMo Audit,"June 26, 2018","August 10, 2019","August 10, 2019","July 5, 2019",,"December 3, 2019","Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium|Imeldaziekenhuis, Bonheiden, Belgium|Universitair Ziekenhuis Brussel, Brussel, Belgium|UZ Gent, Gent, Belgium|Virga Jesse Ziekenhuis, Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|AZ Turnhout, Turnhout, Belgium|AZ Jan Portaels, Vilvoorde, Belgium",,https://ClinicalTrials.gov/show/NCT04007003
Principal Investigator,kyungsang Yoo,Seoul National University Hospital,,NCT03867942,kyungsang yoo,kyungsang,male,1.0,4,508,NCT03867942,BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.,,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Dyslipidemias",Drug: Monolayer group|Drug: Bilayer group,Gemigliptin AUC|Rosuvastain AUC|Rosuvastain Cmax|Gemigliptin Cmax,LG Chem,All,19 Years to 45 Years   (Adult),Phase 1,48,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LG-GSCL006,"March 21, 2019","May 24, 2019","August 31, 2019","March 8, 2019",,"March 8, 2019",,,https://ClinicalTrials.gov/show/NCT03867942
Principal Investigator,"Kristina Groti Antonic, MD, PhD",University Medical Centre Ljubljana,,NCT03792321,kristina groti antonic,kristina,female,0.98,29132,509,NCT03792321,"Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients"" (SETH2)",SETH2,Completed,No Results Available,"Hypogonadism, Male|Diabetes Mellitus, Type 2|Obesity",Drug: Testosterone Undecanoate|Drug: Placebo,"Effects of testosterone replacement therapy on glycemic control - fasting plasma glucose (FPG) mmol/l|Effects of testosterone replacement therapy on glycemic control - glycated hemoglobin A1c (HbA1c) %|Effects of testosterone replacement therapy on parameters of metabolic syndrome - change in HOMA-IR|Effects of testosterone replacement therapy on vascular function - change in flow mediated dilatation (FMD) %|Effects of testosterone replacement therapy on vascular morphology - intima-media thickness (IMT)|Effects of testosterone replacement therapy on non-alcoholic fatty liver disease (NAFLD)|Effects of testosterone replacement therapy on bone mineral density (BMD)|Effects of testosterone replacement on total testosterone (TT), calculated free testosterone (cFT), and calculated bioavailable testosterone (BT) concentrations|Effects of testosterone replacement on prostate specific antigen (PSA)|Effects of testosterone replacement on hematocrit",University Medical Centre Ljubljana,Male,"35 Years and older   (Adult, Older Adult)",Phase 4,55,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SBCE-KG-2014-1,"January 10, 2014","March 5, 2015","March 5, 2018","January 3, 2019",,"January 4, 2019",,,https://ClinicalTrials.gov/show/NCT03792321
Principal Investigator,"Nicole Ehrhardt, MD",George Washington University,,NCT03805412,nicole ehrhardt,nicole,female,0.98,102075,515,NCT03805412,Continuous Glucose Monitoring in Diabetes and Prediabetes,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|PreDiabetes|Obesity",Device: DEXCOM G6 RT-CGM,BMI|waist circumference|Body Fat Percentage|Questionnaire: Perception continuous glucose monitoring(CGM)|Effect of real-time continuous glucose monitoring on glycemic variability|Mean glucose|food frequency|physical activity,"Nicole Ehrhardt, MD|DexCom, Inc.|George Washington University",All,18 Years to 55 Years   (Adult),Not Applicable,45,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,180609,"January 10, 2019",June 2020,June 2020,"January 15, 2019",,"February 6, 2020","GWU Medical Faculty Associates, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT03805412
Principal Investigator,"Bastiaan E de Galan, MD, PhD",Radboud University,,NCT03976271,bastiaan e de galan,bastiaan,male,0.99,561,516,NCT03976271,Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses,HCIR,Recruiting,No Results Available,"Hypoglycemia|Inflammatory Response|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Procedure: hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp,"Inflammatory responses of hypoglycaemia by measuring the cytokine production of isolated monocytes using ELISA|Atherogenic responses of (recurrent) hypoglycaemia using foam cell formation.|Metabolomics profile of each group|Epigenetic modifications|Cardiac function responses to hypoglycaemia using echocardiography|Cognitive function responses to hypoglycaemia using cognitive function tests (TAP, PASAT)|Oxidative stress responses using oxidative stress marker","Radboud University|Rigshospitalet, Denmark",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,112,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,HCIR,"August 12, 2019","October 4, 2020","December 4, 2020","June 6, 2019",,"April 22, 2020","Nordsjællands University Hospital, Hillerød, Nordsjaelland, Denmark|Radboudumc, Nijmegen, Gelderland, Netherlands",,https://ClinicalTrials.gov/show/NCT03976271
Principal Investigator,"Ulrik Pedersen-Bjergaard, MD, PhD",Nordsjællands University Hospital,,NCT03976271,ulrik pedersen-bjergaard,ulrik,male,0.98,548,516,NCT03976271,Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses,HCIR,Recruiting,No Results Available,"Hypoglycemia|Inflammatory Response|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Procedure: hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp,"Inflammatory responses of hypoglycaemia by measuring the cytokine production of isolated monocytes using ELISA|Atherogenic responses of (recurrent) hypoglycaemia using foam cell formation.|Metabolomics profile of each group|Epigenetic modifications|Cardiac function responses to hypoglycaemia using echocardiography|Cognitive function responses to hypoglycaemia using cognitive function tests (TAP, PASAT)|Oxidative stress responses using oxidative stress marker","Radboud University|Rigshospitalet, Denmark",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,112,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,HCIR,"August 12, 2019","October 4, 2020","December 4, 2020","June 6, 2019",,"April 22, 2020","Nordsjællands University Hospital, Hillerød, Nordsjaelland, Denmark|Radboudumc, Nijmegen, Gelderland, Netherlands",,https://ClinicalTrials.gov/show/NCT03976271
Principal Investigator,"Satish Garg, MD",Barbara Davis Center,,NCT03808376,satish garg,satish,male,0.99,1744,522,NCT03808376,PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days,PROMISE,"Active, not recruiting",No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: Continuous Glucose Monitoring System,Effectiveness Measure - mean absolute relative difference (MARD)|Safety Endpoint - Incidence of device-related or sensor insertion/removal procedure-related serious adverse,"Senseonics, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,181,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CTP-0036,"December 27, 2018",March 2020,March 2020,"January 17, 2019",,"December 18, 2019","John Muir Physician Network Clinical Research Center, Concord, California, United States|AMCR Institute Inc., Escondido, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Atlanta Diabetes Care, Atlanta, Georgia, United States|Rocky mountain Diabetes Center C/O Research Department, Idaho Falls, Idaho, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Rainier Clinical Research Center, Renton, Washington, United States",,https://ClinicalTrials.gov/show/NCT03808376
Principal Investigator,"Meaghan Stumpf, MD",University of Virginia,,NCT04094064,meaghan stumpf,meaghan,female,0.99,92,525,NCT04094064,Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).,,Recruiting,No Results Available,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: Continuous Glucose Monitor,Mean Absolute Relative Difference between CGM value and capillary blood glucose|Duration of Hemodialysis|Volume removed during hemodialysis therapy|Basic Metabolic Panel prior to hemodialysis session|Medications|Daily Weights,"University of Virginia|DexCom, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,HSR190012,"February 19, 2020",May 2020,May 2020,"September 18, 2019",,"February 26, 2020","Meaghan Stumpf, MD, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT04094064
Principal Investigator,"Sungsoo Park, MD, PhD",Korea University Anam Hospital,,NCT03821961,sungsoo park,sungsoo,male,0.98,110,526,NCT03821961,18F-FDOPA PET/CT Imaging in Patients Undergoing Metabolic Surgery,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|PreDiabetes|Obesity",Procedure: Metabolic Surgery,Change in Uptake value of 18F-FDOPA PET/CT from baseline|Change in Glycated Hemoglobin from baseline|Change in Fasting Plasma Glucose from baseline|Changes in c-peptide level from baseline|Changes in Insulinogenic index from baseline|Changes in HOMA-IR(homeostatic model assessment for insulin resistance) from baseline|Changes in Matsuda index from baseline|Change in Body Mass Index (BMI) from baseline|Change in Systolic Blood Pressure from baseline|Change in serum level of HDL cholesterol from baseline|Change in serum level of Triglycerides from baseline|Change in serum level of LDL cholesterol from baseline|Change in serum level of Total Cholesterol from baseline|Change in serum level of High-sensitivity C-reactive Protein|Change in number of diabetes medication from baseline|Change in dosage of diabetes medication from baseline|Change in number of hypertension medication from baseline|Change in dosage of hypertension medication from baseline|Change in number of dyslipidemia medication from baseline|Change in dosage of dyslipidemia medication from baseline|Change in serum level of amino acid metabolites from baseline|Change in BDI scores of questionnaire from baseline|Change in HDRS scores of questionnaire from baseline|Change in SF-36 scores of questionnaire from baseline|Change in IWQOL scores of questionnaire from baseline|Change in MAQOL scores of questionnaire from baseline,Korea University Anam Hospital|Myungmoon Pharma. Co. Ltd.,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,30,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STARDOM-PET,"September 3, 2018","November 30, 2020","December 31, 2020","January 30, 2019",,"February 26, 2020","Korea University Anam Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03821961
Principal Investigator,"Bruno Caramelli, MD, PhD",University of Sao Paulo,,NCT04117763,bruno caramelli,bruno,male,0.99,103169,527,NCT04117763,Effect of Empagliflozin on Ventricular Repolarization.,EMPATHYHEART,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Coronary Heart Disease|Arrythmia, Cardiac",Drug: Empagliflozin 25 MG,Arrhythmogenic burden,University of Sao Paulo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 4,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,99613518.9.0000.0068,"October 4, 2019","January 31, 2021","January 31, 2021","October 7, 2019",,"April 7, 2020","InCor, São Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT04117763
Principal Investigator,"Wouter van Marken Lichtenbelt, Prof. Dr.",Maastricht University,,NCT03829982,wouter van marken lichtenbelt,wouter,male,0.99,3855,531,NCT03829982,The Effects of Light on Glucose Metabolism,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Glucose Intolerance|Prediabetic State",Behavioral: Exposure to bright light during the day|Behavioral: Exposure to dim light during the day,Postprandial glucose (mg/dL)|Glucose levels (mmol/L) in the postprandial state|Free fatty acid levels (µmol/L) in the postprandial state|Triglycerides levels (mmol/L) in the postprandial state|Insulin levels (µU/mL) in the postprandial state|Continuous interstitial glucose (mg/dL)|Energy expenditure|Core body temperature (CBT) and skin temperature,Maastricht University|Maastricht University Medical Center,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NL63655.068.17,"July 13, 2018",December 2019,December 2019,"February 4, 2019",,"August 16, 2019","Maastricht University, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT03829982
